{"title": "vacunas anti-rotavirus al: Topics by WorldWideScience.org", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2013-04-11", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "[Inmunogenicidad, inocuidad y eficacia de una vacuna tetravalente obtenida por recombinaci\u00f3n gen\u00e9tica de rotavirus aislados de monos rhesus y seres humanos en Bel\u00e9m, Brasil Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Bel\u00e9m, Brazil](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998000500007) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nA. C. Linhares\n1998-05-01\nFull Text Available Se evalu\u00f3 la inocuidad, inmunogenicidad y eficacia de una vacuna tetravalente obtenida por recombinaci\u00f3n gen\u00e9tica de rotavirus aislados de monos rhesus y seres humanos (RRV-TV (4 x 10(4 unidades formadoras de placas por dosis en un ensayo prospectivo, aleatorio, a doble ciego y controlado con placebo que se efectu\u00f3 con 540 lactantes brasile\u00f1os. Se administraron dosis de vacuna o de placebo a la edad de 1, 3 y 5 meses. No se observaron diferencias significativas en la frecuencia de diarrea o v\u00f3mito en los beb\u00e9s de ninguno de los dos grupos despu\u00e9s de administrar la dosis correspondiente. De 2 a 3% de los vacunados tuvieron fiebre baja los d\u00edas tercero a quinto despu\u00e9s de recibir la primera dosis, pero no despu\u00e9s de las dosis segunda o tercera. Se observ\u00f3 una respuesta de anticuerpos del tipo IgA al rotavirus aislado de monos rhesus (RRV en 58% de los vacunados y en 33% de quienes recibieron placebo. La respuesta de anticuerpos neutralizantes a cada serotipo no pas\u00f3 de 20% cuando se determin\u00f3 con la prueba de reducci\u00f3n de focos de fluorescencia, pero fue superior a 40% al medirse con la prueba de neutralizaci\u00f3n a base de reducci\u00f3n de placas. Se presentaron 91 casos de diarrea causada por rotavirus entre los ni\u00f1os que recibieron las tres dosis (de vacuna o de placebo durante un seguimiento de 2 a\u00f1os, 36 de ellos en los ni\u00f1os vacunados. La eficacia general de la vacuna fue de 8% (P = 0,005 contra toda clase de diarrea y de 35% (P = 0,03 contra la diarrea causada por rotavirus. La protecci\u00f3n durante el primer a\u00f1o de seguimiento, cuando predomin\u00f3 el rotavirus G del serotipo 1, fue de 57% (P = 0,008, pero se redujo a 12% en el segundo a\u00f1o. Se obtuvieron resultados similares al restringir el an\u00e1lisis a episodios en que el rotavirus fue el \u00fanico agente pat\u00f3geno identificado. Se observ\u00f3 en la vacuna una mayor tendencia a proteger contra casos de enfermedad con un promedio de seis o m\u00e1s deposiciones diarias. Estos resultados\n[The epidemiology of rotavirus diarrhea in Latin America: anticipating rotavirus vaccines La epidemiolog\u00eda de la diarrea por rotavirus en Am\u00e9rica Latina: perspectivas de vacunaci\u00f3n frente al rotavirus](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892004001200002) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nErin M. Kane\n2004-12-01\nFull Text Available OBJECTIVE: To assess the disease burden and characterize the epidemiology of rotavirus diarrhea in Latin America. METHODS: We conducted a literature review of studies of children OBJETIVO: Valorar la carga de enfermedad e identificar las caracter\u00edsticas epidemiol\u00f3gicas de la diarrea causada por rotavirus en Am\u00e9rica Latina. M\u00c9TODOS: Realizamos una revisi\u00f3n de la literatura que abarcaba los estudios de ni\u00f1os menores de 5 a\u00f1os que fueron hospitalizados o atendidos como pacientes ambulatorios a causa de la diarrea, y en los cuales se busc\u00f3 al rotavirus como agente etiol\u00f3gico de la diarrea. Nuestro trabajo de revisi\u00f3n incluye los estudios publicados desde el a\u00f1o 1998 sobre pacientes ingresados y ambulatorios, que incluyeron a 100 ni\u00f1os o m\u00e1s, y que informaron sobre actividades de vigilancia que se prolongaron durante al menos 12 meses consecutivos. RESULTADOS: Un total de 18 estudios de pacientes ingresados y 10 estudios de pacientes ambulatorios satisficieron los criterios de inclusi\u00f3n de nuestro trabajo de revisi\u00f3n. Se detect\u00f3 el rotavirus en el 31% (mediano de los pacientes ingresados (intervalo del 16% al 52% y en el 30.5% de los pacientes ambulatorios (intervalo del 4% al 42%. La tasa mediana de detecci\u00f3n fue mayor en los estudios que emplearon un ensayo de encimoinmunoan\u00e1lisis (ELISA (pacientes ingresados: 38%, pacientes ambulatorios: 33% frente a otros m\u00e9todos de detecci\u00f3n menos sensibles. La distribuci\u00f3n de la enfermedad rotav\u00edrica seg\u00fan la edad difer\u00eda entre pa\u00edses, aunque la proporci\u00f3n de ni\u00f1os hospitalizados durante el primer a\u00f1o de vida fue del 65% al 85%. En la mayor\u00eda de los pa\u00edses se produjeron ingresos hospitalarios por rotavirus durante todo el a\u00f1o, y el rotavirus normalmente mostraba un m\u00e1ximo estacional en el invierno tanto en las zonas de clima tropical como en aquellas de clima templado. CONCLUSIONES: La importante carga de enfermedad que se atribuye al rotavirus en Am\u00e9rica Latina sugiere que las\n[Rotavirus diarrhea disease burden in Peru: the need for a rotavirus vaccine and its potential cost savings Carga de morbilidad de la diarrea por rotavirus en Per\u00fa: la necesidad de una vacuna y su potencial de ahorro](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001001000004) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nPeter Ehrenkranz\n2001-10-01\nFull Text Available Objective. To assess the disease burden of rotavirus diarrhea in Peru as well the need for and the potential cost savings with a rotavirus vaccine in that country. Methods. To assess the burden of rotavirus diarrhea in Peru, we reviewed published and unpublished reports where rotavirus was sought as the etiologic agent of diarrhea in children. Rotavirus detection rates obtained from these studies were combined with diarrhea incidence rates from a number of national surveys in order to estimate both the burden of rotavirus diarrhea in the country and its associated medical costs. Results. Rotavirus is a significant cause of morbidity and mortality in Peruvian children. In their first 5 years of life, an estimated 1 in 1.6 children will experience an episode of rotavirus diarrhea, 1 in 9.4 will seek medical care, 1 in 19.7 will require hospitalization, and 1 in 375 will die of the disease. Per year, this represents approximately 384 000 cases, 64 000 clinic visits, 30 000 hospitalizations, and 1 600 deaths. The annual cost of medical care alone for these children is approximately US$ 2.6 million--and that does not take into account the indirect or societal costs of the illness and the deaths. Conclusions. Rotavirus immunization provides the prospect of decreasing the morbidity and mortality from diarrhea in Peru, but a vaccine regimen would have to be relatively inexpensive, a few dollars or less per child. Future cost-effectiveness analyses should explore the total costs (medical as well as indirect or societal associated with rotavirus diarrhea. Newly licensed vaccines should be tested according to both their ability to avert deaths and their efficacy with fewer than three doses. All three of these factors could increase the cost savings associated with a rotavirus vaccine.Objetivos. Evaluar la carga de morbilidad de la diarrea por rotavirus en Per\u00fa, la necesidad de una vacuna y el ahorro que esta podr\u00eda proporcionar en este pa\u00eds. M\ufffd\n[Evaluaci\u00f3n del impacto de la vacuna contra rotavirus en Colombia usando m\u00e9todos r\u00e1pidos de evaluaci\u00f3n](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892013001000002&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nKarol Cotes\n2013-10-01\nFull Text Available OBJETIVO: Estimar la efectividad de la vacuna monovalente antirrotav\u00edrica para prevenir la hospitalizaci\u00f3n por enfermedad diarreica aguda en ni\u00f1os menores de 2 a\u00f1os en cinco ciudades de Colombia. M\u00c9TODOS: Se realiz\u00f3 una encuesta poblacional sobre una muestra probabil\u00edstica de ni\u00f1os mayores de 2 meses y menores de 24 meses de edad en cinco ciudades de Colombia (Barranquilla, Bogot\u00e1, Cali, Cartagena y Riohacha en el per\u00edodo de agosto a octubre de 2010. La vacuna fue introducida en el Programa Ampliado de Inmunizaciones en enero de 2009. Se estimaron las coberturas de vacunaci\u00f3n contra rotavirus por grupos de edad y la incidencia acumulada de hospitalizaci\u00f3n por diarrea severa, y se evalu\u00f3 la magnitud de la asociaci\u00f3n entre la vacunaci\u00f3n con una o dos dosis de vacuna antirrotav\u00edrica y la hospitalizaci\u00f3n por diarrea, utilizando la raz\u00f3n de probabilidades (RP ajustada por edad y otros factores de importancia epidemiol\u00f3gica. La efectividad de la vacunaci\u00f3n se estim\u00f3 usando la expresi\u00f3n 1 - RP. RESULTADOS: La cobertura de vacunaci\u00f3n con una dosis de vacuna fue de 87,3%. En los 12 meses previos a la encuesta 43,2% (1 453 ni\u00f1os de menores de 24 meses presentaron diarrea, y de ellos, 5,2% (174 ni\u00f1os fueron hospitalizados por esta causa. La efectividad de dos dosis de vacuna antirrotav\u00edrica para prevenir la hospitalizaci\u00f3n por diarrea severa fue de 68% (intervalo de confianza de 95%: 55%-77%. CONCLUSIONES: La vacunaci\u00f3n contra rotavirus en Colombia protege contra la hospitalizaci\u00f3n por diarrea por cualquier causa. El uso de encuestas transversales se mostr\u00f3 adecuado para evaluar r\u00e1pidamente la efectividad de un programa de vacunaci\u00f3n con una nueva vacuna.\n[Anticipating rotavirus vaccines: review of epidemiologic studies of rotavirus diarrhea in Argentina En anticipaci\u00f3n de una vacuna antirrotavirus: revisi\u00f3n de estudios epidemiol\u00f3gicos sobre la diarrea por rotavirus en la Argentina](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998000200001) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJorge A. G\u00f3mez\n1998-02-01\n, to more accurately assess the cost-effectiveness of a rotavirus vaccine program, and to indicate what methods might best be used to monitor such a program's impact.En todo el mundo, los rotavirus son la causa m\u00e1s com\u00fan de diarrea grave en los ni\u00f1os peque\u00f1os y actualmente se est\u00e1n ensayando sobre el terreno vacunas que posiblemente permitan inmunizar a la poblaci\u00f3n infantil dentro de varios a\u00f1os. Con el fin de estimar la carga de enfermedad por rotavirus en la Argentina y la utilidad de establecer en el pa\u00eds un sistema de vigilancia de la enfermedad, se revisaron datos sobre la detecci\u00f3n de estos virus, seg\u00fan estudios publicados y otros in\u00e9ditos de nueve ciudades argentinas y uno multic\u00e9ntrico. Los informes revisados indican que se detectaron rotavirus en 20% de 5 226 espec\u00edmenes (con un recorrido de 6 a 54% entre estudios tomados de ni\u00f1os hospitalizados por diarrea y en 9% de 6587 espec\u00edmenes (recorrido de 5 a 22% entre estudios tomados de pacientes ambulatorios, miembros de poblaciones mixtas (ni\u00f1os hospitalizados y ambulatorios y sujetos sometidos a encuestas comunitarias. Los datos correspondientes a hospitales muestran que, si bien los virus se detectaron durante todo el a\u00f1o, en los meses de invierno (mayo a julio hubo un pico de intensidad cuando hasta la mitad de los ni\u00f1os con diarrea tuvieron resultados positivos a los rotavirus. En tres laboratorios se logr\u00f3 serotipificar para la prote\u00edna G a 230 de 294 espec\u00edmenes positivos (78%; los resultados indican que el serotipo G1 fue el m\u00e1s com\u00fan (presente en 60% de los espec\u00edmenes serotipificados, seguido del G2 (en 20%, G4 (en 14% y G3 (en 5%. Sobre la base de los datos obtenidos en el pa\u00eds, se estim\u00f3 que en 1991 en la Argentina hubo aproximadamente 84 500 visitas de pacientes ambulatorios (uno de cada ocho nacimientos y 21 000 hospitalizaciones de 4 d\u00edas en promedio (uno de cada 31 nacimientos asociadas con rotavirus, que en conjunto costaron unos US$ 27,7 millones. Estos datos\n[Estudio de inmunogenicidad para dos vacunas recombinantes contra hepatitis B](http://www.revistabiomedica.org/index.php/biomedica/article/view/2011) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nO. Juliao\n1991-12-01\nFull Text Available Este estudio compara la inmunogenicidad (seroconversi\u00f3n, seroprotecci\u00f3n e Hiperrespuesta, producida por dos vacunas recombinantes contra la hepatitis B (Engerix-B de B\u00e9lgica y Cubana, en dos esquemas (012 y 016 meses, empleando los m\u00e9todos de cuantificaci\u00f3n para Anti-HBsAg (Abbott y Organ\u00f3n, los cuales fueron tambi\u00e9n comparados. En el estudio participaron 257 voluntarios, divididos al azar en 4 grupos (dos vacunas, dos esquemas. Resultados: los dos m\u00e9todos de Abbon y Organon, no presentan diferencias estad\u00edsticas significativas. La vacuna cubana muestra una mayor respuesta inmunog\u00e9nica para dos dosis de vacuna y para el esquema 012. No hay diferencia entre los esquemas 012 y 016 y en el esquema 016 no se ven diferencias estad\u00edsticamente significativas con la vacuna Engerix-B. En esta \u00daltima el esquema 016 muestra mejores resultados que el 012.\n[En anticipaci\u00f3n de una vacuna antirrotavirus: revisi\u00f3n de estudios epidemiol\u00f3gicos sobre la diarrea por rotavirus en la Argentina](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998000600003&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJorge A. G\u00f3mez\n1998-06-01\nFull Text Available En todo el mundo, los rotavirus son la causa m\u00e1s com\u00fan de diarrea grave en los ni\u00f1os peque\u00f1os y actualmente se est\u00e1n ensayando sobre el terreno vacunas que posiblemente permitan inmunizar a la poblaci\u00f3n infantil dentro de varios a\u00f1os. Con el fin de estimar la carga de enfermedad por rotavirus en la Argentina y la utilidad de establecer en el pa\u00eds un sistema de vigilancia de la enfermedad, se revisaron datos sobre la detecci\u00f3n de estos virus, seg\u00fan estudios publicados y otros in\u00e9ditos de nueve ciudades argentinas y uno multic\u00e9ntrico. Los informes revisados indican que se detectaron rotavirus en 20% de 5 226 espec\u00edmenes (con un recorrido de 6 a 54% entre estudios tomados de ni\u00f1os hospitalizados por diarrea y en 9% de 6 587 espec\u00edmenes (recorrido de 5 a 22% entre estudios tomados de pacientes ambulatorios, miembros de poblaciones mixtas (ni\u00f1os hospitalizados y ambulatorios y sujetos de encuestas comunitarias. Los datos hospitalarios muestran que, si bien los virus se detectaron durante todo el a\u00f1o, en los meses de invierno (mayo a julio hubo un pico de intensidad cuando hasta la mitad de los ni\u00f1os con diarrea dieron resultados positivos a los rotavirus. En tres laboratorios se logr\u00f3 serotipificar para la prote\u00edna G 230 de 294 espec\u00edmenes positivos (78%; los resultados indican que el serotipo G1 fue el m\u00e1s com\u00fan (presente en 60% de los espec\u00edmenes serotipificados seguido del G2 (en 20%, G4 (en 14% y G3 (en 5%. Sobre la base de los datos obtenidos en el pa\u00eds, se estim\u00f3 que en 1991 en la Argentina hubo aproximadamente 84 500 visitas de pacientes ambulatorios (1 de cada 8 nacimientos y 21 000 hospitalizaciones de 4 d\u00edas en promedio (1 de cada 31 nacimientos asociadas con rotavirus, que en conjunto costaron unos US$27,7 millones. Estos datos preliminares muestran que la carga de enfermedad por rotavirus en los ni\u00f1os argentinos es muy pesada y podr\u00eda disminuirse con una vacuna segura y efectiva. Adem\u00e1s se necesita ampliar la\n[En anticipaci\u00f3n de una vacuna antirrotavirus: revisi\u00f3n de estudios epidemiol\u00f3gicos sobre la diarrea por rotavirus en la Argentina](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998000600003) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nG\u00f3mez Jorge A.\n1998-01-01\nFull Text Available En todo el mundo, los rotavirus son la causa m\u00e1s com\u00fan de diarrea grave en los ni\u00f1os peque\u00f1os y actualmente se est\u00e1n ensayando sobre el terreno vacunas que posiblemente permitan inmunizar a la poblaci\u00f3n infantil dentro de varios a\u00f1os. Con el fin de estimar la carga de enfermedad por rotavirus en la Argentina y la utilidad de establecer en el pa\u00eds un sistema de vigilancia de la enfermedad, se revisaron datos sobre la detecci\u00f3n de estos virus, seg\u00fan estudios publicados y otros in\u00e9ditos de nueve ciudades argentinas y uno multic\u00e9ntrico. Los informes revisados indican que se detectaron rotavirus en 20% de 5 226 espec\u00edmenes (con un recorrido de 6 a 54% entre estudios tomados de ni\u00f1os hospitalizados por diarrea y en 9% de 6 587 espec\u00edmenes (recorrido de 5 a 22% entre estudios tomados de pacientes ambulatorios, miembros de poblaciones mixtas (ni\u00f1os hospitalizados y ambulatorios y sujetos de encuestas comunitarias. Los datos hospitalarios muestran que, si bien los virus se detectaron durante todo el a\u00f1o, en los meses de invierno (mayo a julio hubo un pico de intensidad cuando hasta la mitad de los ni\u00f1os con diarrea dieron resultados positivos a los rotavirus. En tres laboratorios se logr\u00f3 serotipificar para la prote\u00edna G 230 de 294 espec\u00edmenes positivos (78%; los resultados indican que el serotipo G1 fue el m\u00e1s com\u00fan (presente en 60% de los espec\u00edmenes serotipificados seguido del G2 (en 20%, G4 (en 14% y G3 (en 5%. Sobre la base de los datos obtenidos en el pa\u00eds, se estim\u00f3 que en 1991 en la Argentina hubo aproximadamente 84 500 visitas de pacientes ambulatorios (1 de cada 8 nacimientos y 21 000 hospitalizaciones de 4 d\u00edas en promedio (1 de cada 31 nacimientos asociadas con rotavirus, que en conjunto costaron unos US$27,7 millones. Estos datos preliminares muestran que la carga de enfermedad por rotavirus en los ni\u00f1os argentinos es muy pesada y podr\u00eda disminuirse con una vacuna segura y efectiva. Adem\u00e1s se necesita ampliar la\n[Outbreak of rotavirus gastroenteritis with high mortality, Nicaragua, 2005 Brote de gastroenteritis por rotavirus con alta mortalidad, Nicaragua, 2005](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000400008) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJuan Jos\u00e9 Amador\n2008-04-01\n\u00f1os de edad que provoc\u00f3 numerosas consultas, hospitalizaciones y muertes en Nicaragua. Se analiz\u00f3 si la vacunaci\u00f3n habr\u00eda evitado estos casos de enfermedad y fallecimiento, se buscaron factores de riesgo de muerte y se elabor\u00f3 un perfil cl\u00ednico de los ni\u00f1os hospitalizados con diarrea. M\u00c9TODOS: Se realiz\u00f3 un estudio de casos y controles para determinar si los ni\u00f1os que murieron tuvieron acceso a programas de vacunaci\u00f3n, como medida indirecta del acceso a la vacuna contra rotavirus. Se identificaron los factores de riesgo de muerte en los ni\u00f1os que fallecieron durante el brote en comparaci\u00f3n con los controles con diarrea sobrevivientes, emparejados seg\u00fan la edad. Se tomaron muestras de heces fecales, datos cl\u00ednicos y de vacunaci\u00f3n de los ni\u00f1os hospitalizados con diarrea para realizar el diagn\u00f3stico de rotavirus, elaborar el perfil cl\u00ednico y pronosticar el acceso futuro a una vacuna contra rotavirus. RESULTADOS: El brote ocurrido entre febrero y abril de 2005 ocasion\u00f3 47 470 consultas y 52 muertes. Aproximadamente 80% de los casos y controles y 60% de los ni\u00f1os hospitalizados con diarrea tuvieron acceso a la vacunaci\u00f3n programada y posiblemente tuvieron acceso a una vacuna contra rotavirus. Si en los programas de vacunaci\u00f3n se hubiera dispuesto de una vacuna de 85% de eficacia, se hubieran prevenido hasta 51% de los casos graves de rotavirus y hasta 68% de las muertes. El estudio de 35 pares de casos y controles demostr\u00f3 que la enfermedad grave, la desnutrici\u00f3n y la atenci\u00f3n por curanderos tradicionales fueron los factores de riesgo de muerte. Se encontr\u00f3 rotavirus en 42% de las muestras de ni\u00f1os hospitalizados, asociado con la enfermedad grave y la deshidrataci\u00f3n. CONCLUSIONES: El efecto de los brotes estacionales de la enfermedad por rotavirus podr\u00eda reducirse mediante la vacunaci\u00f3n contra rotavirus, el perfeccionamiento de los programas de rehidrataci\u00f3n oral y el entrenamiento de los curanderos tradicionales en el tratamiento correcto de\n[Regional meeting for the Americas assesses progress against rotavirus Reuni\u00f3n regional para las Am\u00e9ricas eval\u00faa el progreso contra los rotavirus](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892004000100014) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\n2004-01-01\nFull Text Available La diarrea provocada por la infecci\u00f3n por rotavirus es una de las principales causas de morbilidad y mortalidad en el mundo. Los rotavirus ocasionan un total de alrededor de 111 millones de casos de diarrea y 440 000 muertes, 82% de ellas en pa\u00edses en desarrollo. Solo en la Regi\u00f3n de las Am\u00e9ricas, los rotavirus causan aproximadamente 75 000 ingresos hospitalarios y 15 000 muertes cada a\u00f1o. Con el objetivo de evaluar la marcha de la lucha contra los rotavirus en la Regi\u00f3n, a principios de septiembre de 2003 se celebr\u00f3 en Lima, Per\u00fa, una reuni\u00f3n cuyos participantes examinaron la informaci\u00f3n epidemiol\u00f3gica, debatieron acerca de los adelantos alcanzados en el desarrollo de nuevas vacunas contra rotavirus y describieron sus experiencias con la vigilancia de la infecci\u00f3n rotav\u00edrica. En los pr\u00f3ximos a\u00f1os pueden aparecer en el mercado varias vacunas, entre ellas Rotarix (GlaxoSmithKline y RotaTeq (Merck. Ambas vacunas ya han pasado exitosamente por los estudios de fases I y II y en estos momentos se llevan a cabo extensos estudios de fase III. No obstante, a\u00fan no se conoce lo suficiente acerca del impacto econ\u00f3mico de la enfermedad, la efectividad en funci\u00f3n del costo que pueda llegar a alcanzar la vacunaci\u00f3n y la vigilancia de los rotavirus en el laboratorio. La reuni\u00f3n realizada en Lima gener\u00f3 varias recomendaciones, entre ellas algunas de car\u00e1cter general acerca de los estudios epidemiol\u00f3gicos sobre rotavirus, la metodolog\u00eda de los estudios de corte econ\u00f3mico y una base de datos para su vigilancia. En relaci\u00f3n con los laboratorios y las t\u00e9cnicas anal\u00edticas, las recomendaciones se centraron en las redes de laboratorios, el mejor momento para recolectar las muestras de heces y la manera de almacenar y procesar esas muestras.\n[A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy.](https://www.ncbi.nlm.nih.gov/pubmed/23596320)\nPatel, Manish; Glass, Roger I; Jiang, Baoming; Santosham, Mathuram; Lopman, Ben; Parashar, Umesh\n2013-07-15\nIdentifying an immunological correlate of protection for rotavirus vaccines (Rotarix [RV1] and RotaTeq [RV5]) would substantially facilitate testing of interventions for improving efficacy in developing countries and evaluating additional candidate rotavirus vaccines. We accessed PubMed and ClinicalTrials.gov to identify immunogenicity and efficacy trials for RV1 and RV5 to correlate anti-rotavirus serum immunoglobulin A (IgA) antibody titers vs efficacy in regions stratified by all-cause under-5 mortality rates (u5MR). We established a cutoff point for IgA geometric mean concentration or titer (GMC) that predicted lower efficacy and calculated pooled vaccine efficacy among countries with high vs low IgA titers. We observed an inverse correlation between u5MR and IgA titers for RV1 (r(2) = 0.72; P efficacy and IgA titers for both vaccines (r(2) = 0.56; P = .005). Postimmunization anti-rotavirus IgA GMC vaccine efficacy. Efficacy during first 2 years of life was significantly lower among countries with IgA GMC 90 (85%; 95% CI, 82-88). We observed a significant correlation between IgA titers and rotavirus vaccine efficacy and hypothesize that a critical level of IgA antibody titer is associated with a sufficient level of sustained protection after rotavirus vaccination.\n[Cost-effectiveness analysis of routine rotavirus vaccination in Brazil An\u00e1lisis de la relaci\u00f3n costo-efectividad de la vacunaci\u00f3n programada contra rotavirus en Brasil](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000400001) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nPatr\u00edcia Coelho de So\u00e1rez\n2008-04-01\nFull Text Available OBJECTIVE: The objective of this study was to conduct a cost-effectiveness analysis of a universal rotavirus vaccination program among children OBJETIVO: Analizar la relaci\u00f3n costo-efectividad de un programa universal de vacunaci\u00f3n contra rotavirus en ni\u00f1os de hasta 5 a\u00f1os en Brasil. M\u00c9TODOS: Se consider\u00f3 una cohorte hipot\u00e9tica anual de aproximadamente 3 300 000 reci\u00e9n nacidos con un seguimiento de 5 a\u00f1os. Mediante un modelo de \u00e1rbol de decisi\u00f3n se analizaron los posibles efectos cl\u00ednicos y econ\u00f3micos de la infecci\u00f3n por rotavirus con la vacunaci\u00f3n programada de ni\u00f1os y sin ella. Las probabilidades y los costos unitarios se tomaron de investigaciones publicadas y de los datos oficiales nacionales. Para evaluar el impacto de diferentes estimados de los par\u00e1metros clave se realiz\u00f3 un an\u00e1lisis de sensibilidad. El an\u00e1lisis se efectu\u00f3 tanto desde la perspectiva del sistema sanitario como de la sociedad. RESULTADOS: Se estim\u00f3 que el programa de vacunaci\u00f3n evitar\u00eda aproximadamente 1 735 351 (54% de los 3 210 361 casos de gastroenteritis por rotavirus y 703 (75% de las 933 muertes asociadas con la infecci\u00f3n por rotavirus en un per\u00edodo de 5 a\u00f1os. A un precio de la vacuna de 18,6 reales brasile\u00f1os (R$ por dosis, este programa costar\u00eda R$ 121 673 966 y ahorrar\u00eda R$ 38 536 514 en costos directos al sistema de salud p\u00fablica y R$ 71 778 377 en costos directos e indirectos a la sociedad. El costo estimado del programa por a\u00f1o de vida salvado ser\u00eda de R$ 1 028 y R$ 1 713, desde el punto de vista de la sociedad y del sistema de salud, respectivamente. CONCLUSIONES: La estrategia de vacunaci\u00f3n universal contra rotavirus present\u00f3 una buena relaci\u00f3n costo-efectividad seg\u00fan ambas perspectivas. Sin embargo, estos resultados son muy sensibles a cambios en la incidencia de diarreas, la proporci\u00f3n de casos graves, la cobertura de vacunaci\u00f3n y el precio de la vacuna.\nCrawford, Sue E.; Ramani, Sasirekha; Tate, Jacqueline E.; Parashar, Umesh D.; Svensson, Lennart; Hagbom, Marie; Franco, Manuel A.; Greenberg, Harry B.; O\u2019Ryan, Miguel; Kang, Gagandeep; Desselberger, Ulrich; Estes, Mary K.\n2017-01-01\nRotavirus infections are a leading cause of severe, dehydrating gastroenteritis in children rotavirus over a decade ago, rotavirus infections still result in >200,000 deaths annually, mostly in low-income countries. Rotavirus primarily infects enterocytes and induces diarrhoea through the destruction of absorptive enterocytes (leading to malabsorption), intestinal secretion stimulated by rotavirus non-structural protein 4 and activation of the enteric nervous system. In addition, rotavirus infections can lead to antigenaemia (which is associated with more severe manifestations of acute gastroenteritis) and viraemia, and rotavirus can replicate in systemic sites, although this is limited. Reinfections with rotavirus are common throughout life, although the disease severity is reduced with repeat infections. The immune correlates of protection against rotavirus reinfection and recovery from infection are poorly understood, although rotavirus-specific immunoglobulin A has a role in both aspects. The management of rotavirus infection focuses on the prevention and treatment of dehydration, although the use of antiviral and anti-emetic drugs can be indicated in some cases. PMID:29119972\n[Evaluaci\u00f3n del impacto econ\u00f3mico de la vacuna antirrotav\u00edrica en Venezuela Assessment of the economic impact of the antiretroviral vaccine in Venezuela](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892006000900001) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nDagna Constenla\n2006-10-01\nFull Text Available OBJETIVO: El objetivo de este estudio fue evaluar el costo de la atenci\u00f3n m\u00e9dica de la gastroenteritis por rotavirus y la relaci\u00f3n costo-efectividad de la vacuna antirrotav\u00edrica en la poblaci\u00f3n venezolana menor de 5 a\u00f1os de edad. M\u00c9TODOS: Se utiliz\u00f3 un modelo econ\u00f3mico que integra la informaci\u00f3n epidemiol\u00f3gica, la eficacia de la vacuna y los costos de atenci\u00f3n m\u00e9dica de la gastroenteritis por rotavirus, desde la perspectiva de la sociedad. Para determinar la efectividad de la vacuna, se estim\u00f3 el n\u00famero de casos de hospitalizaci\u00f3n, de consultas m\u00e9dicas y de muertes evitados despu\u00e9s de su administraci\u00f3n. La relaci\u00f3n costo-efectividad de la vacuna se evalu\u00f3 partiendo del n\u00famero de a\u00f1os de vida ajustados por discapacidad (AVAD y de casos evitados. RESULTADOS: En Venezuela, los servicios de salud invierten, aproximadamente, 4,2 millones de d\u00f3lares estadounidenses (US$ por a\u00f1o para cubrir los costos de atenci\u00f3n m\u00e9dica causados por el rotavirus. Un programa de vacunaci\u00f3n antirrotav\u00edrica evitar\u00eda aproximadamente el 52% (186 de las muertes, el 54% (7 232 de las hospitalizaciones y el 50% (55 168 de las consultas ambulatorias durante los primeros cinco a\u00f1os de vida, en una cohorte vacunada. Para un precio estimado de US$ 24 por r\u00e9gimen de vacuna, se genera una relaci\u00f3n costo-efectividad de US$ 1 352 por AVAD. CONCLUSIONES: Los resultados de este estudio apuntan a que la vacunaci\u00f3n antirrotav\u00edrica es una estrategia costoefectiva en la prevenci\u00f3n de la gastroenteritis por rotavirus en Venezuela, ya que puede evitar muertes y a\u00f1os de vida ajustados por discapacidad en la poblaci\u00f3n menor de cinco a\u00f1os de edad.OBJECTIVE: To assess the cost of medical care for rotavirus gastroenteritis and the cost-effectiveness of the antiretroviral vaccine in Venezuelan children under five. METHODS: We used an economic model that comprises epidemiologic information, vaccine efficacy, and the cost of medical care in connection with\n[Rotavirus morbidity and mortality in children in Brazil Morbilidad y mortalidad por rotavirus en ni\u00f1os en Brasil](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000200004) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAna Marli Christovam Sartori\n2008-02-01\nFull Text Available OBJECTIVE: To study the epidemiology of rotavirus and estimate rotavirus-associated morbidity and mortality in children OBJETIVOS: Analizar la epidemiolog\u00eda del rotavirus y estimar la morbilidad y la mortalidad asociadas con las infecciones por rotavirus en ni\u00f1os < 5 a\u00f1os de edad en Brasil en 2004, antes de incluir la vacuna contra el rotavirus en el Programa Nacional de Inmunizaciones (PNI. M\u00c9TODOS: Para estimar la morbilidad por rotavirus se revisaron los estudios publicados (1999-2006 que abordaban la incidencia de diarrea aguda en ni\u00f1os < 5 a\u00f1os de edad y la frecuencia de las infecciones por rotavirus en ni\u00f1os con diarrea en Brasil. Los casos de diarrea se dividieron en tres categor\u00edas de gravedad seg\u00fan el nivel de atenci\u00f3n que requirieron: casos leves que solo requirieron atenci\u00f3n domiciliaria, casos moderados que requirieron la visita a un servicio ambulatorio de salud y casos graves que requirieron hospitalizaci\u00f3n. Para estimar la mortalidad por rotavirus se utiliz\u00f3 el n\u00famero de muertes registradas por diarrea en ni\u00f1os de < 5 a\u00f1os, seg\u00fan el Sistema de Informaci\u00f3n sobre Mortalidad (SIM del Sistema \u00danico de Salud (SUS de Brasil, y se calcul\u00f3 la proporci\u00f3n de muertes causadas por este virus. RESULTADOS: Se estim\u00f3 que las infecciones por rotavirus causan anualmente 3 525 053 casos de diarrea, 655 853 visitas a servicios ambulatorios de salud, 92 453 hospitalizaciones y 850 muertes en ni\u00f1os < 5 a\u00f1os de edad en Brasil. CONCLUSIONES: Las infecciones por rotavirus constituyen una importante causa de morbilidad y mortalidad en Brasil.\n[Realidad y nuevos horizontes de la vacuna del virus del papiloma humano](https://www.openaire.eu/search/publication?articleId=od______1472::a09ac4cf255ae73a6b4363b1bbc0a6ad)\nGarc\u00eda G\u00f3mez, Nuria\n2014-01-01\nLa vacuna frente al VPH es la primera vacuna destinada a la prevenci\u00f3n del c\u00e1ncer inducido por un virus, el CCU (problema de salud p\u00fablica mundial), y de lesiones precursoras. Disponemos de 2 vacunas profil\u00e1cticas: Gardasil\u00ae (frente a VPH 6, 11, 16 y 18) y Cervarix\u00ae (frente a VPH 16 y 18). El trabajo consiste en una revisi\u00f3n bibliogr\u00e1fica que tiene como objetivo conocer la situaci\u00f3n que vive actualmente la vacuna del VPH en Espa\u00f1a, utilizando como palabras clave virus, vacun...\n[Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: analysis of clinical trials of human rotavirus vaccine.](https://www.ncbi.nlm.nih.gov/pubmed/24240068)\nCheuvart, Brigitte; Neuzil, Kathleen M; Steele, A Duncan; Cunliffe, Nigel; Madhi, Shabir A; Karkada, Naveen; Han, Htay Htay; Vinals, Carla\n2014-01-01\nClinical trials of the human rotavirus vaccine Rotarix\u2122 (RV1) have demonstrated significant reductions in severe rotavirus gastroenteritis (RVGE) in children worldwide. However, no correlate of vaccine efficacy (VE) has yet been established. This paper presents 2 analyses which aimed to investigate whether serum anti-RV IgA measured by ELISA 1 or 2 mo post-vaccination can serve as a correlate of efficacy against RVGE: (1) In a large Phase III efficacy trial (Rota-037), the Prentice criteria for surrogate endpoints was applied to anti-RV IgA seropositivity 1 mo post-vaccination. These criteria determine whether a significant vaccine group effect can be predicted from the surrogate, namely seropositivity (anti-RV IgA concentration>20 U/mL); (2) Among other GSK-sponsored RV1 VE studies, 8 studies which assessed immunogenicity at 1 or 2 mo post-vaccination in all or a sub-cohort of enrolled subjects and had at least 10 RVGE episodes were included in a meta-analysis to measure the regression between clinical VE and VE predicted from immunogenicity (VE1). In Rota-037, anti-RV IgA seropositivity post-vaccination was associated with a lower incidence of any or severe RVGE, however, the proportion of vaccine group effect explained by seropositivity was only 43.6% and 32.7% respectively. This low proportion was due to the vaccine group effect observed in seronegative subjects. In the meta-analysis, the slope of the regression between clinical VE and VE1 was statistically significant. These two independent analyses support the hypothesis that post-vaccination anti-RV IgA seropositivity (antibody concentration \u226520 U/mL) may serve as a useful correlate of efficacy in clinical trials of RV1 vaccines.\n[Los laboratorios p\u00fablicos productores de vacunas: el nuevo paradigma](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998001000001&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAkira Homma\nFull Text Available Los laboratorios p\u00fablicos productores de vacunas de Am\u00e9rica Latina y el Caribe han contribuido en diferente grado al control y a la erradicaci\u00f3n de las enfermedades prevenibles por vacunaci\u00f3n y varios est\u00e1n produciendo las vacunas que se aplican rutinariamente en los programas nacionales de inmunizaci\u00f3n, como la vacuna antituberculosa (a base del bacilo de Calmette-Gu\u00e9rin, BCG, la vacuna contra difteria-t\u00e9tanos-pertussis (DTP, el toxoide tet\u00e1nico (TT, la vacuna antisarampionosa y la vacuna antipoliomiel\u00edtica oral. Gracias a los adelantos cient\u00edficos recientes, se prev\u00e9 un aumento importante del n\u00famero de vacunas seguras y eficaces que estar\u00e1n disponibles en un futuro cercano para uso en los programas normales de vacunaci\u00f3n. Sin embargo, los gastos asociados con el desarrollo de estas vacunas y con los derechos de propiedad intelectual que las protegen son cuantiosos. Adem\u00e1s, pocos laboratorios en Am\u00e9rica Latina poseen la capacidad t\u00e9cnica para investigar y elaborar estas vacunas. Tales factores tendr\u00e1n un impacto en la celeridad con que se incorporar\u00e1n en los esquemas de vacunaci\u00f3n de los pa\u00edses de la Regi\u00f3n. En la actualidad, los laboratorios p\u00fablicos productores de vacunas de la Regi\u00f3n no est\u00e1n capacitados para competir en este nuevo contexto y corren el riesgo de ser desplazados del mercado por completo. De ah\u00ed la necesidad de que cambien radicalmente su manejo gerencial y su capacidad cientificot\u00e9cnica, lo cual exige que los gobiernos se comprometan a mejorar y fortalecer aquellos aspectos pol\u00edticos y financieros que garanticen la participaci\u00f3n de los laboratorios nacionales en el suministro sostenible de vacunas a los programas de vacunaci\u00f3n, as\u00ed como en la investigaci\u00f3n, desarrollo y producci\u00f3n de vacunas nuevas\n[Vacuna Sint\u00e9tica contra la Malaria](http://revistamedicina.net/ojsanm/index.php/Revistamedicina/article/view/903) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nManuel Elkin Patarroyo\n1993-12-01\nFull Text Available\nEl doctor Manuel Elkin Patarroyo hace un recuento de lo que fueron sus primeros a\u00f1os de estudio y los primeros pasos que se dieron para fundar el Instituto de Inmunolog\u00eda, ayudado por muchos de los Acad\u00e9micos. Siempre ha querido representar al pueblo colombiano en sus valores de trabajo, disciplina, estudio, pensamiento y generosidad, en aras de un pueblo que sufre, que en definitiva es el objetivo del M\u00e9dico, el paciente.\nPosteriormente comenta qu\u00e9 es lo que se ha hecho con toda la profundidad que se merece pero con simpleza de palabras y en t\u00e9rminos sencillos, c\u00f3mo se desarroll\u00f3 la Vacuna Sint\u00e9tica contra la malaria: \u00bfPor qu\u00e9 malaria?, porque esta es una enfermedad de gran trascendencia; aclara que \u00e9l no le teme ni le molesta el cuestionamiento cient\u00edfico sobre el desarrollo de esta investigaci\u00f3n, por el contrario lo acepta y lo goza porque es el ejercicio intelectual; lo que s\u00ed le molesta es el morbo alrededor de ello, por esto pidi\u00f3 al doctor Mu\u00f1oz que al final se adelante un debate al respecto.\nDice a continuaci\u00f3n que las vacunas tradicionales son biol\u00f3gicas como todo el mundo lo sabe, es el microorganismo causal mismo que se muta ose mata, pero que descomponiendo la estructura qu\u00edmica de sus mol\u00e9culas, con el concepto de la s\u00edntesis qu\u00edmica se podr\u00edan rehacer qu\u00edmicamente y ser utilizadas como vacuna.\nDecidieron entonces atacar el problema de la vacuna a trav\u00e9s de esta metodolog\u00eda creando la vacuna contra la malaria de la cual se conoce su estructura qu\u00edmica, y aclara que las vacunas qu\u00edmicas tienen otra ventaja, que son puras, con menos reacciones adversas que las tradicionales.\nDice el doctor Patarroyo que decidieron aislar, e identificar m\u00e1s de la mitad de las prote\u00ednas del par\u00e1sito y dividiendo la muestra en dos fracciones, una de ellas se seleccion\u00f3 para averiguar su composici\u00f3n qu\u00edmica y la otra para saber cu\u00e1l podr\u00eda ser \u00fatil como vacuna. As\u00ed, fueron al Amazonas y all\n[Aproximaci\u00f3n al uso de hongos entomopat\u00f3genos y vacunas para el control sostenible de garrapatas en sistemas ganaderos: revisi\u00f3n](http://www.redalyc.org/articulo.oa?id=83743886006) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAna Carolina Moncada Gonz\u00e1lez\n2015-01-01\nFull Text Available La resistencia desarrollada por las garrapatas frente a los acaricidas de s\u00edntesis, hace necesario replantear las estrategias utilizadas actualmen - te para su control. Los programas de manejo integrado de par\u00e1sitos se presentan como una alternativa que, al promover estrategias de con - trol basadas en la ecolog\u00eda y la epidemiolog\u00eda de cada especie de par\u00e1sito, reducen el riesgo de desarrollo de resistencia. Dichas estrategias incluyen la aplicaci\u00f3n de vacunas antigarrapata y hongos entomopat\u00f3genos que afectan la viabi - lidad y la reproducci\u00f3n en las garrapatas. Sin embargo, la informaci\u00f3n obtenida entre estudios sobre hongos y vacunas ha sido inconsistente, por lo que hoy en d\u00eda ambas representan \u00e1reas de investigaci\u00f3n bastante activas. El prop\u00f3sito de este trabajo consisti\u00f3 en realizar una revisi\u00f3n descriptiva sobre los mecanismos de acci\u00f3n de la vacuna antigarrapata y los hongos entomopat\u00f3genos, en la b\u00fasqueda de una po - sible complementariedad que permita el dise\u00f1o de planes de aplicaci\u00f3n conjunta, con miras a mejorar los resultados de control en sistemas ganaderos. En la primera parte del documento se revisa la actual problem\u00e1tica asociada al uso y abuso de los acaricidas de s\u00edntesis, haciendo un \u00e9nfasis particular en el tema de resistencia; posteriormente, se describen los mecanismos de acci\u00f3n de hongos y vacunas que afectan la re - producci\u00f3n y supervivencia en garrapatas, y se incluye informaci\u00f3n relevante sobre su eficacia. Se espera que la informaci\u00f3n aqu\u00ed recolectada, sirva como base para elaborar estudios que permitan identificar la utilidad de los hongos entomopat\u00f3genos y las vacunas antigarrapata al interior de los programas de manejo integrado de par\u00e1sitos en ganader\u00eda.\n[Vaccines against dengue: a review of current candidate vaccines at advanced development stages Vacunas contra el dengue: una revisi\u00f3n de las vacunas candidatas en etapas avanzadas de desarrollo](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892007000300011) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJoachim Hombach\n2007-04-01\nFull Text Available Los esfuerzos sistem\u00e1ticos para desarrollar una vacuna contra el dengue comenzaron durante la Segunda Guerra Mundial, inspirados en el desarrollo exitoso de una vacuna contra la fiebre amarilla. Sin embargo, la falta de modelos adecuados de la enfermedad, la informaci\u00f3n incompleta acerca de los mecanismos patog\u00e9nicos y los insuficientes incentivos econ\u00f3micos han dificultado los avances. Debido al impacto actual del dengue en todo el mundo y su explosiva diseminaci\u00f3n, ha aumentado el inter\u00e9s en el desarrollo de vacunas contra el dengue y se ha avanzado considerablemente en el camino hacia la evaluaci\u00f3n cl\u00ednica de vacunas candidatas. La Iniciativa para la Investigaci\u00f3n en Vacunas, de la Organizaci\u00f3n Mundial de la Salud, est\u00e1 facilitando el desarrollo de y los ensayos con las vacunas candidatas. Las vacunas contra el dengue que se encuentran actualmente en etapas avanzadas de desarrollo son de tres tipos fundamentales: 1 vivas atenuadas; 2 vivas recombinantes; y 3 de subunidades e inactivadas. La mayor\u00eda de las vacunas en cartera son vivas atenuadas, siguiendo el camino exitoso de otras vacunas vivas contra flavivirus, especialmente de la desarrollada contra la fiebre amarilla. En general, las vacunas contra el dengue que se encuentran actualmente en desarrollo est\u00e1n bastante avanzadas y son muy diversas. Muy pronto comenzar\u00e1 la evaluaci\u00f3n de estas vacuna candidatas en ensayos de eficacia basados en poblaciones expuestas, lo que requerir\u00e1 resolver varios problemas t\u00e9cnicos, operacionales y regulatorios.\n[La vacuna en Cuba durante el gobierno de Someruelos](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::9c7220297c636745e06628ec37f2b47e)\nV\u00e1zquez Cienfuegos, Sigfrido\n2004-01-01\nLa Real Expedici\u00f3n Filantr\u00f3pica de la Vacuna (1803-1806), dirigida por Francisco Javier de Balmis, se dirigi\u00f3 al Nuevo Mundo para paliar las epidemias de viruelas que hab\u00edan venido asolando Am\u00e9rica desde casi el mismo momento del Descubrimiento. Para entonces en la isla de Cuba ya se hab\u00eda iniciado una labor con el mismo objetivo por el m\u00e9dico cubano Tom\u00e1s Romay, apoyado en el fomento de la introducci\u00f3n y aplicaci\u00f3n de la vacuna por el marqu\u00e9s de Someruelos gobernador y capit\u00e1n general de la ...\n[PRACTICAS MEDICAS, PRACTICAS POLITICAS. ROSAS Y LA \u00abVACUNA INDIGENA\u00bb](http://www.revistas.usach.cl/ojs/index.php/historiasocial/article/view/319) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMAR\u00cdA SILVIA DI LISCIA\n2011-10-01\nFull Text Available BUENOS AIRES, 1830. Se declara una epidemia de viruela entre los indios \u00abpampas\u00bb que est\u00e1n en la ciudad para honrar al Restaurador de las Leyes. Los caciques no disimulan su admiraci\u00f3n ante la valent\u00eda de Rosas, quien los visita sin alarma ante el contagio y los estimula a vacunarse para eliminar el temible mal. Un n\u00famero estimado en m\u00e1s de cien indios acepta, entonces, inmunizarse, coloc\u00e1ndose, seg\u00fan el testimonio de Parish, la \u00abvacuna a ind\u00edgenas \u00bb. Buenos Aires, 1833. Francisco X. Mu\u00f1iz, m\u00e9dico de la campa\u00f1a bonaerense, inicia las investigaciones con las que diez a\u00f1os despu\u00e9s se logra el redescubrimiento del cow pox, es decir, la viruela vacuna, llamada por Sarmiento \u00abla vacuna ind\u00edgena\u00bb.\n[Estudio de inmunogenicidad de la vacuna antitifo\u00eddica cubana de polisac\u00e1rido Vi vax-TyVi\u00ae en ratones](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200001&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJuan Carlos Ram\u00edrez\n2006-08-01\nFull Text Available Salmonella enterica serovar Typhi es un microorganismo que provoca m\u00e1s de 16 millones de casos de fiebre tifoidea con aproximadamente 600 000 muertes al a\u00f1o en todo el mundo. Dentro de las vacunas antitifo\u00eddicas la de polisac\u00e1rido capsular Vi ha encontrado, gracias a sus incuestionables ventajas, una gran aceptaci\u00f3n entre productores y consumidores. El presente trabajo aborda el estudio de inmunogenicidad de la vacuna antitifo\u00eddica cubana de polisac\u00e1rido Vi vax-TyVi\u00e2 en ratones. El estudio estuvo conformado por un grupo control no inoculado y un segundo grupo que recibi\u00f3 0,05 mL de la vacuna por v\u00eda intramuscular. Se tomaron muestras de sangre a los -3, 7, 14, 21, 28, 42, 56 y 84 d\u00edas. La actividad de anticuerpos IgG antipolisac\u00e1rido Vi de los sueros individuales fue determinada por ELISA. Los datos fueron analizados por grupo y por sexo y se calcul\u00f3 el porcentaje de seroconversi\u00f3n, consider\u00e1ndose respondedor aquel animal que al menos aumentara en cuatro veces su t\u00edtulo inicial. La respuesta de anticuerpos inducida por la vacuna mostr\u00f3 un aumento notable de los t\u00edtulos de IgG antipolisac\u00e1rido Vi en el grupo vacunado (100% de seroconversi\u00f3n, mientras que el grupo control no increment\u00f3 sus niveles m\u00ednimos iniciales (0% de respondedores. Aunque m\u00e1s dispersa, la respuesta de anticuerpos antiVi fue significativamente mayor en las hembras que en los machos.\n[Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAlejandro Roque Vald\u00e9s\n2004-04-01\nFull Text Available El presente trabajo es un art\u00edculo de revisi\u00f3n que pretende abordar un tema tan controvertido como actual: la posible asociaci\u00f3n causal que se ha querido establecer entre el autismo y las vacunas infantiles. A partir de la \u00faltima d\u00e9cada del siglo XX se producen una serie de cambios en la clasificaci\u00f3n, nomenclatura y criterios diagn\u00f3sticos del autismo. Los hallazgos de estudios epidemiol\u00f3gicos llevados a cabo bajo estos nuevos ponderados han revelado que las tasas de prevalencia del autismo son en la actualidad muy superiores a las de hace 15 a\u00f1os. Entre los factores que se esgrimen para explicar este fen\u00f3meno est\u00e1n las vacunas, y entre los mecanismos que se invocan para tratar de inculpar a las vacunas en la etiolog\u00eda del autismo est\u00e1n el exceso de mercurio derivado del tiomersal que se emplea como conservante de las mismas y procesos autoinmunes que de forma directa o indirectamente act\u00faan sobre el SNC, induciendo lesiones a nivel de la mucosa intestinal, lo cual favorecer\u00e1 la absorci\u00f3n de macromol\u00e9culas, ant\u00edgenos y toxinas que una vez en el torrente sangu\u00edneo llegar\u00edan al SNC produciendo all\u00ed las lesiones responsables de la g\u00e9nesis del autismo.\n[Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6\u2013specific IgA mAb](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=150959)\nFeng, Ningguo; Lawton, Jeffrey A.; Gilbert, Joana; Kuklin, Nelly; Vo, Phuoc; Prasad, B.V. Venkataram; Greenberg, Harry B.\n2002-01-01\nRotaviruses are the leading cause of severe diarrheal disease in young children. Intestinal mucosal IgA responses play a critical role in protective immunity against rotavirus reinfection. Rotaviruses consist of three concentric capsid layers surrounding a genome of 11 segments of double-stranded RNA. The outer layer proteins, VP4 and VP7, which are responsible for viral attachment and entry, are targets for protective neutralizing antibodies. However, IgA mAb\u2019s directed against the intermediate capsid protein VP6, which do not neutralize the virus, have also been shown to protect mice from rotavirus infection and clear chronic infection in SCID mice. We investigated whether the anti-VP6 IgA (7D9) mAb could inhibit rotavirus replication inside epithelial cells and found that 7D9 acted at an early stage of infection to neutralize rotavirus following antibody lipofection. Using electron cryomicroscopy, we determined the three-dimensional structure of the virus-antibody complex. The attachment of 7D9 IgA to VP6 introduces a conformational change in the VP6 trimer, rendering the particle transcriptionally incompetent and preventing the elongation of initiated transcripts. Based on these observations, we suggest that anti-VP6 IgA antibodies confers protection in vivo by inhibiting viral transcription at the start of the intracellular phase of the viral replication cycle. PMID:11994409\n[Economic impact of a rotavirus vaccination program in Mexico Impacto econ\u00f3mico de un programa de vacunaci\u00f3n contra rotavirus en M\u00e9xico](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892009000600003) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nDagna Constenla\n2009-06-01\nvacunar. A partir de datos nacionales publicados se estim\u00f3 el n\u00famero de casos y muertes por rotavirus, los a\u00f1os de vida ajustados por la discapacidad (AVAD que se evitar\u00edan y la relaci\u00f3n costo-efectividad incremental (US$/AVAD de una cohorte anual hipot\u00e9tica de 2 285 000 ni\u00f1os; se parti\u00f3 de algunos supuestos sobre el costo, la cobertura y las tasas de eficacia. RESULTADOS: Con una cobertura de 93% y un precio de la vacuna de US$ 16,00 por esquema (dos dosis, se estima que un programa de vacunaci\u00f3n contra rotavirus en M\u00e9xico evitar\u00eda 651 muertes (0,28 muertes por 1 000 ni\u00f1os, 13 833 hospitalizaciones (6,05 hospitalizaciones por 1 000 ni\u00f1os y 414 927 visitas de consulta externa (182 consultas por 1 000 ni\u00f1os por gastroenteritis aguda asociada a rotavirus (GAR. La vacunaci\u00f3n podr\u00eda reducir la carga econ\u00f3mica por GAR en M\u00e9xico al evitar gastos por US$ 14 millones (71% de la carga total por atenci\u00f3n sanitaria. A un precio de US$ 16,00 por esquema, la relaci\u00f3n costo-efectividad ser\u00eda de US$ 1 139,00 por AVAD evitado. Una reducci\u00f3n en el precio del programa de vacunaci\u00f3n contra rotavirus (US $8,00 por esquema generar\u00eda una menor relaci\u00f3n costo-efectividad incremental de US$ 303,00 por AVAD evitado. CONCLUSIONES: Un programa nacional de vacunaci\u00f3n contra rotavirus en M\u00e9xico reducir\u00eda la incidencia y la mortalidad infantiles y ser\u00eda altamente efectivo en funci\u00f3n del costo, seg\u00fan los umbrales de las intervenciones de costo-efectividad de la Organizaci\u00f3n Mundial de la Salud.\n[Vaccines against dengue: a review of current candidate vaccines at advanced development stages Vacunas contra el dengue: una revisi\u00f3n de las vacunas candidatas en etapas avanzadas de desarrollo](https://www.openaire.eu/search/publication?articleId=doajarticles::d1c5d56abb3c55f6f0d140a1ec694442)\nJoachim Hombach\n2007-01-01\nLos esfuerzos sistem\u00e1ticos para desarrollar una vacuna contra el dengue comenzaron durante la Segunda Guerra Mundial, inspirados en el desarrollo exitoso de una vacuna contra la fiebre amarilla. Sin embargo, la falta de modelos adecuados de la enfermedad, la informaci\u00f3n incompleta acerca de los mecanismos patog\u00e9nicos y los insuficientes incentivos econ\u00f3micos han dificultado los avances. Debido al impacto actual del dengue en todo el mundo y su explosiva diseminaci\u00f3n, ha aumentado el inter\u00e9s e...\n[Prescripci\u00f3n de vacunas no incluidas en el calendario vacunal en la Comunitat Valenciana durante el per\u00edodo 2004-2009](http://www.redalyc.org/articulo.oa?id=17020115007) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAna Ruiz Palacio\n2011-01-01\nFull Text Available Fundamentos, En el marco de las pol\u00edticas de uso racional del medicamento, y al objeto de conseguir una gesti\u00f3n eficiente de los programas de vacunaciones, el objetivo de este trabajo es conocer el n\u00famero de envases de las vacunas prescritas no incluidas en los programas de vacunaci\u00f3n en la Comunitat Valenciana y en sus departamentos de salud, as\u00ed como el gasto que produjeron en 2009, y analizar la evoluci\u00f3n desde 2004, centrando el an\u00e1lisis en la vacuna heptavalente conjugada frente al Streptococcus pneumoniae en menores de dos a\u00f1os. M\u00e9todo, Estudio descriptivo retrospectivo de las vacunas prescritas mediante receta en la Comunitat Valenciana durante el a\u00f1o 2009 y su evoluci\u00f3n desde 2004. Variables, n\u00famero de envases, tipo de beneficiario (activo/pensionista, departamento y gasto generado. Fuentes, Gestor de Prestaci\u00f3n Farmac\u00e9utica (GAIA y Sistema Informaci\u00f3n Poblacional (SIP. Resultados: En 2009 la prescripci\u00f3n mediante receta de vacunas no incluidas en los programas de vacunaci\u00f3n gener\u00f3 un gasto de 683.445,71 ] correspondiente a 17.353 envases, lo que supuso el 87! del total del gasto en vacunas recetadas. La vacuna frente al S. pneumoniae gener\u00f3 el 72! del gasto total de las vacunas no incluidas en el calendario. La evoluci\u00f3n 2004-2009 muestra un aumento del gasto de 735.334 ] (24,66! en 2005 a partir del cual se produjo un descenso acusado y paulatino que alcanz\u00f3 los 1.562.650,67 ] (-228.64!. El gasto por departamentos para la vacuna del neumococo conjugada heptavalente por mil ni\u00f1os/as menores de dos a\u00f1os oscil\u00f3 entre 17.377 y 324 ]. Conclusiones: La tendencia descendente del gasto en recetas prescritas se mantuvo durante 2009, fundamentalmente de vacunas conjugadas frente a neumococo. No obstante, se observ\u00f3 gran variabilidad interdepartamental en las tasas de prescripci\u00f3n que debe ser corregida.\n[Los laboratorios p\u00fablicos productores de vacunas: el nuevo paradigma](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998001000001) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAkira Homma\n1998-10-01\nFull Text Available Los laboratorios p\u00fablicos productores de vacunas de Am\u00e9rica Latina y el Caribe han contribuido en diferente grado al control y a la erradicaci\u00f3n de las enfermedades prevenibles por vacunaci\u00f3n y varios est\u00e1n produciendo las vacunas que se aplican rutinariamente en los programas nacionales de inmunizaci\u00f3n, como la vacuna antituberculosa (a base del bacilo de Calmette-Gu\u00e9rin, BCG, la vacuna contra difteria-t\u00e9tanos-pertussis (DTP, el toxoide tet\u00e1nico (TT, la vacuna antisarampionosa y la vacuna antipoliomiel\u00edtica oral. Gracias a los adelantos cient\u00edficos recientes, se prev\u00e9 un aumento importante del n\u00famero de vacunas seguras y eficaces que estar\u00e1n disponibles en un futuro cercano para uso en los programas normales de vacunaci\u00f3n. Sin embargo, los gastos asociados con el desarrollo de estas vacunas y con los derechos de propiedad intelectual que las protegen son cuantiosos. Adem\u00e1s, pocos laboratorios en Am\u00e9rica Latina poseen la capacidad t\u00e9cnica para investigar y elaborar estas vacunas. Tales factores tendr\u00e1n un impacto en la celeridad con que se incorporar\u00e1n en los esquemas de vacunaci\u00f3n de los pa\u00edses de la Regi\u00f3n. En la actualidad, los laboratorios p\u00fablicos productores de vacunas de la Regi\u00f3n no est\u00e1n capacitados para competir en este nuevo contexto y corren el riesgo de ser desplazados del mercado por completo. De ah\u00ed la necesidad de que cambien radicalmente su manejo gerencial y su capacidad cientificot\u00e9cnica, lo cual exige que los gobiernos se comprometan a mejorar y fortalecer aquellos aspectos pol\u00edticos y financieros que garanticen la participaci\u00f3n de los laboratorios nacionales en el suministro sostenible de vacunas a los programas de vacunaci\u00f3n, as\u00ed como en la investigaci\u00f3n, desarrollo y producci\u00f3n de vacunas nuevasIn Latin America and the Caribbean, public laboratories that produce vaccines have contributed in varying degrees to the control and eradication of vaccine-preventable diseases, and several of them\n[El estado actual de las vacunas contra las drogas](http://riiad.org/index.php/riiad/article/view/riiad.2017.2.05) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMaura Epifan\u00eda Matus Ortega\n2017-12-01\nFull Text Available Introducci\u00f3n: por lo com\u00fan, la adicci\u00f3n a las drogas se trata con psicoterapia y farmacolog\u00eda que evita la uni\u00f3n de las sustancias psicoactivas a receptores espec\u00edficos en el cerebro. El resultado de estos tratamientos no ha sido del todo satisfactorio, por lo que el desarrollo de terapias m\u00e1s eficaces representa un reto constante para tratar las adicciones. Una alternativa a la farmacolog\u00eda antiadictiva es la vacunaci\u00f3n activa dirigida contra las sustancias de abuso. Objetivo: esta revisi\u00f3n re\u00fane la informaci\u00f3n disponible sobre los fundamentos y avances cient\u00edficos en la generaci\u00f3n de una terapia inmunol\u00f3gica, que coadyuve al tratamiento de la adicci\u00f3n a sustancias como la hero\u00edna-morfina, la coca\u00edna, la nicotina y la anfetamina. M\u00e9todo: se consideraron los reportes cient\u00edficos disponibles en PubMed \u2013de 2005 a abril de 2017\u2013, sobre los fundamentos, la metodolog\u00eda empleada, los estudios precl\u00ednicos y cl\u00ednicos, y los resultados obtenidos en dichas investigaciones para generar vacunas contra las drogas. Resultados: las vacunas lograron mitigar los efectos producidos por las sustancias en los estudios precl\u00ednicos en modelos de estudio en animales; sin embargo, con pacientes humanos los resultados no han sido del todo satisfactorios. Discusi\u00f3n y conclusiones: a pesar de los esfuerzos realizados por diferentes grupos de investigaci\u00f3n y compa\u00f1\u00edas farmac\u00e9uticas para generar vacunas terap\u00e9uticas contra el uso de diferentes drogas, ninguna ha alcanzado la fase III de estudios cl\u00ednicos. En la actualidad, se contin\u00faa con los esfuerzos para lograr que las vacunas contra las adicciones alcancen su m\u00e1xima eficiencia y eficacia, y contribuyan al tratamiento de la adicci\u00f3n a las drogas.\nLlor Vila, Carles\n2005-01-01\nLa vacunaci\u00f3n antigripal, con m\u00e1s de 50 a\u00f1os de existencia, tiene una eficacia, una efectividad y una seguridad contrastadas, pero la respuesta inmunitaria oscila entre el 60 y el 90%, siendo algo menor en la poblaci\u00f3n anciana. Cl\u00e1sicamente se han utilizado las vacunas inactivadas trivalentes en las campa\u00f1as de vacunaci\u00f3n antigripal pero se considera que su aceptabilidad no es \u00f3ptima. Desde hace unos a\u00f1os se est\u00e1n investigando otros tipos de vacunas antigripales con el objetivo de mejorar su ...\n[Evaluaci\u00f3n de la informaci\u00f3n sanitaria disponible en internet sobre la vacuna antigripal](https://www.openaire.eu/search/publication?articleId=doajarticles::10bf287ae0007ca1c04dfbe102687a3b)\nI. Hern\u00e1ndez-Garc\u00eda; R. Gonz\u00e1lez Celador\n2014-01-01\nFundamento: La calidad de la informaci\u00f3n sanitaria en internet preocupa a gobiernos y usuarios. Nuestro objetivo fue determinar en qu\u00e9 medida la informaci\u00f3n sobre la vacuna antigripal se adhiere al gold est\u00e1ndar representado por lo establecido por el Ministerio de Sanidad espa\u00f1ol. Material y m\u00e9todos: Entre junio-julio 2014 se evalu\u00f3 la adhesi\u00f3n al gold est\u00e1ndar de la informaci\u00f3n sobre indicaciones, efectos adversos y contraindicaciones de la vacuna. Dicha informaci\u00f3n se obtuvo a trav\u00e9s de Goo...\n[Identidad de la vacuna contra Streptococcus pneumoniae \u201cQuimi-Vio\u201d mediante la t\u00e9cnica Dot Blot empleando los anticuerpos monoclonales contra los polisac\u00e1ridos capsulares 1,5, 6B, 14 y 19F de la bacteria](http://revistabionatura.com/2017.02.01.7.html) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nElizabeth Gonz\u00e1lez Aznar\n2017-02-01\nFull Text Available Streptococcus pneumoniae (neumococo constituye una de las principales causas de enfermedades infecciosas bacterianas, particularmente en ni\u00f1os menores de 2 a\u00f1os de edad. Basadas en el polisac\u00e1rido capsular (PsC, su principal factor de virulencia, existen dos tipos de vacunas aprobadas para uso en humanos: las vacunas polisacar\u00eddicas planas y las vacunas polisacar\u00eddicas conjugadas. Quimi-Vio, la vacuna antineumoc\u00f3cica cubana, pertenece al segundo grupo y est\u00e1 compuesta por los PsC de los siete serotipos de mayor incidencia y circulaci\u00f3n en Cuba (1, 5, 6B, 14, 18C, 19F y 23F. El objetivo de este trabajo fue realizar el ensayo de identidad de la vacuna cubana Quimi-Vio empleando los AcM contra los PsC 1, 5, 6B, 14, y 19F de Sp obtenidos recientemente en el Instituto Finlay de Vacunas, teniendo en cuenta que los Ensayos de identidad de las vacunas son requisito indispensable para la liberaci\u00f3n final de los lotes. La t\u00e9cnica empleada para la realizaci\u00f3n del ensayo de identidad de Quimi-Vio fue el Dot Blot, donde empleando membrana de Nitrocelulosa se realiz\u00f3 la captura de tres lotes de vacuna Quimi-Vio y como control positivo de la t\u00e9cnica los respectivos PsC de los serotipos 1, 5, 6B, 14, y 19F sin conjugar y una vacuna comercial Prevenar-13. Para la identidad de los PsC de neumococo se emplearon los respectivos AcM a una concentraci\u00f3n de 10\u00b5g/mL y como segundo anticuerpo anti IgG de rat\u00f3n conjugado a peroxidasa teniendo en cuenta que los AcMs empleados son murinos. Cada AcM fue capaz de identificar de forma altamente especifica al PsC homologo (mismo serotipo, tanto en su forma no conjugada y monovalente como en el contexto de las vacunas Quimi-Vio y Prevenar 13V, donde adem\u00e1s de estar conjugado al TT se encuentra mezclado con otros PsC de forma multivalente. La t\u00e9cnica Dot Blot empleando los AcMs contra los PsC serotipos 1, 5,6B, 14 y 19F permite identificar de forma espec\u00edfica cada PsC en la formulaci\u00f3n multivalente, por lo\n[Eficacia de la vacuna meningoc\u00f3cica de polisac\u00e1rido capsular del grupo C](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1135-57271997000200003) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nGonz\u00e1lez Enr\u00edquez Jes\u00fas\n1997-01-01\nFull Text Available FUNDAMENTO: Este trabajo consiste esencialmente en una revisi\u00f3n sistem\u00e1tica de la literatura cient\u00edfica sobre los efectos, intensidad y duraci\u00f3n de la respuesta serol\u00f3gica, as\u00ed como sobre la eficacia, efectividad y seguridad de la vacuna meningoc\u00f3cica de polisac\u00e1rido capsular del grupo C. M\u00c9TODOS: B\u00fasqueda en repertorio MEDLINE en el periodo 1970-1996. B\u00fasqueda espec\u00edfica de ensayos cl\u00ednicos aleatorizados y estudios de intervenci\u00f3n prospectivos en humanos con vacunas de polisac\u00e1ridos capsulares de meningococo en el mismo repertorio y periodo. An\u00e1lisis cr\u00edtico de literatura cient\u00edfica y s\u00edntesis de evidencia. RESULTADOS: La vacuna de polisac\u00e1rido capsular del serogrupo C es considerada segura y ha mostrado una eficacia superior al 85% en adultos y ni\u00f1os mayores, 70% (IC95%: 5-91% en ni\u00f1os menores de 5 a\u00f1os y 55% (IC90%: 14-76% en ni\u00f1os de 2-3 a\u00f1os. La vacuna no se ha mostrado eficaz en ni\u00f1os menores de 2 a\u00f1os. La duraci\u00f3n de niveles de anticuerpos protectores disminuye con la edad. La proporci\u00f3n de ni\u00f1os menores de 6 a\u00f1os efectivamente protegidos al a\u00f1o de la vacunaci\u00f3n es baja. La vacunaci\u00f3n no limita la respuesta serol\u00f3gica de vacunaciones ulteriores. CONCLUSIONES: La vacuna meningoc\u00f3cica de polisac\u00e1rido capsular del serogrupo C est\u00e1 indicada en adultos y ni\u00f1os mayores de 2 a\u00f1os como protecci\u00f3n contra la enfermedad meningoc\u00f3cica causada por este serogrupo en situaciones de alto riesgo de enfermedad. La escasa protecci\u00f3n que ofrece la vacuna en los menores de 2 a\u00f1os, la limitada eficacia en menores de 5 a\u00f1os y la corta duraci\u00f3n de la inmunidad que confiere a estas edades, hace que la vacunaci\u00f3n rutinaria no est\u00e9 recomendada y que la vacuna se use fundamentalmente en el control de brotes epid\u00e9micos causados por serogrupo C.\n[Modulation of rotavirus severe gastroenteritis by the combination of probiotics and prebiotics.](https://www.ncbi.nlm.nih.gov/pubmed/28634691)\nGonzalez-Ochoa, Guadalupe; Flores-Mendoza, Lilian K; Icedo-Garcia, Ramona; Gomez-Flores, Ricardo; Tamez-Guerra, Patricia\n2017-09-01\nAnnual mortality rates due to infectious diarrhea are about 2.2 million; children are the most vulnerable age group to severe gastroenteritis, representing group A rotaviruses as the main cause of disease. One of the main factors of rotavirus pathogenesis is the NSP4 protein, which has been characterized as a viral toxin involved in triggering several cellular responses leading to diarrhea. Furthermore, the rotavirus protein NSP1 has been associated with interferon production inhibition by inducing the degradation of interferon regulatory factors IRF3, IRF5, and IRF7. On the other hand, probiotics such as Bifidobacterium and Lactobacillus species in combination with prebiotics such as inulin, HMO, scGOS, lcFOS have been associated with improved generalized antiviral response and anti-rotavirus effect by the reduction of rotavirus infectivity and viral shedding, decreased expression of NSP4 and increased levels of specific anti-rotavirus IgAs. Moreover, these probiotics and prebiotics have been related to shorter duration and severity of rotavirus diarrhea, to the prevention of infection and reduced incidence of reinfections. In this review we will discuss in detail about the rotavirus pathogenesis and immunity, and how probiotics such as Lactobacillus and Bifidobacterium species in combination with prebiotics have been associated with the prevention or modulation of rotavirus severe gastroenteritis.\n[VARIABILIDAD EN LA NOTIFICACI\u00d3N DE REACCIONES ADVERSAS A LAS VACUNAS DE LA GRIPE PAND\u00c9MICA Y ESTACIONAL. TEMPORADAS 2009-2010 Y 2010-2011, COMUNITAT VALENCIANA](http://www.redalyc.org/articulo.oa?id=17023106004) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAna Mar\u00eda Alguacil Ramos\n2012-01-01\nFull Text Available Fundamentos: La p\u00e9rdida de confianza en la seguridad de las vacunas derivada de situaciones de alarma, como en el caso de la gripe pand\u00e9mica, puede afectar tanto a las coberturas vacunales como a la sensibilidad frente a la notificaci\u00f3n de las sospechas de reacciones adversas asociadas a vacunas (SRAAV. El objetivo del trabajo es describir los efectos adversos a la vacuna frente a la gripe pand\u00e9mica notificados en la temporada 2009-2010 y comparar si existen diferencias con los descritos con la vacuna de la gripe estacional en las temporadas 2009-2010 y 2010-2011 en la Comunitat Valenciana (CV. M\u00e9todos: Se realiz\u00f3 un estudio descriptivo de los individuos vacunados frente a la gripe que presentaron alguna SRAAV a la vacuna antigripal y que fue notificada a trav\u00e9s del Sistema de Informaci\u00f3n Vacunal, durante las temporadas 2009-2010 (incluyendo la vacunaci\u00f3n pand\u00e9mica y 2010-2011 en CV. se calcularon las tasas de notificaci\u00f3n de sospechas de reacciones adversas asociadas a vacunas por cada mil dosis de vacunas administradas y sus intervalos de confianza al 95%. Resultados: Durante el periodo 2009-2010 la tasa de notificaci\u00f3n de SRAAV para la vacuna de la gripe estacional fue de 0,02 por mil dosis administradas, para la vacuna pand\u00e9mica de 0,95. En el periodo 2010-2011 la tasa para la vacuna de la gripe estacional fue de 0,04 por mil. Conclusiones: Durante las temporadas analizadas se increment\u00f3 el n\u00famero de notificaciones de SRAAV para las vacunas pand\u00e9micas en comparaci\u00f3n con el resto de vacunas antigripales. La mayor tasa de notificaci\u00f3n de SRAAV correspondi\u00f3 al grupo de profesionales sociosanitarios, tanto para las vacunas frente a la gripe estacional como pand\u00e9- mica.\n[Registro de ensayos con vacunas del Programa Mundial de Vacunas e Inmunizaci\u00f3n de la OMS](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998001000006) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nRobertson S. E.\n1998-01-01\nFull Text Available En 1995, el Programa Mundial de Vacunas e Inmunizaci\u00f3n de la OMS estableci\u00f3 un registro para ensayos con vacunas. En septiembre de 1996, este registro conten\u00eda 50 ensayos de vacunaci\u00f3n patrocinados por la OMS, de los cuales 25 (50% eran estudios ya terminados. Las vacunas que se hab\u00edan estudiado con mayor frecuencia fueron las de sarampi\u00f3n (9 ensayos, poliovirus (8 ensayos, c\u00f3lera (8 ensayos, Escherichia coli enterotox\u00edgena (4 ensayos y neumococo (4 ensayos. Casi 80% de estos ensayos se llevaron a cabo en pa\u00edses en desarrollo, principalmente en el \u00c1frica. En los 25 ensayos ya terminados, los resultados investigados fueron la respuesta inmunitaria (24 ensayos, las reacciones adversas (13 ensayos, la morbilidad (4 ensayos y la mortalidad (1 ensayo. La OMS contribuy\u00f3 a estos ensayos con el aporte indirecto de fondos, ayuda con el dise\u00f1o metodol\u00f3gico, visitas a las localidades, el an\u00e1lisis de los datos, la adquisici\u00f3n de vacunas y la investigaci\u00f3n de su potencia.\n[Vacuna contra el VPH (HPV Vaccine)](https://www2c.cdc.gov/podcasts/player.asp?f=8630175) [Centers for Disease Control (CDC) Podcasts](http://www2c.cdc.gov/podcasts/search.asp)\n2013-07-25\nDesde el 2006, hay una vacuna que protege contra los tipos de VPH que causan c\u00c3\u00a1ncer con mayor frecuencia. Este podcast habla sobre la importancia de que los padres hablen con los proveedores de atenci\u00c3\u00b3n m\u00c3\u00a9dica de sus hijos sobre ponerles la vacuna contra el VPH. Created: 7/25/2013 by MMWR. Date Released: 11/4/2013.\n[Evaluaci\u00f3n de la toxicidad por dosis \u00fanica y tolerancia local de la vacuna vax-SPIRAL\u00ae en ratas Sprague Dawley](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2004000200002&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJuan F. Infante\n2004-04-01\nFull Text Available Las pruebas precl\u00ednicas de toxicidad en dosis \u00fanica y en dosis repetidas brindan una valiosa informaci\u00f3n sobre la seguridad del producto, al incluir el estudio macrosc\u00f3pico e histopatol\u00f3gico de \u00f3rganos importantes, as\u00ed como evaluaciones de las v\u00edas de administraci\u00f3n y el r\u00e9gimen de dosificaci\u00f3n. Cuba desarroll\u00f3 una vacuna polivalente de c\u00e9lulas inactivadas qu\u00edmicamente adyuvadas con hidr\u00f3xido de aluminio, vax-SPIRAL\u00ae. Esta vacuna presenta ventajas en relaci\u00f3n con otras vacunas como la procedente de la antigua URSS. El esquema de vacunaci\u00f3n para humanos consiste en dos dosis de 0,5 mL, separadas por un intervalo \u00f3ptimo de seis semanas. El objetivo de este estudio de toxicidad en ratas Sprague Dawley fue determinar la toxicidad potencial, letalidad, \u00f3rganos y sistemas susceptibles y otros eventos adversos, as\u00ed como la toxicidad en el sitio de inoculaci\u00f3n despu\u00e9s de la administraci\u00f3n de una dosis de la vacuna en estudio. Los resultados indicaron que, bajo las condiciones en estudio y seg\u00fan los criterios establecidos para evaluar los datos obtenidos, la vacuna antileptospir\u00f3sica trivalente no produce efectos t\u00f3xicos en el modelo animal usado. Las \u00fanicas alteraciones encontradas fueron formaciones granulomatosas a nivel del sitio de inoculaci\u00f3n. Estas formaciones han sido reportadas como pertenecientes al adyuvante de dep\u00f3sito (hidr\u00f3xido de aluminio, tambi\u00e9n usado en otras vacunas de aplicaci\u00f3n parenteral.\n[La vacuna contra el virus del papiloma humano](https://www.openaire.eu/search/publication?articleId=od______3040::cc271e44d67bb301b8673ae704eb1321)\nTobar Ruiz, Mar\u00eda\n2015-01-01\nLa carciog\u00e9nesis est\u00e1 condicionada por factores dependientes del virus como de los h\u00e1bitos del hu\u00e9sped. En cuanto a la vacunaci\u00f3n se han descubierto vacunas seguras y eficaces, siendo las dos vacunas destacadas la tetravalente o Gardasil y la bivalente o Cervarix. E nfermer\u00eda es la profesional que administra la vacuna y conoce los efectos adversos posibl es a causa de su administraci\u00f3n, y es por esa raz\u00f3n por la que mi inter\u00e9s se centr\u00f3 en la vacunaci\u00f3n.\n[Vacuna contra la fiebre hemorr\u00e1gica argentina Candid#1 producida en la Argentina: Inmunogenicidad y seguridad](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802010000300002&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nDelia A. Enria\n2010-06-01\nFull Text Available Se realiz\u00f3 un estudio cl\u00ednico en 946 voluntarios humanos sanos, donde se compar\u00f3 la vacuna Candid#1 producida en Argentina con la elaborada en EE.UU., que hab\u00eda sido utilizada en estudios previos. Como objetivo primario se evalu\u00f3 la equivalencia en la eficacia utilizando como marcador subrogante a la inmunogenicidad medida por detecci\u00f3n de anticuerpos neutralizantes. Como objetivo secundario se evalu\u00f3 la equivalencia en inocuidad comparando las tasas de reacciones adversas. Ambas vacunas mostraron una tasa equivalente de inmunogenicidad ligeramente superior al 95.5%, que es la eficacia estimada para Candid #1 en estudios previos. No se observaron eventos adversos graves relacionados con la vacuna. Los eventos adversos generales considerados relacionados fueron de escasa significaci\u00f3n cl\u00ednica y de resoluci\u00f3n espont\u00e1nea o con tratamiento sintom\u00e1tico; se presentaron en los receptores de ambas vacunas en tasas equivalentes (29.9% para la vacuna fabricada en la Argentina y 35.0% para la fabricada en EE.UU., e incluyeron: cefalea, decaimiento, mialgias, plaquetopenia leve (< 150 000 plaquetas/mm\u00b3, n\u00e1useas y/o v\u00f3mitos, leucopenia leve (< 4 000 blancos/mm\u00b3, fiebre, dolor retroocular, mareos, microhematuria, lumbalgia y exantema. Estos resultados indican que la vacuna Candid #1 elaborada en la Argentina es equivalente a la elaborada en los EE.UU. Este estudio permiti\u00f3 el registro del biol\u00f3gico producido en la Argentina ante la autoridad regulatoria del pa\u00eds (ANMAT.\n[Vacunas de bacterias recombinantes vivas](https://www.openaire.eu/search/publication?articleId=od______3272::e04c2a8ca070b76a97f8c299cefc6434)\nBlanco Le\u00f3n, Marina\n2016-01-01\nLa vacunaci\u00f3n es uno de los logros m\u00e1s importantes en la historia de la medicina, que ha ido evolucionando a lo largo de los a\u00f1os permitiendo una reducci\u00f3n significativa de la mortalidad infantil, una disminuci\u00f3n de la incidencia de enfermedades e incluso la erradicaci\u00f3n de algunas de ellas en pa\u00edses enteros. Las vacunas de nueva generaci\u00f3n surgen para reducir o eliminar las carencias de las vacunas \u201ctradicionales\u201d. T\u00e9cnicas biotecnol\u00f3gicas basadas en el ADN recombinante han dado lugar, entre...\n[Un caso de osteocondritis costal t\u00edfica tratado con vacunas y antivirus](https://www.openaire.eu/search/publication?articleId=od______1326::8fd162326a4cf806bef07884700a3945)\nLleras Acosta, F.; Rueda H., Alfonso\n2011-01-01\nPor considerala de importancia pr\u00e1ctica, presentamos la historiacl\u00ednica de una enferma afectada de osteocondritis costal de origen Eberthiano, tratada con \u00e9xito completo por las autovacunas y antivirus, Debemos esta interesante observaci\u00f3n al Dr. Juan N. Carpas y al interno de su servicio de mujeres, Sr. Azuero, quienes galantemente nos suministraron los datos cl\u00ednicos y las observaciones relativas a los efectos producidos por las vacunas.\n[Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries Efectividad potencial en funci\u00f3n del costo de la vacunaci\u00f3n contra la gastroenteritis por rotavirus en ocho pa\u00edses de Am\u00e9rica Latina y el Caribe](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892007000300003) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nRichard D. Rheingans\n2007-04-01\n, Chile, Honduras, M\u00e9xico, Panam\u00e1, Rep\u00fablica Dominicana y Venezuela. M\u00c9TODOS: Se elabor\u00f3 un modelo econ\u00f3mico para estimar la efectividad en funci\u00f3n del costo de la vacunaci\u00f3n, desde la perspectiva del sistema de salud, a partir de las constancias epidemiol\u00f3gicas nacionales oficiales y publicadas, los estimados de costos espec\u00edficos de cada pa\u00eds y los datos de eficacia de la vacuna. El modelo se aplic\u00f3 a los primeros cinco a\u00f1os de vida de la cohorte de nacidos en 2003 en cada uno de esos pa\u00edses. La principal medida de salud fueron los a\u00f1os de vida ajustados por discapacidad (AVAD y la principal medida sint\u00e9tica fue el costo incremental por AVAD evitado. Se emple\u00f3 una tasa de descuento de 3% para el pron\u00f3stico de los costos y beneficios. El impacto de la incertidumbre relacionada con las variables clave sobre la efectividad en funci\u00f3n del costo se realiz\u00f3 mediante el an\u00e1lisis de sensibilidad. RESULTADOS: Seg\u00fan los estimados obtenidos mediante el modelo econ\u00f3mico, la vacunaci\u00f3n podr\u00eda evitar m\u00e1s de 65% de las consultas m\u00e9dicas, de las muertes y del costo de tratamiento asociados con la gastroenteritis por rotavirus en los ocho pa\u00edses analizados. Con un costo total de US$ 24,00 (por las dos dosis de la vacuna, la raz\u00f3n incremental de la efectividad en funci\u00f3n del costo vari\u00f3 entre US$ 269/AVAD en Honduras y US$ 10 656/AVAD en Chile. Las razones de la efectividad en funci\u00f3n del costo fueron sensibles a las diversas hip\u00f3tesis sobre el precio de la vacuna, la mortalidad y la eficacia de la vacuna. CONCLUSIONES: La vacunaci\u00f3n permitir\u00eda reducir eficazmente la carga de morbilidad y los costos de la atenci\u00f3n sanitaria de la gastroenteritis por rotavirus en los pa\u00edses analizados de Am\u00e9rica Latina y el Caribe. Desde la perspectiva de los sistemas de salud, se prev\u00e9 que la vacunaci\u00f3n universal de todos los ni\u00f1os ser\u00e1 efectiva en funci\u00f3n del costo, seg\u00fan los est\u00e1ndares vigentes en la actualidad.\nWhy get vaccinated?Rotavirus is a virus that causes diarrhea, mostly in babies and young children. The diarrhea can be severe, and lead ... and fever are also common in babies with rotavirus.Before rotavirus vaccine, rotavirus disease was a common ...\n[Un caso de Osteocondritis costal t\u00edfica tratado con vacunas y antivirus](https://revistas.unal.edu.co/index.php/revfacmed/article/view/22140) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nF. Lleras Acosta\n1932-05-01\nFull Text Available Por considerala de importancia pr\u00e1ctica, presentamos la historia cl\u00ednica de una enferma afectada de osteocondritis costal de origen Eberthiano, tratada con \u00e9xito completo por las autovacunas y antivirus, Debemos esta interesante observaci\u00f3n al Dr. Juan N. Carpas y al interno de su servicio de mujeres, Sr. Azuero, quienes galantemente nos suministraron los datos cl\u00ednicos y las observaciones relativas a los efectos producidos por las vacunas.\n[Inmunoterapia en melanoma: vacunas de c\u00e9lulas dendr\u00edticas](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1726-46342015000300021&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nIvan Lozada-Requena\nFull Text Available La presente es una revisi\u00f3n narrativa que muestra la informaci\u00f3n accesible a la comunidad cient\u00edfica sobre melanoma e inmunoterapia. Las c\u00e9lulas dendr\u00edticas tienen la capacidad de participar en la inmunidad innata y adaptativa, pero no son ajenas a la evasi\u00f3n inmune de los tumores. Conocer su biolog\u00eda y rol ha llevado a generar in vitro varios prospectos de vacunas celulares aut\u00f3logas contra diversos tipos de c\u00e1ncer en humanos y modelos animales; sin embargo, en vista de la poca eficiencia que han mostrado, se deben implementar estrategias para potenciar su capacidad natural ya sea a trav\u00e9s de la coexpresi\u00f3n de mol\u00e9culas clave para activar o reactivar al sistema inmune, en combinaci\u00f3n con biosimilares o drogas quimioterape\u00faticas y no se debe descartar la acci\u00f3n de productos naturales como alternativa inmunoestimulante o adyuvante. Todos los tipos de inmunoterap\u00eda deber\u00edan medir el impacto de las c\u00e9lulas supresoras de origen mieloide, las que pueden atacar al sistema inmune y ayudar a la progresi\u00f3n tumoral, respectivamente. Esto puede reducir la actividad de las vacunas celulares y/o sus combinaciones pudiendo ser la diferencia entre el \u00e9xito o no de la inmunoterapia. Aunque en melanoma existen biosimilares aprobados por la Food and Drug Administration (FDA no todos tienen el \u00e9xito esperado por lo que es necesario evaluar otras estrategias que incluyan vacunas celulares cargadas con p\u00e9ptidos antig\u00e9nicos tumorales expresados exclusivamente o ant\u00edgenos provenientes de extractos tumorales y sus respectivos adyuvantes.\n[Perspectivas para nuevas vacunas antituberculosas en la era posgen\u00f3mica.](http://www.revistabiomedica.org/index.php/biomedica/article/view/1320) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nLuis F. Garc\u00eda\n2004-06-01\nFull Text Available A pesar de que la vacunaci\u00f3n con Mycobacterium bovis BCG es el procedimiento m\u00e1s utilizado a nivel mundial para prevenir la tuberculosis, su eficicacia es muy cuestionable, lo cual ha motivado la b\u00fasqueda de nuevas opciones inmunoprofil\u00e1cticas. El conocimiento generado con el secuenciamiento completo de una cepa de Mycobacterium tuberculosis H37Rv y la aplicaci\u00f3n de nuevas tecnolog\u00edas inmunol\u00f3gicas, bioqu\u00edmicas y gen\u00e9ticas han permitido realizar una disecci\u00f3n fina del transcriptoma y el proteoma de M. tuberculosis, lo cual ha generado una gran cantidad de conocimiento sobre la biolog\u00eda de este microorganismo. Dado que alrededor de una tercera parte de la poblaci\u00f3n mundial puede estar infectada con M. tuberculosis y que \u00e9ste s\u00f3lo se detecta cuando se inicia la enfermedad, la mayor parte de los esfuerzos se han dedicado al dise\u00f1o de vacunas posinfecci\u00f3n que induzcan un aumento selectivo de la inmunidad celular espec\u00edfica del hospedero a largo plazo, no generen reacciones adversas y sean de bajo costo. Dentro de las nuevas estrategias que est\u00e1n siendo utilizadas para el desarrollo de vacunas, se destaca la utilizaci\u00f3n de mezclas de prote\u00ednas con una alta inmunogenicidad, cepas de M. bovis BCG recombinantes y de M. tuberculosis gen\u00e9ticamente atenuadas o modificadas para inducir una mayor respuesta inmune, y las vacunas de ADN desnudo. Los candidatos con m\u00e1s potencial incluyen las vacunas de subunidades micobacterianas, las cuales expresan mol\u00e9culas ampliamente reconocidas por el sistema inmune y cuyo reconocimiento resulta en el incremento de la respuesta Th1 y aqu\u00e9llas que utilizan vectores virales dise\u00f1ados para expresar mol\u00e9culas micobacterianas antig\u00e9nicas. Aunque los modelos animales son de valor limitado, puesto que la patolog\u00eda observada en ellos s\u00f3lo reproduce parcialmente la observada en humanos, los resultados obtenidos con estas vacunas son muy prometedores y algunas est\u00e1n siendo actualmente evaluadas en\n... Staying Safe Videos for Educators Search English Espa\u00f1ol Rotavirus KidsHealth / For Parents / Rotavirus What's in this article? ... the Doctor Print en espa\u00f1ol El rotavirus About Rotavirus Almost all kids have had a rotavirus infection ...\n[Rotavirus vaccine effectiveness in preventing hospitalizations due to gastroenteritis: a descriptive epidemiological study from Germany.](https://www.ncbi.nlm.nih.gov/pubmed/29649603)\nPietsch, C; Liebert, U G\n2018-04-10\nRotavirus infections are common causes of infant hospitalization. The present study examined the effectiveness of anti-rotavirus vaccination in preventing rotavirus-related hospitalizations in Germany, following its state and nationwide introductions in 2008 and 2013, respectively. During 15 consecutive seasons 9557 stool samples of hospitalized children of 5 years and younger with acute gastroenteritis were screened for rotavirus A. Rotavirus G and P genotypes were assessed after vaccine introduction. Vaccine effectiveness was determined by comparison of rotavirus incidence in pre-vaccine and post-vaccine cohorts. The herd effect was calculated as the difference between the observed reduction of rotavirus-related hospitalizations and the expected direct vaccine effect. The number of rotavirus-related hospitalizations declined after vaccine introduction. Approximately 26% (503/1955) of prevented cases could be attributed to the herd effect. Human rotaviruses of genotypes G3P[8], G1P[8], G9P[8], G4P[8], G2P[4] and G12P[8] were most frequent. Uncommon genotypes remained rare. The direct, indirect, total and overall vaccine effectiveness was 86% (95% confidence interval (CI) 83.2-89.1%), 48% (95% CI 42.8-52.6%), 93% (95% CI 91.3-94.3%) and 69% (95% CI 66.5-72.0%), respectively. There was no significant difference in vaccine-type or in genotype-specific vaccine effectiveness. Anti-rotavirus vaccination efficiently reduced rotavirus-related hospitalizations in Germany in the past decade. The vaccines analysed in this article provide a broadly heterologous and long-lasting protection. The herd effect substantially contributed to the observed drop in the number of incidences of severe rotavirus infections. Presumably, constant high vaccine coverage will lead to a continued upward trend in the overall vaccine efficiency. Copyright \u00a9 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.\nYen, Catherine; Tate, Jacqueline E; Hyde, Terri B; Cortese, Margaret M; Lopman, Benjamin A; Jiang, Baoming; Glass, Roger I; Parashar, Umesh D\n2014-01-01\nRotavirus is the leading cause of severe diarrhea among children rotavirus vaccines have been efficacious and effective, with many countries reporting substantial declines in diarrheal and rotavirus-specific morbidity and mortality. However, the full public health impact of these vaccines has not been realized. Most countries, including those with the highest disease burden, have not yet introduced rotavirus vaccines into their national immunization programs. Research activities that may help inform vaccine introduction decisions include (1) establishing effectiveness, impact, and safety for rotavirus vaccines in low-income settings; (2) identifying potential strategies to improve performance of oral rotavirus vaccines in developing countries, such as zinc supplementation; and (3) pursuing alternate approaches to oral vaccines, such as parenteral immunization. Policy- and program-level barriers, such as financial implications of new vaccine introductions, should be addressed to ensure that countries are able to make informed decisions regarding rotavirus vaccine introduction. PMID:24755452\n[Desarrollo de vacunas contra el virus de la inmunodeficiencia humana tipo 1: Relevancia de la inmunidad celular contra subtipos](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802010000600014&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAna Mar\u00eda Rodr\u00edguez\n2010-12-01\nFull Text Available Han pasado casi 30 a\u00f1os de la detecci\u00f3n de los primeros casos de infecci\u00f3n con HIV-1 y a\u00fan no se ha conseguido desarrollar una vacuna efectiva y segura. A pesar del impacto positivo sobre la pandemia que se ha conseguido gracias a los avances en la terapia antirretroviral (TARV, el HIV/sida sigue constituyendo un grave problema para la salud p\u00fablica, especialmente en los pa\u00edses en desarrollo, donde es dif\u00edcil el acceso al tratamiento. En el mundo, 33 millones de personas viven con el virus del sida, mientras que en la Argentina se calcula que habr\u00eda unos 120 000 infectados. Uno de los desaf\u00edos para lograr una vacuna contra el HIV es la variabilidad viral. El grupo M, responsable de la pandemia, se encuentra dividido en 10 subtipos y varios sub-subtipos, adem\u00e1s de las 48 formas recombinantes circulantes y m\u00e1s de cien formas recombinantes \u00fanicas. La epidemia de HIV en nuestro pa\u00eds es tan compleja como en el resto del mundo, con la co-circulaci\u00f3n principalmente de virus pertenecientes al subtipo B y recombinantes BF (CRF12_BF y derivadas. A pesar de la cantidad de trabajos dedicados a la caracterizaci\u00f3n de la respuesta inmune y al desarrollo de vacunas, no queda claro cu\u00e1l es el impacto de la variabilidad en la elecci\u00f3n del ant\u00edgeno. Trabajos realizados en nuestro laboratorio demuestran el papel que juega la inmunidad celular con respecto a las variantes recombinantes BF, tanto en humanos como en modelos animales. Estos resultados son de importancia en el desarrollo de futuras vacunas para nuestra regi\u00f3n.\n[Vacunas, biotecnolog\u00eda y su relaci\u00f3n con el aborto provocado](https://www.openaire.eu/search/publication?articleId=doajarticles::4639710bd8874709386dd27339826e1d)\nJos\u00e9 Luis Redondo Calder\u00f3n\n2008-01-01\nLas vacunas de c\u00e9lulas diploides humanas (WI-38, MRC-5) tienen un origen \u00e9ticamente objetable, dado que dichas c\u00e9lulas proceden de abortos provocados. Entre ellas destacan vacunas empleadas contra rub\u00e9ola, sarampi\u00f3n, parotiditis, rabia, poliomielitis, viruela, hepatitis A, varicela y herpes z\u00f3ster. Actualmente se encuentran en desarrollo otras vacunas cultivadas en c\u00e9lulas (293, PER.C6) transformadas mediante virus, procedentes de abortos. Entre ellas hay vacunas contra la gripe, virus respi...\n... Search Form Controls Cancel Submit Search The CDC Rotavirus Note: Javascript is disabled or is not supported ... message, please visit this page: About CDC.gov . Rotavirus Home About Rotavirus Symptoms Transmission Treatment Photos Vaccination ...\n... Search Form Controls Cancel Submit Search The CDC Rotavirus Note: Javascript is disabled or is not supported ... message, please visit this page: About CDC.gov . Rotavirus Home About Rotavirus Symptoms Transmission Treatment Photos Vaccination ...\n[Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine.](https://www.ncbi.nlm.nih.gov/pubmed/23597719)\nDanchin, M; Kirkwood, C D; Lee, K J; Bishop, R F; Watts, E; Justice, F A; Clifford, V; Cowley, D; Buttery, J P; Bines, J E\n2013-05-28\nRV3 is a human neonatal rotavirus strain (G3P[6]) that has been associated with asymptomatic neonatal infection and replicates well in the infant gut. RV3-BB rotavirus vaccine has been developed as a rotavirus vaccine candidate for administration at birth. A single-centre, double-blind, randomised placebo-controlled Phase I study evaluated the safety and tolerability of a single oral dose of the second generation RV3-BB rotavirus vaccine (8.3\u00d710(6)FFU/mL) in 20 adults, 20 children and 20 infants (10 vaccine and 10 placebo per age cohort). Vaccine take was defined as seroconversion (a 3-fold increase in serum anti-rotavirus IgA or serum neutralising antibody (SNA) from baseline at day 28 post-dose) or evidence of RV3-BB viral replication in the faeces by RT-PCR analysis 3-6 days post-vaccination. RV3-BB presence was confirmed by sequence analysis. The RV3-BB vaccine was well tolerated in all participants, with no pattern of adverse events shown to be associated with the study vaccine. In the infant cohort, vaccine take was demonstrated in 8/9 infants following a single dose of vaccine compared with 2/7 placebo recipients. In the infant vaccine group, 5/9 infants exhibited either IgA or SNA seroconversion and 7/9 infants had evidence of RV3-BB replication on days 3-6, compared with 2/7 infants who seroconverted and 0/10 infants with evidence of replication in the placebo group. Two infants in the placebo group had serological evidence of a rotavirus infection within the 28-day study period: one demonstrated an IgA and the other an SNA response, with wild-type virus replication detected in another infant. A single dose of RV3-BB rotavirus vaccine was well tolerated in adults, children and infants. Most infants (8/9) who received RV3-BB demonstrated vaccine take following a single dose. These data support progression of RV3-BB to Phase II immunogenicity and efficacy trials. Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.\n[How can a multilevel promotion of breastfeeding reduce the required budget for rotavirus vaccination in Indonesia?](https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2Ffc35074c-bf0d-40e5-b7ec-0c349ee5cfb9/uquery/Rotavirus/id/19/Language/EN)\nZakiyah, N.; Suwantika, A.A.; Postma, M.J.\n2014-01-01\nObjectives: Breast milk is considered to give protection against rotavirus infection since it contains anti-rotavirus maternal antibodies and other nonspecific inhibitors. Multilevel promotion of breastfeeding is a complex intervention that modifies behavioral determinants through multiple levels of\n[Desarrollo de una vacuna profil\u00e1ctica de segunda generaci\u00f3n contra el papilomavirus humano](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802011000500015&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAlonso Leonardo\n2011-06-01\nFull Text Available Los papilomavirus humanos (HPV son el agente etiol\u00f3gico del c\u00e1ncer cervical (CC, la segunda causa de muerte por c\u00e1ncer en mujeres. Se estima que medio mill\u00f3n de nuevos c\u00e1nceres se diagnostica cada a\u00f1o, ocurriendo la mayor\u00eda de ellos en pa\u00edses en v\u00edas de desarrollo debido a la ausencia o ineficiencia de los programas masivos de detecci\u00f3n temprana. Recientemente se han introducido en el mercado dos vacunas profil\u00e1cticas contra las principales cepas oncog\u00e9nicas de HPV, la cepa 16 y 18, responsables por el 80% de todos los CC. Estas vacunas se obtienen en forma recombinante y han demostrado ser extremadamente seguras y eficaces. Sin embargo, su impacto inmediato en la incidencia de la infecci\u00f3n por HPV en pa\u00edses en v\u00edas de desarrollo ser\u00e1 m\u00ednimo, debido principalmente al alto costo de las mismas. Existe la necesidad de contar con vacunas de segunda generaci\u00f3n, de bajo costo y de aplicaci\u00f3n masiva que permitan disminuir sensiblemente el n\u00famero de CC en la poblaci\u00f3n. Con este objetivo hemos desarrollado una plataforma de expresi\u00f3n recombinante que permite obtener part\u00edculas tipo virus (VLPs con las cuales es posible formular vacunas efectivas y accesibles contra la infecci\u00f3n por HPV.\n[Chicken Egg Yolk Antibodies (IgY) for Prophylaxis and Treatment of Rotavirus Diarrhea in Human and Animal Neonates: A Concise Review](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5355572)\nThu, Hlaing Myat; Myat, Theingi Win; Win, Mo Mo; Thant, Kyaw Zin; Rahman, Shofiqur; Umeda, Kouji; Nguyen, Sa Van; Icatlo, Faustino C.; Higo-Moriguchi, Kyoko; Taniguchi, Koki; Tsuji, Takao; Oguma, Keiji; Kim, Sang Jong; Bae, Hyun Suk\n2017-01-01\nThe rotavirus-induced diarrhea of human and animal neonates is a major public health concern worldwide. Until recently, no effective therapy is available to specifically inactivate the rotavirion particles within the gut. Passive immunotherapy by oral administration of chicken egg yolk antibody (IgY) has emerged of late as a fresh alternative strategy to control infectious diseases of the alimentary tract and has been applied in the treatment of diarrhea due to rotavirus infection. The purpose of this concise review is to evaluate evidence on the properties and performance of anti-rotavirus immunoglobulin Y (IgY) for prevention and treatment of rotavirus diarrhea in human and animal neonates. A survey of relevant anti-rotavirus IgY basic studies and clinical trials among neonatal animals (since 1994-2015) and humans (since 1982-2015) have been reviewed and briefly summarized. Our analysis of a number of rotavirus investigations involving animal and human clinical trials revealed that anti-rotavirus IgY significantly reduced the severity of clinical manifestation of diarrhea among IgY-treated subjects relative to a corresponding control or placebo group. The accumulated information as a whole depicts oral IgY to be a safe and efficacious option for treatment of rotavirus diarrhea in neonates. There is however a clear need for more randomized, placebo controlled and double-blind trials with bigger sample size to further solidify and confirm claims of efficacy and safety in controlling diarrhea caused by rotavirus infection especially among human infants with health issues such as low birth weights or compromised immunity in whom it is most needed. PMID:28316465\n[Engineering and expression of a human rotavirus candidate vaccine in Nicotiana benthamiana.](https://www.ncbi.nlm.nih.gov/pubmed/26626122)\nP\u00eara, Francisco F P G; Mutepfa, David L R; Khan, Ayesha M; Els, Johann H; Mbewana, Sandiswa; van Dijk, Alberdina A A; Rybicki, Edward P; Hitzeroth, Inga I\n2015-12-02\nHuman rotaviruses are the main cause of severe gastroenteritis in children and are responsible for over 500 000 deaths annually. There are two live rotavirus vaccines currently available, one based on human rotavirus serotype G1P[8], and the other a G1-G4 P[8] pentavalent vaccine. However, the recent emergence of the G9 and other novel rotavirus serotypes in Africa and Asia has prompted fears that current vaccines might not be fully effective against these new varieties. We report an effort to develop an affordable candidate rotavirus vaccine against the new emerging G9P[6] (RVA/Human-wt/ZAF/GR10924/1999/G9P[6]) strain. The vaccine is based on virus-like particles which are both highly immunogenic and safe. The vaccine candidate was produced in Nicotiana benthamiana by transient expression, as plants allow rapid production of antigens at lower costs, without the risk of contamination by animal pathogens. Western blot analysis of plant extracts confirmed the successful expression of two rotavirus capsid proteins, VP2 and VP6. These proteins assembled into VLPs resembling native rotavirus particles when analysed by transmission electron microscopy (TEM). Expression of the rotavirus glycoprotein VP7 and the spike protein VP4 was also tried. However, VP7 expression caused plant wilting during the course of the time trial and expression could never be detected for either protein. We therefore created three fusion proteins adding the antigenic part of VP4 (VP8*) to VP6 in an attempt to produce more appropriately immunogenic particles. Fusion protein expression in tobacco plants was detected by western blot using anti-VP6 and anti-VP4 antibodies, but no regular particles were observed by TEM, even when co-expressed with VP2. Our results suggest that the rotavirus proteins produced in N. benthamiana are candidates for a subunit vaccine specifically for the G9P[6] rotavirus strain. This could be more effective in developing countries, thereby possibly providing a higher\n[Identification of Rotavirus VP6-Specific CD4+ T Cell Epitopes in a G1P[8] Human Rotavirus-Infected Rhesus Macaque](https://doi.org/10.4137/VRT.S563) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nWei Zhao\n2008-01-01\nFull Text Available A non-human primate model was used to evaluate its potential for identification of rotavirus viral protein 6 (VP6 CD4+ T cell epitopes. Four juvenile rhesus macaques were inoculated with a mixed inoculum (G1P[8] and G9P[8] of human rotaviruses. Infection accompanied by G1P[8] shedding was achieved in the two macaques that had no rotavirus immunoglobulin A (IgA in plasma. To measure the interferon gamma (IFN-\u03b3 and tumor necrosis factor (TNF anti-viral cytokines produced by peripheral CD4+ cells that recognize VP6 epitopes, whole blood cells from one infected macaque were stimulated in vitro with VP6 peptides. Stimulation with peptide pools derived from the simian rotavirus VP6 161\u2013395 region revealed reactivity of CD4+ T cells with the VP6 281\u2013331 domain. A VP6 301\u2013315 region was identified as the epitope responsible for IFN-\u03b3 production while a broader VP6 293\u2013327 domain was linked to TNF production. These results suggest that human rotavirus-infected macaques can be used for identification of additional epitopes and domains to address specific questions related to the development of pediatric vaccines.\n[Cytokines in the management of rotavirus infection: A systematic review of in vivo studies.](https://www.ncbi.nlm.nih.gov/pubmed/28414969)\nGandhi, Gopalsamy Rajiv; Santos, Victor Santana; Denadai, Marina; da Silva Calisto, Valdete Kaliane; de Souza Siqueira Quintans, Jullyana; de Oliveira E Silva, Ana Mara; de Souza Ara\u00fajo, Adriano Antunes; Narain, Narendra; Cuevas, Luis Eduardo; J\u00fanior, Lucindo Jos\u00e9 Quintans; Gurgel, Ricardo Queiroz\n2017-08-01\nRotavirus is a leading cause of childhood diarrhoea. Rotavirus vaccines are effective against severe rotavirus gastroenteritis, but have lower efficacy in low income countries in Africa. Anti-rotavirus treatment is not available. This study reviews the literature of animal studies evaluating whether cytokine mediated pathways of immune activation could improve rotavirus therapy. We performed a systematic review of articles in English published from 2010 to 2016 reporting agents with in vivo antirotavirus activity for the management of rotavirus infection. The search was carried in PubMed, EMBASE, Scopus and Web of Science. Animal experiments where cytokines were investigated to assess the outcome of rotavirus therapy were included. A total of 869 publications were identified. Of these, 19 pertained the objectives of the review, and 11 articles described the effect of probiotics/commensals on rotavirus infection and immune responses in animals. Eight further in vivo studies evaluated the immunomodulating effects of herbs, secondary metabolites and food-derived products on cytokine responses of rotavirus-infected animals. Studies extensively reported the regulatory roles for T-helper (Th)1 (interferon gamma (IFN-\u03b3), interleukin (IL)-2, IL-12) and Th2 (IL-4, IL-6, IL-10) cytokines responses to rotavirus pathogenesis and immunity, inhibiting rotavirus infection through suppression of inflammation by viral inhibition. Th1 and Th2 cytokines stimulate the immune system, inhibiting rotavirus binding and/or replication in animal models. Th1/Th2 cytokine responses have optimal immunomodulating effects to reduce rotavirus diarrhoea and enhance immune responses in experimental rotavirus infection. Copyright \u00a9 2017 Elsevier Ltd. All rights reserved.\n[A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America Nueva vacuna combinada DTPw-HB/Hib para la vacunaci\u00f3n primaria y de refuerzo de menores de un a\u00f1o en Am\u00e9rica Latina](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892006000300006) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMiguel Tregnaghi\n2006-03-01\n, la Organizaci\u00f3n Mundial de la Salud (OMS recomend\u00f3 que se incluyeran vacunas conjugadas contra Haemophilus influenzae tipo B (Hib en los programas de vacunaci\u00f3n de ni\u00f1os menores de un a\u00f1o, siempre que ello estuviera en consonancia con las prioridades nacionales. La compa\u00f1\u00eda GlaxoSmithKline Biologicals ha creado una nueva vacuna pentavalente que es una combinaci\u00f3n de la vacuna contra la difteria (D, el t\u00e9tanos (T y la tos ferina (P (con ant\u00edgeno tosfer\u00ednico a base de c\u00e9lulas completas y las vacunas contra la hepatitis B (HB y contra Haemophilus influenzae tipo B (Hib (DTPw-HB/Hib, con un total de 5 \u00b5g de fosfato de polirribosilrribitol (FPR. Hemos evaluado la inmunogenia y reactogenia observadas al aplicarse las dosis primaria y de refuerzo de esta nueva vacuna a ni\u00f1os sanos y las hemos comparado con las observadas al aplicar un r\u00e9gimen de referencia a base de las vacunas autorizadas DTPw-HB (Tritanrix y antiHib (Hiberix en forma de inyecciones simult\u00e1neas. M\u00c9TODOS: Llevamos a cabo un estudio aleatorizado y con doble enmascaramiento de septiembre de 1998 a agosto de 1999 para establecer la inmunogenia y reactogenia observadas al administrarles a ni\u00f1os sanos la nueva vacuna combinada pentavalente (DTPw-HB/Hib en una sola inyecci\u00f3n, y compararlas con las observadas con el r\u00e9gimen de referencia. RESULTADOS: Se obtuvieron excelentes respuestas inmunitarias con ambos reg\u00edmenes. Todos los ni\u00f1os vacunados en ambos grupos alcanzaron concentraciones s\u00e9ricas protectoras de anticuerpos antiFPR > 0,15 \u00b5g un mes despu\u00e9s de recibir la dosis primaria. La vacuna combinada DTPw-HB/Hib no dio resultados inferiores a los obtenidos con las vacunas autorizadas en t\u00e9rminos de los porcentajes de seroprotecci\u00f3n, seropositividad y respuesta frente a todos los componentes antig\u00e9nicos de la vacuna. La persistencia de anticuerpos contra todos los ant\u00edgenos contenidos en ella hasta el momento en que se administr\u00f3 la dosis de refuerzo fue parecida en ambos grupos, y\n[Una vacuna contra la tuberculosi, provada en cabres](https://www.openaire.eu/search/publication?articleId=od______1404::6574285bd1662fef225103ab5f2fa6f1)\nP\u00e9rez del Val, Bernat\n2012-01-01\nInvestigadors del CReSA han dut a terme el primer estudi de vacunaci\u00f3 contra la tuberculosi utilitzant com a model experimental la cabra dom\u00e8stica, que reprodueix amb molta similitud la resposta a la tuberculosi en humans. La vacuna, anomenada AdAg85A, ha estat dissenyada per investigadors de McMaster University (Canad\u00e0) per prevenir la tuberculosi en humans, i actualment es troba en fase I d\u2019assajos cl\u00ednics. De moment, aquest estudi mostra que la inoculaci\u00f3 d\u2019aquesta nova vacuna, com a refor...\n[INTRODUCCI\u00d3N DE NUEVAS VACUNAS: PROCESOS POL\u00cdTICOS, ADMINISTRATIVOS Y FINANCIEROS EN LA TOMA DE DECISIONES DEL PAI-BRASIL](http://revistamedicina.net/ojsanm/index.php/Revistamedicina/article/view/92) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nCarla Magda A.S. Domingues\n2012-07-01\nFull Text Available Se presentan los antecedentes del PAI en el Brasil remont\u00e1ndose al a\u00f1o de 1804 en que se inicia el programa de vacunaci\u00f3n en Brasil aplicando la vacuna contra la viruela hasta llegar a 1973 cuando se crea el Programa Nacional de Inmunizaciones en Brasil, y a partir de ah\u00ed se mantiene un esquema b\u00e1sico de vacunaci\u00f3n hasta llegar al 2012 cuando se introducen las vacunas VIP y pentavalentes. Muestra las alteraciones sufridas en el Calendario de Vacunaci\u00f3n del 2012, para llegar a la reformulaci\u00f3n de un Nuevo Calendario de Vacunaci\u00f3n a partir del 2012. Se\u00f1ala las estrategias nacionales de vacunaci\u00f3n enmarcadas en acciones de rutina, campa\u00f1as y control de brotes. Hace referencia a los criterios de inclusi\u00f3n de nuevas vacunas referidos a aspectos: epidemiol\u00f3gicos, inmunol\u00f3gicos, tecnol\u00f3gicos, log\u00edstica, socio-econ\u00f3micos, aprobaci\u00f3n por los Comit\u00e9s y presupuesto. Registra las novedades ocurridas en el Sistema de Informaciones del Programa Nacional de Inmunizaciones, relacionadas con la situaci\u00f3n actual, propuesta y Resoluci\u00f3n Ministerial. Por \u00faltimo se\u00f1ala los desaf\u00edos que debe enfrentar el Sistema enmarcados principalmente en la capacidad para mantener altas coberturas de vacunaci\u00f3n.\n[Rotavirus infection and the current status of rotavirus vaccines](http://www.sciencedirect.com/science/article/pii/S0929664612000952) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nShou-Chien Chen\n2012-04-01\nFull Text Available Among children, rotaviruses are the most common cause of severe gastroenteritis worldwide and of diarrheal deaths in developing countries. Current vaccines (e.g., Rotarix, GlaxoSmithKline Biologicals; RotaTeq, Merck and Company effectively reduce rotaviral gastroenteritis, emergency department visits, and hospitalizations. The tremendous burden of rotavirus-related diarrhea in children across the world continues to drive the remarkable pace of vaccine development. This review assesses the global epidemiological and economic burden of rotavirus diseases, summarizes the relevant principles of the development of rotavirus vaccines, and presents data on the efficacy and effectiveness of currently licensed vaccines in both developed and developing countries.\n[VACUNAS E INFECCIONES RESPIRATORIAS](http://www.sciencedirect.com/science/article/pii/S0716864017300160) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nDr. Rodolfo Villena\n2017-01-01\nFull Text Available Las vacunas han demostrado ser una excelente estrategia para reducir la morbimortalidad en infecciones respiratorias, con un perfil de seguridad adecuado. Nuestro PNI incorpora varias de ellas con este objetivo, logrando resultados de alto impacto a nivel de salud p\u00fablica. Para que esto prosiga se requiere de nuestro compromiso y conocimiento para estimular, difundir y obtener altas tasas de cobertura, de manera de lograr efectos de protecci\u00f3n indirecta, conocidos como inmunidad comunitaria. Por otro lado, se debe mantener la vigilancia epidemiol\u00f3gica de los agentes inmunoprevenibles para conocer su oscilaci\u00f3n temporal, serogrupos, sero y/o genotipos, de manera de establecer directrices adecuadas de edad y esquemas de vacunaci\u00f3n para la poblaci\u00f3n. Debemos avanzar en estos temas y realizar estudios de efectividad de las vacunas que hemos introducido, para conocer su aporte en la prevenci\u00f3n de infecciones respiratorias, de manera de objetivar sus beneficios, conocer el impacto en poblaciones de riesgo y avanzar en la vacunaci\u00f3n de embarazadas, para otorgar mejores estrategias de prevenci\u00f3n a nuestra poblaci\u00f3n.\n[Impact of rotavirus vaccination on child mortality, morbidity, and rotavirus-related hospitalizations in Bolivia.](https://www.ncbi.nlm.nih.gov/pubmed/28627429)\nInchauste, Lucia; Patzi, Maritza; Halvorsen, Kjetil; Solano, Susana; Montesano, Raul; I\u00f1iguez, Volga\n2017-08-01\nThe public health impact of rotavirus vaccination in countries with high child mortality rates remains to be established. The RV1 rotavirus vaccine was introduced in Bolivia in August 2008. This study describes the trends in deaths, hospitalizations, and healthcare visits due to acute gastroenteritis (AGE) and in rotavirus-related hospitalizations, among children rotavirus-related AGE was assessed using data from the active surveillance hospitals. Compared with the 2001-2008 pre-vaccine baseline, the mean number of rotavirus-related hospitalizations was reduced by 40.8% (95% confidence interval (CI) 21.7-66.4%) among children rotavirus disease. Over the post-vaccine period, changes in rotavirus epidemiology were observed, manifested by variations in seasonality and by a shift in the mean age of those with rotavirus infection. The significant decrease in main AGE-related health indicators in children rotavirus vaccine provides evidence of a substantial public health impact of rotavirus vaccination in Bolivia, as a measure for protecting children against AGE. Copyright \u00a9 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.\n[Rotavirus vaccines: an overview.](https://www.openaire.eu/search/publication?articleId=od_______908::f1b3fdda30fee87b8342a3ebe47df54f)\nMidthun, K; Kapikian, A Z\n1996-01-01\nRotavirus vaccine development has focused on the delivery of live attenuated rotavirus strains by the oral route. The initial \"Jennerian\" approach involving bovine (RIT4237, WC3) or rhesus (RRV) rotavirus vaccine candidates showed that these vaccines were safe, well tolerated, and immunogenic but induced highly variable rates of protection against rotavirus diarrhea. The goal of a rotavirus vaccine is to prevent severe illness that can lead to dehydration in infants and young children in both...\n[La evidencia acerca de la controversia de las vacunas que contienen timerosal y su asociaci\u00f3n con el autismo](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1726-46342013000200018&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nLisset Garc\u00eda-Fern\u00e1ndez\n2013-06-01\nFull Text Available La vacunaci\u00f3n es una de las medidas de mayor impacto en la salud p\u00fablica para la reducci\u00f3n de la morbimortalidad infantil. El timerosal es un compuesto org\u00e1nico del mercurio utilizado como preservante de los frascos multidosis. Eventualmente, en el Per\u00fa, surgen olas de controversia acerca de la seguridad de estas vacunas, asoci\u00e1ndolas especialmente con el autismo. Como resultado de estas controversias, se han propuesto, incluso, leyes que proh\u00edben este tipo de vacunas, lo que tendr\u00eda un importante impacto en los costos y en los aspectos log\u00edsticos de la estrategia nacional de vacunaci\u00f3n. En este art\u00edculo se revisa la literatura sobre las principales controversias acerca de las vacunas que contienen timerosal y su supuesta asociaci\u00f3n con el autismo. Se realiza una aproximaci\u00f3n hist\u00f3rica sobre estas controversias, se hace una actualizaci\u00f3n de la evidencia cient\u00edfica disponible al momento, y se revisa la posici\u00f3n de los organismos internacionales m\u00e1s importantes con respecto a este tema. Se concluye que la evidencia cient\u00edfica no apoya la noci\u00f3n que exista una asociaci\u00f3n entre el uso del timerosal en las vacunas con los trastornos del espectro autista en ni\u00f1os.\n[Burden of Norovirus and Rotavirus in Children after Rotavirus Vaccine Introduction, Cochabamba, Bolivia](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4710432)\nMcAtee, Casey L.; Webman, Rachel; Gilman, Robert H.; Mejia, Carolina; Bern, Caryn; Apaza, Sonia; Espetia, Susan; Pajuelo, M\u00f3nica; Saito, Mayuko; Challappa, Roxanna; Soria, Richard; Ribera, Jose P.; Lozano, Daniel; Torrico, Faustino\n2016-01-01\nThe effectiveness of rotavirus vaccine in the field may set the stage for a changing landscape of diarrheal illness affecting children worldwide. Norovirus and rotavirus are the two major viral enteropathogens of childhood. This study describes the prevalence of norovirus and rotavirus 2 years after widespread rotavirus vaccination in Cochabamba, Bolivia. Stool samples from hospitalized children with acute gastroenteritis (AGE) and outpatients aged 5\u201324 months without AGE were recruited from an urban hospital serving Bolivia's third largest city. Both viruses were genotyped, and norovirus GII.4 was further sequenced. Norovirus was found much more frequently than rotavirus. Norovirus was detected in 69/201 (34.3%) of specimens from children with AGE and 13/71 (18.3%) of those without diarrhea. Rotavirus was detected in 38/201 (18.9%) of diarrheal specimens and 3/71 (4.2%) of non-diarrheal specimens. Norovirus GII was identified in 97.8% of norovirus-positive samples; GII.4 was the most common genotype (71.4% of typed specimens). Rotavirus G3P[8] was the most prevalent rotavirus genotype (44.0% of typed specimens) and G2P[4] was second most prevalent (16.0% of typed specimens). This community is likely part of a trend toward norovirus predominance over rotavirus in children after widespread vaccination against rotavirus. PMID:26598569\n[Burden of Norovirus and Rotavirus in Children After Rotavirus Vaccine Introduction, Cochabamba, Bolivia.](https://www.ncbi.nlm.nih.gov/pubmed/26598569)\nMcAtee, Casey L; Webman, Rachel; Gilman, Robert H; Mejia, Carolina; Bern, Caryn; Apaza, Sonia; Espetia, Susan; Pajuelo, M\u00f3nica; Saito, Mayuko; Challappa, Roxanna; Soria, Richard; Ribera, Jose P; Lozano, Daniel; Torrico, Faustino\n2016-01-01\nThe effectiveness of rotavirus vaccine in the field may set the stage for a changing landscape of diarrheal illness affecting children worldwide. Norovirus and rotavirus are the two major viral enteropathogens of childhood. This study describes the prevalence of norovirus and rotavirus 2 years after widespread rotavirus vaccination in Cochabamba, Bolivia. Stool samples from hospitalized children with acute gastroenteritis (AGE) and outpatients aged 5-24 months without AGE were recruited from an urban hospital serving Bolivia's third largest city. Both viruses were genotyped, and norovirus GII.4 was further sequenced. Norovirus was found much more frequently than rotavirus. Norovirus was detected in 69/201 (34.3%) of specimens from children with AGE and 13/71 (18.3%) of those without diarrhea. Rotavirus was detected in 38/201 (18.9%) of diarrheal specimens and 3/71 (4.2%) of non-diarrheal specimens. Norovirus GII was identified in 97.8% of norovirus-positive samples; GII.4 was the most common genotype (71.4% of typed specimens). Rotavirus G3P[8] was the most prevalent rotavirus genotype (44.0% of typed specimens) and G2P[4] was second most prevalent (16.0% of typed specimens). This community is likely part of a trend toward norovirus predominance over rotavirus in children after widespread vaccination against rotavirus. \u00a9 The American Society of Tropical Medicine and Hygiene.\n[Efectividad comunitaria de las vacunas frente a la Parotiditis Infecciosa. Estudio de casos](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1135-57271999000400003) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nLim\u00f3n Mora Juan\n1999-01-01\nFull Text Available FUNDAMENTO: En nuestro pa\u00eds existen dos tipos de vacunas disponibles frente a la parotiditis infecciosa. En los \u00faltimos tiempos se han planteado dudas sobre la eficacia global de estas vacunas y de la eficacia comparada entre ambas (cepa Rubini y cepa Jeryl Lynn. En el distrito sanitario de A.P. \"Sevilla Este\" se registraron 256 casos durante 1997 (90,1 casos por 100.000 habitantes. Con este estudio se pretende aprovechar la aparici\u00f3n de casos de parotiditis para evaluar poblaciones afectadas e incidencia comparada seg\u00fan tipo de vacuna recibida durante la infancia. M\u00c9TODOS: An\u00e1lisis descriptivo de los casos (edad, distribuci\u00f3n territorial, antecedentes vacunales,... y an\u00e1lisis evolutivo (tasas de incidencia anuales en el distrito sanitario y su entorno. Se eval\u00faa la efectividad global de las vacunas frente a la parotiditis. Igualmente se estiman las tasas de incidencia de casos entre los vacunados con cepa Rubini y Jeryl Lynn. RESULTADOS: Se observan las tasas de incidencias m\u00e1s elevadas en ni\u00f1os entre 1 y 4 a\u00f1os. Se han estimado niveles de efectividad global para estas vacunas. Adem\u00e1s se observa una incidencia de casos significativamente m\u00e1s elevada entre los ni\u00f1os vacunados con cepa Rubini que en los que lo hicieron con Jeryl Lynn (riesgo relativo de 6,5 con Intervalo de confianza 95% 3,6-11,8. CONCLUSIONES: La efectividad que se desprende de este estudio no parece ser tan buena como la eficacia te\u00f3rica preconizada para las vacunas frente a la parotiditis. Se plantea la conveniencia de realizar otros estudios de casos seg\u00fan tipos de vacunas utilizadas. Igualmente son de gran inter\u00e9s los datos a suministrar por estudios seroepidemiol\u00f3gicos.\n[Vacunas en situaciones especiales. Embarazo, inmunodepresi\u00f3n, transplante](https://www.openaire.eu/search/publication?articleId=od______1404::05502ca26081377cb9ac9b967d7e66d8)\nFarjas Abad\u00eda, M\u00aa Pilar\n2005-01-01\nEn las recomendaciones de vacunaci\u00f3n de grupos de poblaci\u00f3n que por su situaci\u00f3n de salud requieren medidas espec\u00edficas deben conjugarse: Las limitaciones en la aplicaci\u00f3n de determinadas vacunas por la mayor probabilidad de efectos secundarios en estos pacientes (por ejemplo la aplicaci\u00f3n de vacunas de virus vivos en pacientes inmunodeprimidos). El mayor riesgo de infecci\u00f3n frente a determinados agentes que genera la patolog\u00eda o situaci\u00f3n inmunitaria del paciente, y que determina un mayor in...\n[Current status of rotavirus vaccines.](https://www.ncbi.nlm.nih.gov/pubmed/26454434)\nWang, Ching-Min; Chen, Shou-Chien; Chen, Kow-Tong\n2015-11-01\nRotaviruses remain the major cause of childhood diarrheal disease worldwide and of diarrheal deaths of infants and children in developing countries. The huge burden of childhood rotavirus-related diarrhea in the world continues to drive the remarkable pace of vaccine development. Research articles were searched using terms \"rotavirus\" and \"rotavirus vaccine\" in MEDLINE and PubMed. Articles not published in the English language, articles without abstracts, and opinion articles were excluded from the review. After preliminary screening, all articles were reviewed and synthesized to provide an overview of current vaccines and vaccination programs. In this review of the global rotavirus vaccines and vaccination programs, the principles of rotavirus vaccine development and the efficacy of the currently licensed vaccines from both developed and developing countries were summarized. Rotavirus is a common cause of diarrhea in children in both developed and developing countries. Rotavirus vaccination is a cost-effective measure to prevent rotavirus diarrhea.\n[Rotavirus vaccine and health-care utilization for rotavirus gastroenteritis in Tsu City, Japan](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5330216)\nKamiya, Hajime; Suga, Shigeru; Nagao, Mizuho; Ichimi, Ryoji; Fujisawa, Takao; Umemoto, Masakazu; Tanaka, Takaaki; Ito, Hiroaki; Tanaka, Shigeki; Ido, Masaru; Taniguchi, Koki; Ihara, Toshiaki; Nakano, Takashi\n2016-01-01\nBackground Rotavirus vaccines were introduced in Japan in November 2011. We evaluated the subsequent reduction of the health-care burden of rotavirus gastroenteritis. Methods We conducted active surveillance for rotavirus gastroenteritis among children under 5 years old before and after the vaccine introduction. We surveyed hospitalization rates for rotavirus gastroenteritis in children in Tsu City, Mie Prefecture, Japan, from 2007 to 2015 and surveyed the number of outpatient visits at a Tsu City clinic from 2010 to 2015. Stool samples were obtained for rotavirus testing and genotype investigation. We assessed rotavirus vaccine coverage for infants living in Tsu City. Results In the pre-vaccine years (2007\u20132011), hospitalization rates for rotavirus gastroenteritis in children under 5 years old were 5.5, 4.3, 3.1 and 3.9 cases per 1000 person-years, respectively. In the post-vaccine years (2011\u20132015), the rates were 3.0, 3.5, 0.8 and 0.6 cases per 1000 person-years, respectively. The hospitalization rate decreased significantly in the 2013\u20132014 and 2014\u20132015 seasons compared to the average of the seasons before vaccine introduction (P rotavirus infection was 66. In the post-vaccine years (2011\u20132015), the numbers for each season was 23, 23, 7 and 5, respectively. The most dominant rotavirus genotype shifted from G3P[8] to G1P[8] and to G2P[4]. The coverage of one dose of rotavirus vaccine in Tsu City was 56.5% in 2014. Conclusion After the vaccine introduction, the hospitalization rates and outpatient visits for rotavirus gastroenteritis greatly decreased. PMID:28246579\nRotavirus is a virus that causes gastroenteritis. Symptoms include severe diarrhea, vomiting, fever, and dehydration. Almost all ... the U.S. are likely to be infected with rotavirus before their 5th birthday. Infections happen most often ...\n[LA VACUNACI\u00d3N ANTI-NEUMOC\u00d3CICA CON LA VACUNA CONJUGADA 13-VALENTE EN POBLACI\u00d3N INMUNOCOMPETENTE DE 65 A\u00d1OS: ANALISIS DEL IMPACTO PRESUPUESTARIO EN ESPA\u00d1A APLICANDO UN MODELO DE TRANSMISI\u00d3N DIN\u00c1MICA](http://www.redalyc.org/articulo.oa?id=17043728001) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nReyes Lorente Anto\u00f1anzas\n2016-01-01\nFull Text Available Fundamentos: Las infecciones causadas por el Streptococcus pneumoniae en el adulto tienen repercusiones importantes en la salud. El objetivo fue analizar el impacto econ\u00f3mico y sanitario en 5 a\u00f1os de la vacunaci\u00f3n de la cohorte espa\u00f1ola de 65 a\u00f1os inmunocompetente con la vacuna antineumoc\u00f3cica conjugada 13-valente.M\u00e9todos: Mediante un modelo de transmisi\u00f3n din\u00e1mica basado en ecuaciones diferenciales se analiz\u00f3 la carga de la enfermedad neumoc\u00f3cica (EN en sujetos de 65 a\u00f1os en 5 a\u00f1os, siendo vacunada anualmente el 36,5% de la cohorte. Se aplic\u00f3 la eficacia de la vacuna del 52,5% observada en el estudio CAPITA en pacientes de 65 a\u00f1os inmunocompetentes, cobertura de serotipos vacunales del 63,4% (estudio CAPA, incidencia de infecci\u00f3n neumoc\u00f3cica de 162,2/100.000 casos a\u00f1o (CMBD 2010-2013 y proporci\u00f3n de vacunados previamente al arranque del modelo del 0,99%. La perspectiva fue la del Sistema Nacional de Salud (SNS. Costes de casos de EN seg\u00fan CMBD y precio de venta de laboratorio de la vacuna conjugada.Resultados: En 5 a\u00f1os la vacunaci\u00f3n con vacuna conjugada 13-valente espera evitar 10.360 casos de EN (7.411 hospitalizaciones por neumon\u00edas y 699 muertes (14.736 a\u00f1os de vida ganados -AVG-, en una cohorte de 65 a 69 a\u00f1os de edad. El coste de vacunaci\u00f3n esperado de 36,5 millones de euros se compensar\u00eda completamente por la reducci\u00f3n de 41,5 millones de costes m\u00e9dicos evitados, con un ahorro neto acumulado de 3,8 millones de euros a precios constantes (4,9 a precios corrientes.Conclusi\u00f3n: La vacunaci\u00f3n con vacuna conjugada 13-valente en adultos de 65 a\u00f1os inmunocompetentes resulta eficiente para el Sistema Nacional de Salud, reduciendo la carga de enfermedad y evitando un n\u00famero importante de muertes.\n[VACUNAS E INFECCIONES RESPIRATORIAS](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::61ee14b25b56c72855596bb426219d56)\nDr. Rodolfo Villena\n2017-01-01\nLas vacunas han demostrado ser una excelente estrategia para reducir la morbimortalidad en infecciones respiratorias, con un perfil de seguridad adecuado. Nuestro PNI incorpora varias de ellas con este objetivo, logrando resultados de alto impacto a nivel de salud p\u00fablica. Para que esto prosiga se requiere de nuestro compromiso y conocimiento para estimular, difundir y obtener altas tasas de cobertura, de manera de lograr efectos de protecci\u00f3n indirecta, conocidos como inmunidad comunitaria. ...\n[VIGILANCIA DE LA GRIPE PAND\u00c9MICA EN LA COMUNIDAD VALENCIANA Y VACUNA ANTIGRIPAL ESTACIONAL](http://www.redalyc.org/articulo.oa?id=17015304012) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nRosa Mar\u00eda Carb\u00f3 Malonda\n2010-01-01\nFull Text Available Fundamento: En la Comunidad Valenciana se ha llevado a cabo la vigilancia de la Gripe pand\u00e9mica. Algunos estudios sobre efectividad de la vacuna estacional para Gripe AnH1N1 han presentado resultados no consistentes. El objetivo del trabajo es describir los resultados de la vigilancia epidemiol\u00f3gica y la efectividad de la vacuna estacional para Gripe pand\u00e9mica en las semanas 28 a 51 de 2009. M\u00e9todos: Se estudiaron los casos en atenci\u00f3n primaria, hospitalizados confirmados, aislamientos virales y prote\u00edna C reactiva (PCR y coberturas vacunales. Se calcul\u00f3 la efectividad vacunal por el m\u00e9todo de screening de Farrington, en tres grupos de edad y dos periodos: vacunados de las temporadas 2008-9 y 2009-10. Resultados: En el primer periodo (semanas 28 a 40 los casos se concentraron en el grupo de 15 a 64 a\u00f1os (7.207 casos, seguido de los menores de 15 a\u00f1os (1.596 casos. En el segundo periodo (semanas 45 a 47 afect\u00f3 m\u00e1s a menores de 15 a\u00f1os (28.218 casos. En ambos periodos las tasas de incidencia en mayores de 65 a\u00f1os fue de 56,3 y 125,1 respectivamente. En el periodo estudiado (semanas 28 a 51 se confirmaron 5.481 casos de los que 1.746 (31,8% fueron hospitalizados. La curva de personas hospitalizadas presentaba un perfil similar al de atenci\u00f3n primaria, y tambi\u00e9n el seguimiento microbiol\u00f3gico del virus. La efectividad vacunal en el segundo periodo fue del 25% en adultos entre 15 y 64 a\u00f1os y del 51% en mayores de 64 a\u00f1os. Conclusiones: Se observ\u00f3 una protecci\u00f3n edad dependiente con efectividad vacunal positiva en los mayores de 64 a\u00f1os, aunque puede estar confundida por exposici\u00f3n natural al virus, vacunas previas y o respuesta inmunitaria.\n[Characterization of in vivo anti-rotavirus activities of saponin extracts from Quillaja Saponaria Molina](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3106224)\nTam, Ka Ian; Roner, Michael R.\n2011-01-01\nRotavirus is the leading cause of severe diarrhea disease in newborns and young children worldwide with approximately 300,000 pre-adolescent deaths each year. Quillaja saponins are a natural aqueous extract obtained from the Chilean soapbark tree. The extract is approved for use in humans by the FDA for use in beverages as a food addictive. We have demonstrated that Quillaja extracts have strong antiviral activities in vitro against six different viruses. In this study, we evaluated the in vivo antiviral activity of these extracts against rhesus rotavirus (RRV) using a mouse model. We established that at a dosage of 0.015 mg/mouse of saponin extract, RRV induced diarrhea can be significantly reduced from 79% to 11% when mice are exposed to 500 plaque-forming-units (PFU) for each of five consecutive days. Additionally, while a reduction of RRV induced diarrhea depended both on the concentration of virus introduced and on the amount of Quillaja extract given to each mouse, the severity and interval of diarrhea under a variety of conditions tested, in all the treated mice were greatly reduced when compared to those that did not receive the Quillaja extracts. Mechanistically, there is strong evidence that the Quillaja extracts are able to \u201cblock\u201d rotavirus infection by inhibiting virus-host attachment through disruption of cellular membrane proteins and/or virus receptors. We believe that Quillaja extracts have promise as antivirals to reduce rotavirus infection and the severity of the disease in humans. PMID:21549151\n[Impacto de la introducci\u00f3n de la vacuna contra el rotavirus en la hospitalizaci\u00f3n por gastroenteritis aguda grave en el Hospital del Ni\u00f1o de la Ciudad de Panam\u00e1 Impact of rotavirus vaccine introduction on hospital admissions for severe acute gastroenteritis at the Children's Hospital in Panama City](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000900005) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJavier Nieto Guevara\n2008-09-01\nFull Text Available OBJETIVOS: Determinar si la introducci\u00f3n de la vacunaci\u00f3n infantil contra el rotavirus en Panam\u00e1 permiti\u00f3 reducir la tasa de hospitalizaci\u00f3n por gastroenteritis en ni\u00f1os menores de 5 a\u00f1os. M\u00c9TODOS: Estudio observacional de corte transversal en dos per\u00edodos: del 1 de enero al 31 de agosto de 2005 (antes de la introducci\u00f3n de la vacunaci\u00f3n contra el rotavirus y del 1 de enero al 31 de agosto de 2007 (un a\u00f1o despu\u00e9s de la introducci\u00f3n. Se estudiaron todos los ni\u00f1os y ni\u00f1as entre 2 meses y 5 a\u00f1os de edad hospitalizados con diagn\u00f3stico de gastroenteritis aguda grave en la sala de corta estancia de gastroenteritis del Hospital del Ni\u00f1o, en Ciudad de Panam\u00e1, Panam\u00e1. Las variables fueron: n\u00famero de episodios de gastroenteritis, n\u00famero de casos hospitalizados por gastroenteritis aguda grave, d\u00edas de hospitalizaci\u00f3n y uso de antibi\u00f3ticos, seg\u00fan dos grupos de edad (de 2 meses a 1 a\u00f1o y de m\u00e1s de 1 a\u00f1o a 5 a\u00f1os. Se calcul\u00f3 el riesgo relativo (RR con intervalos de confianza de 95% (IC95% y un nivel de significaci\u00f3n P OBJECTIVES: To determine if infant rotavirus vaccination in Panama has reduced the rate of hospital admission for gastroenteritis among children under 5 years of age. METHODS: An observational, cross-sectional study of two time periods: 1 January-31 August 2005 (prior to initiating rotavirus vaccination and 1 January-31 August 2007 (one year after introducing rotavirus vaccination. All the children from 2 months-5 years of age admitted with a diagnosis of acute gastroenteritis to the short-stay gastroenteritis area of the Children's Hospital in Panama City, Panama, were studied. The variables were: number of gastroenteritis episodes; number of cases admitted for severe acute gastroenteritis; number of days hospitalized; and antibiotics treatment for each of the two age groups (2 months-1 year and >1-5 years. The relative risk (RR was calculated with a 95% confidence interval (95%CI and a significance level of P\n[El legado de la Real Expedici\u00f3n Filantr\u00f3pica de la Vacuna (1803-1810: las juntas de vacuna](http://asclepio.revistas.csic.es/index.php/asclepio/article/view/71/74) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nRam\u00edrez Mart\u00edn, Susana Mar\u00eda\n2004-06-01\nFull Text Available The Royal Vaccination Expedition, directed by the physicians Francisco Xavier Balmis and Jos\u00e9 Salvany, was the most important scientific and medical achievement of the Spanish colonial era. It took place at a time of political restlessness, and its achievements were thus conditioned by each of the cultures into which the vaccine was introduced. As its legacy, the philantropic expedition left the Vaccination Boards, established in the Americas as centers of medical expertise to sustain the expedition\u00b4s principal objetive: the battle against the smallpox epidemics in pursuit of public health.\nLa Expedici\u00f3n de la Vacuna, dirigida por los m\u00e9dicos Francisco Xavier Balmis y Jos\u00e9 Salvany, es la gesta cient\u00edfica y sanitaria m\u00e1s importante de \u00e9poca colonial. Su desarrollo tuvo lugar en un momento pol\u00edtico convulso y los resultados estuvieron condicionados por las sociedades donde la vacuna se estableci\u00f3. El legado de esta expedici\u00f3n filantr\u00f3pica fue la creaci\u00f3n de las Juntas de Vacuna. Estas instituciones se erigieron como centros creadores de saber m\u00e9dico en Am\u00e9rica y consolidaron el objetivo primario de la expedici\u00f3n: la b\u00fasqueda de la salud p\u00fablica luchando contra las epidemias de viruela.\n[Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine Vacunaci\u00f3n primaria y de refuerzo con la vacuna pentavalente DTPw-HB/Hib en ni\u00f1os costarricenses vacunados al nacer contra la hepatitis B](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892002001000005) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nIdis Faingezicht\n2002-10-01\nprotective/seropositive titers for Hib, HB, and tetanus and about 50% for diphtheria and Bordetella pertussis. At 15 months of age, virtually all the toddlers responded with a strong boost response to all the vaccine antigens, whether they received the DTPw-HB/Hib pentavalent vaccine or the DTPw/Hib vaccine as a booster. Both booster regimens were equally well tolerated, indicating that up to five doses of the HB vaccine can be given without impact on safety. Conclusions. Our study confirms that the DTPw-HB/Hib pentavalent vaccine is highly immunogenic as a primary vaccination in children who received an HB vaccine at birth, with the pentavalent combination inducing both persisting immunity and boostable memory. The pentavalent vaccine was safe both for primary and booster vaccinations. Thus, this study in Costa Rican infants supports the routine use of the pentavalent DTPw-HB/Hib vaccine as part of childhood vaccination programs in Latin America and the Caribbean.Objetivos. La vacuna combinada pentavalente DTPw-HB/Hib ha sido creada siguiendo la recomendaci\u00f3n de la Organizaci\u00f3n Mundial de la Salud de a\u00f1adir las vacunas contra la hepatitis b (HB y el Haemophilus influenzae tipo b (Hib a los programas de vacunaci\u00f3n infantil. Los objetivos del presente estudio consistieron en: 1 analizar la inmunogenicidad y reactogenicidad de la vacuna combinada pentavalente DTPw-HB/Hib en comparaci\u00f3n con las inyecciones separadas de las vacunas DTPw-HB e Hib como vacunaci\u00f3n primaria en un grupo de ni\u00f1os que hab\u00edan recibido al nacer una dosis de vacuna contra la HB, y 2 evaluar la persistencia de anticuerpos en el segundo a\u00f1o de vida, as\u00ed como la respuesta a las dosis de recuerdo de DTPw-HB/Hib o DTPw/Hib. M\u00e9todos. En la primera parte del estudio (fase de vacunaci\u00f3n primaria, realizada en 1998-1999, se analiz\u00f3 la inmunogenicidad y reactogenicidad de la vacuna combinada DTPw-HB/Hib en comparaci\u00f3n con inyecciones separadas de las vacunas DTPw-HB e Hib como vacunaci\u00f3n primaria a\n[Perfil de seguridad de la vacuna antileptospir\u00f3sica trivalente vax-SPIRAL\u00ae](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2010000300001&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nGiset Jim\u00e9nez\n2010-12-01\nFull Text Available Con el objetivo de mostrar el perfil de seguridad de la vacuna antileptospir\u00f3sica cubana, vax-SPIRAL\u00ae, se realiz\u00f3 un estudio observacional descriptivo y transversal, a partir de la base de datos de la red nacional de farmacovigilancia a medicamentos. Se estim\u00f3 la frecuencia de reportes por dosis de vacunas administradas, la valoraci\u00f3n de causalidad, severidad, localizaci\u00f3n y los eventos adversos con mayor asociaci\u00f3n estad\u00edstica, a partir del c\u00e1lculo de disproporcionalidad de las combinaciones de eventos adversos a vacunas de todos los diagn\u00f3sticos en los reportes de eventos del grupo farmacol\u00f3gico de vacunas y el c\u00e1lculo de la Raz\u00f3n de Riesgo Proporcional (PRR y la Raz\u00f3n Diferencial de Riesgo (ROR. Hubo 1,62 reportes por 100 000 dosis administradas y 1,9 diagn\u00f3sticos por reporte en personas entre 18 y 77 a\u00f1os de edad y una media \u00b1DE de 40 \u00b1 13 a\u00f1os, con predominio del sexo femenino (65,54%. No se reportaron casos graves; el 74,17% fueron con severidad leve y el 66,96% fueron manifestaciones adversas sist\u00e9micas. El 94,17% de los reportes estuvieron relacionados con la vacuna. Los eventos adversos m\u00e1s frecuentes fueron: fiebre/hipertermia (18,75%, cefalea (14,73%, dolor local (13,84%, enrojecimiento/eritema/rubor en el sitio de inyecci\u00f3n (12,05%, malestar general (8,48% y manifestaciones de hipersensibilidad m\u00ednimas, s\u00f3lo a nivel cut\u00e1neo. Entre los que mostraron mayor asociaci\u00f3n: cefalea, malestar general y rubor. Los resultados obtenidos son similares y con mejor perfil de seguridad que los de la vacuna francesa SPIROLEPT, por lo cual se recomienda para la protecci\u00f3n en grupos de riesgo de leptospirosis.\n[IMPLICACIONES \u00c9TICAS Y SOCIALES DE LA INTRODUCCI\u00d3N DE LA VACUNA CONTRA EL VIRUS DEL PAPILOMA HUMANO EN M\u00c9XICO: REFLEXIONES SOBRE UNA PROPUESTA DE INTERVENCI\u00d3N](https://www.openaire.eu/search/publication?articleId=od______3056::d4191acb1173d7dbea934cb8c961809f)\nPrieto de la Rosa,Alejandra; Guti\u00e9rrez Delgado,Cristina; Feinholz Klip,Dafna; Morales Gonz\u00e1lez,Gisela; Witlen,Renee\n2008-01-01\nEl objetivo de este trabajo es identificar aspectos \u00e9ticos y sociales relacionados con la introducci\u00f3n de la vacuna contra el virus del papiloma humano (VPH) en M\u00e9xico para una decisi\u00f3n informada y justa que considere no s\u00f3lo los aspectos financieros. De acuerdo con la informaci\u00f3n sobre eficiencia y costo de la vacuna, su introducci\u00f3n al sistema p\u00fablico mexicano puede acarrear consecuencias no previstas para las participantes y para toda la sociedad, por lo que debe examinarse en el contexto ...\n[Global Seasonality of Rotavirus Disease](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4103797)\nPatel, Manish M.; Pitzer, Virginia; Alonso, Wladimir J.; Vera, David; Lopman, Ben; Tate, Jacqueline; Viboud, Cecile; Parashar, Umesh D.\n2012-01-01\nBackground A substantial number of surveillance studies have documented rotavirus prevalence among children admitted for dehydrating diarrhea. We sought to establish global seasonal patterns of rotavirus disease before widespread vaccine introduction. Methods We reviewed studies of rotavirus detection in children with diarrhea published since 1995. We assessed potential relationships between seasonal prevalence and locality by plotting the average monthly proportion of diarrhea cases positive for rotavirus according to geography, country development, and latitude. We used linear regression to identify variables that were potentially associated with the seasonal intensity of rotavirus. Results Among a total of 99 studies representing all six geographical regions of the world, patterns of year-round disease were more evident in low- and low-middle income countries compared with upper-middle and high income countries where disease was more likely to be seasonal. The level of country development was a stronger predictor of strength of seasonality (P=0.001) than geographical location or climate. However, the observation of distinctly different seasonal patterns of rotavirus disease in some countries with similar geographical location, climate and level of development indicate that a single unifying explanation for variation in seasonality of rotavirus disease is unlikely. Conclusion While no unifying explanation emerged for varying rotavirus seasonality globally, the country income level was somewhat more predictive of the likelihood of having seasonal disease than other factors. Future evaluation of the effect of rotavirus vaccination on seasonal patterns of disease in different settings may help understand factors that drive the global seasonality of rotavirus disease. PMID:23190782\n[Aceptabilidad de la vacuna contra el virus papiloma humano en padres de adolescentes, en colombia](https://www.openaire.eu/search/publication?articleId=od______1326::8ba7ba7cedd44552d4d60ca52f50c9aa)\nWiesner, Carolina; Pi\u00f1eros, Marion; Cort\u00e9s, Claudia; Jaime Ardila, Jaime Ardila\n2012-01-01\nObjetivo La vacuna contra el VPH es una nueva tecnolog\u00eda disponible para el control del c\u00e1ncer de cuello uterino. Se espera, que en el menor tiempo posible esta vacuna pueda tener cobertura universal. Este art\u00edculo presenta la aceptabilidad que tiene los padres de adolescentes en Colombia hacia la vacuna contra el VPH y hace una aproximaci\u00f3n a sus determinantes. M\u00e9todos Estudio cualitativo en cuatro regiones en Colombia. Se realizaron 17 grupos focales con padres de ni\u00f1as y ni\u00f1os entre 11 a 1...\n[Human neonatal rotavirus vaccine (RV3-BB) targets rotavirus from birth](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5774175)\nThobari, Jarir At; Satria, Cahya Dewi; Handley, Amanda; Watts, Emma; Cowley, Daniel; Nirwati, Hera; Ackland, James; Standish, Jane; Justice, Frances; Byars, Gabrielle; Lee, Katherine J.; Barnes, Graeme L.; Bachtiar, Novilia S.; Icanervilia, Ajeng Viska; Boniface, Karen; Bogdanovic-Sakran, Nada; Pavlic, Daniel; Bishop, Ruth F.; Kirkwood, Carl D.; Buttery, Jim P.; Soenarto, Yati\n2018-01-01\nBackground A birth dose strategy using a neonatal rotavirus vaccine to target early prevention of rotavirus disease may address remaining barriers to global vaccine implementation. Methods We conducted a randomized, placebo-controlled trial in Indonesia to evaluate the efficacy of an oral human neonatal rotavirus vaccine (RV3-BB) to prevent rotavirus gastroenteritis. Healthy newborns received three doses of RV3-BB administered in a neonatal schedule at 0-5 days, 8 and 14 weeks or infant schedule at 8, 14 and 18 weeks, or placebo. Laboratory-confirmed rotavirus gastroenteritis was graded using a modified Vesikari score. The primary analysis was efficacy against severe rotavirus gastroenteritis from two weeks after all doses to 18 months in the combined vaccine group (neonatal and infant schedule) compared with placebo. Results Vaccine efficacy against severe rotavirus gastroenteritis to 18 months was 63% in the combined vaccine group (95% CI 34, 80; p<0.001), 75% in the neonatal vaccine group (95% confidence interval [CI] 44, 91; p<0.001) and 51% in the infant vaccine group (95% CI 7, 76; p=0.03) in the per protocol analysis, with similar results in the intention-to-treat analysis. Vaccine efficacy to 12 months was 94% in the neonatal vaccine group (95%CI 56, 99; p=0.006). Vaccine take occurred in 78/83 (94%) in the neonatal vaccine group and 83/84 (99%) in the infant vaccine group. The vaccine was well tolerated, with similar incidence of adverse events in vaccine and placebo recipients. Conclusion RV3-BB was efficacious, immunogenic and well-tolerated when administered in a neonatal or infant schedule in Indonesia. PMID:29466164\n[Impact of rotavirus vaccination on rotavirus and all-cause gastroenteritis in peri-urban Kenyan children.](https://www.ncbi.nlm.nih.gov/pubmed/28780116)\nWandera, Ernest Apondi; Mohammad, Shah; Bundi, Martin; Komoto, Satoshi; Nyangao, James; Kathiiko, Cyrus; Odoyo, Erick; Miring'u, Gabriel; Taniguchi, Koki; Ichinose, Yoshio\n2017-09-12\nA monovalent rotavirus vaccine (RV1) was introduced into the National Immunization Program in Kenya in July 2014. We examined the impact of the vaccine on hospitalization for all-cause acute gastroenteritis (AGE) and rotavirus-specific AGE and strain distribution at a large referral hospital which serves a predominantly peri-urban population in Central Kenya. Data on rotavirus AGE and strain distribution were derived from ongoing hospital-based AGE surveillance. Hospital administrative data were used to compare trends in all-cause AGE. Pre-vaccine (July 2009-June 2014) and post-vaccine (July 2014-June 2016) periods were compared for changes in hospitalization for all-cause AGE and rotavirus AGE and strain distribution. Following the vaccine introduction, the proportion of children aged rotavirus declined by 30% (95% CI: 19-45%) in the first year and 64% (95% CI: 49-77%) in the second year. Reductions in rotavirus positivity were most pronounced among the vaccine-eligible group (rotavirus and all-cause AGE were reduced substantially. There was an increased detection of G2P[4], G3P[6] and G3P[8], which coincided temporally with the timing of the vaccine introduction. Thus, introducing the rotavirus vaccine into the routine immunization program in Kenya has resulted in a notable decline in rotavirus and all-cause AGE hospitalizations in Central Kenya. This provides early evidence for public health policy makers in Kenya to support the sustained use of the rotavirus vaccine in routine immunizations. Copyright \u00a9 2017 Elsevier Ltd. All rights reserved.\n[Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies](http://www.biomedcentral.com/1471-2180/7/86) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nHammarstr\u00f6m Lennart\n2007-09-01\nFull Text Available Abstract Background Rotavirus is a worldwide cause of infectious infantile diarrhea that claims over 600,000 lives annually. Recently, two new vaccine candidates have been developed but their efficacy in developing countries, still remains to be proven. Oral delivery of specific immunoglobulins provides passive immunity and is a fast acting treatment for rotavirus diarrhea. Probiotic bacteria have also gained considerable attention lately as treatment for rotavirus diarrhea. Here we report an evaluation of the therapeutic potential of different probiotics and their combination with anti \u2013 rotavirus antibodies in a mouse model of rotavirus diarrhea. Results Of the six probiotic bacteria tested, Lactobacillus rhamnosus strain GG had the strongest influence in reducing prevalence, duration and severity of diarrhea and was therefore chosen for combination treatment with immunoglobulins. The combination treatment reduced the diarrhea outcome measures significantly, prevented histopathological changes and reduced the virus load in the intestines. Conclusion The advantages associated with immunoglobulins and probiotics based therapy is that the treatment provides a rapid therapeutic effect and is cost efficient. These components do not require special storage conditions and could potentially complement the rehydration therapy that is currently used.\n[Manejo m\u00e9dico de la exposici\u00f3n al virus de la hepatitis B](https://www.openaire.eu/search/publication?articleId=doajarticles::e763456eb267d72953262b77223c70f4)\nMancel Mart\u00ednez; Craig Shapiro; Ana Bracho; Fernando De La Hoz\n1991-01-01\nSe hace una revisi\u00f3n de los conocimientos actuales sobre el tratamiento en el caso de una probable exposici\u00f3n al virus de la hepatitis B. Se presenta la pormenorizaci\u00f3n de las diferentes clases de exposici\u00f3n as\u00ed como la indicaci\u00f3n y dosificaci\u00f3n de la inmunoglobulina espec\u00edfica y de la vacuna anti-hepatitis B. Esta revisi\u00f3n tiene como fundamento las recomendaciones del CDC de Atlanta y de la Organizaci\u00f3n Mundial de la Salud.\n[Manejo m\u00e9dico de la exposici\u00f3n al virus de la hepatitis B](http://www.revistabiomedica.org/index.php/biomedica/article/view/2007) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMancel Mart\u00ednez\n1991-12-01\nFull Text Available Se hace una revisi\u00f3n de los conocimientos actuales sobre el tratamiento en el caso de una probable exposici\u00f3n al virus de la hepatitis B. Se presenta la pormenorizaci\u00f3n de las diferentes clases de exposici\u00f3n as\u00ed como la indicaci\u00f3n y dosificaci\u00f3n de la inmunoglobulina espec\u00edfica y de la vacuna anti-hepatitis B. Esta revisi\u00f3n tiene como fundamento las recomendaciones del CDC de Atlanta y de la Organizaci\u00f3n Mundial de la Salud.\n[Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.](https://www.ncbi.nlm.nih.gov/pubmed/20006144)\nCiarlet, Max; Sch\u00f6del, Florian\n2009-12-30\nInitial approaches for rotavirus vaccines were based on the classical \"Jennerian\" approach and utilized simian and bovine rotavirus strains, which provided cross-protection against human rotavirus strains but did not cause illness in infants and young children because of their species-specific tropism. The demonstrated efficacy of these vaccines was not consistent across studies. Thus, human-animal reassortants containing an animal rotavirus backbone with human rotavirus surface G and/or P proteins were developed, which demonstrated more consistent efficacy than that observed with the non-reassortant rotavirus strains. The pentavalent rotavirus vaccine, RotaTeq, contains 5 human-bovine reassortant rotaviruses consisting of a bovine (WC3) backbone with human rotavirus surface proteins representative of the most common G (G1, G2, G3, G4) or P (P1A[8]) types worldwide. The present review focuses on the development of the pentavalent rotavirus vaccine RotaTeq. Results of a large-scale Phase III clinical study showed that three doses of RotaTeq were immunogenic, efficacious, and well tolerated with no increased clinical risk of intussusception. RotaTeq was efficacious against rotavirus gastroenteritis of any severity (74%) and severe disease (98-100%), using a validated clinical scoring system. Reductions in rotavirus-associated hospitalizations and emergency department (ED) visits, for up to 2 years post-vaccination, were 95% in Europe, 97% in the United States, and 90% in the Latin American/Caribbean regions. RotaTeq was recently shown to be up to 100% effective in routine use in the US in reducing hospitalizations and ED visits and 96% effective in reducing physician visits. Additional studies in 8 different locations in the US have shown 85-95% reduction in rotavirus-associated hospitalizations and/or ED visits in the first 2-2.5 years of routine use.\n[Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates.](https://www.ncbi.nlm.nih.gov/pubmed/22885016)\nWen, Xiaobo; Cao, Dianjun; Jones, Ronald W; Li, Jianping; Szu, Shousun; Hoshino, Yasutaka\n2012-09-21\nTwo currently licensed live oral rotavirus vaccines (Rotarix\u00ae and RotaTeq\u00ae) are highly efficacious against severe rotavirus diarrhea. However, the efficacy of such vaccines in selected low-income African and Asian countries is much lower than that in middle or high-income countries. Additionally, these two vaccines have recently been associated with rare case of intussusception in vaccinated infants. We developed a novel recombinant subunit parenteral rotavirus vaccine which may be more effective in low-income countries and also avert the potential problem of intussusception. Truncated recombinant VP8* (\u0394VP8*) protein of human rotavirus strain Wa P[8], DS-1 P[4] or 1076 P[6] expressed in Escherichia coli was highly soluble and was generated in high yield. Guinea pigs hyperimmunized intramuscularly with each of the \u0394VP8* proteins (i.e., P[8], P[4] or P[6]) developed high levels of homotypic as well as variable levels of heterotypic neutralizing antibodies. Moreover, the selected \u0394VP8* proteins when administered to mice at a clinically relevant dosage, route and schedule, elicited high levels of serum anti-VP8* IgG and/or neutralizing antibodies. Our data indicated that the \u0394VP8* proteins may be a plausible additional candidate as new parenteral rotavirus vaccines. Published by Elsevier Ltd.\nPatarroyo, Manuel Elkin\n2017-01-01\nLa malaria es una enfermedad parasitaria producida por la picadura de un mosquito; una afecci\u00f3n que en el a\u00f1o 2015 registr\u00f3 212 millones de casos y 429.000 muertes. Cada dos minutos, la malaria provoc\u00f3 la muerte de un ni\u00f1o menor de cinco a\u00f1os en todo el mundo. Diferentes cient\u00edficos a lo largo de todo el mundo han hecho m\u00faltiples intentos para combatir esta enfermedad con una vacuna efectiva que pueda erradicarla de ra\u00edz.\n[ESTRUCTURA MOLECULAR Y ANTIG\u00c9NICA DE LA VACUNA](https://revistas.unal.edu.co/index.php/actabiol/article/view/11338) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nV\u00cdCTOR ANDR\u00c9S VANEGAS\n2008-09-01\nFull Text Available La prote\u00edna L1 del Virus del Papiloma Humano (VPH constituye el 80% de la c\u00e1pside viral. Las vacunas profil\u00e1cticas contra el VPH son sintetizadas a partir de la prote\u00edna L1 ensamblada en Part\u00edculas similares al Virus (del ingl\u00e9s VLP, las cuales son altamente inmunog\u00e9nicas generando anticuerpos espec\u00edficos de tipo y en algunos casos pueden presentar reacci\u00f3n cruzada entre tipos de VPH filogen\u00e9ticamente pr\u00f3ximos. La estructura de la prote\u00edna L1 del VPH es importante porque confiere estabilidad a la c\u00e1pside mediante el establecimiento de interacciones intra e intercapsom\u00e9ricas lo que asegura la integridad viral y antig\u00e9nicamente porque contiene los ep\u00edtopes que inducen la respuesta inmune protectora. En estudios en los que se evalu\u00f3 la antigenicidad de la prote\u00edna L1 se determin\u00f3 que los ep\u00edtopes inmunodominantes de la c\u00e1pside viral se encuentran en los bucles B-C, D-E, F-G, H-I y en el extremo C-terminal. Estos bucles son poco conservados entre los diferentes genotipos y se encuentran en segmentos de la prote\u00edna expuestos en la superficie de la c\u00e1pside. Los amino\u00e1cidos situados en los bucles B-C, F-G y H-I son primordiales para el reconocimiento por los anticuerpos neutralizantes. Los diferentes subtipos y variantes presentan cambios en estos amino\u00e1cidos o en residuos que conforman otros ep\u00edtopes. En esta revisi\u00f3n se presentar\u00e1 un estado del arte de la prote\u00edna L1 del VPH genotipo 16, la estructura y su importancia en el desarrollo de vacunas contra la infecci\u00f3n producida por este virus.\n[Efectividad de la vacuna VA-MENGOC-BC\u00ae contra cepas heter\u00f3logas de meningococo B](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2016000200003&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nRolando Ochoa-Azze\n2016-08-01\nFull Text Available La efectividad de las vacunas de ves\u00edculas de membrana externa de Neisseria meningitidis serogrupo B ha sido cuestionada por algunos investigadores, limit\u00e1ndola a la cepa vacunal. VA-MENGOC-BC\u00ae es una vacuna antimeningoc\u00f3cica basada en dicha tecnolog\u00eda. Presentamos un metaan\u00e1lisis de estudios realizados en diferentes contextos epidemiol\u00f3gicos, evaluando su efectividad contra cepas heter\u00f3logas de meningococo B en varios grupos de edades. Se demuestra que la vacuna es efectiva contra cepas hom\u00f3logas, heter\u00f3logas y de diferentes complejos clonales.\n[Evaluaci\u00f3n de la toxicidad por dosis \u00fanica de la vacuna antitet\u00e1nica vax-TET en ratas Sprague Dawley](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2007000300004&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nYulie\u00e9 L\u00f3pez.\n2007-12-01\nFull Text Available La vacuna vax-TET\u00ae est\u00e1 indicada en la prevenci\u00f3n del t\u00e9tanos y es efectiva si se logra un completo y apropiado esquema de inmunizaci\u00f3n. Para investigar el potencial t\u00f3xico de este producto se realiz\u00f3 una prueba toxicol\u00f3gica con una dosis \u00fanica, por v\u00eda intramuscular, en un volumen de 0,2 mL en ratas Sprague Dawley. La composici\u00f3n de la vacuna de ensayo probada fue la misma de la vacuna comercial. Los animales fueron observados diariamente en busca de s\u00edntomas locales y sist\u00e9micos de toxicidad. Se realizaron mediciones del consumo de agua y alimento, as\u00ed como del peso corporal. Dos semanas despu\u00e9s de la inoculaci\u00f3n las ratas fueron sacrificadas por m\u00e9todos de eutanasia sin dolor y sometidas a necropsia. No se observaron muertes ni s\u00edntomas de toxicidad en los animales estudiados. Tampoco se encontraron diferencias de inter\u00e9s toxicol\u00f3gico entre los grupos experimentales en cuanto a las variables medidas. El estudio anatomopatol\u00f3gico revel\u00f3 la presencia de formaciones granulomatosas de tipo macrof\u00e1gico asociadas, fundamentalmente, al hidr\u00f3xido de aluminio. Estos resultados permitieron concluir que, bajo las condiciones del estudio y seg\u00fan los criterios establecidos, esta vacuna no produce efectos adversos en el modelo animal usado, por lo que se considera potencialmente no t\u00f3xica para humanos.\n[Influenza. Vacunas cl\u00e1sicas y novedosas a las puertas de otra pandemia](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200005&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nRaiza Mart\u00ednez\n2006-08-01\nFull Text Available Los virus de la influenza A, adem\u00e1s del hombre, infectan otros mam\u00edferos y una gran variedad de especies de aves. Desde 1997 se sabe que cepas aviares son capaces de infectar al hombre provocando una enfermedad generalmente leve. El brote actual de gripe aviar H5N1 en humanos ha puesto en alerta a la comunidad cient\u00edfica internacional, no solo por su elevada mortalidad sino por su potencialidad en la generaci\u00f3n de una nueva pandemia. Las autoridades sanitarias han puesto en marcha un amplio programa para la preparaci\u00f3n ante esta contingencia, que abarca diferentes campos, desde el diagn\u00f3stico y la detecci\u00f3n precoz de los brotes tanto en animales como en humanos, la caracterizaci\u00f3n sistem\u00e1tica de las cepas circulantes, el sacrificio de aves infectadas, la producci\u00f3n masiva de antivirales y por supuesto el desarrollo y producci\u00f3n a gran escala de vacunas eficaces. En este \u00faltimo tema se trabaja intensamente tanto en el mejoramiento de las vacunas ya existentes como en la b\u00fasqueda de alternativas basadas en tecnolog\u00edas de nueva generaci\u00f3n.\n[Enfermedad meningoc\u00f3cica: epidemiolog\u00eda y vacunas, un enfoque pr\u00e1ctico](http://www.sciencedirect.com/science/article/pii/S0716864014700689) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nC. Giannina Izquierdo, Dra.\n2014-05-01\nLas principales estrategias para la prevenci\u00f3n de la enfermedad son el uso de vacunas (prevenci\u00f3n primaria y el uso de quimioprofilaxis a los contactos de un caso \u00edndice (prevenci\u00f3n secundaria. A la fecha existen numerosas vacunas contra Nmen, todas ellas con adecuados perfiles de seguridad e inmunogenicidad, por lo que la elecci\u00f3n de la vacuna a utilizar depender\u00e1 del serogrupo prevalente en cada pa\u00eds; de las caracter\u00edsticas de la poblaci\u00f3n m\u00e1s afectada y de la factibilidad de disponer de ella e insertarla dentro de los programas nacionales o campa\u00f1as respectivas de vacunaci\u00f3n.\n[Annual changes in rotavirus hospitalization rates before and after rotavirus vaccine implementation in the United States.](https://www.ncbi.nlm.nih.gov/pubmed/29444124)\nShah, Minesh P; Dahl, Rebecca M; Parashar, Umesh D; Lopman, Benjamin A\n2018-01-01\nHospitalizations for rotavirus and acute gastroenteritis (AGE) have declined in the US with rotavirus vaccination, though biennial peaks in incidence in children aged less than 5 years occur. This pattern may be explained by lower rotavirus vaccination coverage in US children (59% to 73% from 2010-2015), resulting in accumulation of susceptible children over two successive birth cohorts. Retrospective cohort analysis of claims data of commercially insured US children aged rotavirus and for AGE from the 2002-2015 rotavirus seasons were examined. Median age and rotavirus vaccination coverage for biennial rotavirus seasons during pre-vaccine (2002-2005), early post-vaccine (2008-2011) and late post-vaccine (2012-2015) years. Age-stratified hospitalization rates decreased from pre-vaccine to early post-vaccine and then to late post-vaccine years. The clearest biennial pattern in hospitalization rates is the early post-vaccine period, with higher rates in 2009 and 2011 than in 2008 and 2010. The pattern diminishes in the late post-vaccine period. For rotavirus hospitalizations, the median age and the difference in age between biennial seasons was highest during the early post-vaccine period; these differences were not observed for AGE hospitalizations. There was no significant difference in vaccination coverage between biennial seasons. These observations provide conflicting evidence that incomplete vaccine coverage drove the biennial pattern in rotavirus hospitalizations that has emerged with rotavirus vaccination in the US. As this pattern is diminishing with higher vaccine coverage in recent years, further increases in vaccine coverage may reach a threshold that eliminates peak seasons in hospitalizations.\n[Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children.](https://www.ncbi.nlm.nih.gov/pubmed/22252206)\nGrant, Lindsay R; Watt, James P; Weatherholtz, Robert C; Moulton, Lawrence H; Reid, Raymond; Santosham, Mathuram; O'Brien, Katherine L\n2012-02-01\nBefore the widespread use of rotavirus vaccines, rotavirus was a leading cause of gastroenteritis among children. Navajo and White Mountain Apache children suffer a disproportionate burden of severe rotavirus disease compared with the general U.S. population. We enrolled Navajo and White Mountain Apache infants in a multicenter, double-blind, placebo-controlled trial of pentavalent human-bovine reassortant rotavirus vaccine (PRV). Subjects received 3 doses of vaccine or placebo at 4 to 10 week intervals, with the first dose given between 6 and 12 weeks of age. Gastroenteritis episodes were identified by active surveillance. Disease severity was determined by a standardized scoring system. There were 509 and 494 randomized children who received vaccine and placebo, respectively. Among placebo recipients, the incidence of rotavirus gastroenteritis was 34.2 episodes/100 child-years (95% confidence interval [95% CI]: 25.8-38.9) versus 8.1 episodes/100 child-years (95% CI: 5.4-12.5) in the vaccine group. The percentage of rotavirus episodes caused by serotypes G1, G2, and G3 was 72.3%, 23.4%, and 2.1%, respectively. There were no severe rotavirus episodes among vaccinees and 4 among placebo recipients. PRV was 77.1% (95% CI: 59.7-87.6), 89.5% (95% CI: 65.9-97.9), and 82.9% (95% CI: 61.1-93.6) effective against G1-G4 rotavirus disease, severe and moderate rotavirus disease combined, and outpatient visits for rotavirus disease, respectively. The risk of adverse events was similar for the vaccine and placebo groups. PRV was highly effective in preventing rotavirus disease and related health care utilization in these American Indian infants. Vaccine efficacy and immunogenicity were similar to the overall study population enrolled in the multicenter trial.\n[Impact and Effectiveness of Monovalent Rotavirus Vaccine Against Severe Rotavirus Diarrhea in Ghana.](https://www.ncbi.nlm.nih.gov/pubmed/27059357)\nArmah, George; Pringle, Kimberly; Enweronu-Laryea, Christabel C; Ansong, Daniel; Mwenda, Jason M; Diamenu, Stanley K; Narh, Clement; Lartey, Belinda; Binka, Fred; Grytdal, Scott; Patel, Manish; Parashar, Umesh; Lopman, Ben\n2016-05-01\nGhana was among the first African nations to introduce monovalent rotavirus vaccine (RV1) into its childhood immunization schedule in April 2012. We aimed to assess the impact of vaccine introduction on rotavirus and acute gastroenteritis (AGE) hospitalizations and to estimate vaccine effectiveness (VE). Using data from 2 teaching hospitals, monthly AGE and rotavirus admissions by age were examined 40 months before and 31 months after RV1 introduction using interrupted time-series analyses. From January 2013, we enrolled children vaccination by rotavirus case-patient status, controlling for potential confounders. Vaccine coverage ranged from 95% to 100% for dose 1 and 93% to 100% for dose 2. In the first 3 years after vaccine introduction, the percentage of hospital admissions positive for rotavirus fell from 48% in the prevaccine period to 28% (49% adjusted rate reduction; 95% confidence interval [CI], 32%-63%) postvaccination among vaccine coverage, it was not possible to arrive at robust VE estimates; any-dose VE against rotavirus hospitalization was estimated at 60% (95% CI, -2% to 84%;P= .056). Results from the first 3 years following RV1 introduction suggest substantial reductions of pediatric diarrheal disease as a result of vaccination. Our VE estimate is consistent with the observed rotavirus decrease and with efficacy estimates from elsewhere in sub-Saharan Africa. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.\n[Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines](http://www.dovepress.com/prevention-of-rotavirus-gastroenteritis-in-infants-and-children-rotavi-a4944) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAruna Chandran\n2010-07-01\nFull Text Available Aruna Chandran1, Sean Fitzwater1, Anjie Zhen2, Mathuram Santosham11Department of International Health, Division of Health Systems, 2Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USAAbstract: Rotavirus infection is the most common cause of severe gastroenteritis globally, with greater than 86% of deaths occurring in low-income and middle-income countries. There are two rotavirus vaccines currently licensed in the United States and prequalified by the World Health Organization. RV1 is a monovalent attenuated human rotavirus strain, given orally in two doses. RV5 is a pentavalent human-bovine reassortant rotavirus vaccine, given orally in three doses. A third rotavirus vaccine, LLV, is a lamb rotavirus strain given orally as a single dose, which is currently available only in China. RV1 and RV5 have been shown to be highly efficacious in developed countries, and initial results from trials in Africa and Asia are promising as well. At least three other vaccines are in development, which are being developed by manufacturers of developing countries. Further studies are needed to clarify issues including administration of oral rotavirus vaccines with breastfeeding and other oral vaccines, and alterations in dosing schedule. Using new data on global diarrheal burden, rotavirus is estimated to cause 390,000 deaths in children younger than 5 years. Should rotavirus vaccines be introduced in the routine immunization programs of all countries, a potential of 170,000 deaths could be prevented annually. The largest impact on mortality would be seen in low-income and middle-income countries, despite poor immunization coverage and lower efficacy. Therefore, international efforts are needed to ensure that rotavirus vaccines reach the populations with highest burden of rotavirus disease.Keywords: vaccination, mortality, rotavirus, gastroenteritis\n[ABO blood grouping in Egyptian children with rotavirus gastroenteritis](https://www.termedia.pl/ABO-blood-grouping-in-Egyptian-children-with-rotavirus-gastroenteritis,41,30725,1,1.html) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nHala Gouda Elnady\n2017-09-01\nFull Text Available Introduction : Rotavirus gastroenteritis is an important public health problem all over the world, causing a notable economic burden in both developing and developed countries. Aim: To explore the relationship between blood group typing, rotavirus gastroenteritis, and its severity in Egyptian children. Material and methods: A cross sectional case control study was conducted on 231 cases of acute gastroenteritis attending the outpatient clinic of Al-Zahraa University Hospital. Full history taking, clinical examination, and clinical data collection were done. Blood samples were collected for an ABO grouping. Stool samples were tested for viral gastroenteritis agents. Results : Rota positive cases of GE were significantly more prevalent among cases with blood group A (p < 0.05 and significantly less among cases with blood group B (p < 0.05. The rate of hospitalisation was highly significantly greater among cases with group A (p < 0.005, and significantly lower among cases with group AB and O (p < 0.05. As regards the degree of dehydration, moderate and severe cases were highly significant in groups A and O (p < 0.005. Rota-positive gastroenteritis showed significant positive correlations with indicators of severity such as hospitalisation, degree of dehydration, and duration of fever (p < 0.005. Conclusions : Blood group A is highly associated with paediatric rotavirus gastroenteritis. This could highlight an important risk factor, which could play a significant role for the pathogenesis of rotavirus gastroenteritis and severity as well. Furthermore, more intervention care could be needed for blood group A paediatric patients, if gastroenteritis especially rotavirus affect this group to avoid comorbidities.\n[Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth.](https://www.ncbi.nlm.nih.gov/pubmed/29466164)\nBines, Julie E; At Thobari, Jarir; Satria, Cahya Dewi; Handley, Amanda; Watts, Emma; Cowley, Daniel; Nirwati, Hera; Ackland, James; Standish, Jane; Justice, Frances; Byars, Gabrielle; Lee, Katherine J; Barnes, Graeme L; Bachtiar, Novilia S; Viska Icanervilia, Ajeng; Boniface, Karen; Bogdanovic-Sakran, Nada; Pavlic, Daniel; Bishop, Ruth F; Kirkwood, Carl D; Buttery, Jim P; Soenarto, Yati\n2018-02-22\nA strategy of administering a neonatal rotavirus vaccine at birth to target early prevention of rotavirus gastroenteritis may address some of the barriers to global implementation of a rotavirus vaccine. We conducted a randomized, double-blind, placebo-controlled trial in Indonesia to evaluate the efficacy of an oral human neonatal rotavirus vaccine (RV3-BB) in preventing rotavirus gastroenteritis. Healthy newborns received three doses of RV3-BB, administered according to a neonatal schedule (0 to 5 days, 8 weeks, and 14 weeks of age) or an infant schedule (8 weeks, 14 weeks, and 18 weeks of age), or placebo. The primary analysis was conducted in the per-protocol population, which included only participants who received all four doses of vaccine or placebo within the visit windows, with secondary analyses performed in the intention-to-treat population, which included all participants who underwent randomization. Among the 1513 participants in the per-protocol population, severe rotavirus gastroenteritis occurred up to the age of 18 months in 5.6% of the participants in the placebo group (28 of 504 babies), in 1.4% in the neonatal-schedule vaccine group (7 of 498), and in 2.7% in the infant-schedule vaccine group (14 of 511). This resulted in a vaccine efficacy of 75% (95% confidence interval [CI], 44 to 91) in the neonatal-schedule group (PBill and Melinda Gates Foundation and others; Australian New Zealand Clinical Trials Registry number, ACTRN12612001282875 .).\n[Rotavirus diarrhea disease burden in Peru: the need for a rotavirus vaccine and its potential cost savings.](https://www.ncbi.nlm.nih.gov/pubmed/11715170)\nEhrenkranz, P; Lanata, C F; Penny, M E; Salazar-Lindo, E; Glass, R I\n2001-10-01\nTo assess the disease burden of rotavirus diarrhea in Peru as well the need for and the potential cost savings with a rotavirus vaccine in that country. To assess the burden of rotavirus diarrhea in Peru, we reviewed published and unpublished reports where rotavirus was sought as the etiologic agent of diarrhea in children. Rotavirus detection rates obtained from these studies were combined with diarrhea incidence rates from a number of national surveys in order to estimate both the burden of rotavirus diarrhea in the country and its associated medical costs. Rotavirus is a significant cause of morbidity and mortality in Peruvian children. In their first 5 years of life, an estimated 1 in 1.6 children will experience an episode of rotavirus diarrhea, 1 in 9.4 will seek medical care, 1 in 19.7 will require hospitalization, and 1 in 375 will die of the disease. Per year, this represents approximately 384,000 cases, 64,000 clinic visits, 30,000 hospitalizations, and 1,600 deaths. The annual cost of medical care alone for these children is approximately US$ 2.6 million--and that does not take into account the indirect or societal costs of the illness and the deaths. Rotavirus immunization provides the prospect of decreasing the morbidity and mortality from diarrhea in Peru, but a vaccine regimen would have to be relatively inexpensive, a few dollars or less per child. Future cost-effectiveness analyses should explore the total costs (medical as well as indirect or societal) associated with rotavirus diarrhea. Newly licensed vaccines should be tested according to both their ability to avert deaths and their efficacy with fewer than three doses. All three of these factors could increase the cost savings associated with a rotavirus vaccine.\n[Rotavirus diarrhea disease burden in Peru: the need for a rotavirus vaccine and its potential cost savings](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001001000004&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nPeter Ehrenkranz\n2001-10-01\nFull Text Available Objective. To assess the disease burden of rotavirus diarrhea in Peru as well the need for and the potential cost savings with a rotavirus vaccine in that country. Methods. To assess the burden of rotavirus diarrhea in Peru, we reviewed published and unpublished reports where rotavirus was sought as the etiologic agent of diarrhea in children. Rotavirus detection rates obtained from these studies were combined with diarrhea incidence rates from a number of national surveys in order to estimate both the burden of rotavirus diarrhea in the country and its associated medical costs. Results. Rotavirus is a significant cause of morbidity and mortality in Peruvian children. In their first 5 years of life, an estimated 1 in 1.6 children will experience an episode of rotavirus diarrhea, 1 in 9.4 will seek medical care, 1 in 19.7 will require hospitalization, and 1 in 375 will die of the disease. Per year, this represents approximately 384 000 cases, 64 000 clinic visits, 30 000 hospitalizations, and 1 600 deaths. The annual cost of medical care alone for these children is approximately US$ 2.6 million--and that does not take into account the indirect or societal costs of the illness and the deaths. Conclusions. Rotavirus immunization provides the prospect of decreasing the morbidity and mortality from diarrhea in Peru, but a vaccine regimen would have to be relatively inexpensive, a few dollars or less per child. Future cost-effectiveness analyses should explore the total costs (medical as well as indirect or societal associated with rotavirus diarrhea. Newly licensed vaccines should be tested according to both their ability to avert deaths and their efficacy with fewer than three doses. All three of these factors could increase the cost savings associated with a rotavirus vaccine.\n[Protect Your Child from Rotavirus Disease](https://www.cdc.gov/features/rotavirus/)\n... Submit What's this? Submit Button Past Emails Prevent Rotavirus Language: English (US) Espa\u00f1ol (Spanish) Recommend on Facebook ... likely to get rotavirus from December to June. Rotavirus Can Cause Dehydration Symptoms of Dehydration Decrease in ...\n[Las vacunas nos protegen (Vaccines Help Protect Us)](https://www2c.cdc.gov/podcasts/player.asp?f=8630647) [Centers for Disease Control (CDC) Podcasts](http://www2c.cdc.gov/podcasts/search.asp)\n2013-04-23\nEn este podcast, los ni\u00c3\u00b1os de Kidtastics hablan sobre la importancia de las vacunas y c\u00c3\u00b3mo funcionan. Created: 4/23/2013 by Centers for Disease Control and Prevention (CDC). Date Released: 12/11/2013.\n[Reaching every child with rotavirus vaccine: Report from the 10th African rotavirus symposium held in Bamako, Mali.](https://www.ncbi.nlm.nih.gov/pubmed/28893479)\nSow, Samba O; Steele, A Duncan; Mwenda, Jason M; Armah, George E; Neuzil, Kathleen M\n2017-10-09\nThe Center for Vaccine Development - Mali (CVD - Mali), the World Health Organization's regional office in Africa (WHO/AFRO), and the CVD at the University of Maryland School of Medicine hosted the 10th African Rotavirus Symposium in Bamako, Mali on 1-2 June 2016. The symposium is coordinated by WHO/AFRO, the Regional Rotavirus Reference Laboratories, and the African Rotavirus Network (ARN), with support from the Bill & Melinda Gates Foundation. The event brings together leading rotavirus researchers, scientists, and policy-makers from across Africa and the world. Over 150 participants, from 31 countries, including 27 in Africa, joined forces to address the theme \"Reaching Every Child in Africa with Rotavirus Vaccines.\" This symposium, the first in francophone Africa, occurred at an unprecedented time when 33 African countries had introduced rotavirus vaccines into their national immunization programs. The symposium concluded with a Call to Action to introduce rotavirus vaccines in the 21 remaining African countries, to increase access in countries with existing vaccination programs, and to continue surveillance and research on rotavirus and other diarrheal diseases. Copyright \u00a9 2017.\n[Analysis by rotavirus gene 6 reverse transcriptase-polymerase chain reaction assay of rotavirus-positive gastroenteritis cases observed during the vaccination phase of the Rotavirus Efficacy and Safety Trial (REST)](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4896777)\nMatson, David O; Vesikari, Timo; Dennehy, Penelope; Dallas, Michael D; Goveia, Michelle G; Itzler, Robbin F; Ciarlet, Max\n2014-01-01\nDuring the vaccination phase of the Rotavirus Efficacy and Safety Trial (REST), the period between the administration of dose 1 through 13 days after the administration of dose 3, there were more wild-type rotavirus gastroenteritis (RVGE) cases among vaccine recipients compared with placebo recipients using the protocol-specified microbiological plaque assay in the clinical-efficacy cohort, a subset of subjects where vaccine efficacy against RVGE of any severity was assessed. In this study, a rotavirus genome segment 6-based reverse transcriptase\u2013polymerase chain reaction assay was applied post hoc to clarify the accuracy of type categorization of all these RVGE cases in vaccine recipients during the vaccination phase of REST. The assay characterized 147 (90%) of 163 re-assayed RVGE cases or rotavirus-associated health care contacts as type-determinable: either wild-type or vaccine-type rotavirus strains. In the clinical-efficacy cohort (N = 5673), 19 (18.8%) of 101 samples from RVGE cases contained wild-type rotavirus, 70 (69.3%) vaccine virus, and 12 (11.9%) were indeterminable. In the large-scale cohort (N = 68,038), 10 (34.5%) of 29 samples from RVGE-related health care contacts contained wild-type rotavirus strains, 15 (51.7%) vaccine-type rotavirus strains, and 4 (13.8%) were indeterminable. Of the 33 samples from RVGE cases in placebo recipients, all were confirmed to contain wild-type rotaviruses. Altogether, this post-hoc re-evaluation showed that the majority (75%) of type-determinable RVGE cases or health care contacts that occurred during the vaccination phase of REST in vaccine recipients were associated with vaccine-type rotavirus strains rather than wild-type rotavirus strains. PMID:25424931\n[Analysis by rotavirus gene 6 reverse transcriptase-polymerase chain reaction assay of rotavirus-positive gastroenteritis cases observed during the vaccination phase of the Rotavirus Efficacy and Safety Trial (REST).](https://www.ncbi.nlm.nih.gov/pubmed/25424931)\nMatson, David O; Vesikari, Timo; Dennehy, Penelope; Dallas, Michael D; Goveia, Michelle G; Itzler, Robbin F; Ciarlet, Max\n2014-01-01\nDuring the vaccination phase of the Rotavirus Efficacy and Safety Trial (REST), the period between the administration of dose 1 through 13 days after the administration of dose 3, there were more wild-type rotavirus gastroenteritis (RVGE) cases among vaccine recipients compared with placebo recipients using the protocol-specified microbiological plaque assay in the clinical-efficacy cohort, a subset of subjects where vaccine efficacy against RVGE of any severity was assessed. In this study, a rotavirus genome segment 6-based reverse transcriptase-polymerase chain reaction assay was applied post hoc to clarify the accuracy of type categorization of all these RVGE cases in vaccine recipients during the vaccination phase of REST. The assay characterized 147 (90%) of 163 re-assayed RVGE cases or rotavirus-associated health care contacts as type-determinable: either wild-type or vaccine-type rotavirus strains. In the clinical-efficacy cohort (N = 5673), 19 (18.8%) of 101 samples from RVGE cases contained wild-type rotavirus, 70 (69.3%) vaccine virus, and 12 (11.9%) were indeterminable. In the large-scale cohort (N = 68,038), 10 (34.5%) of 29 samples from RVGE-related health care contacts contained wild-type rotavirus strains, 15 (51.7%) vaccine-type rotavirus strains, and 4 (13.8%) were indeterminable. Of the 33 samples from RVGE cases in placebo recipients, all were confirmed to contain wild-type rotaviruses. Altogether, this post-hoc re-evaluation showed that the majority (75%) of type-determinable RVGE cases or health care contacts that occurred during the vaccination phase of REST in vaccine recipients were associated with vaccine-type rotavirus strains rather than wild-type rotavirus strains.\n[[Nosocomial rotavirus gastroenteritis].](https://www.ncbi.nlm.nih.gov/pubmed/27642146)\nMarinosci, A; Doit, C; Koehl, B; Belhacel, K; Mariani Kurkdjian, P; Melki, I; Renaud, A; Lemaitre, C; Ammar Khodja, N; Blachier, A; Bonacorsi, S; Faye, A; Lorrot, M\n2016-11-01\nRotavirus is the most common cause of gastroenteritis in children requiring hospitalization. It is a very resistant and contagious virus causing nosocomial gastroenteritis. In France, the vaccine against rotavirus has been available since 2006, but the vaccine is not recommended for infant vaccination. The aim of this retrospective study was to describe nosocomial rotavirus gastroenteritis (NRGE) and to assess its impact on children hospitalized in the General Pediatrics Department of Robert-Debr\u00e9 Hospital (Paris) between 1 January 2009 and 31 December 2013. We analyzed the demographic characteristics of children (age, term birth, underlying diseases) and the severity of the NRGE (oral or intravenous hydration), and assessed whether these children could benefit from vaccination against rotavirus. One hundred thirty-six children presented nosocomial rotavirus infection, with an incidence of 2.5 NRGE per 1000 days of hospitalization. The incidence of NRGE was stable between 2009 and 2013 despite the introduction of specific hygiene measures. The average age of the children was 7 months (range: 0.5-111 months). Most often NRGE occurred in children hospitalized for respiratory diseases (65% of cases) and requiring prolonged hospitalization (median: 18 days). One-third of children were born premature (25%). Hydration was oral in 80 patients (59%), by intravenous infusion in 18 patients (13%), and intraosseous in one patient. Half of the patients were aged less than 5 months and could benefit from the protection afforded by vaccination. NRGE are common. Rotavirus mass vaccination should have a positive impact on the incidence of NRGE by reducing the number of children hospitalized for gastroenteritis, therefore indirectly reducing the number of hospital cross-infections of hospitalized children who are too young to be vaccinated. Copyright \u00a9 2016 Elsevier Masson SAS. All rights reserved.\n[Molecular characterization of rotavirus strains detected during a clinical trial of a human rotavirus vaccine in Blantyre, Malawi](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3982048)\nNakagomi, Toyoko; Nakagomi, Osamu; Dove, Winifred; Doan, Yen Hai; Witte, Desiree; Ngwira, Bagrey; Todd, Stacy; Steele, A Duncan; Neuzil, Kathleen M; Cunliffe, Nigel A\n2014-01-01\nThe human, G1P[8] rotavirus vaccine (Rotarix) significantly reduced severe rotavirus gastroenteritis episodes in a clinical trial in South Africa and Malawi, but vaccine efficacy was lower in Malawi (49.5%) than reported in South Africa (76.9%) and elsewhere. The aim of this study was to examine the molecular relationships of circulating wild-type rotaviruses detected during the clinical trial in Malawi to RIX4414 (the strain contained in Rotarix) and to common human rotavirus strains. Of 88 rotavirus-positive, diarrhoeal stool specimens, 43 rotaviruses exhibited identifiable RNA migration patterns when examined by polyacrylamide gel electrophoresis. The genes encoding VP7, VP4, VP6 and NSP4 of 5 representative strains possessing genotypes G12P[6], G1P[8], G9P[8], and G8P[4] were sequenced. While their VP7 (G) and VP4 (P) genotype designations were confirmed, the VP6 (I) and NSP4 (E) genotypes were either I1E1 or I2E2, indicating that they were of human rotavirus origin. RNA-RNA hybridization using 21 culture-adapted strains showed that Malawian rotaviruses had a genomic RNA constellation common to either the Wa-like or DS-1 like human rotaviruses. Overall, the Malawi strains appear similar in their genetic make-up to rotaviruses described in countries where vaccine efficacy is greater, suggesting that the lower efficacy in Malawi is unlikely to be explained by the diversity of circulating strains. PMID:22520123\n[Rotavirus Infections - Multiple Languages](https://medlineplus.gov/languages/rotavirusinfections.html)\n... Are Here: Home \u2192 Multiple Languages \u2192 All Health Topics \u2192 Rotavirus Infections URL of this page: https://medlineplus.gov/ ... V W XYZ List of All Topics All Rotavirus Infections - Multiple Languages To use the sharing features ...\n[Estrategia y resultados de la farmacovigilancia de vacunas desde el Instituto Finlay, 2009](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2010000200006&lng=es&nrm=iso) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nIv\u00e1n E. Cuevas-Valdespino\n2010-08-01\nFull Text Available El objetivo de este trabajo fue mostrar la estrategia y los resultados de la farmacovigilancia desde el Instituto Finlay, como titular de registros sanitarios. Se concret\u00f3 la biograf\u00eda de los productos en la etapa de poscomercializaci\u00f3n y se examin\u00f3 el balance riesgo/beneficio. Esto fue posible gracias a convenios con instituciones que permitieron el acceso a bases de datos digitales y auditables, donde se encontr\u00f3 la notificaci\u00f3n espont\u00e1nea de eventos adversos y el cumplimiento de las buenas pr\u00e1cticas, reglamentos y regulaciones de la autoridad reguladora. La miner\u00eda de datos para la b\u00fasqueda de la agrupaci\u00f3n de eventos raros e inesperados para un mismo lote o de accidentes, la confecci\u00f3n de los informes peri\u00f3dicos de seguridad y la pr\u00e1ctica sistem\u00e1tica para completar la informaci\u00f3n de seguridad solicitada en subpoblaciones y grupos especiales permiti\u00f3 actualizar el perfil de seguridad de las vacunas. Se confirm\u00f3 que la vacuna antileptospir\u00f3sica trivalente, la antitifo\u00eddica Vi y el toxoide tet\u00e1nico, presentaron una frecuencia de eventos adversos menor de 0,1 reporte por cada 100.000 dosis administradas, mientras las dem\u00e1s vacunas tuvieron valores entre 1 y 10 por cada 10.000 vacunados. Entre el 80% y 95% de las notificaciones fueron relacionadas causalmente con la vacuna, y solo el 0,89% fueron de severidad grave, casi todas en ni\u00f1os menores de un a\u00f1o. Las manifestaciones generales fueron las que predominaron. Los resultados presentados muestran la importancia que tiene la farmacovigilancia desde la industria para obtener una valiosa informaci\u00f3n de la seguridad en la aplicaci\u00f3n de las vacunas.\n[Efectividad y duraci\u00f3n de la inmunidad de la vacuna frente al meningococo serogrupo A y C](http://www.redalyc.org/articulo.oa?id=17074415) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nLuis Garc\u00eda Comas\n2000-01-01\nFull Text Available FUNDAMENTO: La Comunidad de Madrid detect\u00f3 a partir de 1995 un incremento del n\u00famero de casos de enfermedad meningoc\u00f3cica por serogrupo C. En 1997 se realiz\u00f3 una campa\u00f1a de inmunizaci\u00f3n masiva sobre la poblaci\u00f3n de 18 meses a 19 a\u00f1os. El objetivo de este estudio es conocer la respuesta inmunitaria producida por la vacuna y su relaci\u00f3n con la edad. M\u00c9TODOS: Se seleccion\u00f3 una muestra de 1.003 ni\u00f1os vacunados durante la campa\u00f1a. Se extrajo una muestra de sangre antes de la vacunaci\u00f3n y tras uno, seis (solo <5a y doce meses. Para valorar la respuesta inmune se midieron niveles de anticuerpos bactericidas y totales. RESULTADOS: La prevalencia de seroconversi\u00f3n medida por anticuerpos bactericidas es 89,6%. La respuesta es baja en menores de 3 a\u00f1os (34,8%, aumenta con la edad y a partir de los 7 a\u00f1os supera el 90%. A los 6 meses, la prevalencia de niveles protectores en menores de 5 a\u00f1os desciende notablemente (31,3%. Al a\u00f1o, la prevalencia desciende notablemente, especialmente en menores de 7 a\u00f1os. La proporci\u00f3n de individuos con respuesta de anticuerpos totales al mes supera el 90% y se mantiene elevada al a\u00f1o en todos los grupos edad (97,5%. CONCLUSIONES: La respuesta medida mediante anticuerpos totales entra en contradicci\u00f3n con la respuesta cl\u00ednica a la vacunaci\u00f3n y la medida mediante anticuerpos bactericidas infraestima la protecci\u00f3n si se compara con los resultados de efectividad vacunal, por lo que es necesario buscar indicadores biol\u00f3gicos que se correlacionen de manera adecuada con la respuesta cl\u00ednica tras la vacunaci\u00f3n.\n[Cost-effectiveness of Rotavirus vaccination in Vietnam](http://www.biomedcentral.com/1471-2458/9/29) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nGoldie Sue J\n2009-01-01\nFull Text Available Abstract Background Rotavirus is the most common cause of severe diarrhea leading to hospitalization or disease-specific death among young children. New rotavirus vaccines have recently been approved. Some previous studies have provided broad qualitative insights into the health and economic consequences of introducing the vaccines into low-income countries, representing several features of rotavirus infection, such as varying degrees of severity and age-dependency of clinical manifestation, in their model-based analyses. We extend this work to reflect additional features of rotavirus (e.g., the possibility of reinfection and varying degrees of partial immunity conferred by natural infection, and assess the influence of the features on the cost-effectiveness of rotavirus vaccination. Methods We developed a Markov model that reflects key features of rotavirus infection, using the most recent data available. We applied the model to the 2004 Vietnamese birth cohort and re-evaluated the cost-effectiveness (2004 US dollars per disability-adjusted life year [DALY] of rotavirus vaccination (Rotarix\u00ae compared to no vaccination, from both societal and health care system perspectives. We conducted univariate sensitivity analyses and also performed a probabilistic sensitivity analysis, based on Monte Carlo simulations drawing parameter values from the distributions assigned to key uncertain parameters. Results Rotavirus vaccination would not completely protect young children against rotavirus infection due to the partial nature of vaccine immunity, but would effectively reduce severe cases of rotavirus gastroenteritis (outpatient visits, hospitalizations, or deaths by about 67% over the first 5 years of life. Under base-case assumptions (94% coverage and $5 per dose, the incremental cost per DALY averted from vaccination compared to no vaccination would be $540 from the societal perspective and $550 from the health care system perspective. Conclusion\n[Molecular characterization of rotavirus strains detected during a clinical trial of a human rotavirus vaccine in Blantyre, Malawi.](https://www.ncbi.nlm.nih.gov/pubmed/22520123)\nNakagomi, Toyoko; Nakagomi, Osamu; Dove, Winifred; Doan, Yen Hai; Witte, Desiree; Ngwira, Bagrey; Todd, Stacy; Duncan Steele, A; Neuzil, Kathleen M; Cunliffe, Nigel A\n2012-04-27\nThe human, G1P[8] rotavirus vaccine (Rotarix\u2122) significantly reduced severe rotavirus gastroenteritis episodes in a clinical trial in South Africa and Malawi, but vaccine efficacy was lower in Malawi (49.5%) than reported in South Africa (76.9%) and elsewhere. The aim of this study was to examine the molecular relationships of circulating wild-type rotaviruses detected during the clinical trial in Malawi to RIX4414 (the strain contained in Rotarix\u2122) and to common human rotavirus strains. Of 88 rotavirus-positive, diarrhoeal stool specimens, 43 rotaviruses exhibited identifiable RNA migration patterns when examined by polyacrylamide gel electrophoresis. The genes encoding VP7, VP4, VP6 and NSP4 of 5 representative strains possessing genotypes G12P[6], G1P[8], G9P[8], and G8P[4] were sequenced. While their VP7 (G) and VP4 (P) genotype designations were confirmed, the VP6 (I) and NSP4 (E) genotypes were either I1E1 or I2E2, indicating that they were of human rotavirus origin. RNA-RNA hybridization using 21 culture-adapted strains showed that Malawian rotaviruses had a genomic RNA constellation common to either the Wa-like or the DS-1 like human rotaviruses. Overall, the Malawi strains appear similar in their genetic make-up to rotaviruses described in countries where vaccine efficacy is greater, suggesting that the lower efficacy in Malawi is unlikely to be explained by the diversity of circulating strains. Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.\n[Rotavirus infection in Saudi Arabia](https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=38058367) [International Nuclear Information System (INIS) ](http://inis.iaea.org/search/)\nKheyami, Ali M.; Cunliffe, Nigel A.; Hart, C. Anthony\n2006-01-01\nHuman rotavirus, an important causative agent of severe gastroenteritis in infants and young children worldwide, leads to high morbidity in both developing and developed countries. Effective control depends upon an accurate understanding of disease burden and the relative importance of circulating serotypes. We examined the epidemiology and disease burden of rotavirus in Saudi Arabia through a review of 22 published studies of rotavirus and the antilogy diarrhea carried out from 1982 to 2003. The prevalence of rotavirus ranged between 10% to 46% with a median of 30%. Most cases were among children less than 2 years of age, and particularly in first year of life. There were significant differences in the seasonability within Saudi Arabia with increased infection during winter in some cities and during summer in others. G1 was the predominant serotype followed by G4, G3 and G2, in 4 studies where strains have been G-typed. The prevalence of noticeable strains ranged from 11.0% to 31.3%. No data were available on P types... Results of electropherotyping in 4 studies revealed that the long elctropherotype was predominant. Rotavirus is an important cause of severe diarrhea in Saudi children. However, the available data on rotavirus strains in circulation are limited. And there is an urgent need for up-to-date and comprehensive studies to evaluate rotavirus strains in circulation and identify unusual types that could be incorporated into future vaccines. (author)\n[Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nKang G\n2006-01-01\nFull Text Available Rotavirus, the most common cause of severe diarrhea and a leading cause of mortality in children, has been a priority target for vaccine development for the past several years. The first rotavirus vaccine licensed in the United States was withdrawn because of an association of the vaccine with intussusception. However, the need for a vaccine is greatest in the developing world, because the benefits of preventing deaths due to rotavirus disease are substantially greater than the risk of intussusception. Early vaccines were based on animal strains. More recently developed and licenced vaccines are either animal-human reassortants or are based on human strains. In India, two candidate vaccines are in the development process, but have not yet reached efficacy trials. Many challenges regarding vaccine efficacy and safety remain. In addition to completing clinical evaluations of vaccines in development in settings with the highest disease burden and virus diversity, there is also a need to consider alternative vaccine development strategies.\n[WAWASAN AL-QURAN TENTANG PENDIDIKAN ANTI KORUPSI](http://ejournal.stitmuh-pacitan.ac.id/index.php/attajdid/article/view/22) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMuh Mustakim\n2013-01-01\nQuranic perspectives on anti-corruption education is reflected in at least three (3 pronunciation: gulul, al-suht, al-sariqah. The implementation of the Anti-corruption education: The importance of knowing: the first theory about corruption; causes, effects and type (tilawah. Second, keep yourself in order not to fall in corruption (tazkiyah, third, establish and foster self-confidence in dealing with the problem (takwiniyah not to fear in the truth, learning manners and wise (hikmah. Fourth, Growing power of faith and self-confidence (quwwatul Imaniyah, and the fifth, habituation evaluation in every activity and action (mutabaah.\n[Rotavirus antigenemia in children is associated with viremia.](http://europepmc.org/articles/PMC1852122?pdf=render) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nSarah E Blutt\n2007-04-01\nFull Text Available Antigenemia is commonly detected in rotavirus-infected children. Although rotavirus RNA has been detected in serum, definitive proof of rotavirus viremia has not been shown. We aimed to analyze a defined patient population to determine if infectious virus could be detected in sera from children with rotavirus antigenemia.Serum samples obtained upon hospitalization from children with gastroenteritis (57 stool rotavirus-positive and 41 rotavirus-negative, children with diagnosed bronchiolitis of known (n = 58 or unknown (n = 17 viral etiology, children with noninfectious, nonchronic conditions (n = 17, and healthy adults (n = 28 were tested for rotavirus antigen by enzyme immunoassay (EIA. Results of serum antigen testing were assessed for association with clinical and immunological attributes of the children. Rotavirus antigenemia was detected in 90% (51/57 of children with rotavirus-positive stools, in 89% (8/9 of children without diarrhea but with rotavirus-positive stools, in 12% (2/17 of children with bronchiolitis of unknown etiology without gastroenteritis, and in 12% (5/41 of children with gastroenteritis but with rotavirus-negative stools. Antigenemia was not detected in sera from children with noninfectious nonchronic conditions, children with bronchiolitis of known etiology and no gastroenteritis, or healthy adults. Neither age nor timing of serum collection within eight days after onset of gastroenteritis significantly affected levels of antigenemia, and there was no correlation between antigenemia and viral genotype. However, there was a negative correlation between serum rotavirus antigen and acute rotavirus-specific serum IgA (r = -0.44, p = 0.025 and IgG (r = -0.40, p = 0.01 titers. We examined 11 antigen-positive and nine antigen-negative sera for infectious virus after three blind serial passages in HT-29 cells using immunofluorescence staining for rotavirus structural and nonstructural proteins. Infectious virus was detected in\n[Rotavirus Antigenemia in Children Is Associated with Viremia](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1852122)\nBlutt, Sarah E; Matson, David O; Crawford, Sue E; Staat, Mary Allen; Azimi, Parvin; Bennett, Berkeley L; Piedra, Pedro A; Conner, Margaret E\n2007-01-01\nBackground Antigenemia is commonly detected in rotavirus-infected children. Although rotavirus RNA has been detected in serum, definitive proof of rotavirus viremia has not been shown. We aimed to analyze a defined patient population to determine if infectious virus could be detected in sera from children with rotavirus antigenemia. Methods and Findings Serum samples obtained upon hospitalization from children with gastroenteritis (57 stool rotavirus-positive and 41 rotavirus-negative), children with diagnosed bronchiolitis of known (n = 58) or unknown (n = 17) viral etiology, children with noninfectious, nonchronic conditions (n = 17), and healthy adults (n = 28) were tested for rotavirus antigen by enzyme immunoassay (EIA). Results of serum antigen testing were assessed for association with clinical and immunological attributes of the children. Rotavirus antigenemia was detected in 90% (51/57) of children with rotavirus-positive stools, in 89% (8/9) of children without diarrhea but with rotavirus-positive stools, in 12% (2/17) of children with bronchiolitis of unknown etiology without gastroenteritis, and in 12% (5/41) of children with gastroenteritis but with rotavirus-negative stools. Antigenemia was not detected in sera from children with noninfectious nonchronic conditions, children with bronchiolitis of known etiology and no gastroenteritis, or healthy adults. Neither age nor timing of serum collection within eight days after onset of gastroenteritis significantly affected levels of antigenemia, and there was no correlation between antigenemia and viral genotype. However, there was a negative correlation between serum rotavirus antigen and acute rotavirus-specific serum IgA (r = \u22120.44, p = 0.025) and IgG (r = \u22120.40, p = 0.01) titers. We examined 11 antigen-positive and nine antigen-negative sera for infectious virus after three blind serial passages in HT-29 cells using immunofluorescence staining for rotavirus structural and nonstructural proteins\n[An evaluation of the inhibitory effects against rotavirus infection of edible plant extracts](http://www.virologyj.com/content/9/1/137) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nKnipping Karen\n2012-07-01\nFull Text Available Abstract Background Rotaviruses are the single most important cause of severe diarrhea in young children worldwide. The developments of specific, potent and accessible antiviral treatments that restrain rotavirus infection remain important to control rotavirus disease. Methods 150 plant extracts with nutritional applications were screened in vitro on MA-104 cells for their antiviral activity against rhesus rotavirus (RRV. One extract (Aspalathus linearis (Burm.f. R.Dahlgren was also tested for its effect on the loss of transepithelial resistance (TER of Caco-2 cells caused by simian rotavirus (SA-11 infection. Results Aqueous extracts of Nelumbo nucifera Gaertn. fruit, Urtica dioica L. root, Aspalathus linearis (Burm.f. R.Dahlgren leaves, Glycyrrhiza glabra L. root and Olea europaea L. leaves were found to have strong significant antiviral activity with a 50% inhibitory concentration (IC50 Glycyrrhiza glabra was found to have the strongest antiviral activity (IC50 46 \u03bcM, followed by luteolin and vitexin from Aspalathus linearis (IC50 respectively 116 \u03bcM and 129 \u03bcM and apigenin-7-O-glucoside from Melissa officinalis (IC50 150 \u03bcM. A combination of Glycyrrhiza glabra L. + Nelumbo nucifera Gaertn. and Urtica dioica L. + Nelumbo nucifera Gaertn. showed synergy in their anti-viral activities. Aspalathus linearis (Burm.f. R.Dahlgren showed no positive effect on the maintenance of the TER. Conclusions These results indicate that nutritional intervention with extracts of Nelumbo nucifera Gaertn., Aspalathus linearis (Burm.f. R.Dahlgren, Urtica dioica L., Glycyrrhiza glabra L. and Olea europaea L. might be useful in the treatment of diarrhea caused by rotavirus infection.\n[Immunogenicity of rotavirus vaccine (RotarixTM) in infants with environmental enteric dysfunction.](https://www.ncbi.nlm.nih.gov/pubmed/29281659)\nMwape, Innocent; Bosomprah, Samuel; Mwaba, John; Mwila-Kazimbaya, Katayi; Laban, Natasha Makabilo; Chisenga, Caroline Cleopatra; Sijumbila, Gibson; Simuyandi, Michelo; Chilengi, Roma\n2017-01-01\nDeployment of rotavirus vaccines has contributed to significant declines in diarrheal morbidity and mortality globally. Unfortunately, vaccine performance in low-middle income countries (LMICs) is generally lower than in developed countries. The cause for this has been associated with several host and maternal factors including poor water sanitation and hygiene (WASH) status, which are predominant in LMICs. More recently, environmental enteric dysfunction (EED) has specifically been hypothesized to contribute to poor vaccine uptake and response. The aim of this study was to examine the association between serological biomarkers of EED and seroconversion to rotavirus vaccine in Zambian infants. This was a retrospective cohort study of 142 infants who had been fully immunized with Rotarix\u2122, and had known seroconversion status. Seroconversion was defined as 4-fold or more increase in rotavirus-specific IgA titres between pre-vaccination and one month post-dose two vaccination. We performed ELISA assays to assess soluble CD14 (sCD14), Endotoxin Core IgG Antibodies (EndoCAb), intestinal fatty acid binding protein (i-FABP) and Zonulin according to the manufacturers protocols. Generalised linear model with family-poisson, link-log and robust standard error was used to estimate the independent effects of biomarkers on seroconversion adjusting for important cofounders. The median concentration of Zonulin, Soluble CD14, EndoCaB, and IFABP were 209.3 (IQR = 39.7, 395.1), 21.5 (IQR = 21.5, 21.5), 0.3 (IQR = 0.3, 0.3), and 107.7 (IQR = 6.4, 1141.4) respectively. In multivariable analyses adjusting for the independent effect of other biomarkers and confounders (i.e. age of child at vaccination, breast-milk anti-rotavirus IgA, infant serum anti-rotavirus IgG, and IgA seropositivity at baseline), there was strong evidence of about 24% increase in seroconversion due to doubling Zonulin concentration (Adjusted risk ratio (aRR) = 1.24; 95% CI = 1.12 to1.37; pzonulin and IFABP\n[No se ha demostrado asociaci\u00f3n entre la presencia del timerosal en las vacunas y el autismo](https://www.openaire.eu/search/publication?articleId=od______3056::5d7a8a9d35638166a4e7ccabd8678667)\nCabezas S\u00e1nchez, C\u00e9sar\n2007-01-01\nEl timerosal es un compuesto org\u00e1nico que contiene etilmercurio, el cual ha sido usado como preservante de algunas vacunas, sobre todo en la presentaci\u00f3n de multidosis desde los a\u00f1os 30. El etilmercurio es diferente del metilmercurio, este \u00faltimo s\u00ed se conoce que es neurot\u00f3xico; sin embargo, el metabolismo del etilmercurio es diferente del metilmercurio. En realidad se quiso inferir que la toxicidad del metilmercurio era similar al etilmercurio presente en el timerosal.\n[Provada amb \u00e8xit en cabres una nova vacuna contra la tuberculosi](https://www.openaire.eu/search/publication?articleId=od______1404::4dfcdb9afa501d98d59e07e37c0dec1f)\nP\u00e9rez del Val, Bernat\n2014-01-01\nInvestigadors del CReSA proven per primer cop i amb \u00e8xit una nova vacuna contra la tuberculosi que millora la protecci\u00f3 de l\u2019\u00fanica vacuna existent en l\u2019actualitat, l\u2019efic\u00e0cia de la qual \u00e9s for\u00e7a limitada. Els estudis s\u2019han realitzat emprant cabres dom\u00e8stiques, que reprodueixen amb elevada similitud les caracter\u00edstiques patol\u00f2giques i la resposta immunol\u00f2gica a la infecci\u00f3 tuberculosa activa en humans i que, pel fet de ser hostes naturals de la tuberculosi, tamb\u00e9 permeten estudiar l\u2019\u00fas potenci...\n[Conocimientos de los pediatras de Salvador, Brasil, sobre la vacuna antisarampionosa](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891997001200001) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMoreira Luiza A. Cabus\n1997-01-01\nFull Text Available El \u00e9xito de las iniciativas internacionales para la erradicaci\u00f3n del sarampi\u00f3n depende en gran medida del grado de conocimiento sobre la vacunaci\u00f3n. En 1992 se evaluaron mediante un estudio transversal los conocimientos sobre la vacuna antisarampionosa de los pediatras de la ciudad brasile\u00f1a de Salvador, Bahia. Del total de 506 pediatras residentes en la ciudad, 299 (59% pudieron ser localizados y respondieron a un cuestionario de 15 preguntas en las que se planteaban situaciones hipot\u00e9ticas sobre indicaciones y contraindicaciones de esta vacuna. El promedio de aciertos fue de 9,3 preguntas de las 15, lo que muestra el poco conocimiento de los pediatras sobre la vacunaci\u00f3n antisarampiososa. Situaciones comunes en la pr\u00e1ctica pedi\u00e1trica brasile\u00f1a -desnutrici\u00f3n, infecci\u00f3n de v\u00edas respiratorias altas, diarrea y estado prematuro- fueron a menudo err\u00f3neamente consideradas como contraindicaciones para la inmunizaci\u00f3n. M\u00e1s de la mitad (62% de los pediatras no conoc\u00edan la v\u00eda correcta de administraci\u00f3n de la vacuna. Los conocimientos sobre la vacuna no variaron en funci\u00f3n del tiempo transcurrido desde la formaci\u00f3n universitaria del pediatra o de su trabajo en centros sanitarios de la Secretar\u00eda Estatal de Salud. Los profesores universitarios, los pediatras con maestr\u00eda y los que cursaban estudios de posgrado tuvieron una media de aciertos ligeramente superior a la del resto. Estos resultados indican la necesidad de reforzar la ense\u00f1anza sobre la vacunaci\u00f3n antisarampionosa en las facultades de medicina y en los programas de formaci\u00f3n continuada para pediatras.\n[Conocimientos de los pediatras de Salvador, Brasil, sobre la vacuna antisarampionosa](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891997001200001&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nLuiza A. Cabus Moreira\n1997-12-01\nFull Text Available El \u00e9xito de las iniciativas internacionales para la erradicaci\u00f3n del sarampi\u00f3n depende en gran medida del grado de conocimiento sobre la vacunaci\u00f3n. En 1992 se evaluaron mediante un estudio transversal los conocimientos sobre la vacuna antisarampionosa de los pediatras de la ciudad brasile\u00f1a de Salvador, Bahia. Del total de 506 pediatras residentes en la ciudad, 299 (59% pudieron ser localizados y respondieron a un cuestionario de 15 preguntas en las que se planteaban situaciones hipot\u00e9ticas sobre indicaciones y contraindicaciones de esta vacuna. El promedio de aciertos fue de 9,3 preguntas de las 15, lo que muestra el poco conocimiento de los pediatras sobre la vacunaci\u00f3n antisarampiososa. Situaciones comunes en la pr\u00e1ctica pedi\u00e1trica brasile\u00f1a -desnutrici\u00f3n, infecci\u00f3n de v\u00edas respiratorias altas, diarrea y estado prematuro- fueron a menudo err\u00f3neamente consideradas como contraindicaciones para la inmunizaci\u00f3n. M\u00e1s de la mitad (62% de los pediatras no conoc\u00edan la v\u00eda correcta de administraci\u00f3n de la vacuna. Los conocimientos sobre la vacuna no variaron en funci\u00f3n del tiempo transcurrido desde la formaci\u00f3n universitaria del pediatra o de su trabajo en centros sanitarios de la Secretar\u00eda Estatal de Salud. Los profesores universitarios, los pediatras con maestr\u00eda y los que cursaban estudios de posgrado tuvieron una media de aciertos ligeramente superior a la del resto. Estos resultados indican la necesidad de reforzar la ense\u00f1anza sobre la vacunaci\u00f3n antisarampionosa en las facultades de medicina y en los programas de formaci\u00f3n continuada para pediatras.\n[Milk from Brazilian women presents secretory IgA antibodies and neutralizes rotavirus G9P[5](http://www.sciencedirect.com/science/article/pii/S2255553613000785) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nSimone M.R. Santos\n2013-09-01\nConclusions: The high correlation between anti-rotavirus antibody levels and neutralizing capacity of the milk samples suggests a possible protective role of these antibodies against infection. These results also support the encouragement of the breast-feeding practice.\n[Pathogenesis of Rotavirus Infection](https://www.narcis.nl/publication/RecordID/oai%3Arepub.eur.nl%3A6760/uquery/Gene%2Bexpression%2BmRNA%2B/id/8/Language/EN)\nJ.A. Boshuizen\n2005-01-01\ntextabstractRotaviruses comprise a genus within the family of the Reoviridae and are recognized as the single most significant cause of severe gastroenteritis, malnutrition and diarrhea in young children. Each year rotavirus causes the death of about 440.000 children <5 years of age (313). The\n[Ensayo precl\u00ednico de la vacuna candid #1 producida en Argentina contra la Fiebre Hemorr\u00e1gica Argentina Preclinical assay of Candid #1 vaccine against Argentine Hemorrhagic Fever made in Argentina](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802005000400008) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAna M. Ambrosio\n2005-08-01\nFull Text Available Se compar\u00f3 en cobayos la seguridad, inmunogenicidad y eficacia protectora de un lote de vacuna Candid #1(C#1 fabricada en Estados Unidos de Am\u00e9rica (EE.UU. y distintos lotes de la misma vacuna fabricados en Argentina (Arg. El lote TSI 5-1-92 (EE.UU. y los lotes Exp N\u00ba 3, 7A y 8A (Arg fueron inoculados (0.5 ml, IM en cobayos de 250-400 g. Para cada ensayo diez animales recibieron soluci\u00f3n fisiol\u00f3gica y sirvieron como control. Todos fueron desafiados con la cepa pat\u00f3gena P23790 de virus Junin. Se registr\u00f3: a temperatura rectal, b peso corporal, c presencia de anticuerpos neutralizantes (AcNT pre y post-vacunaci\u00f3n, d respuesta al desaf\u00edo. Todos los animales vacunados desarrollaron AcNT anti virus Junin (rango = 40- 81920 y sobrevivieron al desaf\u00edo. En cada grupo control 8/10 animales murieron (d\u00eda 23.3 \u00b1 5.4 post-desaf\u00edo. Los cobayos resultaron id\u00e9nticamente protegidos de una descarga letal de virus Junin por la vacuna importada y los diferentes lotes de C#1 producidos en Argentina.Candid #1 vaccine against Argentine Hemorrhagic Fever produced in USA versus lots of the same vaccine made in Argentina were compared in guinea pigs regarding safety, immunogenicity and protective efficacy against a challenge with pathogenic Junin virus. Lots N\u00ba Exp 3, 7A and 8A of Argentine origin as well as lot TSI 5-1-92 from USA were inoculated in guinea pigs of 250-400 g in two consecutive assays. Ten animals inoculated with saline performed as normal controls in each experiment. Parameters studied were: a temperature; b body weight; c neutralizing antibodies to Junin virus; d response to viral challenge. Animals gained weight and remained normothermic up to the challenge. Guinea pigs that received Candid #1 from any manufacturer elicited neutralizing antibodies to Junin virus (titles from 40 to 81920 and survived to challenge whilst 8/10 animals died in each control group. Data presented demonstrated that Candid #1 vaccines from USA or Argentine\n[Semipolar MOVPE AlGaN on (10 anti 10) m-plane sapphire; MOVPE von semipolarem AlGaN auf (10 anti 10) m-plane Saphir](http://www.etde.org/etdeweb/details.jsp?query_id=1&page=0&osti_id=21484941) [Energy Technology Data Exchange (ETDEWEB)](https://www.etde.org/etdeweb/fieldedsearch.jsp)\nMehnke, Frank; Stellmach, Joachim; Frentrup, Martin; Kusch, Gunnar; Wernicke, Tim; Pristovsek, Markus; Kneissl, Michael [Technische Universitaet Berlin, Institut fuer Festkoerperphysik, Hardenbergstr. 36, 10623 Berlin (Germany)\n2011-07-01\nThe energy gap of AlGaN varies between 3.4 eV and 6.2 eV and allows light emitting diodes (LED) in the ultraviolet spectral region. The authors studied semipolar (11 anti 22) AlGaN layers that were deposited on (10 anti 10) m-plane sapphire using MOVPE (metalorganic vapor phase epitaxy) without nucleation layer with a substrate temperature below 1100 C in H2 atmosphere. The layers are preferably (11 anti 22) oriented. The sample show a surface roughness between 15 and 2 nm. The Al content of the smoothest samples is about 60% determined by transmission experiments. Below 60% Al content a triangular morphology was observed, the opening angle increased with decreasing Al content. The absorption edge was 0.05 eV (GaN) to 0.35 eV (AlN) below the band edge of (0001) oriented AlGaN layers. Further investigations of semipolar AlGaN layers to study the applicability for UV LEDs are under preparation.\n[Subunit Rotavirus Vaccine Administered Parenterally to Rabbits Induces Active Protective Immunity](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=110343)\nCiarlet, Max; Crawford, Sue E.; Barone, Christopher; Bertolotti-Ciarlet, Andrea; Ramig, Robert F.; Estes, Mary K.; Conner, Margaret E.\n1998-01-01\nVirus-like particles (VLPs) are being evaluated as a candidate rotavirus vaccine. The immunogenicity and protective efficacy of different formulations of VLPs administered parenterally to rabbits were tested. Two doses of VLPs (2/6-, G3 2/6/7-, or P[2], G3 2/4/6/7-VLPs) or SA11 simian rotavirus in Freund\u2019s adjuvants, QS-21 (saponin adjuvant), or aluminum phosphate (AlP) were administered. Serological and mucosal immune responses were evaluated in all vaccinated and control rabbits before and after oral challenge with 103 50% infective doses of live P[14], G3 ALA lapine rotavirus. All VLP- and SA11-vaccinated rabbits developed high levels of rotavirus-specific serum and intestinal immunoglobulin G (IgG) antibodies but not intestinal IgA antibodies. SA11 and 2/4/6/7-VLPs afforded similar but much higher mean levels of protection than 2/6/7- or 2/6-VLPs in QS-21. The presence of neutralizing antibodies to VP4 correlated (P < 0.001, r = 0.55; Pearson\u2019s correlation coefficient) with enhanced protection rates, suggesting that these antibodies are important for protection. Although the inclusion of VP4 resulted in higher mean protection levels, high levels of protection (87 to 100%) from infection were observed in individual rabbits immunized with 2/6/7- or 2/6-VLPs in Freund\u2019s adjuvants. Therefore, neither VP7 nor VP4 was absolutely required to achieve protection from infection in the rabbit model when Freund\u2019s adjuvant was used. Our results show that VLPs are immunogenic when administered parenterally to rabbits and that Freund\u2019s adjuvant is a better adjuvant than QS-21. The use of the rabbit model may help further our understanding of the critical rotavirus proteins needed to induce active protection. VLPs are a promising candidate for a parenterally administered subunit rotavirus vaccine. PMID:9765471\n[Impact of routine rotavirus vaccination on all-cause and rotavirus hospitalizations during the first four years following vaccine introduction in Rwanda.](https://www.ncbi.nlm.nih.gov/pubmed/29754701)\nSibomana, Hassan; Rugambwa, Celse; Mwenda, Jason M; Sayinzoga, Felix; Iraguha, Gisele; Uwimana, Jeanine; Parashar, Umesh D; Tate, Jacqueline E\n2018-05-10\nRwanda introduced pentavalent rotavirus vaccine into its national immunization program in 2012. To determine the long-term impact of rotavirus vaccine on disease burden in a high burden setting, we examined trends in rotavirus and all-cause diarrhea hospitalizations in the first four years following rotavirus vaccine introduction. We used data from an active surveillance system, from a review of pediatric ward registries, and from the Health Management Information System to describe trends in rotavirus and all-cause diarrhea hospitalizations from January 2009 through December 2016. Percent reductions were calculated to compare the number of all-cause and rotavirus diarrhea hospitalizations pre- and post-rotavirus vaccine introduction. The proportion of diarrhea hospitalizations due to rotavirus declined by 25-44% among all children introduction to 12-13% post-vaccine introduction. In the national hospital discharge data, substantial decreases were observed in all-cause diarrhea hospitalizations among children introduction era. Published by Elsevier Ltd.\n[Prevalence of rotavirus genotypes in children younger than 5 years of age before the introduction of a universal rotavirus vaccination program: report of rotavirus surveillance in Turkey.](http://europepmc.org/articles/PMC4249891?pdf=render) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nRiza Durmaz\nFull Text Available BACKGROUND: Group A rotaviruses are the most common causative agent of acute gastroenteritis among children less than 5 years of age throughout the world. This sentinel surveillance study was aimed to obtain baseline data on the rotavirus G and P genotypes across Turkey before the introduction of a universal rotavirus vaccination program. METHODS: Rotavirus antigen-positive samples were collected from 2102 children less than 5 years of age who attended hospitals participating in the Turkish Rotavirus Surveillance Network. Rotavirus antigen was detected in the laboratories of participating hospitals by commercial serological tests such as latex agglutination, immunochromatographic test or enzyme immunoassay. Rotavirus G and P genotypes were determined by reverse transcription polymerase chain reaction (RT-PCR using consensus primers detecting the VP7 and VP4 genes, followed by semi-nested type-specific multiplex PCR. RESULTS: RT-PCR found rotavirus RNA in 1644 (78.2% of the samples tested. The highest rate of rotavirus positivity (38.7% was observed among children in the 13 to 24 month age group, followed by children in the age group of 25 to 36 months (28.3%. A total of eight different G types, six different P types, and 42 different G-P combinations were obtained. Four common G types (G1, G2, G3, and G9 and two common P types (P[8] and P[4] accounted for 95.1% and 98.8% of the strains, respectively. G9P[8] was the most common G/P combination found in 40.5% of the strains followed by G1P[8] (21.6%, G2P[8] (9.3%, G2P[4] (6.5%, G3P[8] (3.5%, and finally, G4P[8] (3.4%. These six common genotypes included 83.7% of the strains tested in this study. The rate of uncommon genotypes was 14%. CONCLUSION: The majority of the strains analyzed belonged to the G1-G4 and G9 genotypes, suggesting high coverage of current rotavirus vaccines. This study also demonstrates a dramatic increase in G9 genotype across the country.\n[Prevalence of Rotavirus Genotypes in Children Younger than 5 Years of Age before the Introduction of a Universal Rotavirus Vaccination Program: Report of Rotavirus Surveillance in Turkey](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4249891)\nDurmaz, Riza; Kalaycioglu, Atila Taner; Acar, Sumeyra; Bakkaloglu, Zekiye; Karagoz, Alper; Korukluoglu, Gulay; Ertek, Mustafa; Torunoglu, Mehmet Ali\n2014-01-01\nBackground Group A rotaviruses are the most common causative agent of acute gastroenteritis among children less than 5 years of age throughout the world. This sentinel surveillance study was aimed to obtain baseline data on the rotavirus G and P genotypes across Turkey before the introduction of a universal rotavirus vaccination program. Methods Rotavirus antigen-positive samples were collected from 2102 children less than 5 years of age who attended hospitals participating in the Turkish Rotavirus Surveillance Network. Rotavirus antigen was detected in the laboratories of participating hospitals by commercial serological tests such as latex agglutination, immunochromatographic test or enzyme immunoassay. Rotavirus G and P genotypes were determined by reverse transcription polymerase chain reaction (RT-PCR) using consensus primers detecting the VP7 and VP4 genes, followed by semi-nested type-specific multiplex PCR. Results RT-PCR found rotavirus RNA in 1644 (78.2%) of the samples tested. The highest rate of rotavirus positivity (38.7%) was observed among children in the 13 to 24 month age group, followed by children in the age group of 25 to 36 months (28.3%). A total of eight different G types, six different P types, and 42 different G\u2013P combinations were obtained. Four common G types (G1, G2, G3, and G9) and two common P types (P[8] and P[4]) accounted for 95.1% and 98.8% of the strains, respectively. G9P[8] was the most common G/P combination found in 40.5% of the strains followed by G1P[8] (21.6%), G2P[8] (9.3%), G2P[4] (6.5%), G3P[8] (3.5%), and finally, G4P[8] (3.4%). These six common genotypes included 83.7% of the strains tested in this study. The rate of uncommon genotypes was 14%. Conclusion The majority of the strains analyzed belonged to the G1\u2013G4 and G9 genotypes, suggesting high coverage of current rotavirus vaccines. This study also demonstrates a dramatic increase in G9 genotype across the country. PMID:25437502\n[Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants.](https://www.ncbi.nlm.nih.gov/pubmed/22228235)\nVesikari, Timo; Prymula, Roman; Schuster, Volker; Tejedor, Juan-C; Cohen, Robert; Bouckenooghe, Alain; Damaso, Silvia; Han, Htay Htay\n2012-05-01\nRotavirus is the main cause of severe gastroenteritis and diarrhea in infants and young children less than 5 years of age. Potential impact of breast-feeding on the efficacy and immunogenicity of human rotavirus G1P[8] vaccine was examined in this exploratory analysis. Healthy infants (N = 3994) aged 6-14 weeks who received 2 doses of human rotavirus vaccine/placebo according to a 0-1 or 0-2 month schedule were followed for rotavirus gastroenteritis during 2 epidemic seasons. Rotavirus IgA seroconversion rate (anti-IgA antibody concentration \u2265 20 mIU/mL) and geometric mean concentrations were measured prevaccination and 1-2 months post-dose 2. Vaccine efficacy against any and severe rotavirus gastroenteritis was analyzed according to the infants being breast-fed or exclusively formula-fed at the time of vaccination. Antirotavirus IgA seroconversion rate was 85.5% (95% confidence interval [CI]: 82.4-88.3) in breast-fed and 89.2% (95% CI: 84.2-93) in exclusively formula-fed infants; geometric mean concentrations in the respective groups were 185.8 U/mL (95% CI: 161.4-213.9) and 231.5 U/mL (95% CI: 185.9-288.2). Vaccine efficacy was equally high in breast-fed and exclusively formula-fed children in the first season but fell in breast-fed infants in the second rotavirus season. During the combined 2-year efficacy follow-up period, vaccine efficacy against any rotavirus gastroenteritis was 76.2% (95% CI: 68.7-82.1) and 89.8% (95% CI: 77.6-95.9) and against severe rotavirus gastroenteritis 88.4% (95% CI: 81.6-93) and 98.1% (95% CI: 88.2-100) in the breast-fed and exclusively formula-fed infants, respectively. The difference in immunogenicity of human rotavirus vaccine in breast-fed and exclusively formula-fed infants was small. Vaccine efficacy was equally high in breast-fed and exclusively formula-fed children in the first season. Breast-feeding seemed to reduce slightly the efficacy in the second season.\n[An\u00e1lisis econ\u00f3mico de las vacunas 10-valente y 13-valente contra neumococo: revisi\u00f3n sistem\u00e1tica](https://www.openaire.eu/search/publication?articleId=od______1325::3699ed70c8821c924c79160abcf4fcaf)\nTorres Garrido, Alba Luz; Vargas-Zambrano, Juan-Camilo\n2014-01-01\nIntroducci\u00f3n: Las vacunas cl\u00e1sicamente han representado un m\u00e9todo econ\u00f3mico y eficaz para el control y prevenci\u00f3n de m\u00faltiples enfermedades infecciosas. En los \u00faltimos a\u00f1os se han introducido nuevas vacunas contra neumococo a precios elevados, y los diferentes an\u00e1lisis econ\u00f3micos a nivel mundial de estas vacunas no muestran tendencias. El objetivo de este trabajo era resumir la evidencia existente a trav\u00e9s de los diferentes estudios econ\u00f3micos evaluando las dos vacunas de segunda generaci\u00f3n c...\n[Rotavirus Immunization in Africa: A Perspective Re-visited](https://www.ajol.info/index.php/ajhs/article/viewFile/30763/23063) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\ntrials in developed countries, the history of rotavirus vaccine in Africa has not been good. The earlier rotavirus vaccine candidates, based on bovine rotavirus strains, were ... trials in Peru and Brazil [19,20]. Other more obvious reasons may include vaccine-related issues (such as the antigenic make-up of the bovine rotavirus ...\n[Zoonotic Transmission of Rotavirus in Denmark; a Case Report](http://www.forskningsdatabasen.dk/en/catalog/2389446027) [DEFF Research Database (Denmark)](http://forskningsbasen.deff.dk/?lang=eng)\nMidgley, Sofie; Gram, N.; Hjulsager, Charlotte Kristiane\nRotavirus type A infection is a common cause of hospitalisation of children. However, in our laboratory almost 30% of rotavirus positive samples are from adults. Due to this an epidemiological study into the riskfactors for rotavirus infection in adults was set up. All identified rotavirus positive...... adults are sent a questionnaire to identify potential risk factors. Rotavirus type A infection can also occur in a range of animals, including domestic dogs, cats, cattle, horses, and birds. There is some data suggesting direct transmission between animals and humans. Rotavirus typing is carried out...... in Denmark as part of the EuroRotaNet vaccine study. Samples positive for rotavirus are type...\n[Human rotavirus vaccine Rotarix\u2122 provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/22974466)\nSteele, Andrew Duncan; Neuzil, Kathleen M; Cunliffe, Nigel A; Madhi, Shabir A; Bos, Pieter; Ngwira, Bagrey; Witte, Desiree; Todd, Stacy; Louw, Cheryl; Kirsten, Mari; Aspinall, Sanet; Van Doorn, Leen Jan; Bouckenooghe, Alain; Suryakiran, Pemmaraju V; Han, Htay Htay\n2012-09-13\nRotaviruses are the most important cause of severe acute gastroenteritis worldwide in children rotavirus vaccine Rotarix\u2122 significantly reduced severe rotavirus gastroenteritis episodes in a Phase III clinical trial conducted in infants in South Africa and Malawi. This paper examines rotavirus vaccine efficacy in preventing severe rotavirus gastroenteritis, during infancy, caused by the various G and P rotavirus types encountered during the first rotavirus-season. Healthy infants aged 5-10 weeks were enrolled and randomized into three groups to receive either two (10 and 14 weeks) or three doses of Rotarix\u2122 (together forming the pooled Rotarix\u2122 group) or three doses of placebo at a 6,10,14-week schedule. Weekly home visits were conducted to identify gastroenteritis episodes. Rotaviruses were detected by ELISA and genotyped by RT-PCR and nucleotide sequencing. The percentage of infants with severe rotavirus gastroenteritis caused by the circulating G and P types from 2 weeks post-last dose until one year of age and the corresponding vaccine efficacy was calculated with 95% CI. Overall, 4939 infants were vaccinated and 4417 (pooled Rotarix\u2122 = 2974; placebo = 1443) were included in the per protocol efficacy cohort. G1 wild-type was detected in 23 (1.6%) severe rotavirus gastroenteritis episodes from the placebo group. This was followed in order of detection by G12 (15 [1%] in placebo) and G8 types (15 [1%] in placebo). Vaccine efficacy against G1 wild-type, G12 and G8 types were 64.1% (95% CI: 29.9%; 82%), 51.5% (95% CI:-6.5%; 77.9%) and 64.4% (95% CI: 17.1%; 85.2%), respectively. Genotype P[8] was the predominant circulating P type and was detected in 38 (2.6%) severe rotavirus gastroenteritis cases in placebo group. The remaining circulating P types comprised of P[4] (20 [1.4%] in placebo) and P[6] (13 [0.9%] in placebo). Vaccine efficacy against P[8] was 59.1% (95% CI: 32.8%; 75.3%), P[4] was 70.9% (95% CI: 37.5%; 87.0%) and P[6] was 55.2% (95% CI: -6\n[Vacunas y timerosal: no hay evidencias cient\u00edficas que muestren riesgo de autismo y desordenes neurol\u00f3gicos](https://www.openaire.eu/search/publication?articleId=od______3056::c178bdb2747b8762099be70feeaa7237)\nCabezas, C\u00e9sar\n2008-01-01\nEl timerosal es un compuesto org\u00e1nico que contiene etilmercurio, el cual ha sido usado como preservante de algunas vacunas, sobre todo en la presentaci\u00f3n de multidosis, desde los a\u00f1os 30. El etilmercurio es diferente delmetilmercurio, este \u00faltimo s\u00ed se conoce que es neurot\u00f3xico; sin embargo, el metabolismo del etilmercurio es diferente del metilmercurio. En realidad, se quiso inferir que la toxicidad del metilmercurio era similar al etilmercurio presente en el timerosal.\n[Emergence of Double- and Triple-Gene Reassortant G1P[8] Rotaviruses Possessing a DS-1-Like Backbone after Rotavirus Vaccine Introduction in Malawi.](https://www.ncbi.nlm.nih.gov/pubmed/29142125)\nJere, Khuzwayo C; Chaguza, Chrispin; Bar-Zeev, Naor; Lowe, Jenna; Peno, Chikondi; Kumwenda, Benjamin; Nakagomi, Osamu; Tate, Jacqueline E; Parashar, Umesh D; Heyderman, Robert S; French, Neil; Cunliffe, Nigel A; Iturriza-Gomara, Miren\n2018-02-01\ngenome reassortment, respectively. These evolutionary mechanisms generate novel strains and have the potential to lead to the emergence of vaccine escape mutants. While multiple African countries have introduced a rotavirus vaccine, there are few data describing the evolution of rotaviruses that circulated before and after vaccine introduction. We report the emergence of atypical DS-1-like G1P[8] strains during the postvaccine era in Malawi. Three distinct G1P[8] lineages circulated chronologically from 1998 to 2014; mutation and reassortment drove lineage turnover in 2005 and 2013, respectively. Amino acid substitutions within the outer capsid VP7 glycoprotein did not affect the structural conformation of mapped antigenic sites, suggesting a limited effect on the recognition of G1-specific vaccine-derived antibodies. The genes that constitute the remaining genetic backbone may play important roles in immune evasion, and vaccine effectiveness against such atypical strains needs careful evaluation. Copyright \u00a9 2018 Jere et al.\n[One Family's Struggles with Rotavirus](https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_ndovhy&server=pvlbsrch10&v%3astate=root%7croot-70-10%7c0&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc73&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&)\nFull Text Available ... getvaxed about GETVAXED print ads go to GETVAXED.ORG cme Immunizations Rotavirus One family's struggles with rotavirus ... free-of-charge. Branded videos contain the \"PKIDs.ORG\" end slate; unbranded videos are provided for organizations ...\n[One Family's Struggles with Rotavirus](https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_seiady&server=pvlbsrch13&v%3astate=root%7croot&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc3&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&)\nFull Text Available ... GETVAXED print ads go to GETVAXED.ORG cme Immunizations Rotavirus One family's struggles with rotavirus We provide ... not possible without a visit to your doctor. Immunizations stop disease from spreading. Check with your family ...\n[The impact of rotavirus gastroenteritis on the family](http://www.biomedcentral.com/1471-2431/9/11) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nKelly Claudia M\n2009-02-01\nFull Text Available Abstract Background Rotavirus is the leading cause of severe diarrhea in young children and causes substantial morbidity and mortality. Although the clinical aspects have been well described, little information is available regarding the emotional, social, and economic impact of rotavirus gastroenteritis on the family of a sick child. The objectives of this study were to: 1 assess the family impact of rotavirus gastroenteritis through qualitative interviews with parents; 2 compare the clinical severity of rotavirus-positive and negative gastroenteritis; 3 test a questionnaire asking parents to rank the importance of various factors associated with a case of rotavirus gastroenteritis. Methods The study enrolled parents and children (2\u201336 months of age brought to one of the study sites (outpatient clinic or ER if the child experienced \u2265 3 watery or looser-than normal stools and/or forceful vomiting within any 24-hour period within the prior 3 days. The clinical severity of each child's illness was rated using a clinical scoring system and stool samples were tested for rotavirus antigen. Parents of rotavirus-positive children were invited to participate in focus group or individual interviews and subsequently completed a questionnaire regarding the impact of their child's illness. Results Of 62 enrolled children, 43 stool samples were collected and 63% tested positive for rotavirus. Illness was more severe in children with rotavirus-positive compared to rotavirus-negative gastroenteritis (92% vs. 37.5% rated as moderate/severe. Seventeen parents of rotavirus-positive children participated in the interviews and completed the written questionnaire. Parents were frightened by the severity of vomiting and diarrhea associated with rotavirus gastroenteritis, and noted that family life was impacted in several ways including loss of sleep, missed work, and an inability to complete normal household tasks. They expressed frustration at the lack of a\n[Rotavirus vaccination in Europe: drivers and barriers.](https://www.ncbi.nlm.nih.gov/pubmed/24758998)\nParez, N; Giaquinto, C; Du Roure, C; Martinon-Torres, F; Spoulou, V; Van Damme, P; Vesikari, T\n2014-05-01\nRotavirus gastroenteritis is a vaccine-preventable disease that confers a high medical and economic burden in more developed countries and can be fatal in less developed countries. Two vaccines with high efficacy and good safety profiles were approved and made available in Europe in 2006. We present an overview of the status of rotavirus vaccination in Europe. We discuss the drivers (including high effectiveness and effect of universal rotavirus vaccination) and barriers (including low awareness of disease burden, perception of unfavourable cost-effectiveness, and potential safety concerns) to the implementation of universal rotavirus vaccination in Europe. By February, 2014, national universal rotavirus vaccination had been implemented in Belgium, Luxembourg, Austria, Finland, Greece, Luxembourg, Norway, and the UK. Four other German states have issued recommendations and reimbursement is provided by sickness funds. Other countries were at various stages of recommending or implementing universal rotavirus vaccination. Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.\n[Desarrollo de un m\u00e9todo de CLAR-IR para la determinaci\u00f3n de etanol residual en vacuna Development of a HPLC-IR method for determination of residual ethanol in vaccine](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75152009000200004) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMatilde Cuevas Valdespino\n2009-08-01\nFull Text Available Los ingredientes farmac\u00e9uticos activos de la vacuna antimeningoc\u00f3cica cubana VA-MENGOC-BC TM (ves\u00edculas de membrana externa purificadas de Neisseria meningitidis, serogrupo B y polisac\u00e1rido capsular purificado de Neisseria meningitidis, serogrupo C son conservados en etanol, de ah\u00ed que dicha vacuna posea un contenido de etanol residual, cuya concentraci\u00f3n real no se conoc\u00eda hasta el momento. Las regulaciones internacionales plantean que los productos biofarmac\u00e9uticos y sus ingredientes farmac\u00e9uticos activos deben tener bien caracterizadas todas sus impurezas, por lo que el objetivo de este trabajo fue el desarrollo de un m\u00e9todo de determinaci\u00f3n de etanol mediante cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n-\u00edndice de refracci\u00f3n para estos fines y su comparaci\u00f3n con un m\u00e9todo utilizado frecuentemente para cuantificar este solvente, como es la cromatograf\u00eda gaseosa. El m\u00e9todo evaluado result\u00f3 ser \u00fatil y con una buena robustez para la determinaci\u00f3n de este solvente org\u00e1nico en esta vacuna antimenigoc\u00f3cica. No se detectaron diferencias estad\u00edsticamente significativas entre los resultados obtenidos al evaluar las mismas muestras de vacuna mediante ambos m\u00e9todos cromatogr\u00e1ficos (cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n y cromatograf\u00eda gaseosa, lo que indica la posibilidad del uso de la cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n en sustituci\u00f3n de la cromatograf\u00eda gaseosa para esta determinaci\u00f3n.Active pharmaceutical ingredients of Cuban anti-meningococcal vaccine VA-MENGOC-BC TM (vesicles of purified external membranes of Neisseria meningitidis, B serum-group, and purified capsular polysaccharide of Neisseria meningitidis, serum-group C are stored in ethanol, thus that such vaccine has residual ethanol content, of which real concentration is not known just now. International regulations propose that the biopharmaceutical products and its active pharmaceutical ingredients must to have well defined all impurities, thus\n[Rotavirus vaccines and vaccination in Latin America](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892000001000002) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nLinhares Alexandre C.\n2000-01-01\nFull Text Available Worldwide, rotaviruses account for more than 125 million cases of infantile gastroenteritis and nearly 1 million deaths per year, mainly in developing countries. Rather than other control measures, vaccination is most likely to have a major impact on rotavirus disease incidence. The peak incidence of rotavirus diarrhea occurs between 6 and 24 months of age. In developing countries, however, cases are not uncommon among children younger than 6 months. G serotypes 1 to 4 are responsible for most disease, but there are indications that in Brazil that G type 5 is of emerging epidemiological importance. Both homotypic and heterotypic responses are elicited during natural rotavirus infection, and the immunological response at the intestinal mucosal surface is probably the more consistent predictor of clinical immunity. With the primary objective of protecting children against life-threatening dehydrating diarrhea, many approaches to rotavirus vaccine development have been attempted. One vaccine, the tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV, was given licensing approval in the United States of America, introduced to the market, and later withdrawn. A number of studies have found better efficacy of RRV-TV in developed countries than in developing ones. Field trials with a 4 X 10(4 plaque-forming units (PFU preparation of RRV-TV have been carried out in two countries in Latin America, Brazil and Peru. Those trials yielded protective efficacy rates against all rotavirus diarrhea ranging from 18% to 35%. Data from a large catchment trial in Venezuela with a higher RRV-TV dose, of 4 X 10(5 PFU/dose, indicated an efficacy rate of 48% against all rotavirus diarrhea and 88% against severe rotavirus diarrhea. It appears that breast-feeding does not compromise the efficacy of RRV-TV if three doses of the vaccine are administered. Similarly, possible interference of oral poliovirus vaccine with the \"take\" of the rotavirus vaccine can be\n[Rotavirus vaccines and vaccination in Latin America](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892000001000002&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAlexandre C. Linhares\n2000-11-01\nFull Text Available Worldwide, rotaviruses account for more than 125 million cases of infantile gastroenteritis and nearly 1 million deaths per year, mainly in developing countries. Rather than other control measures, vaccination is most likely to have a major impact on rotavirus disease incidence. The peak incidence of rotavirus diarrhea occurs between 6 and 24 months of age. In developing countries, however, cases are not uncommon among children younger than 6 months. G serotypes 1 to 4 are responsible for most disease, but there are indications that in Brazil that G type 5 is of emerging epidemiological importance. Both homotypic and heterotypic responses are elicited during natural rotavirus infection, and the immunological response at the intestinal mucosal surface is probably the more consistent predictor of clinical immunity. With the primary objective of protecting children against life-threatening dehydrating diarrhea, many approaches to rotavirus vaccine development have been attempted. One vaccine, the tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV, was given licensing approval in the United States of America, introduced to the market, and later withdrawn. A number of studies have found better efficacy of RRV-TV in developed countries than in developing ones. Field trials with a 4 X 10(4 plaque-forming units (PFU preparation of RRV-TV have been carried out in two countries in Latin America, Brazil and Peru. Those trials yielded protective efficacy rates against all rotavirus diarrhea ranging from 18% to 35%. Data from a large catchment trial in Venezuela with a higher RRV-TV dose, of 4 X 10(5 PFU/dose, indicated an efficacy rate of 48% against all rotavirus diarrhea and 88% against severe rotavirus diarrhea. It appears that breast-feeding does not compromise the efficacy of RRV-TV if three doses of the vaccine are administered. Similarly, possible interference of oral poliovirus vaccine with the \"take\" of the rotavirus vaccine can be\n[Efectividad y duraci\u00f3n de la inmunidad de la vacuna frente al meningococo serogrupo A y C](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::079e97a5d510c0250481d9007f374dfc)\nGarc\u00eda Comas Luis; Ram\u00edrez Fern\u00e1ndez Rosa; Casta\u00f1eda L\u00f3pez Rosario; Sanz Moreno Juan Carlos; V\u00e1zquez Moreno Julio; Lasheras Carbajo M\u00aa Dolores; Barranco Ordo\u00f1ez Dolores; Ruiz Contreras Jes\u00fas; Jover Ibarra Jos\u00e9\n2000-01-01\nFUNDAMENTO: La Comunidad de Madrid detect\u00f3 a partir de 1995 un incremento del n\u00famero de casos de enfermedad meningoc\u00f3cica por serogrupo C. En 1997 se realiz\u00f3 una campa\u00f1a de inmunizaci\u00f3n masiva sobre la poblaci\u00f3n de 18 meses a 19 a\u00f1os. El objetivo de este estudio es conocer la respuesta inmunitaria producida por la vacuna y su relaci\u00f3n con la edad. M\u00c9TODOS: Se seleccion\u00f3 una muestra de 1.003 ni\u00f1os vacunados durante la campa\u00f1a. Se extrajo una muestra de sangre antes de la vacunaci\u00f3n y tras uno,...\n[Incidence and cost of rotavirus hospitalizations in Denmark](http://www.cdc.gov/eid/content/13/6/pdfs/855.pdf) [DEFF Research Database (Denmark)](http://forskningsbasen.deff.dk/?lang=eng)\nFischer, Thea K\u00f8lsen; Nielsen, Nete Munk; Wohlfahrt, Jan\n2007-01-01\nIn anticipation of licensure and introduction of rotavirus vaccine into the western market, we used modeling of national hospital registry data to determine the incidence and direct medical costs of annual rotavirus-associated admissions over >11 years in Denmark. Diarrhea-associated hospitalizat......In anticipation of licensure and introduction of rotavirus vaccine into the western market, we used modeling of national hospital registry data to determine the incidence and direct medical costs of annual rotavirus-associated admissions over >11 years in Denmark. Diarrhea......-associated hospitalizations coded as nonspecified viral or presumed infectious have demonstrated a marked winter peak similar to that of rotavirus-associated hospitalizations, which suggests that the registered rotavirus-coded admissions are grossly underestimated. We therefore obtained more realistic estimates by 2...... different models, which indicated 2.4 and 2.5 (for children rotavirus-associated admissions per 1,000 children per year, respectively. These admissions amount to associated direct medical costs of US $1.7-1.8 million per year. Using 2 simple...\n[Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine.](https://www.ncbi.nlm.nih.gov/pubmed/28481726)\nCowley, Daniel; Boniface, Karen; Bogdanovic-Sakran, Nada; Kirkwood, Carl D; Bines, Julie E\n2017-08-03\nThe RV3-BB human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth. A phase IIa safety and immunogenicity trial was undertaken in Dunedin, New Zealand between January 2012 and April 2014. Healthy, full-term (\u2265 36 weeks gestation) babies, who were 0-5 d old were randomly assigned (1:1:1) to receive 3 doses of oral RV3-BB vaccine with the first dose given at 0-5 d after birth (neonatal schedule), or the first dose given at about 8 weeks after birth (infant schedule), or to receive placebo (placebo schedule). Vaccine take (serum immune response or stool shedding of vaccine virus after any dose) was detected after 3 doses of RV3-BB vaccine in >90% of participants when the first dose was administered in the neonatal and infant schedules. The aim of the current study was to characterize RV3-BB shedding and virus replication following administration of RV3-BB in a neonatal and infant vaccination schedule. Shedding was defined as detection of rotavirus by VP6 reverse transcription polymerase chain reaction (RT-PCR) in stool on days 3-7 after administration of RV3-BB. Shedding of rotavirus was highest following vaccination at 8 weeks of age in both neonatal and infant schedules (19/30 and 17/27, respectively). Rotavirus was detected in stool on days 3-7, after at least one dose of RV3-BB, in 70% (21/30) of neonate, 78% (21/27) of infant and 3% (1/32) placebo participants. In participants who shed RV3-BB, rotavirus was detectable in stool on day 1 following RV3-BB administration and remained positive until day 4-5 after administration. The distinct pattern of RV3-BB stool viral load demonstrated using a NSP3 quantitative qRT-PCR in participants who shed RV3-BB, suggests that detection of RV3-BB at day 3-7 was the result of replication rather than passage through the gastrointestinal tract.\n[Protein-energy malnutrition alters IgA responses to rotavirus vaccination and infection but does not impair vaccine efficacy in mice.](https://www.ncbi.nlm.nih.gov/pubmed/24200975)\nMaier, Elizabeth A; Weage, Kristina J; Guedes, Marjorie M; Denson, Lee A; McNeal, Monica M; Bernstein, David I; Moore, Sean R\n2013-12-17\nConflicting evidence links malnutrition to the reduced efficacy of rotavirus vaccines in developing countries, where diarrhea and undernutrition remain leading causes of child deaths. Here, we adapted mouse models of rotavirus vaccination (rhesus rotavirus, RRV), rotavirus infection (EDIM), and protein-energy malnutrition (PEM) to test the hypothesis that undernutrition reduces rotavirus vaccine immunogenicity and efficacy. We randomized wild type Balb/C dams with 3-day-old pups to a control diet (CD) or an isocaloric, multideficient regional basic diet (RBD) that produces PEM. At 3 weeks of age, we weaned CD and RBD pups to their dams' diet and subrandomized weanlings to receive a single dose of either live oral rotavirus vaccine (RRV) or PBS. At 6 weeks of age, we orally challenged all groups with murine rotavirus (EDIM). Serum and stool specimens were collected before and after RRV and EDIM administration to measure viral shedding and antibody responses by ELISA. RBD pups and weanlings exhibited significant failure to thrive compared to age-matched CD mice (Pvaccination induced higher levels of serum anti-RV IgA responses in RBD vs. CD mice (PVaccination protected CD and RBD mice equally against EDIM infection, as measured by viral shedding. In unvaccinated RBD mice, EDIM shedding peaked 1 day earlier (Pvaccination (Pvaccination mitigated stool IgA responses to EDIM more in CD vs. RBD mice (Pvaccination and infection, undernutrition does not impair rotavirus vaccine efficacy nor exacerbate infection in this mouse model of protein-energy malnutrition. Alternative models are needed to elucidate host-pathogen factors undermining rotavirus vaccine effectiveness in high-risk global settings. Copyright \u00a9 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.\n[Administraci\u00f3n de vacunas y casos de muerte s\u00fabita del lactante en el Per\u00fa, 2001: \u00bfasociaci\u00f3n o coincidencia temporal?](http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342006000100007&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJavier Vargas H\nFull Text Available Objetivos: Describir las caracter\u00edsticas cl\u00ednicas, socioecon\u00f3micas, y patol\u00f3gicas de nueve casos de lactantes que fallecieron horas despu\u00e9s de administr\u00e1rseles vacunas antipolio y DPT junto con anti Haemophilus influenzae b o asociada con antihepatitis B o BCG. Materiales y m\u00e9todos: Revisi\u00f3n de la historia cl\u00ednica, entrevista con el equipo de salud a cargo de la vacunaci\u00f3n y con los padres del lactante fallecido. Revisi\u00f3n de los informes del protocolo de autopsia e informes de anatom\u00eda patol\u00f3gica y entrevista con los m\u00e9dicos legistas y pat\u00f3logos. Evaluaci\u00f3n de control de calidad de las vacunas administradas. Realizaci\u00f3n de ex\u00e1menes de inmunohistoqu\u00edmica de tejidos pulmonares para el diagn\u00f3stico de virus. Resultados: Entre agosto y diciembre de 2001 se notificaron en el Per\u00fa, nueve casos de fallecimiento de lactantes entre ocho horas y tres d\u00edas despu\u00e9s de la aplicaci\u00f3n de vacunas DPT y antipolio. Despu\u00e9s de la vacunaci\u00f3n, los s\u00edntomas iniciaron entre 30 minutos a tres horas y la muerte se produjo entre ocho a 78 horas. Los s\u00edntomas m\u00e1s frecuentes fueron irritabilidad 8/9, llanto persistente 6/9, somnolencia 5/9, sangrado por nariz y boca 5/9. Todos los casos procedieron de familias pobres o muy pobres. El control de calidad se corrobor\u00f3 que las vacunas cumplieron con los est\u00e1ndares establecidos por la OMS. Las causas de la muerte reportadas en las necropsias fueron neumon\u00eda en dos casos y edema pulmonar en cinco casos, los informes de anatom\u00eda patol\u00f3gica mostraron una neumonitis intersticial y meningitis linfocitaria. No se observaron efectos citop\u00e1ticos virales en los tejidos pulmonares y los estudios toxicol\u00f3gicos fueron negativos. Conclusiones: No existe evidencia de una asociaci\u00f3n causal entre los eventos fatales y la administraci\u00f3n de las vacunas.\n[Rotavirus and the Vaccine (Drops) to Prevent It](https://www.cdc.gov/vaccines/parents/diseases/child/rotavirus.html)\n... Resources Maternal Immunization Resources Related Links Vaccines & Immunizations Rotavirus and the Vaccine (Drops) to Prevent It Language: ... the vaccine. Why should my child get the rotavirus vaccine? The rotavirus vaccine: Protects your child from ...\n[Immunogenicity of rotavirus vaccine (RotarixTM in infants with environmental enteric dysfunction.](http://europepmc.org/articles/PMC5744930?pdf=render) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nInnocent Mwape\nFull Text Available Deployment of rotavirus vaccines has contributed to significant declines in diarrheal morbidity and mortality globally. Unfortunately, vaccine performance in low-middle income countries (LMICs is generally lower than in developed countries. The cause for this has been associated with several host and maternal factors including poor water sanitation and hygiene (WASH status, which are predominant in LMICs. More recently, environmental enteric dysfunction (EED has specifically been hypothesized to contribute to poor vaccine uptake and response. The aim of this study was to examine the association between serological biomarkers of EED and seroconversion to rotavirus vaccine in Zambian infants.This was a retrospective cohort study of 142 infants who had been fully immunized with Rotarix\u2122, and had known seroconversion status. Seroconversion was defined as 4-fold or more increase in rotavirus-specific IgA titres between pre-vaccination and one month post-dose two vaccination. We performed ELISA assays to assess soluble CD14 (sCD14, Endotoxin Core IgG Antibodies (EndoCAb, intestinal fatty acid binding protein (i-FABP and Zonulin according to the manufacturers protocols. Generalised linear model with family-poisson, link-log and robust standard error was used to estimate the independent effects of biomarkers on seroconversion adjusting for important cofounders.The median concentration of Zonulin, Soluble CD14, EndoCaB, and IFABP were 209.3 (IQR = 39.7, 395.1, 21.5 (IQR = 21.5, 21.5, 0.3 (IQR = 0.3, 0.3, and 107.7 (IQR = 6.4, 1141.4 respectively. In multivariable analyses adjusting for the independent effect of other biomarkers and confounders (i.e. age of child at vaccination, breast-milk anti-rotavirus IgA, infant serum anti-rotavirus IgG, and IgA seropositivity at baseline, there was strong evidence of about 24% increase in seroconversion due to doubling Zonulin concentration (Adjusted risk ratio (aRR = 1.24; 95% CI = 1.12 to1.37; p<0\n[Centers for Disease Control (CDC) Podcasts](http://www2c.cdc.gov/podcasts/search.asp)\nCDC's Dr. Jon Gentsch discusses rotaviruses, the most important cause of severe gastroenteritis in children less than five years of age. Essentially, all children around the world get the disease during the first few years of life.\n[Human rotavirus vaccine Rotarix\u2122 provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial](http://www.biomedcentral.com/1471-2334/12/213) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nSteele Andrew\n2012-09-01\nFull Text Available Abstract Background Rotaviruses are the most important cause of severe acute gastroenteritis worldwide in children Rotarix\u2122 significantly reduced severe rotavirus gastroenteritis episodes in a Phase III clinical trial conducted in infants in South Africa and Malawi. This paper examines rotavirus vaccine efficacy in preventing severe rotavirus gastroenteritis, during infancy, caused by the various G and P rotavirus types encountered during the first rotavirus-season. Methods Healthy infants aged 5\u201310 weeks were enrolled and randomized into three groups to receive either two (10 and 14 weeks or three doses of Rotarix\u2122 (together forming the pooled Rotarix\u2122 group or three doses of placebo at a 6,10,14-week schedule. Weekly home visits were conducted to identify gastroenteritis episodes. Rotaviruses were detected by ELISA and genotyped by RT-PCR and nucleotide sequencing. The percentage of infants with severe rotavirus gastroenteritis caused by the circulating G and P types from 2 weeks post-last dose until one year of age and the corresponding vaccine efficacy was calculated with 95% CI. Results Overall, 4939 infants were vaccinated and 4417 (pooled Rotarix\u2122 = 2974; placebo = 1443 were included in the per protocol efficacy cohort. G1 wild-type was detected in 23 (1.6% severe rotavirus gastroenteritis episodes from the placebo group. This was followed in order of detection by G12 (15 [1%] in placebo and G8 types (15 [1%] in placebo. Vaccine efficacy against G1 wild-type, G12 and G8 types were 64.1% (95% CI: 29.9%; 82%, 51.5% (95% CI:-6.5%; 77.9% and 64.4% (95% CI: 17.1%; 85.2%, respectively. Genotype P[8] was the predominant circulating P type and was detected in 38 (2.6% severe rotavirus gastroenteritis cases in placebo group. The remaining circulating P types comprised of P[4] (20 [1.4%] in placebo and P[6] (13 [0.9%] in placebo. Vaccine efficacy against P[8] was 59.1% (95% CI: 32.8%; 75.3%, P[4] was 70.9% (95% CI: 37.5%; 87\n[Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5443368)\nChen, Mee-Yew; Kirkwood, Carl D.; Bines, Julie; Cowley, Daniel; Pavlic, Daniel; Lee, Katherine J.; Orsini, Francesca; Watts, Emma; Barnes, Graeme; Danchin, Margaret\n2017-01-01\nABSTRACT Background: Maternal antibodies, acquired passively via placenta and/or breast milk, may contribute to the reduced efficacy of oral rotavirus vaccines observed in children in developing countries. This study aimed to investigate the effect of rotavirus specific maternal antibodies on the serum IgA response or stool excretion of vaccine virus after any dose of an oral rotavirus vaccine, RV3-BB, in parallel to a Phase IIa clinical trial conducted at Dunedin Hospital, New Zealand. At the time of the study rotavirus vaccines had not been introduced in New Zealand and the burden of rotavirus disease was evident. Methods: Rotavirus specific IgG and serum neutralizing antibody (SNA) levels in cord blood and IgA levels in colostrum and breast milk samples collected \u223c4 weeks, \u223c20 weeks and \u223c28 weeks after birth were measured. Infants were randomized to receive the first dose of vaccine at 0\u20135 d (neonatal schedule) or 8 weeks (infant schedule). Breast feeding was with-held for 30 minutes before and after vaccine administration. The relationship between rotavirus specific IgG and SNA levels in cord blood and IgA in colostrum and breast milk at the time of first active dose of RV3-BB vaccine and level of IgA response and stool excretion after 3 doses of vaccine was assessed using linear and logistic regression. Results: Forty infants received 3 doses of RV3-BB rotavirus vaccine and were included in the analysis of the neonatal and infant groups. Rotavirus specific IgA in colostrum (neonatal schedule group) and breast milk at 4 weeks (infant schedule group) was identified in 14/21 (67%) and 14/17 (82%) of infants respectively. There was little evidence of an association between IgA in colostrum or breast milk IgA at 4 weeks, or between cord IgG or SNA level, and IgA response or stool excretion after 3 doses of RV3-BB, or after one dose (neonatal schedule) (all p>0.05). Conclusions: The level of IgA in colostrum or breast milk and level of placental Ig\n[Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand.](https://www.ncbi.nlm.nih.gov/pubmed/28059609)\nChen, Mee-Yew; Kirkwood, Carl D; Bines, Julie; Cowley, Daniel; Pavlic, Daniel; Lee, Katherine J; Orsini, Francesca; Watts, Emma; Barnes, Graeme; Danchin, Margaret\n2017-05-04\nMaternal antibodies, acquired passively via placenta and/or breast milk, may contribute to the reduced efficacy of oral rotavirus vaccines observed in children in developing countries. This study aimed to investigate the effect of rotavirus specific maternal antibodies on the serum IgA response or stool excretion of vaccine virus after any dose of an oral rotavirus vaccine, RV3-BB, in parallel to a Phase IIa clinical trial conducted at Dunedin Hospital, New Zealand. At the time of the study rotavirus vaccines had not been introduced in New Zealand and the burden of rotavirus disease was evident. Rotavirus specific IgG and serum neutralizing antibody (SNA) levels in cord blood and IgA levels in colostrum and breast milk samples collected \u223c4 weeks, \u223c20 weeks and \u223c28 weeks after birth were measured. Infants were randomized to receive the first dose of vaccine at 0-5 d (neonatal schedule) or 8 weeks (infant schedule). Breast feeding was with-held for 30 minutes before and after vaccine administration. The relationship between rotavirus specific IgG and SNA levels in cord blood and IgA in colostrum and breast milk at the time of first active dose of RV3-BB vaccine and level of IgA response and stool excretion after 3 doses of vaccine was assessed using linear and logistic regression. Forty infants received 3 doses of RV3-BB rotavirus vaccine and were included in the analysis of the neonatal and infant groups. Rotavirus specific IgA in colostrum (neonatal schedule group) and breast milk at 4 weeks (infant schedule group) was identified in 14/21 (67%) and 14/17 (82%) of infants respectively. There was little evidence of an association between IgA in colostrum or breast milk IgA at 4 weeks, or between cord IgG or SNA level, and IgA response or stool excretion after 3 doses of RV3-BB, or after one dose (neonatal schedule) (all p>0.05). The level of IgA in colostrum or breast milk and level of placental IgG and SNA did not impact on the serum IgA response or\nAlejandro Roque Vald\u00e9s\n2004-01-01\nEl presente trabajo es un art\u00edculo de revisi\u00f3n que pretende abordar un tema tan controvertido como actual: la posible asociaci\u00f3n causal que se ha querido establecer entre el autismo y las vacunas infantiles. A partir de la \u00faltima d\u00e9cada del siglo XX se producen una serie de cambios en la clasificaci\u00f3n, nomenclatura y criterios diagn\u00f3sticos del autismo. Los hallazgos de estudios epidemiol\u00f3gicos llevados a cabo bajo estos nuevos ponderados han revelado que las tasas de prevalencia del autismo s...\n[Estimating rotavirus gastroenteritis hospitalisations by using hospital episode statistics before and after the introduction of rotavirus vaccine in Australia.](https://www.ncbi.nlm.nih.gov/pubmed/23246261)\nJayasinghe, Sanjay; Macartney, Kristine\n2013-01-30\nHospital discharge records and laboratory data have shown a substantial early impact from the rotavirus vaccination program that commenced in 2007 in Australia. However, these assessments are affected by the validity and reliability of hospital discharge coding and stool testing to measure the true incidence of hospitalised disease. The aim of this study was to assess the validity of these data sources for disease estimation, both before and after, vaccine introduction. All hospitalisations at a major paediatric centre in children aged <5 years from 2000 to 2009 containing acute gastroenteritis (AGE) ICD 10 AM diagnosis codes were linked to hospital laboratory stool testing data. The validity of the rotavirus-specific diagnosis code (A08.0) and the incidence of hospitalisations attributable to rotavirus by both direct estimation and with adjustments for non-testing and miscoding were calculated for pre- and post-vaccination periods. A laboratory record of stool testing was available for 36% of all AGE hospitalisations (n=4948) the rotavirus code had high specificity (98.4%; 95% CI, 97.5-99.1%) and positive predictive value (96.8%; 94.8-98.3%), and modest sensitivity (61.6%; 58-65.1%). Of all rotavirus test positive hospitalisations only a third had a rotavirus code. The estimated annual average number of rotavirus hospitalisations, following adjustment for non-testing and miscoding was 5- and 6-fold higher than identified, respectively, from testing and coding alone. Direct and adjusted estimates yielded similar percentage reductions in annual average rotavirus hospitalisations of over 65%. Due to the limited use of stool testing and poor sensitivity of the rotavirus-specific diagnosis code routine hospital discharge and laboratory data substantially underestimate the true incidence of rotavirus hospitalisations and absolute vaccine impact. However, this data can still be used to monitor vaccine impact as the effects of miscoding and under-testing appear to be\n[Introduktion. Om rotavirus. Teknologi](http://www.sst.dk/publ/Publ2012/06juni/MTV-RotavirusMedBilag.pdf%20) [DEFF Research Database (Denmark)](http://forskningsbasen.deff.dk/?lang=eng)\nWejse, Christian\n2012-01-01\nvil skyldes rotavirus. Typisk vil b\u00f8rnene f\u00e5 feber, opkastninger og/eller diarr\u00e9. Sygdommen g\u00e5r s\u00e6dvanligvis over af sig selv i l\u00f8bet af 3 til 7 dage. Nogle b\u00f8rn f\u00e5r dog v\u00e6ske- og saltmangel i en s\u00e5dan grad, at de m\u00e5 indl\u00e6gges p\u00e5 hospital til behandling med drop og v\u00e6ske direkte ind i \u00e5rerne. 85 \u2013 90...... % af danske b\u00f8rn f\u00f8lger det danske b\u00f8rnevaccinationsprogram og bliver vaccineret mod en r\u00e6kke infektioner. Der findes i Danmark to velafpr\u00f8vede og godkendte vacciner mod rotavirus. Begge vacciner gives gennem munden og ikke gennem indspr\u00f8jtning i huden, som de \u00f8vrige vacciner i det danske...... b\u00f8rnevaccinationsprogram. Verdenssundhedsorganisation (WHO=World Health Organisation) samt nationale og europ\u00e6iske faglige selskaber har anbefalet at vaccinere mod rotavirus. I en r\u00e6kke europ\u00e6iske lande er vaccination mod rotavirus indf\u00f8rt i det nationale b\u00f8rnevaccinationsprogram. Andre europ\u00e6iske lande har fravalgt...\n[Surveillance of Rotavirus Diarrhea in Hasan Sadikin Hospital Bandung](http://journal.fk.unpad.ac.id/index.php/mkb/article/view/29) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nDwi Prasetyo\n2010-12-01\nFull Text Available The diarrhea morbidity in Indonesia has increased, however, all the reports had not been done carefully, so that accurate surveillance are essential for improving quality of morbidity data. To determine the prevalence and clinical manifestations of rotavirus diarrhea and to characterize the circulating rotavirus strains, children below 5 years old who were admitted to Hasan Sadikin Hospital, Bandung because of diarrhea, from January 2006 through March 2007 were enrolled in a surveillance study and had stool specimens tested for the presence of rotavirus using enzyme immunoassay (EIA. The strains of rotavirus were determined using reverse transcriptase-polymerase chain reaction (RT-PCR. Rotavirus were detected in 47.8% analyzed samples (87/184, G and P-genotype of rotavirus were G[1] (37.5% and P[6] (53.5%. Most subjects were males (56%, 6\u201311 months of age (35%. Most common clinical manifestations besides diarrhea were dehydration (72.7% and vomiting (50%. Subjects with positive rotavirus more common had dehydration (72% vs 28% and vomiting (61% vs 39%. In conclusion, vomiting and dehydration are the prominent clinical manifestations of diarrhea with positive rotavirus infection. G1 and P6 are the most common genotype of rotavirus.\n[Human rotavirus genotypes circulating in Brazil before and after a nationwide rotavirus vaccination program established in 2006](http://www.dovepress.com/human-rotavirus-genotypes-circulating-in-brazil-before-and-after-a-nat-a6925) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nCaruzo TAR\n2011-04-01\nFull Text Available Thabata AR CaruzoGenetics, Evolution and Bioagents Department, Institute of Biology, State University of Campinas, Campinas, S\u00e3o Paulo, BrazilAbstract: Accounting for an estimated 600,000 deaths worldwide each year, rotaviruses are recognized as the most important etiologic agents causing severe acute gastroenteritis among children under the age of five years. In Brazil, until rotavirus vaccination was established in the public health system in 2006, acute gastroenteritis striking children under five years and caused by these viruses was clearly associated with 3.5 million episodes of diarrhea, 650,000 visits to outpatient health care facilities, 92,000 hospitalizations, and 850 deaths each year. After the introduction of the rotavirus vaccine in Brazil in March 2006, studies all over the country have been comparing rotavirus genotypes circulating in the recent pre- and postvaccination era. Most of these studies have reported a high prevalence of the G2P[4] genotype and also a decrease in rotavirus detection all over Brazil after the introduction of the vaccine. So far, these are preliminary studies, as a longer period of time is necessary to establish if this high prevalence of G2P[4] is due to selective pressure by the vaccine on the circulating viruses or to a normal genotype fluctuation, and if it will have any impact on vaccine efficacy in the future. This review describes results from the most recent studies addressing this issue and on rotavirus genotypic variability in Brazil.Keywords: human rotavirus, vaccine, genotypes, prevalence, Brazil\n[How do the rotavirus NSP4 and bacterial enterotoxins lead differently to diarrhea?](http://www.virologyj.com/content/4/1/31) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nVasseur Monique\n2007-03-01\nFull Text Available Abstract Rotavirus is the major cause of infantile gastroenteritis and each year causes 611 000 deaths worldwide. The virus infects the mature enterocytes of the villus tip of the small intestine and induces a watery diarrhea. Diarrhea can occur with no visible tissue damage and, conversely, the histological lesions can be asymptomatic. Rotavirus impairs activities of intestinal disaccharidases and Na+-solute symports coupled with water transport. Maldigestion of carbohydrates and their accumulation in the intestinal lumen as well as malabsorption of nutrients and a concomitant inhibition of water reabsorption can lead to a malabsorption component of diarrhea. Since the discovery of the NSP4 enterotoxin, diverse hypotheses have been proposed in favor of an additional secretion component in the pathogenesis of diarrhea. Rotavirus induces a moderate net chloride secretion at the onset of diarrhea, but the mechanisms appear to be quite different from those used by bacterial enterotoxins that cause pure secretory diarrhea. Rotavirus failed to stimulate Cl- secretion in crypt, whereas it stimulated Cl- reabsorption in villi, questioning, therefore, the origin of net Cl- secretion. A solution to this riddle was that intestinal villi do in fact secrete chloride as a result of rotavirus infection. Also, the overall chloride secretory response is regulated by a phospholipase C-dependent calcium signaling pathway induced by NSP4. However, the overall response is weak, suggesting that NSP4 may exert both secretory and subsequent anti-secretory actions, as did carbachol, hence limiting Cl- secretion. All these characteristics provide the means to make the necessary functional distinction between viral NSP4 and bacterial enterotoxins.\n[CNS complications of rotavirus gastroenteritis](https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=49051232) [International Nuclear Information System (INIS) ](http://inis.iaea.org/search/)\nVolosinova, D.\n2010-01-01\nRotavirus infection may be accompanied by serious complications, e.g. disabilities central nervous system (CNS). Theory rotavirus penetration across the blood-brain barrier and subsequent rota-associated convulsions by the 2-year case-history of the patient. Rotavirosis minor gastrointestinal symptoms may lead to erroneous diagnosis. (author)\n[PROTECTIVE ACTIVITY STUDY OF A CANDIDATE VACCINE AGAINST ROTAVIRUS INFECTION BASED ON RECOMBINANT PROTEIN FliCVP6VP8](http://mimmun.ru/mimmun/article/view/1065) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nI. V. Dukhovlinov\n2016-01-01\nFull Text Available Rotavirus infection is among leading causes of severe diarrhea which often leads to severe dehydration, especially, in children under 5 years old. In Russia, the incidence of rotavirus infection is constantly increased, due to higher rates of actual rotavirus infection cases and improved diagnostics of the disease. Immunity to rotavirus is unstable, thus causing repeated infections intra vitam. Anti-infectious resistance in reconvalescents is explained by induction of specific IgM, IgG, and, notably, IgA antibodies. Due to absence of market drugs with direct action against rotavirus, a rational vaccination is considered the most effective way to control the disease. Currently available vaccines for prevention of rotavirus infection are based on live attenuated rotavirus strains, human and/or animal origin, which replicate in human gut. Their implementation may result into different complications. Meanwhile, usage of vaccines based on recombinant proteins is aimed to avoid risks associated with introduction of a complete virus into humans. In this paper, we studied protective activity of candidate vaccines against rotavirus.In this work we studied protective activity of a candidate vaccine against rotavirus infection based on recombinant FliCVP6VP8 protein which includes VP6 and VP8, as well as components of Salmonella typhimurium flagellin (FliC as an adjuvant. Different components are joined by flexible bridges. Efficiency of the candidate vaccine was studied in animal model using Balb/c mice. We have shown high level of protection which occurs when the candidate vaccine is administered twice intramuscularly. Complete protection of animals against mouse rotavirus EDC after intramuscular immunization with a candidate vaccine was associated with arising rotavirus-specific IgA and IgG antibodies in serum and intestine of immunized animals. The efficacy of candidate vaccine based on recombinant protein FliCVP6VP8 against rotavirus infection was\n[Dot Blot para determinar la identidad antig\u00e9nica en vacunas conjugadas contra Streptococcus pneumoniae serotipo 19F](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2017000100001&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nOsmir Cabrera-Blanco\n2017-04-01\nFull Text Available Las autoridades regulatorias recomiendan el uso de t\u00e9cnicas de Resonancia Magn\u00e9tica Nuclear o t\u00e9cnicas serol\u00f3gicas para la determinaci\u00f3n de la identidad de los ant\u00edgenos presentes en las vacunas conjugadas. Con la aparici\u00f3n de las vacunas conjugadas multivalentes, se ha hecho necesario recurrir a t\u00e9cnicas inmunoqu\u00edmicas con la utilizaci\u00f3n de anticuerpos monoclonales para aumentar la sensibilidad en la determinaci\u00f3n de la identidad de los ant\u00edgenos en dichas vacunas conjugadas. El objetivo del presente trabajo fue establecer las condiciones \u00f3ptimas de trabajo que permitieran utilizar la t\u00e9cnica del Dot Blot para determinar la identidad de los ant\u00edgenos en vacunas conjugadas de Streptococcus pneumoniae serotipo 19F. Para ello se estudiaron los tiempos de incubaci\u00f3n, la influencia del reactivo en la soluci\u00f3n de bloqueo; tambi\u00e9n las concentraciones \u00f3ptimas del anticuerpo monoclonal y de los ingredientes farmac\u00e9uticos activos, as\u00ed como los vol\u00famenes de aplicaci\u00f3n \u00f3ptimos para estos y vacunas. Se utiliz\u00f3 un anticuerpo monoclonal contra el polisac\u00e1rido capsular del serotipo 19F de neumococo. Las muestras empleadas en este trabajo fueron lotes de ingredientes farmac\u00e9uticos activos de conjugados de polisac\u00e1rido capsular 19F y lotes de un candidato vacunal cubano conjugado heptavalente contra neumococos. Los resultados mostraron que para la determinaci\u00f3n de la identidad antig\u00e9nica fueron suficientes 10 \u00b5L de muestras de los principios activos a una concentraci\u00f3n de 125 \u00b5g/mL e igual volumen para las vacunas heptavalentes. Qued\u00f3 demostrado que una concentraci\u00f3n de 1 \u00b5g/mL para el anticuerpo monoclonal y tiempos de incubaci\u00f3n de 30 min a 37 \u00b0C fueron suficientes para la determinaci\u00f3n. Estos resultados permiten concluir que quedaron establecidas las condiciones \u00f3ptimas de trabajo para determinar la identidad antig\u00e9nica por Dot Blot del polisac\u00e1rido capsular de S. pneumoniae serotipo 19F presente en las vacunas\n[Severe Rotavirus gastroenteritis in a patient with infant leukemia](http://www.dicle.edu.tr/fakulte/tip/dergi/yayin/381/21.pdf) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nHatice Uygun\n2011-03-01\nFull Text Available Rotavirus is the most common cause of severe gastroenteritis in infants and young children. Reports about the clinical relevance of rotavirus in immunocompromised children are rare. We herein presented a case of life-threatening Rotavirus gastroenteritis in an infant with acute myeloblastic leukemia which could be prevented by recently recommended Rotavirus vaccination.\n[Outstanding challenges for rotavirus vaccine introduction in low-income countries](http://www.danmedj.dk/portal/page/portal/danmedj.dk/dmj_forside/PAST_ISSUE/2011/DMB_2011_10/A4323/A4323.pdf) [DEFF Research Database (Denmark)](http://forskningsbasen.deff.dk/?lang=eng)\nUstrup, Marte; Madsen, Lizell B; Bygbjerg, Ib C\n2011-01-01\nRotavirus infections are the most common cause of severe diarrhoea in children worldwide. Two internationally licensed rotavirus vaccines have proven to be efficacious in middle and high-income countries and they could potentially be valuable tools for the prevention of rotavirus....... There is also a need for political commitment to prevent rotavirus infections as well as a need for an overall strengthening of the health systems in low-income countries. If these challenges were met, rotavirus vaccination could substantially improve child health and survival from rotavirus...\n[Evaluaci\u00f3n de los programas de vacunaci\u00f3n mediante estudios serol\u00f3gicos y vacunas distribuidas Evaluation of vaccination programs through serological studies and distributed vaccines](http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0213-91112005000600006) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nPedro Plans\n2005-12-01\nFull Text Available Antecedentes: El objetivo del estudio fue comparar las coberturas vacunales en escolares para la vacuna triple v\u00edrica (sarampi\u00f3n-rub\u00e9ola-parotiditis, DTP (difteria-t\u00e9tanos-tos ferina y poliomielitis, obtenidas a partir de las vacunas distribuidas a los centros de vacunaci\u00f3n, las vacunaciones declaradas y el an\u00e1lisis serol\u00f3gico de anticuerpos. M\u00e9todos: La cobertura vacunal se obtuvo a partir de los antecedentes de vacunaci\u00f3n recogidos en un cuestionario y mediante el an\u00e1lisis serol\u00f3gico de anticuerpos frente al sarampi\u00f3n para la vacuna triple v\u00edrica, y el t\u00e9tanos para la vacuna DTP en una muestra representativa de escolares en 2001. La cobertura vacunal por registros se obtuvo dividiendo el n\u00famero de individuos que pod\u00edan haber completado la vacunaci\u00f3n por la poblaci\u00f3n objetivo. Se evalu\u00f3 la concordancia entre los antecedentes de vacunaci\u00f3n y los resultados serol\u00f3gicos mediante el \u00edndice kappa. Resultados: En los escolares de 6-8 y 9-11 a\u00f1os de edad se obtuvo una cobertura vacunal por cuestionario del 85,5 y el 87,6% para la vacuna DTP, del 89,9 y el 89,6% para la vacuna triple v\u00edrica, y del 90,4 y el 89,4% para la vacuna poliomiel\u00edtica, respectivamente, mientras la cobertura vacunal por an\u00e1lisis serol\u00f3gico fue del 100 y el 99,6% para la vacuna DTP, y del 85,5 y el 93,3% para la vacuna triple v\u00edrica, respectivamente. La cobertura vacunal por registros fue significativamente mayor que la obtenida mediante estos 2 m\u00e9todos: un 93,5 y un 100% para la vacuna DTP, un 96,3 y un 98,8% para la vacuna triple v\u00edrica, y un 100% para la vacuna poliomiel\u00edtica. La concordancia obtenida entre los antecedentes de vacunaci\u00f3n y los resultados serol\u00f3gicos fue muy baja (\u03ba Background: The objective of this study was to compare vaccination coverage in schoolchildren for the measles-mumps-rubella (MMR and diphtheria-tetanus-pertussis (DTP triple vaccines, and the poliomyelitis vaccine based on: a vaccines distributed to vaccination\n[Vacuna per escur\u00e7ar el tractament contra la tuberculosi](https://www.openaire.eu/search/publication?articleId=od______1404::024354d31010002918ddb339dc0408a6)\nCardona, Pere-Joan\n2006-01-01\nUn grup d'investigadors de la Unitat de Tuberculosi Experimental de la Fundaci\u00f3 Institut Germans Trias i Pujol ha creat una vacuna que permet reduir la durada del tractament de la infecci\u00f3 latent que provoca la tuberculosi de nou mesos a nom\u00e9s un.\n[An evaluation of the Australian Rotavirus Surveillance Program.](https://www.ncbi.nlm.nih.gov/pubmed/19062768)\nRoberts-Witteveen, April R; Patel, Mahomed S; Roche, Paul W\n2008-09-01\nThe Australian Rotavirus Serotyping Program (ARSP) serotypes rotavirus isolates obtained from stool samples sent from Australian laboratories. In collaboration with ARSP the Australian Government Department of Health and Ageing evaluated the program for its utility and capacity to monitor effectiveness of the rotavirus vaccines recently introduced into the Australian National Immunisation Program. The system was described using ARSP annual reports and staff interviews. The attributes of the system were assessed by adapting standard guidelines for evaluating a surveillance system. Email surveys or face to face interviews were conducted with staff of ARSP, participating laboratories, rotavirus vaccine manufacturing companies and representatives of the Communicable Diseases Network Australia. The ability of the ARSP to monitor changes in rotavirus serotype epidemiology was assessed. ARSP serotypes rotavirus isolates received from participating laboratories at least bi-annually, with results being reported at least as often. Serotype analyses have informed formulation of rotavirus vaccines and contributed to forecasting the extent of outbreaks caused by novel serotypes. The ARSP will be able to monitor changes in rotavirus serotype epidemiology and identify probable vaccination failures. Enhancement of the representativeness and sensitivity of the system are needed for the data to remain useful in the public health context. Methods for transferring data between the program and state and territory health departments need to be developed.\n[Vacunas y autoinmunidad: una rara asociaci\u00f3n bajo debate Vaccines and autoimmunity: a strange association under debate](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1726-46342012000200017) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAlexander Batista-Duharte\n2012-06-01\nFull Text Available La posible asociaci\u00f3n entre vacunas y enfermedades autoinmunes es un tema controversial. Existen elementos a favor de esta relaci\u00f3n basados en modelos te\u00f3ricos, ensayos de laboratorio y varios casos cl\u00ednicos publicados. En cambio, los estudios epidemiol\u00f3gicos no han confirmado esta asociaci\u00f3n y, de ellos, puede inferirse que las vacunas no constituyen una causa demostrada de enfermedades autoinmunes. En este trabajo se analizan las evidencias a favor y en contra de esta controversial asociaci\u00f3n, adem\u00e1s, se aborda un nuevo s\u00edndrome asociado con la administraci\u00f3n continuada de adyuvantes vacunales. Se concluye que debido al gran impacto en beneficio de la salud logrado con las vacunas, es necesario continuar desarrollando esta tecnolog\u00eda, pero tambi\u00e9n se debe seguir perfeccionando los dise\u00f1os de las nuevas formulaciones y profundizando estudios b\u00e1sicos, precl\u00ednicos, ensayos cl\u00ednicos y farmacovigilancia de los nuevos candidatos vacunales para establecer el riesgo real de desarrollo de un evento autoinmune posvacunaci\u00f3n.The occurrence and significance of autoimmune manifestations after administration of vaccines remain controversial. Evidence for immunization triggered autoimmunity come from several sources including theoretical models, animal studies, single and multiple case reports. In contrast, several epidemiological studies don\u2019t report this association, which is reassuring and at least indicates that vaccines are not a major cause of autoimmune diseases. We analyzed current scientific data concluded that vaccines bring a positive impact on public health, so it is necessary to continue developing this technology. Evaluation methods should be improved to avoid or anticipate the possible autoimmune side effects that can be presented.\n[Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand](https://www.openaire.eu/search/publication?articleId=od_______908::82c738f1ea1c402e082680d4f3a8efe8)\nChen, Mee-Yew; Kirkwood, Carl D.; Bines, Julie; Cowley, Daniel; Pavlic, Daniel; Lee, Katherine J.; Orsini, Francesca; Watts, Emma; Barnes, Graeme; Danchin, Margaret\n2017-01-01\nBackground: Maternal antibodies, acquired passively via placenta and/or breast milk, may contribute to the reduced efficacy of oral rotavirus vaccines observed in children in developing countries. This study aimed to investigate the effect of rotavirus specific maternal antibodies on the serum IgA response or stool excretion of vaccine virus after any dose of an oral rotavirus vaccine, RV3-BB, in parallel to a Phase IIa clinical trial conducted at Dunedin Hospital, New Zealand. At the time o...\n[Vacunas para la prevenci\u00f3n de la gripe en personas de edad avanzada](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::9f9342f04c4ecfc6206eb357ddd593ea)\nJefferson, Tom; Di Pietrantonj, Carlo; Al-Ansary, Lubna A.; Ferroni, Eliana; Thorning, Sarah; Thomas, Roger E.\n2010-01-01\nAntecedentes: Durante las \u00faltimas cuatro d\u00e9cadas, las vacunas han sido la principal arma global para disminuir la repercusi\u00f3n de la gripe en las personas de edad avanzada, y a nivel mundial se recomiendan para los individuos de 65 a\u00f1os o m\u00e1s de edad. El objetivo principal de la vacunaci\u00f3n contra la gripe en las personas de edad avanzada es reducir el riesgo de complicaciones en quienes son m\u00e1s vulnerables. Objetivos: Evaluar la efectividad de las vacunas sobre la prevenci\u00f3n de la gripe, la...\n[Rotavirus vaccination within the South African Expanded Programme on Immunisation.](https://www.ncbi.nlm.nih.gov/pubmed/22939015)\nSeheri, L Mapaseka; Page, Nicola A; Mawela, Mothahadini P B; Mphahlele, M Jeffrey; Steele, A Duncan\n2012-09-07\nDiarrhoeal diseases are ranked the third major cause of childhood mortality in South African children less than 5 years, where the majority of deaths are among black children. Acute severe dehydrating rotavirus diarrhoea remains an important contributor towards childhood mortality and morbidity and has been well documented in South Africa. As the preventive strategy to control rotavirus diarrhoea, South Africa became the first country in the WHO African Region to adopt the rotavirus vaccine in the national childhood immunisation programme in August 2009. The rotavirus vaccine in use, Rotarix, GSK Biologicals, is given at 6 and 14 weeks of age, along with other vaccines as part of Expanded Programme on Immunisation (EPI). Studies which facilitated the introduction of rotavirus vaccine in South Africa included the burden of rotavirus disease and strain surveillance, economic burden of rotavirus infection and clinical trials to assess the safety and efficacy of vaccine candidates. This paper reviews the epidemiology of rotavirus in South Africa, outlines some of the steps followed to introduce rotavirus vaccine in the EPI, and highlights the early positive impact of vaccination in reducing the rotavirus burden of disease based on the post-marketing surveillance studies at Dr George Mukhari hospital, a sentinel site at University of Limpopo teaching hospital in Pretoria, South Africa, which has conducted rotavirus surveillance for >20 years. Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.\n[Eficacia de la vacuna meningoc\u00f3cica de polisac\u00e1rido capsular del grupo C](https://www.openaire.eu/search/publication?articleId=doajarticles::665616b0e79abcde2883f393f494e02c)\nGonz\u00e1lez Enr\u00edquez Jes\u00fas; Garc\u00eda Comas Luis; Alcaide Jim\u00e9nez Juan Francisco; S\u00e1enz Calvo Antonio; Conde Olasagasti Jos\u00e9\n1997-01-01\nFUNDAMENTO: Este trabajo consiste esencialmente en una revisi\u00f3n sistem\u00e1tica de la literatura cient\u00edfica sobre los efectos, intensidad y duraci\u00f3n de la respuesta serol\u00f3gica, as\u00ed como sobre la eficacia, efectividad y seguridad de la vacuna meningoc\u00f3cica de polisac\u00e1rido capsular del grupo C. M\u00c9TODOS: B\u00fasqueda en repertorio MEDLINE en el periodo 1970-1996. B\u00fasqueda espec\u00edfica de ensayos cl\u00ednicos aleatorizados y estudios de intervenci\u00f3n prospectivos en humanos con vacunas de polisac\u00e1ridos capsular...\n[Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam.](https://www.ncbi.nlm.nih.gov/pubmed/22520119)\nShin, Sunheang; Anh, Dang Duc; Zaman, K; Yunus, M; Mai, Le Thi Phuong; Thiem, Vu Dinh; Azim, Tasnim; Victor, John C; Dallas, Michael J; Steele, A Duncan; Neuzil, Kathleen M; Ciarlet, Max\n2012-04-27\nWe evaluated the immunogenicity of the pentavalent rotavirus vaccine (PRV) in two GAVI-eligible Asian countries, Bangladesh and Vietnam, nested in a larger randomized, double-blind, placebo-controlled efficacy trial conducted over a two-year period from 2007 through 2009. 2036 infants were randomly assigned, in a 1:1 ratio, to receive three oral doses of PRV or placebo approximately at 6, 10, and 14 weeks of age. Concomitant use of EPI vaccines, including oral poliovirus vaccine (OPV) and diphtheria-tetanus-whole cell pertussis (DTwP) vaccine, was encouraged in accordance to the local EPI schedule. A total of 303 infants were evaluated for immunogenicity and blood samples were collected before the first dose (pD1) and approximately 14 days following the third dose (PD3). The seroresponse rates (\u22653-fold rise from pD1 to PD3) and geometric mean titers (GMTs) were measured for anti-rotavirus immunoglobulin A (IgA) and serum neutralizing antibody (SNA) to human rotavirus serotypes G1, G2, G3, G4, and P1A[8], respectively. Nearly 88% of the subjects showed a \u22653-fold increase in serum anti-rotavirus IgA response in the analysis of the two countries combined. When analyzed separately, the IgA response was lower in Bangladeshi children (78.1% [95% CI: 66.0, 87.5]) than in Vietnamese children (97.0% [95% CI: 89.6, 99.6]), with a PD3 GMT of 29.1 (units/mL) and 158.5 (units/mL), respectively. In the combined population, the SNA responses to the individual serotypes tested ranged from 10 (G3) to 50 (G1) percentage points lower than the responses shown in the developed countries. However, the SNA response to G3 in Vietnamese subjects was 37.3% (95% CI: 25.8, 50.0), which was similar to the G3 response rate in developed countries. Three oral doses of PRV were immunogenic in two GAVI-eligible Asian countries: Bangladesh and Vietnam. The GMTs of both the serum anti-rotavirus IgA and SNA responses were generally higher in Vietnamese than in Bangladeshi children. The SNA\n[Household transmission of rotavirus in a community with rotavirus vaccination in Quininde, Ecuador.](http://europepmc.org/articles/PMC3706538?pdf=render) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nBen Lopman\nFull Text Available We studied the transmission of rotavirus infection in households in peri-urban Ecuador in the vaccination era.Stool samples were collected from household contacts of child rotavirus cases, diarrhea controls and healthy controls following presentation of the index child to health facilities. Rotavirus infection status of contacts was determined by RT-qPCR. We examined factors associated with transmissibility (index-case characteristics and susceptibility (household-contact characteristics.Amongst cases, diarrhea controls and healthy control household contacts, infection attack rates (iAR were 55%, 8% and 2%, (n = 137, 130, 137 respectively. iARs were higher from index cases with vomiting, and amongst siblings. Disease ARs were higher when the index child was <18 months and had vomiting, with household contact <10 years and those sharing a room with the index case being more susceptible. We found no evidence of asymptomatic infections leading to disease transmission.Transmission rates of rotavirus are high in households with an infected child, while background infections are rare. We have identified factors associated with transmission (vomiting/young age of index case and susceptibility (young age/sharing a room/being a sibling of the index case. Vaccination may lead to indirect benefits by averting episodes or reducing symptoms in vaccinees.\n[Rotavirus Viremia and Extraintestinal Viral Infection in the Neonatal Rat Model](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1472071)\nCrawford, Sue E.; Patel, Dinesh G.; Cheng, Elly; Berkova, Zuzana; Hyser, Joseph M.; Ciarlet, Max; Finegold, Milton J.; Conner, Margaret E.; Estes, Mary K.\n2006-01-01\nRotaviruses infect mature, differentiated enterocytes of the small intestine and, by an unknown mechanism, escape the gastrointestinal tract and cause viremia. The neonatal rat model of rotavirus infection was used to determine the kinetics of viremia, spread, and pathology of rotavirus in extraintestinal organs. Five-day-old rat pups were inoculated intragastrically with an animal (RRV) or human (HAL1166) rotavirus or phosphate-buffered saline. Blood was collected from a subset of rat pups, and following perfusion to remove residual blood, organs were removed and homogenized to analyze rotavirus-specific antigen by enzyme-linked immunosorbent assay and infectious rotavirus by fluorescent focus assay or fixed in formalin for histology and immunohistochemistry. Viremia was detected following rotavirus infection with RRV and HAL1166. The RRV 50% antigenemia dose was 1.8 \u00d7 103 PFU, and the 50% diarrhea dose was 7.7 \u00d7 105 PFU, indicating that infection and viremia occurred in the absence of diarrhea and that detecting rotavirus antigen in the blood was a more sensitive measure of infection than diarrhea. Rotavirus antigens and infectious virus were detected in multiple organs (stomach, intestines, liver, lungs, spleen, kidneys, pancreas, thymus, and bladder). Histopathological changes due to rotavirus infection included acute inflammation of the portal tract and bile duct, microsteatosis, necrosis, and inflammatory cell infiltrates in the parenchymas of the liver and lungs. Colocalization of structural and nonstructural proteins with histopathology in the liver and lungs indicated that the histological changes observed were due to rotavirus infection and replication. Replicating rotavirus was also detected in macrophages in the lungs and blood vessels, indicating a possible mechanism of rotavirus dissemination. Extraintestinal infectious rotavirus, but not diarrhea, was observed in the presence of passively or actively acquired rotavirus-specific antibody. These\n[[Immunoreactivity of chimeric proteins carrying poliovirus epitopes on the VP6 of rotavirus as a vector].](https://www.ncbi.nlm.nih.gov/pubmed/27830685)\nPan, X-X; Zhao, B-X; Teng, Y-M; Xia, W-Y; Wang, J; Li, X-F; Liao, G-Y; Yang, \u0421; Chen, Y-D\n2016-01-01\nRotavirus and poliovirus continue to present significant risks and burden of disease to children in developing countries. Developing a combined vaccine may effectively prevent both illnesses and may be advantageous in terms of maximizing compliance and vaccine coverage at the same visit. Recently, we sought to generate a vaccine vector by incorporating multiple epitopes into the rotavirus group antigenic protein, VP6. In the present study, a foreign epitope presenting a system using VP6 as a vector was created with six sites on the outer surface of the vector that could be used for insertion of foreign epitopes, and three VP6-based PV1 epitope chimeric proteins were constructed. The chimeric proteins were confirmed by immunoblot, immunofluorescence assay, and injected into guinea pigs to analyze the epitope-specific humoral response. Results showed that these chimeric proteins reacted with anti-VP6F and -PV1 antibodies, and elicited antibodies against both proteins in guinea pigs. Antibodies against the chimeric proteins carrying PV1 epitopes neutralized rotavirus Wa and PV1 infection in vitro. Our study contributes to a better understanding of the use of VP6-based vectors as multiple-epitope delivery vehicles and the epitopes displayed in this form could be considered for development of epitope-based vaccines against rotavirus and poliovirus.\n[Comportamiento reactog\u00e9nico de la vacuna cubana contra la hepatitis B en ni\u00f1os f\u00edsica y mentalmente discapacitados](https://www.openaire.eu/search/publication?articleId=doajarticles::cd2d869696f88a55899ab58f2ce979f2)\nPl\u00e1cido Pedroso Flaquet; Manuel D\u00edaz Gonz\u00e1lez\n2000-01-01\nSe estudi\u00f3 la reactogenicidad de la vacuna recombinante cubana contra el virus de la hepatitis B, derivada de c\u00e9lulas de levadura (Heberbiovac-HB), al aplicar dosis de 5 y 10 mg y emplear el esquema de inmunizaci\u00f3n 0, una segunda dosis al mes y la tercera a los 6 meses a 2 grupos de ni\u00f1os f\u00edsica y mentalmente discapacitados de 5 a 14 a\u00f1os de edad. Los s\u00edntomas observados en el total de la poblaci\u00f3n estudiada fueron de 5,1 %, mientras que en los grupos vacunados con 10 y 5 mg, la sintomatolog\u00ed...\n[Comparative analysis of pentavalent rotavirus vaccine strains and G8 rotaviruses identified during vaccine trial in Africa.](https://www.ncbi.nlm.nih.gov/pubmed/26440913)\nHeylen, Elisabeth; Zeller, Mark; Ciarlet, Max; Lawrence, Jody; Steele, Duncan; Van Ranst, Marc; Matthijnssens, Jelle\n2015-10-06\nRotaTeqTM is a pentavalent rotavirus vaccine based on a bovine rotavirus genetic backbone in vitro reassorted with human outer capsid genes. During clinical trials of RotaTeqTM in Sub-Saharan Africa, the vaccine efficacy over a 2-year follow-up was lower against the genotypes contained in the vaccine than against the heterotypic G8P[6] and G8P[1] rotavirus strains of which the former is highly prevalent in Africa. Complete genome analyses of 43 complete rotavirus genomes collected during phase III clinical trials of RotaTeqTM in Sub-Saharan Africa, were conducted to gain insight into the high level of cross-protection afforded by RotaTeqTM against these G8 strains. Phylogenetic analysis revealed the presence of a high number of bovine rotavirus gene segments in these human G8 strains. In addition, we performed an in depth analysis on the individual amino acid level which showed that G8 rotaviruses were more similar to the RotaTeqTM vaccine than non-G8 strains. Because RotaTeqTM possesses a bovine genetic backbone, the high vaccine efficacy against G8 strains might be partially explained by the fact that all these strains contain a complete or partial bovine-like backbone. Altogether, this study supports the hypothesis that gene segments other than VP7 and VP4 play a role in vaccine-induced immunity.\n[Effect of pentavalent rotavirus vaccine introduction on hospital admissions for diarrhoea and rotavirus in children in Rwanda: a time-series analysis.](https://www.ncbi.nlm.nih.gov/pubmed/26823214)\nNgabo, Fidele; Tate, Jacqueline E; Gatera, Maurice; Rugambwa, Celse; Donnen, Philippe; Lepage, Philippe; Mwenda, Jason M; Binagwaho, Agnes; Parashar, Umesh D\n2016-02-01\nIn May, 2012, Rwanda became the first low-income African country to introduce pentavalent rotavirus vaccine into its routine national immunisation programme. Although the potential health benefits of rotavirus vaccination are huge in low-income African countries that account for more than half the global deaths from rotavirus, concerns remain about the performance of oral rotavirus vaccines in these challenging settings. We conducted a time-series analysis to examine trends in admissions to hospital for non-bloody diarrhoea in children younger than 5 years in Rwanda between Jan 1, 2009, and Dec 31, 2014, using monthly discharge data from the Health Management Information System. Additionally, we reviewed the registries in the paediatric wards at six hospitals from 2009 to 2014 and abstracted the number of total admissions and admissions for diarrhoea in children younger than 5 years by admission month and age group. We studied trends in admissions specific to rotavirus at one hospital that had undertaken active rotavirus surveillance from 2011 to 2014. We assessed changes in rotavirus epidemiology by use of data from eight active surveillance hospitals. Compared with the 2009-11 prevaccine baseline, hospital admissions for non-bloody diarrhoea captured by the Health Management Information System fell by 17-29% from a pre-vaccine median of 4051 to 2881 in 2013 and 3371 in 2014, admissions for acute gastroenteritis captured in paediatric ward registries decreased by 48-49%, and admissions specific to rotavirus captured by active surveillance fell by 61-70%. The greatest effect was recorded in children age-eligible to be vaccinated, but we noted a decrease in the proportion of children with diarrhoea testing positive for rotavirus in almost every age group. The number of admissions to hospital for diarrhoea and rotavirus in Rwanda fell substantially after rotavirus vaccine implementation, including among older children age-ineligible for vaccination, suggesting\n[Efic\u00e1cia e seguran\u00e7a da vacina brasileira contra hepatite B em rec\u00e9m-nascidos Eficiencia y seguridad de la vacuna brasilera contra hepatitis B en reci\u00e9n-nacidos Efficacy and safety of the Brazilian vaccine against Hepatitis B in newborns](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102009000600013) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nExpedito Jos\u00e9 de Albuquerque Luna\n2009-12-01\nFull Text Available OBJETIVO: Analisar a efic\u00e1cia e seguran\u00e7a de vacina recombinante contra hepatite B em rec\u00e9m-nascidos. M\u00c9TODOS: O estudo foi conduzido em hospital geral do munic\u00edpio de Guarulhos, SP, entre 2002 e 2005. A vacina recombinante contra hepatite B do Instituto Butantan (VrHB-IB foi analisada em dois ensaios cl\u00ednicos. Em ambos os ensaios, os rec\u00e9m-nascidos foram alocados aleatoriamente ao grupo experimental ou controle (vacina de refer\u00eancia. Os rec\u00e9m-nascidos receberam tr\u00eas doses das vacinas, uma em at\u00e9 24 h ap\u00f3s o nascimento e as subseq\u00fcentes 30 e 180 dias ap\u00f3s. No primeiro ensaio 538 rec\u00e9m-nascidos completaram o protocolo e no segundo ensaio, 486. Considerou-se crit\u00e9rio de equival\u00eancia a diferen\u00e7a na soroprote\u00e7\u00e3o inferior a 5%. RESULTADOS: A soroprote\u00e7\u00e3o no primeiro ensaio (anti HBs > 10mUI/ml foi de 92,5% (247/267 no grupo experimental, comparada a 98,5% (267/271 no grupo controle (p = 0,001. Com este resultado, a VrHB-IB n\u00e3o atingiu o crit\u00e9rio de equival\u00eancia estabelecido. Ap\u00f3s o aumento da concentra\u00e7\u00e3o de ant\u00edgeno na vacina para 25\u00bcg, a soroprote\u00e7\u00e3o no segundo ensaio foi de 100% no grupo experimental e 99,2% no grupo controle. Nenhum evento adverso grave foi registrado. CONCLUS\u00d5ES: A vacina VrHB-IB modificada foi considerada equivalente \u00e0 vacina de refer\u00eancia e seu uso recomendado \u00e0 vacina\u00e7\u00e3o de rec\u00e9m-nascidos.OBJETIVO: Analizar la eficiencia y seguridad de vacuna recombinante contra hepatitis B en reci\u00e9n-nacidos. M\u00c9TODOS: El estudio fue conducido en hospital general del municipio de Guarulhos, Sureste de Brasil, entre 2002 y 2005. La vacuna recombinante contra hepatitis B del Instituto Butantan (VrHB-IB fue analizada en dos ensayos cl\u00ednicos. En ambos ensayos, los reci\u00e9n-nacidos fueron distribuidos aleatoriamente en el grupo experimental o control (vacuna de referencia. Los reci\u00e9n-nacidos recibieron tres dosis de las vacunas, una en m\u00e1ximo 24 h posterior al nacimiento y las subsecuentes 30 y 180 d\n[Seguridad, reactogenicidad e inmunogenicidad de una nueva vacuna de polisac\u00e1ridos meningoc\u00f3cicos en adultos j\u00f3venes cubanos](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2017000100003&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nRossana Estruch\u2013de la Guardia\n2017-04-01\nFull Text Available Se realiz\u00f3 un estudio aleatorizado, controlado y a doble ciegas, en 352 adultos j\u00f3venes cubanos entre 18 y 35 a\u00f1os de edad, con el objetivo de evaluar la seguridad, reactogenicidad y la inmunogenicidad de una nueva vacuna de polisac\u00e1ridos de Neisseria meningitidis serogrupos A, C y W135, producida por el Instituto Finlay de Vacunas (La Habana, Cuba, con respecto a su similar comercial Mencevax\u00ae ACW de Glaxo Smith Kline. Se tomaron muestras de suero antes y 28 d\u00edas despu\u00e9s de la vacunaci\u00f3n. La reactogenicidad de ambas vacunas fue similar. Los s\u00edntomas y signos, tanto locales como generales fueron leves y aparecieron principalmente durante las primeras 48 h despu\u00e9s de la vacunaci\u00f3n. Ning\u00fan sujeto present\u00f3 eventos adversos graves durante los 28 d\u00edas del per\u00edodo de vigilancia. La vacuna en estudio mostr\u00f3 ser segura y poco reactog\u00e9nica; sus porcentajes de seroconversi\u00f3n a los 28 d\u00edas posteriores a la vacunaci\u00f3n fueron de: 92,19 % para el serogrupo A, 88,89 % para C y 90,06 % para W135. No se detectaron diferencias con respecto a la seroconversi\u00f3n. La seroprotecci\u00f3n alcanzada con la vacuna en estudio fue de 98,44 %, 91,81 % y 95,32 % para los serogrupos A, C y W135 respectivamente y no fue inferior con respecto a la vacuna control para los tres serogrupos estudiados.\n[Impact of rotavirus vaccines in low and middle-income countries.](https://www.ncbi.nlm.nih.gov/pubmed/28719399)\nSindhu, Kulandaipalayam Natarajan Chella; Babji, Sudhir; Ganesan, Santhosh Kumar\n2017-10-01\nRotavirus vaccines are playing a pivotal role in improving lives of infants and young children in low and middle-income countries (LMICs). Many of these countries have adopted the vaccine into their routine immunization, whereas others are considering introduction. This article provides an update on the impact of rotavirus vaccines in LMICs on morbidity and mortality in children aged less than 5 years, and their cost-effectiveness. The WHO, in 2013, updated its recommendation to prioritize introduction of rotavirus vaccines in the routine immunization schedule, without age restrictions. Despite the decreased efficacy of the vaccines in LMICs, data from Sub-Saharan Africa have demonstrated a decrease in rotavirus-related morbidity, with some sites reporting an indirect protective effect on children age ineligible to receive the vaccine. Even with improvements in sanitation, nutritional status in children, and other health-related indices in LMICs, the use of rotavirus vaccines will play an important role in preventing rotavirus-related gastroenteritis. Economic models predict a reduction in economic burden because of rotavirus-related health costs, making vaccine introduction cost-effective in resource-constrained settings. Increasing evidence from impact studies shows the significant impact of rotavirus vaccination on hospitalizations and economic burden because of rotavirus gastroenteritis in LMICs. Universal rotavirus vaccination is recommended, and introductions should be monitored by robust surveillance systems to measure effectiveness and impact.\n[Rotavirus vaccines: safety, efficacy and public health impact.](https://www.ncbi.nlm.nih.gov/pubmed/21668823)\nGray, J\n2011-09-01\nRotaviruses are the cause of acute gastroenteritis, and disease is widespread amongst infants and young children throughout the world. Also, rotavirus is associated with significant mortality in developing countries with more than 500 000 children dying each year as a result of the severe dehydration associated with rotavirus disease. Efforts have been ongoing for more than 30 years to develop a safe and effective rotavirus vaccine. Currently, two vaccines, RotaRix and RotaTeq, have been licensed for use in many countries throughout the world following comprehensive safety and efficiency trials. Monitoring their effectiveness after licensure has confirmed that their incorporation into early childhood vaccination schedules can significantly prevent severe rotavirus diarrhoea, which would have resulted in hospitalizations, emergency room visits or increased diarrhoea-related mortality. Although the efficacy of both vaccines is lower at approximately 40-59% in developing countries, their use could significantly reduce the mortality associated with rotavirus disease that is concentrated in these countries. \u00a9 2011 The Association for the Publication of the Journal of Internal Medicine.\n[Identification of the two rotavirus genes determining neutralization specificities](https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=20063690) [International Nuclear Information System (INIS) ](http://inis.iaea.org/search/)\nOffit, P.A.; Blavat, G.\n1986-01-01\nBovine rotavirus NCDV and simian rotavirus SA-11 represent two distinct rotavirus serotypes. A genetic approach was used to determine which viral gene segments segregated with serotype-specific viral neutralization. There were 16 reassortant rotarviruses derived by coinfection of MA-104 cells in vitro with the SA-11 and NCDV strains. The parental origin of reassortant rotavirus double-stranded RNA segments was determined by gene segment mobility in polyacrylamide gels and by hybridization with radioactively labeled parental viral transcripts. The authors found that two rotavirus gene segments found previously to code for outer capsid proteins vp3 and vp7 cosegreated with virus neutralization specificities\n[Identification of the two rotavirus genes determining neutralization specificities](http://www.etde.org/etdeweb/details.jsp?query_id=1&page=0&osti_id=6207519) [Energy Technology Data Exchange (ETDEWEB)](https://www.etde.org/etdeweb/fieldedsearch.jsp)\nOffit, P.A.; Blavat, G.\n1986-01-01\nBovine rotavirus NCDV and simian rotavirus SA-11 represent two distinct rotavirus serotypes. A genetic approach was used to determine which viral gene segments segregated with serotype-specific viral neutralization. There were 16 reassortant rotarviruses derived by coinfection of MA-104 cells in vitro with the SA-11 and NCDV strains. The parental origin of reassortant rotavirus double-stranded RNA segments was determined by gene segment mobility in polyacrylamide gels and by hybridization with radioactively labeled parental viral transcripts. The authors found that two rotavirus gene segments found previously to code for outer capsid proteins vp3 and vp7 cosegreated with virus neutralization specificities.\n[Performance of rotavirus vaccines in developed and developing countries](https://www.openaire.eu/search/publication?articleId=od_______908::5fac479ef6fc442bc7d919a6997b1203)\nJiang, Victoria; Jiang, Baoming; Tate, Jacqueline; Parashar, Umesh D; Patel, Manish M\n2010-01-01\nThe World Health Organization estimates that rotavirus diarrhea results in approximately half a million deaths and approximately 2.4 million hospitalizations in developing countries each year. Two live oral rotavirus vaccines, RotaTeq\u00ae (RV 5; Merck) and Rotarix\u00ae (RV 1; GlaxoSmithKline) with good efficacy against severe rotavirus disease and a reassuring safety profile could substantially impact the burden of rotavirus disease. In April 2009, WHO provided a recommendation for global introducti...\n[Determinants of Rotavirus Transmission: A Lag Nonlinear Time Series Analysis.](https://www.ncbi.nlm.nih.gov/pubmed/28333764)\nvan Gaalen, Rolina D; van de Kassteele, Jan; Hahn\u00e9, Susan J M; Bruijning-Verhagen, Patricia; Wallinga, Jacco\n2017-07-01\nRotavirus is a common viral infection among young children. As in many countries, the infection dynamics of rotavirus in the Netherlands are characterized by an annual winter peak, which was notably low in 2014. Previous study suggested an association between weather factors and both rotavirus transmission and incidence. From epidemic theory, we know that the proportion of susceptible individuals can affect disease transmission. We investigated how these factors are associated with rotavirus transmission in the Netherlands, and their impact on rotavirus transmission in 2014. We used available data on birth rates and rotavirus laboratory reports to estimate rotavirus transmission and the proportion of individuals susceptible to primary infection. Weather data were directly available from a central meteorological station. We developed an approach for detecting determinants of seasonal rotavirus transmission by assessing nonlinear, delayed associations between each factor and rotavirus transmission. We explored relationships by applying a distributed lag nonlinear regression model with seasonal terms. We corrected for residual serial correlation using autoregressive moving average errors. We inferred the relationship between different factors and the effective reproduction number from the most parsimonious model with low residual autocorrelation. Higher proportions of susceptible individuals and lower temperatures were associated with increases in rotavirus transmission. For 2014, our findings suggest that relatively mild temperatures combined with the low proportion of susceptible individuals contributed to lower rotavirus transmission in the Netherlands. However, our model, which overestimated the magnitude of the peak, suggested that other factors were likely instrumental in reducing the incidence that year.\n[electropherotypes and subgroups of group a rotaviruses circulating ...](https://www.ajol.info/index.php/aam/article/viewFile/43201/26744) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nEmmanuel Ameh\ndiarrhea caused by rotaviruses. The virus is a double stranded RNA (dsRNA) virus with 11 segments. Group A rotaviruses show a characteristic 4-2-3-2 pattern following electrophoresis. The VP6 subgroups, I and II exist. This work was carried out to study the prevalence of rotavirus infection among children 0-5 years with ...\n[Formative research to shape HPV vaccine introduction strategies in Peru Investigaci\u00f3n formativa relacionada con el dise\u00f1o de estrategias para introducir la vacuna contra el VPH en Per\u00fa](http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342010000300007) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nRosario M Bartolini\n2010-06-01\nFull Text Available OBJECTIVE: To understand the sociocultural environment, health systems' capacities, and policy processes related to cervical cancer and HPV vaccines in order to inform HPV vaccine introduction. MATERIAL AND METHODS: Mixed-method formative research using qualitative and quantitative data collection techniques. Participants included girls, parents, community leaders, health and education officials, and policymakers. RESULTS: Respondents, including policymakers, generally supported HPV vaccine introduction, due partly to appreciation for the benefits of vaccination and the desire to prevent cancer. Community-level concerns regarding safety and quality of services will need to be addressed. The immunization system in Peru is strong and has capacity for including the HPV vaccine. CONCLUSION: Formative research provides key insights to help shape an effective program for HPV vaccine introduction.OBJETIVO: Comprender el contexto sociocultural, las capacidades del sistema de salud y las condiciones pol\u00edticas vinculadas al c\u00e1ncer cervical y a la vacuna contra el VPH para dise\u00f1ar una estrategia apropiada de introducci\u00f3n de la vacuna contra el VPH. MATERIAL Y M\u00c9TODOS: Investigaci\u00f3n formativa usando t\u00e9cnicas cualitativas y cuantitativas. Los participantes incluyeron ni\u00f1os, padres, l\u00edderes, funcionarios del sector salud y educaci\u00f3n, y dise\u00f1adores de pol\u00edticas. RESULTADOS: Generalmente se apoya la introducci\u00f3n de la vacuna contra el VPH, dado que se aprecian los beneficios de la vacunaci\u00f3n y se desea prevenir el c\u00e1ncer. En la comunidad se encontraron preocupaciones sobre seguridad, confianza y calidad de atenci\u00f3n. El sistema de inmunizaciones en el Per\u00fa es eficiente y tiene la capacidad para incluir la vacuna contra el VPH. CONCLUSIONES: La investigaci\u00f3n formativa permite comprender elementos clave que ayudan a dise\u00f1ar un programa efectivo para la introducci\u00f3n de la vacuna contra el VPH.\n[Estudios de inmunogenicidad, seguridad y eficacia de la Vacuna Q frente a la leishmaniosis canina](https://www.openaire.eu/search/publication?articleId=od_______296::4dfda7f2f3e4339756541268672e7022)\nFern\u00e1ndez Cotrina, Javier\n2016-01-01\nSe analizaron la seguridad, inmunogenicidad y eficacia protectiva de cuatro dosis de la vacuna Q de Leishmania infantum (VQ). Para ello, cincuenta perros beagle (10 por grupo) fueron vacunados con una dosis \u00fanica de 200, 100, 50 y 25 \u00b5g de VQ. A los perros del grupo control se les inyect\u00f3 el diluyente de la vacuna. Los datos muestran que la vacunaci\u00f3n con VQ indujo una respuesta humoral temprana y espec\u00edfica dependiente de la dosis. Adem\u00e1s, durante el per\u00edodo post-vacunaci\u00f3n no se detect\u00f3 rea...\n[Effectiveness and impact of rotavirus vaccines in Europe, 2006-2014.](https://www.ncbi.nlm.nih.gov/pubmed/25795258)\nKarafillakis, Emilie; Hassounah, Sondus; Atchison, Christina\n2015-04-27\nPrior to the introduction of rotavirus vaccines in 2006, rotavirus was the leading cause of severe gastroenteritis among European children rotavirus vaccines in Europe following the first eight years of routine use. Four publication databases were searched, yielding 276 unique citations from February 1st, 2006 to July 31st, 2014. Twenty four studies on effectiveness (n=9) and impact (n=15) met the inclusion criteria. Across Europe, vaccine effectiveness against rotavirus-related healthcare utilisation ranged from 68% to 98%, consistent with efficacy data from clinical trials. Reductions in rotavirus hospitalisations ranged from 65% to 84%, consistent with findings from post-marketing studies from the US and Latin America. We confirm the significant public health benefit of rotavirus vaccination in Europe and provide further evidence to support implementation of universal rotavirus vaccination in all European countries. Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.\n[Skin Vaccination against Rotavirus Using Microneedles: Proof of Concept in Gnotobiotic Piglets.](http://europepmc.org/articles/PMC5100943?pdf=render) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nYuhuan Wang\nFull Text Available Live-attenuated oral rotavirus (RV vaccines have lower efficacy in low income countries, and additionally are associated with a rare but severe adverse event, intussusception. We have been pursuing the development of an inactivated rotavirus vaccine (IRV using the human rotavirus strain CDC-9 (G1P[8] through parenteral immunization and previously demonstrated dose sparing and enhanced immunogenicity of intradermal (ID unadjuvanted IRV using a coated microneedle patch in comparison with intramuscular (IM administration in mice. The aim of this study was to evaluate the immune response and protection against RV infection and diarrhea conferred by the administration of the ID unadjuvanted IRV using the microneedle device MicronJet600\u00ae in neonatal gnotobiotic (Gn piglets challenged with virulent Wa G1P[8] human RV. Three doses of 5 \u03bcg IRV when administered intradermally and 5 \u03bcg IRV formulated with aluminum hydroxide [Al(OH3] when administered intramuscularly induced comparable rotavirus-specific antibody titers of IgA, IgG, IgG avidity index and neutralizing activity in sera of neonatal piglets. Both IRV vaccination regimens protected against RV antigen shedding in stools, and reduced the cumulative diarrhea scores in the piglets. This study demonstrated that the ID and IM administrations of IRV are immunogenic and protective against RV-induced diarrhea in neonatal piglets. Our findings highlight the potential value of an adjuvant sparing effect of the IRV ID delivery route.\n[Skin Vaccination against Rotavirus Using Microneedles: Proof of Concept in Gnotobiotic Piglets.](https://www.ncbi.nlm.nih.gov/pubmed/27824918)\nWang, Yuhuan; Vlasova, Anastasia; Velasquez, Daniel E; Saif, Linda J; Kandasamy, Sukumar; Kochba, Efrat; Levin, Yotam; Jiang, Baoming\n2016-01-01\nLive-attenuated oral rotavirus (RV) vaccines have lower efficacy in low income countries, and additionally are associated with a rare but severe adverse event, intussusception. We have been pursuing the development of an inactivated rotavirus vaccine (IRV) using the human rotavirus strain CDC-9 (G1P[8]) through parenteral immunization and previously demonstrated dose sparing and enhanced immunogenicity of intradermal (ID) unadjuvanted IRV using a coated microneedle patch in comparison with intramuscular (IM) administration in mice. The aim of this study was to evaluate the immune response and protection against RV infection and diarrhea conferred by the administration of the ID unadjuvanted IRV using the microneedle device MicronJet600\u00ae in neonatal gnotobiotic (Gn) piglets challenged with virulent Wa G1P[8] human RV. Three doses of 5 \u03bcg IRV when administered intradermally and 5 \u03bcg IRV formulated with aluminum hydroxide [Al(OH)3] when administered intramuscularly induced comparable rotavirus-specific antibody titers of IgA, IgG, IgG avidity index and neutralizing activity in sera of neonatal piglets. Both IRV vaccination regimens protected against RV antigen shedding in stools, and reduced the cumulative diarrhea scores in the piglets. This study demonstrated that the ID and IM administrations of IRV are immunogenic and protective against RV-induced diarrhea in neonatal piglets. Our findings highlight the potential value of an adjuvant sparing effect of the IRV ID delivery route.\n[An Exopolysaccharide-Deficient Mutant of Lactobacillus rhamnosus GG Efficiently Displays a Protective Llama Antibody Fragment against Rotavirus on Its Surface.](https://www.ncbi.nlm.nih.gov/pubmed/26092449)\n\u00c1lvarez, Beatriz; Krogh-Andersen, Kasper; Tellgren-Roth, Christian; Mart\u00ednez, Noelia; G\u00fcnayd\u0131n, G\u00f6k\u00e7e; Lin, Yin; Mart\u00edn, M Cruz; \u00c1lvarez, Miguel A; Hammarstr\u00f6m, Lennart; Marcotte, Harold\n2015-09-01\nRotavirus is the leading cause of infantile diarrhea in developing countries, where it causes a high number of deaths among infants. Two vaccines are available, being highly effective in developed countries although markedly less efficient in developing countries. As a complementary treatment to the vaccines, a Lactobacillus strain producing an anti-rotavirus antibody fragment in the gastrointestinal tract could potentially be used. In order to develop such an alternative therapy, the effectiveness of Lactobacillus rhamnosus GG to produce and display a VHH antibody fragment (referred to as anti-rotavirus protein 1 [ARP1]) on the surface was investigated. L. rhamnosus GG is one of the best-characterized probiotic bacteria and has intrinsic antirotavirus activity. Among four L. rhamnosus GG strains [GG (CMC), GG (ATCC 53103), GG (NCC 3003), and GG (UT)] originating from different sources, only GG (UT) was able to display ARP1 on the bacterial surface. The genomic analysis of strain GG (UT) showed that the genes welE and welF of the EPS cluster are inactivated, which causes a defect in exopolysaccharide (EPS) production, allowing efficient display of ARP1 on its surface. Finally, GG (UT) seemed to confer a level of protection against rotavirus-induced diarrhea similar to that of wild-type GG (NCC 3003) in a mouse pup model, indicating that the EPS may not be involved in the intrinsic antirotavirus activity. Most important, GG (EM233), a derivative of GG (UT) producing ARP1, was significantly more protective than the control strain L. casei BL23. Copyright \u00a9 2015, American Society for Microbiology. All Rights Reserved.\n[Desarrollo de vacunas contra el virus de la inmunodeficiencia humana tipo 1: Relevancia de la inmunidad celular contra subtipos](https://www.openaire.eu/search/publication?articleId=doajarticles::3941e408f16fd779b922d875bd01b15f)\nAna Mar\u00eda Rodr\u00edguez; Gabriela Turk; Mar\u00eda Fernanda Pascutti; Juliana Falivene; Mar\u00eda Magdalena Gherardi\n2010-01-01\nHan pasado casi 30 a\u00f1os de la detecci\u00f3n de los primeros casos de infecci\u00f3n con HIV-1 y a\u00fan no se ha conseguido desarrollar una vacuna efectiva y segura. A pesar del impacto positivo sobre la pandemia que se ha conseguido gracias a los avances en la terapia antirretroviral (TARV), el HIV/sida sigue constituyendo un grave problema para la salud p\u00fablica, especialmente en los pa\u00edses en desarrollo, donde es dif\u00edcil el acceso al tratamiento. En el mundo, 33 millones de personas viven con el virus d...\n[Effectiveness of rotavirus vaccines against hospitalisations in Japan.](https://www.ncbi.nlm.nih.gov/pubmed/28693503)\nFujii, Yoshiyuki; Noguchi, Atsuko; Miura, Shinobu; Ishii, Haruka; Nakagomi, Toyoko; Nakagomi, Osamu; Takahashi, Tsutomu\n2017-07-11\nIn Japan, rotavirus hospitalisation occurs at a rate from 2.8 to 13.7 per 1000 child-years among children age less than 5 years, and it imposes a substantial burden to the healthcare system in the country. While both monovalent (RV1) and pentavalent (RV5) rotavirus vaccines are licensed in Japan, neither has been incorporated in the national infant immunization programme. In this study, we estimated vaccine effectiveness (VE) in Japan. This study was conducted in Yuri-Kumiai General Hospital located in a city in the north-western part of Japan. Age-eligible children for rotavirus vaccination were enrolled if they were hospitalized for rotavirus gastroenteritis between September 2013 and August 2016. Rotavirus gastroenteritis was defined by the detection of rotavirus antigen by immunochromatography. \"Vaccinated\" was defined as infant inoculated with at least one dose of either RV1 or RV5. A conditional logistic regression analysis was performed by modelling the year of birth, year of admission, residence of the children and vaccination status, and by matching the age of cases with that of test-negative controls. The adjusted odds ratio of the vaccinated over unvaccinated was then used to calculate VE in the formula of (1 - adjusted odds ratio) \u00d7 100. Out of the 244 patients enrolled, rotavirus antigen was detected in 55 (22.5%) of whom 10 (18.2%) were vaccinated, whereas 94 (49.7%) of 189 test-negative controls were vaccinated. During the study period, the vaccine uptake rate in the controls increased from 36.2% to 61.8%. On the other hand, the vaccination coverage over the three years was 64.2% in Yuri-Honjo city (three quarters of the catchment), and 91.4% in Nikaho city (one quarter of the catchment). The VE was calculated to be 70.4% (95% confidence interval: 36.0-86.4%, P = 0.002). The point estimate of the VE was lower but its 95% confidence interval overlaps those of the efficacies obtained from clinical trials in Japan. The rotavirus vaccine was\n[Estimating the herd immunity effect of rotavirus vaccine.](https://www.ncbi.nlm.nih.gov/pubmed/26116250)\nPollard, Suzanne L; Malpica-Llanos, Tanya; Friberg, Ingrid K; Fischer-Walker, Christa; Ashraf, Sania; Walker, Neff\n2015-07-31\nDiarrhea is one of the leading causes of death in children under 5, and an estimated 39% of these deaths are attributable to rotavirus. Currently two live, oral rotavirus vaccines have been introduced on the market; however, the herd immunity effect associated with rotavirus vaccine has not yet been quantified. The purpose of this meta-analysis was to estimate the herd immunity effects associated with rotavirus vaccines. We performed a systematic literature review of articles published between 2008 and 2014 that measured the impact of rotavirus vaccine on severe gastroenteritis (GE) morbidity or mortality. We assessed the quality of published studies using a standard protocol and conducted meta-analyses to estimate the herd immunity effect in children less than one year of age across all years presented in the studies. We conducted these analyses separately for studies reporting a rotavirus-specific GE outcome and those reporting an all-cause GE outcome. In studies reporting a rotavirus-specific GE outcome, four of five of which were conducted in the United States, the median herd effect across all study years was 22% [19-25%]. In studies reporting an all-cause GE outcome, all of which were conducted in Latin America, the median herd effect was 24.9% [11-30%]. There is evidence that rotavirus vaccination confers a herd immunity effect in children under one year of age in the United States and Latin American countries. Given the high variability in vaccine efficacy across regions, more studies are needed to better examine herd immunity effects in high mortality regions. Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.\n[Prevalence of group a rotavirus, enteric adenovirus, norovirus and astrovirus infections among children with acute gastroenteritis in al-qassim, saudi arabia](https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=39076497) [International Nuclear Information System (INIS) ](http://inis.iaea.org/search/)\nMeqdam, M.M.\n2007-01-01\nTo investigate the prevalence of Rotavirus, Adenovirus, Norovirus, and Astrovirus among Saudi children with gastroenteritis. This study was conducted at the Department of Medical Laboratories, Qassim University during the winter seasons of the years 2004 and 2005. A total of 284 diarrhoeal fecal specimens collected from children were tested for the gastroenteritis causing viruses using enzyme immunoassay. Of the 284 specimens, 142 (50%) were found to be positive for viruses causing gastroenteritis. Rotavirus (66.2%) was the most frequently detected, followed by adenovirus (15.5%), norovirus and astrovirus each with 9.2%. All of rotavirus detected belonged to group A. Eight specimens were found positive by two viruses. The introduction of simple and rapid tests for diagnosis of viruses causing gastroenteritis in our pediatric hospitals will improve patient care by reducing unnecessary treatments and hospital stay for patients. (author)\n[Mortalidad por enfermedad diarreica en menores, antes y despu\u00e9s de la introducci\u00f3n de la vacuna contra el rotavirus Analysis of the mortality due to diarrhea in younger children, before and after the introduction of rotavirus vaccine](http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342009000400004) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMarcelino Esparza-Aguilar\n2009-08-01\nFull Text Available OBJETIVO: Analizar la mortalidad por diarrea en menores de cinco a\u00f1os en M\u00e9xico, antes y despu\u00e9s de la vacunaci\u00f3n contra el rotavirus. MATERIAL Y M\u00c9TODOS: Se compararon defunciones y mortalidad por diarrea mediante diferencias porcentuales anuales por grupo etario, antes (2000-2005 y despu\u00e9s (2006-2007 de la vacunaci\u00f3n. RESULTADOS: Entre 2000 y 2007 la mortalidad por diarrea disminuy\u00f3 42%. En los estados con vacunaci\u00f3n, la mortalidad se redujo 15.8 y 27.7% en menores de uno y de uno a cuatro a\u00f1os, respectivamente, en el periodo de 2006 a 2007. DISCUSI\u00d3N: La reducci\u00f3n observada en la mortalidad por diarrea en menores de cinco a\u00f1os despu\u00e9s de 2005 puede atribuirse en parte a la vacunaci\u00f3n contra el rotavirus.OBJECTIVE: To analyze the mortality due to acute diarrhea in children younger than five years old, before and after the introduction of rotavirus vaccine in Mexico. MATERIAL AND METHODS: Number of deaths and mortality rates due to acute diarrhea were compared by children's age and states' vaccine status using annual percentage differences before (2000-2005 and after (2006-2007 the introduction of the HRV. RESULTS: From 2000-2007, deaths due to acute diarrhea in children under five years of age dropped 42%. In those states that received the HRV early in 2006, diarrhea mortality decreased between 2006-2007 15.8% in children younger than one year old and 22.7% in children 1-4 years old. DISCUSSION: The observed reduction in mortality due to acute diarrhea in children under five years of age after 2005 can be, in part, attributed to the HRV.\n[Presencia de rotavirus en adultos con diarrea en Asunci\u00f3n, Paraguay Incidence of rotavirus in adults with diarrhea in Asunci\u00f3n, Paraguay](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-75412005000200010) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nM. Mart\u00ednez\n2005-06-01\nFull Text Available Desde octubre de 2001 a marzo de 2004 se analizaron 533 heces de individuos mayores de 18 a\u00f1os con cuadros de diarrea, identific\u00e1ndose rotavirus en 92 (17,3% de ellas. La infecci\u00f3n por rotavirus en adultos no mostr\u00f3 un grupo et\u00e1reo m\u00e1s afectado y se present\u00f3 a lo largo de todo el a\u00f1o sin diferencias significativas en las frecuencias trimestrales. En Paraguay, en los ni\u00f1os menores de 5 a\u00f1os, presenta un pico estacional entre los meses de junio y octubre. Los datos presentados refuerzan la necesidad de tener en cuenta a rotavirus en el diagn\u00f3stico diferencial de las diarreas en adultos.From October 2001 to March 2004, 92 out of 533 (17.3% fecal samples of patients over 18 years of age were positive for rotavirus. There were not differences of rotavirus incidence between age groups. Although in Paraguay, rotavirus infections in children less than 5 years old present a seasonal peak pattern (since June to October, in adults rotavirus was present throughout the year with the same frequency. Results presented here reinforce the notion that rotavirus should be considered in the differential diagnosis of diarrhea in adults.\n[La Real Expedici\u00f3n Filantr\u00f3pica de la vacuna (1803 - 1810](http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0465-546X2007000400010) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJorge Veiga de Cabo\n2007-12-01\nFull Text Available La Expedici\u00f3n Filantr\u00f3pica de la vacuna supuso una de las empresas sanitarias realizadas en el Siglo XVIII de mayor envergadura, por su complejidad, dificultad y sobre todo, por constituir una de las misiones de Salud P\u00fablica m\u00e1s importantes realizadas en la Historia. Supone el resultado de un proceso en el que una serie de acontecimientos hist\u00f3ricos, sanitarios y sociales confluyen para generar uno de los primeros programas de intervenci\u00f3n en salud p\u00fablica a escala internacional y de expansi\u00f3n de la vacuna de la viruela. Se crean Centros de producci\u00f3n, almacenamiento y distribuci\u00f3n de la vacuna, y programas de capacitaci\u00f3n t\u00e9cnica enfocados a mantener campa\u00f1as de vacunaci\u00f3n poblacional.One of the most important medical achievements made in the eighteenth century was the Philanthropic Expedition of the Vaccine. Due to its complexity and difficulty it was one of the most important Public Health undertakings in history. It was the outcome of a series of historical, social and health advances that converged in creating one of the earliest international programs for the expansion of the smallpox vaccine, creating centres for the production, storage and distribution of the vaccine together with technical training programs aimed at maintaining population vaccination campaigns.\n[Zooanthroponotic transmission of rotavirus in Haryana State of Northern India.](https://www.ncbi.nlm.nih.gov/pubmed/28161962)\nChoudhary, P; Minakshi, P; Ranjan, K; Basanti, B\nRotaviruses are the major cause of severe gastroenteritis and mortality in young children and animals. Due to segmented nature of dsRNA genome and wide host range, vast genetic and antigenic diversity exists amongst different isolates of rotaviruses. A total of 230 fecal ovine and caprine samples collected from organized farms and villages in Haryana were screened for rotavirus detection. Samples were screened by latex agglutination test and RNA-PAGE followed by RT-PCR and nucleic acid sequencing. The latex agglutination test showed 25 newborn lamb and 4 kid fecal samples positive for rotavirus. However, RNA-PAGE showed only 9 lamb fecal samples positive for rotavirus. All the samples were subjected to RT-PCR employing vp4 and vp7 gene specific primers of group A rotavirus of ovine, bovine and human origin. Only two samples from lamb (Sheep18/Hisar/2013 and Sheep22/Hisar/2013) showed vp4 and vp7 gene specific amplification with human group A rotavirus (GAR) specific primer. However, they did not show any amplification with ovine and bovine rotavirus specific primers. The nucleotide as well as deduced amino acid sequence analysis of vp4 gene of these isolates showed >98/97% and vp7 gene >95/94% nt/aa identity with human GAR from different regions of the world. Based on nucleotide similarity search, Sheep18/Hisar/2013 and Sheep22/Hisar/2013 isolates were genotyped as G1P[8] and G1P[4]. Phylogenetic analysis also confirmed that these isolates were clustered closely with human rotaviruses from different regions of the world. Earlier, higher prevalence of human rotaviruses was reported from the sample collecting area. The amplification of ovine samples with human rotavirus gene specific primers, sequence identity and phylogenetic analysis strongly suggests the zoonotic transmission of human GAR to sheep.\n[Rotavirus Vaccines: a story of success with challenges ahead](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5580433)\nO\u2019Ryan, Miguel\n2017-01-01\nApproximately 40 years have passed since the discovery of the rotavirus and 10 years since the introduction and progressive dissemination of rotavirus vaccines worldwide. Currently, 92 countries have introduced rotavirus vaccines into national or subnational programs with evident impact in disease reduction. Two vaccines have been widely used, and four additional vaccines have been licensed and are being used in defined regions. In this context, one main issue that remains unsolved is the lower vaccine efficacy/effectiveness in low-income countries. An additional partially answered issue relates to rotavirus strain circulation in vaccinated populations. These issues are discussed in this review. The most imperative challenge ahead is to fulfill the WHO\u2019s recommendation to introduce rotavirus vaccines in all countries. PMID:28928954\n[Centers for Disease Control (CDC) Podcasts](http://www2c.cdc.gov/podcasts/search.asp)\n2009-01-06\nCDC's Dr. Jon Gentsch discusses rotaviruses, the most important cause of severe gastroenteritis in children less than five years of age. Essentially, all children around the world get the disease during the first few years of life. Created: 1/6/2009 by Emerging Infectious Diseases. Date Released: 1/6/2009.\n[Cryptosporidium spp. and rotavirus gastroenteritis and change of incidence after rotavirus vaccination among children in Raparin Pediatrics Hospital, Erbil, Iraq](http://mji.ui.ac.id/journal/index.php/mji/article/view/1957) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nSally S. Azeez\n2017-11-01\nFull Text Available Background: Watery diarrhea is the most common medical problem among infants and young children, caused by different microbial etiology including Cryptosporidium spp. and rotavirus, which are usually misdiagnosed in conventional stool test. This study aimed to investigate the incidence of Cryptosporidium and rotavirus gastroenteritis among children in Erbil as well as evaluate the efficacy of rotavirus vaccination procedure applied in Erbil.Methods: Fecal specimens were collected from 400 children (boys and girls, aged one month to five years old, who attended Raparin Pediatrics Hospital in Erbil complaining from diarrhea, between January to August 2014. Modified Ziehl Neelsen technique and nested PCR were used for detection of cryptosporidiosis while rotavirus infection was detected by rapid CerTest.Results: Rate of detection of cryptosporidiosis was remarkably higher using PCR than Ziehl-Neelsen stain (0% versus 6%, and the infection was slightly higher among boys (6.25% vs 5.55% and children \u22642 years (11.7%. The peak of infection reached during spring season (March and April (9.5%. The detection rate of rotavirus was 32.0%, which was slightly higher among males (34.4% vs 30.0% and in children between one to three years old (39.3%. The highest detection rate (38.6% was recorded during winter season (January and February. The infection was significantly higher among non-vaccinated children (65.9% vs 14.1%; p<0.05.Conclusion: The incidence of cryptosporidiosis is declining. However, rotavirus gastroenteritis was relatively high among young children in Erbil. Rotateq vaccine significantly reduced the incidence of rotavirus infection.\n[Estudio de toxicidad por dosis \u00fanica y tolerancia local de una vacuna antimeningoc\u00f3cica tipo B en ratas Sprague Dawley](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200004&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJuan F. N\u00fa\u00f1ez\n2006-08-01\nFull Text Available La vacuna antimeningoc\u00f3cica tipo B, objetivo de este estudio, contiene ves\u00edculas purificadas de la membrana externa del meningococo del serogrupo B de la cepa (Cu- 385 - 83 B:4:P1.19,15. El esquema de vacunaci\u00f3n propuesto en humanos consiste en tres dosis de 0,5 mL, separadas por un intervalo \u00f3ptimo de ocho semanas. El objetivo de este estudio de toxicidad en ratas Sprague Dawley (SD fue determinar la toxicidad potencial, letalidad, \u00f3rganos, sistemas susceptibles y otros eventos adversos, as\u00ed como la toxicidad en el sitio de inoculaci\u00f3n despu\u00e9s de la administraci\u00f3n de una dosis de la vacuna en estudio. Los resultados indicaron que, bajo las condiciones del estudio y seg\u00fan los criterios establecidos para evaluar los resultados, la vacuna antimeningoc\u00f3cica tipo B, no produce efectos t\u00f3xicos en el modelo animal usado. Todo lo que se observ\u00f3 fueron formaciones granulomatosas a nivel del punto de inoculaci\u00f3n. Estas formaciones han sido reportadas como pertenecientes a los adyuvantes de dep\u00f3sito, como el hidr\u00f3xido de aluminio, usado en otras vacunas parenterales. Se concluye que la vacuna antimeningoc\u00f3cica tipo B result\u00f3 satisfactoria en las pruebas de toxicidad por dosis\u00fanica y tolerancia local realizadas en la especie rata.\n[Effectiveness of Pentavalent Rotavirus Vaccine Under Conditions of Routine Use in Rwanda.](https://www.ncbi.nlm.nih.gov/pubmed/27059358)\nTate, Jacqueline E; Ngabo, Fidele; Donnen, Philippe; Gatera, Maurice; Uwimana, Jeannine; Rugambwa, Celse; Mwenda, Jason M; Parashar, Umesh D\n2016-05-01\nRotavirus vaccine efficacy is lower in low-income countries than in high-income countries. Rwanda was one of the first low-income countries in sub-Saharan Africa to introduce rotavirus vaccine into its national immunization program. We sought to evaluate rotavirus vaccine effectiveness (VE) in this setting. VE was assessed using a case-control design. Cases and test-negative controls were children who presented with a diarrheal illness to 1 of 8 sentinel district hospitals and 10 associated health centers and had a stool specimen that tested positive (cases) or negative (controls) for rotavirus by enzyme immunoassay. Due to high vaccine coverage almost immediately after vaccine introduction, the analysis was restricted to children 7-18 weeks of age at time of rotavirus vaccine introduction. VE was calculated as (1 - odds ratio) \u00d7 100, where the odds ratio was the adjusted odds ratio for the rotavirus vaccination rate among case-patients compared with controls. Forty-eight rotavirus-positive and 152 rotavirus-negative children were enrolled. Rotavirus-positive children were significantly less likely to have received rotavirus vaccine (33/44 [73%] unvaccinated) compared with rotavirus-negative children (81/136 [59%] unvaccinated) (P= .002). A full 3-dose series was 75% (95% confidence interval [CI], 31%-91%) effective against rotavirus gastroenteritis requiring hospitalization or a health center visit and was 65% (95% CI, -80% to 93%) in children 6-11 months of age and 81% (95% CI, 25%-95%) in children \u226512 months of age. Rotavirus vaccine is effective in preventing rotavirus disease in Rwandan children who began their rotavirus vaccine series from 7 to 18 weeks of age. Protection from vaccination was sustained after the first year of life. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.\n[Etiolog\u00eda y manejo de la gastroenteritis aguda infecciosa en ni\u00f1os y adultos](http://www.sciencedirect.com/science/article/pii/S071686401470063X) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nA. Yalda Lucero, DRA\n2014-05-01\nFull Text Available La Gastroenteritis Aguda (GEA infecciosa es una patolog\u00eda frecuente y de alto impacto, especialmente en ni\u00f1os menores de cinco a\u00f1os y adultos mayores. En nuestro medio, la causa m\u00e1s frecuente es viral (rotavirus y norovirus seguido de Salmonella, Shigella, E.coli diarreog\u00e9nicas y Campylobacter. Habitualmente son cuadros autolimitados que no requieren estudio de laboratorio espec\u00edfico y cuyo manejo debe centrarse en la reposici\u00f3n hidro-electrol\u00edtica de acuerdo al grado de deshidrataci\u00f3n. Existe evidencia sobre beneficio sintom\u00e1tico del uso de probi\u00f3ticos (Lactobacillus GG y S.boulardii; racecadotrilo en cuanto a la diarrea; y ondasetr\u00f3n para los v\u00f3mitos. En caso de sospecha de agente invasor (bacteria o par\u00e1sito debe realizarse un estudio etiol\u00f3gico e iniciar terapia antimicrobiana de acuerdo al microorganismo identificado. La prevenci\u00f3n de contagio mediante medidas de saneamiento y adecuada manipulaci\u00f3n de agua y alimentos es fundamental. Actualmente se dispone de vacunas efectivas contra algunos de los agentes involucrados (ej. rotavirus, que deben recomendarse en grupos de riesgo.\n[Rotavirus Infection in the Auckland Region After the Implementation of Universal Infant Rotavirus Vaccination: Impact on Hospitalizations and Laboratory Implications.](https://www.ncbi.nlm.nih.gov/pubmed/28746261)\nMcAuliffe, Gary N; Taylor, Susan L; Drinkovi\u0107, Dragana; Roberts, Sally A; Wilson, Elizabeth M; Best, Emma J\n2018-01-01\nIn July 2014, New Zealand introduced universal infant vaccination with RotaTeq (Merk & Co.) administered as 3 doses at 6 weeks, 3 and 5 months of age. We sought to assess the impact of rotavirus vaccination on gastroenteritis (GE) hospitalizations in the greater Auckland region and analyze changes in rotavirus testing in the period around vaccine introduction. Hospitalizations, laboratory testing rates and methods were compared between the pre-vaccine period (2009-2013), post-vaccine period (January 2015 to December 2015) and year of vaccine introduction (2014). There was a 68% decline in rotavirus hospitalizations of children Auckland region. However, continued rotavirus testing at pre-vaccine rates risks generating false positive results. Laboratories and clinicians should consider reviewing their testing algorithms before vaccine introduction.\n[Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomised, double-blind, placebo controlled trial](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3982044)\nCunliffe, Nigel A; Witte, Desiree; Ngwira, Bagrey M; Todd, Stacy; Bostock, Nancy J; Turner, Ann M; Chimpeni, Philips; Victor, John C; Steele, A Duncan; Bouckenooghe, Alain; Neuzil, Kathleen M\n2014-01-01\nRotavirus gastroenteritis is a major cause of morbidity and mortality among African infants and young children. A phase III, placebo-controlled, multi-centre clinical trial of a live, oral G1P[8] human rotavirus vaccine (RIX4414) undertaken in Malawi and South Africa significantly reduced the incidence of severe rotavirus gastroenteritis in the first year of life. We now report on vaccine efficacy in the Malawi cohort of children who were followed into the second year of life. A total of 1,773 healthy infants were enrolled in Blantyre, Malawi into three groups. Two groups received three doses of RIX4414 or placebo at age 6, 10, and 14 weeks and the third group received placebo at 6 weeks and RIX4414 at age 10 and 14 weeks. Subjects were followed by weekly home visits for episodes of gastroenteritis until 1 year of age, and were then re-consented for further follow-up to 18-24 months of age. Severity of gastroenteritis episodes was graded according to the Vesikari scoring system. Seroconversion for anti-rotavirus IgA was determined on a subset of children by using ELISA on pre- and post-vaccine blood samples. Rotavirus VP7 (G) and VP4 (P) genotypes were determined by RT-PCR. A total of 70/1030 (6.8%, 95% CI 5.3 - 8.5) subjects in the pooled (2 dose plus 3 dose) RIX4414 group compared with 53/483 (11.0%, 8.3 \u2013 14.1) subjects in the placebo group developed severe rotavirus gastroenteritis in the entire follow-up period (Vaccine Efficacy 38.1% (9.8 \u2013 57.3). The point estimate of efficacy in the second year of life (17.6%; \u221259.2 \u2013 56.0) was lower than in the first year of life (49.4%; 19.2 \u2013 68.3). There were non-significant trends towards a higher efficacy in the second year of life among children who received the three-dose schedule compared with the two-dose schedule, and a higher anti-rotavirus IgA seroresponse rate in the three-dose RIX4414 group. Rotavirus strains detected included genotype G12 (31%); G9 (23%); and G8 (18%); only 18% of strains belonged\n[Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/22520135)\nCunliffe, Nigel A; Witte, Desiree; Ngwira, Bagrey M; Todd, Stacy; Bostock, Nancy J; Turner, Ann M; Chimpeni, Philips; Victor, John C; Steele, A Duncan; Bouckenooghe, Alain; Neuzil, Kathleen M\n2012-04-27\nRotavirus gastroenteritis is a major cause of morbidity and mortality among African infants and young children. A phase III, placebo-controlled, multi-centre clinical trial of a live, oral G1P[8] human rotavirus vaccine (RIX4414) undertaken in Malawi and South Africa significantly reduced the incidence of severe rotavirus gastroenteritis in the first year of life. We now report on vaccine efficacy in the Malawi cohort of children who were followed into the second year of life. A total of 1773 healthy infants were enrolled in Blantyre, Malawi into three groups. Two groups received three doses of RIX4414 or placebo at age 6, 10, and 14 weeks and the third group received placebo at 6 weeks and RIX4414 at age 10 and 14 weeks. Subjects were followed by weekly home visits for episodes of gastroenteritis until 1 year of age, and were then re-consented for further follow-up to 18-24 months of age. Severity of gastroenteritis episodes was graded according to the Vesikari scoring system. Seroconversion for anti-rotavirus IgA was determined on a subset of children by using ELISA on pre- and post-vaccine blood samples. Rotavirus VP7 (G) and VP4 (P) genotypes were determined by RT-PCR. A total of 70/1030 (6.8%, 95% CI 5.3-8.5) subjects in the pooled (2 dose plus 3 dose) RIX4414 group compared with 53/483 (11.0%, 8.3-14.1) subjects in the placebo group developed severe rotavirus gastroenteritis in the entire follow-up period (vaccine efficacy 38.1% (9.8-57.3)). The point estimate of efficacy in the second year of life (17.6%; -59.2 to 56.0) was lower than in the first year of life (49.4%; 19.2-68.3). There were non-significant trends towards a higher efficacy in the second year of life among children who received the three-dose schedule compared with the two-dose schedule, and a higher anti-rotavirus IgA seroresponse rate in the three-dose RIX4414 group. Rotavirus strains detected included genotype G12 (31%); G9 (23%); and G8 (18%); only 18% of strains belonged to the G1P[8\n[Group A Rotavirus Associated with Encephalitis in Red Fox.](https://www.ncbi.nlm.nih.gov/pubmed/28820385)\nBusi, Chiara; Martella, Vito; Papetti, Alice; Sabelli, Cristiano; Lelli, Davide; Alborali, G Loris; Gibelli, Lucia; Gelmetti, Daniela; Lavazza, Antonio; Cordioli, Paolo; Boniotti, M Beatrice\n2017-09-01\nIn 2011, a group A rotavirus was isolated from the brain of a fox with encephalitis and neurologic signs, detected by rabies surveillance in Italy. Intracerebral inoculation of fox brain homogenates into mice was fatal. Genome sequencing revealed a heterologous rotavirus of avian origin, which could provide a model for investigating rotavirus neurovirulence.\n[[Seasonality of rotavirus infection in Venezuela: relationship between monthly rotavirus incidence and rainfall rates].](https://www.ncbi.nlm.nih.gov/pubmed/26710540)\nGonz\u00e1lez Ch\u00e1vez, Rosabel\n2015-09-01\nIn general, it has been reported that rotavirus infection was detected year round in tropical countries. However, studies in Venezuela and Brazil suggest a seasonal behavior of the infection. On the other hand, some studies link infection with climatic variables such as rainfall. This study analyzes the pattern of behavior of the rotavirus infection in Carabobo-Venezuela (2001-2005), associates the seasonality of the infection with rainfall, and according to the seasonal pattern, estimates the age of greatest risk for infection. The analysis of the rotavirus temporal series and accumulated precipitation was performed with the software SPSS. The infection showed two periods: high incidence (November-April) and low incidence (May-October). Accumulated precipitation presents an opposite behavior. The highest frequency of events (73.8% 573/779) for those born in the period with a low incidence of the virus was recorded at an earlier age (mean age 6.5 +/- 2.0 months) when compared with those born in the station of high incidence (63.5% 568/870, mean age 11.7 +/- 2.2 months). Seasonality of the infection and the inverse relationship between virus incidence and rainfall was demonstrated. In addition, it was found that the period of birth determines the age and risk of infection. This information generated during the preaccine period will be helpful to measure the impact of the vaccine against the rotavirus.\n[Effect of UV-irradiation on rotavirus](https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=22065961) [International Nuclear Information System (INIS) ](http://inis.iaea.org/search/)\nSmirnov, Y.A.; Kapitulets, S.P.; Kaverin, N.V.; Amitina, N.N.; Ginevskaya, V.A.\n1991-01-01\nThe effect of UV-irradiation on the infectivity of the SAll rotavirus was examined. The time behavior of the inactivation of infectivity generally exhibited the one-hit pattern. The effect was studied with respect to two phenomena, viz. the RNA-protein linkage and the formation of uracil dimers. To determine the number of the latter, purified 3 H-uridine-labelled rotavirus was exposed to UV radiation, and the RNA was extracted and analyzed by paper chromatography in the ascending mode. The formation of photodimers was found to be an important mechanism in the rotavirus inactivation on conventional irradiation, whereas RNA-protein linkages were observed on the application of high doses only. (author). 3 figs., 10 refs\n[Oral Vaccination with the Porcine Rotavirus VP4 Outer Capsid Protein Expressed by Lactococcus lactis Induces Specific Antibody Production](http://dx.doi.org/10.1155/2010/708460) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nYi-jing Li\n2010-01-01\nFull Text Available The objective of this study to design a delivery system resistant to the gastrointestinal environment for oral vaccine against porcine rotavirus. Lactococcus lactis NZ9000 was transformed with segments of vP4 of the porcine rotavirus inserted into the pNZ8112 surface-expression vector, and a recombinant L. lactis expressing VP4 protein was constructed. An approximately 27 kDa VP4 protein was confirmed by SDS-PAGE , Western blot and immunostaining analysis. BALB/c mice were immunized orally with VP4-expression recombinant L. lactis and cellular, mucosal and systemic humoral immune responses were examined. Specific anti-VP4 secretory IgA and IgG were found in feces, ophthalmic and vaginal washes and in serum. The induced antibodies demonstrated neutralizing effects on porcine rotavirus infection on MA104 cells. Our findings suggest that oral immunization with VP4-expressing L. lactis induced both specific local and systemic humoral and cellular immune responses in mice.\n[75 FR 48706 - Proposed Vaccine Information Materials for Rotavirus Vaccine](https://www.gpo.gov/fdsys/pkg/FR-2010-08-11/pdf/2010-19782.pdf)\n2010-08-11\n... Vaccine Information Materials for Rotavirus Vaccine AGENCY: Centers for Disease Control and Prevention... information materials for rotavirus vaccine. DATES: Written comments are invited and must be received on or... (chickenpox), pneumococcal conjugate, rotavirus, hepatitis A, meningococcal, human papillomavirus (HPV), and...\n[Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.](https://www.ncbi.nlm.nih.gov/pubmed/23658521)\nVega, Celina G; Bok, Marina; Vlasova, Anastasia N; Chattha, Kuldeep S; G\u00f3mez-Sebasti\u00e1n, Silvia; Nu\u00f1ez, Carmen; Alvarado, Carmen; Lasa, Rodrigo; Escribano, Jos\u00e9 M; Garaicoechea, Lorena L; Fernandez, Fernando; Bok, Karin; Wigdorovitz, Andr\u00e9s; Saif, Linda J; Parre\u00f1o, Viviana\n2013-01-01\nGroup A Rotavirus (RVA) is the leading cause of severe diarrhea in children. The aims of the present study were to determine the neutralizing activity of VP6-specific llama-derived single domain nanoantibodies (VHH nanoAbs) against different RVA strains in vitro and to evaluate the ability of G6P[1] VP6-specific llama-derived single domain nanoantibodies (VHH) to protect against human rotavirus in gnotobiotic (Gn) piglets experimentally inoculated with virulent Wa G1P[8] rotavirus. Supplementation of the daily milk diet with 3B2 VHH clone produced using a baculovirus vector expression system (final ELISA antibody -Ab- titer of 4096; virus neutralization -VN- titer of 256) for 9 days conferred full protection against rotavirus associated diarrhea and significantly reduced virus shedding. The administration of comparable levels of porcine IgG Abs only protected 4 out of 6 of the animals from human RVA diarrhea but significantly reduced virus shedding. In contrast, G6P[1]-VP6 rotavirus-specific IgY Abs purified from eggs of hyperimmunized hens failed to protect piglets against human RVA-induced diarrhea or virus shedding when administering similar quantities of Abs. The oral administration of VHH nanoAb neither interfered with the host's isotype profiles of the Ab secreting cell responses to rotavirus, nor induced detectable host Ab responses to the treatment in serum or intestinal contents. This study shows that the oral administration of rotavirus VP6-VHH nanoAb is a broadly reactive and effective treatment against rotavirus-induced diarrhea in neonatal pigs. Our findings highlight the potential value of a broad neutralizing VP6-specific VHH nanoAb as a treatment that can complement or be used as an alternative to the current strain-specific RVA vaccines. Nanobodies could also be scaled-up to develop pediatric medication or functional food like infant milk formulas that might help treat RVA diarrhea.\n[Recombinant monovalent llama-derived antibody fragments (VHH to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.](http://europepmc.org/articles/PMC3642062?pdf=render) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nCelina G Vega\nFull Text Available Group A Rotavirus (RVA is the leading cause of severe diarrhea in children. The aims of the present study were to determine the neutralizing activity of VP6-specific llama-derived single domain nanoantibodies (VHH nanoAbs against different RVA strains in vitro and to evaluate the ability of G6P[1] VP6-specific llama-derived single domain nanoantibodies (VHH to protect against human rotavirus in gnotobiotic (Gn piglets experimentally inoculated with virulent Wa G1P[8] rotavirus. Supplementation of the daily milk diet with 3B2 VHH clone produced using a baculovirus vector expression system (final ELISA antibody -Ab- titer of 4096; virus neutralization -VN- titer of 256 for 9 days conferred full protection against rotavirus associated diarrhea and significantly reduced virus shedding. The administration of comparable levels of porcine IgG Abs only protected 4 out of 6 of the animals from human RVA diarrhea but significantly reduced virus shedding. In contrast, G6P[1]-VP6 rotavirus-specific IgY Abs purified from eggs of hyperimmunized hens failed to protect piglets against human RVA-induced diarrhea or virus shedding when administering similar quantities of Abs. The oral administration of VHH nanoAb neither interfered with the host's isotype profiles of the Ab secreting cell responses to rotavirus, nor induced detectable host Ab responses to the treatment in serum or intestinal contents. This study shows that the oral administration of rotavirus VP6-VHH nanoAb is a broadly reactive and effective treatment against rotavirus-induced diarrhea in neonatal pigs. Our findings highlight the potential value of a broad neutralizing VP6-specific VHH nanoAb as a treatment that can complement or be used as an alternative to the current strain-specific RVA vaccines. Nanobodies could also be scaled-up to develop pediatric medication or functional food like infant milk formulas that might help treat RVA diarrhea.\n[An update of \u201cCost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model\u201d](http://www.biomedcentral.com/1471-2334/13/54) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nTu Hong Anh T\n2013-01-01\nFull Text Available Abstract Background To update a cost-effectiveness analysis of rotavirus vaccination in the Netherlands previously published in 2011. Methods The rotavirus burden of disease and the indirect protection of older children and young adults (herd protection were updated. Results When updated data was used, routine infant rotavirus vaccination in the Netherlands would potentially become an even more cost-effective strategy than previously estimated with the incremental cost per QALY at only \u20ac3,000-4,000. Break-even total vaccination costs were indicated at \u20ac92\u2013122, depending on the applied threshold. Conclusions We concluded that the results on potentially favourable cost-effectiveness in the previous study remained valid, however, the new data suggested that previous results might represent an underestimation of the economic attractiveness of rotavirus vaccination.\n[Efectividad de la vacuna contra influenza: metan\u00e1lisis de literatura](http://www.revistabiomedica.org/index.php/biomedica/article/view/44) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJos\u00e9 Moreno\n2009-03-01\nConclusiones. Los an\u00e1lisis sugieren la vacunaci\u00f3n como medida masiva de control para influenza en adultos mayores de 65 a\u00f1os. Existe un importante vac\u00edo de conocimiento en la efectividad de la vacuna en ni\u00f1os menores de dos a\u00f1os y madres gestantes.\n[Molecular Epidemiology of Rotavirus in Cats in the United Kingdom](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4298538)\nIturriza-G\u00f3mara, M.; Dove, W.; Sandrasegaram, M.; Nakagomi, T.; Nakagomi, O.; Cunliffe, N.; Radford, A. D.; Morgan, K. L.\n2014-01-01\nRotaviruses are leading causes of gastroenteritis in the young of many species. Molecular epidemiological studies in children suggest that interspecies transmission contributes to rotavirus strain diversity in people. However, population-based studies of rotaviruses in animals are few. We investigated the prevalence, risk factors for infection, and genetic diversity of rotavirus A in a cross-sectional survey of cats housed within 25 rescue catteries across the United Kingdom. Morning litter tray fecal samples were collected during the winter and summer in 2012 from all pens containing kittens and a random sample of those housing adult cats. Group A rotavirus RNA was detected by real-time reverse transcription-PCR, and positive samples were G and P genotyped using nested VP4 and VP7 PCR assays. A total of 1,727 fecal samples were collected from 1,105 pens. Overall, the prevalence of rotavirus was 3.0% (95% confidence interval [CI], 1.2 to 4.9%). Thirteen out of 25 (52%; 95% CI, 31.3 to 72.2%) centers housed at least one rotavirus-positive cat. The prevalence of rotavirus was associated with season (odds ratio, 14.8 [95% CI, 1.1 to 200.4]; P = 0.04) but not age or diarrhea. It was higher during the summer (4.7%; 95% CI, 1.2 to 8.3%) than in winter (0.8%; 95% CI, 0.2 to 1.5%). Asymptomatic epidemics of infection were detected in two centers. G genotypes were characterized for 19 (33.3%) of the 57 rotavirus-positive samples and P genotypes for 36 (59.7%). Two rotavirus genotypes were identified, G3P[9] and G6P[9]. This is the first population-based study of rotavirus in cats and the first report of feline G6P[9], which questions the previous belief that G6P[9] in people is of bovine origin. PMID:25411173\n[Burden of paediatric Rotavirus Gastroenteritis (RVGE and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain](http://www.biomedcentral.com/1471-2458/10/469) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nDiez-Domingo Javier\n2010-08-01\nFull Text Available Abstract Background Rotavirus is the most common cause of gastroenteritis in young children worldwide. The aim of the study was to assess the health outcomes and the economic impact of a universal rotavirus vaccination programme with RotaTeq, the pentavalent rotavirus vaccine, versus no vaccination programme in Spain. Methods A birth cohort was followed up to the age of 5 using a cohort model. Epidemiological parameters were taken from the REVEAL study (a prospective epidemiological study conducted in Spain, 2004-2005 and from the literature. Direct and indirect costs were assessed from the national healthcare payer and societal perspectives by combining health care resource utilisation collected in REVEAL study and unit costs from official sources. RotaTeq per protocol efficacy data was taken from a large worldwide rotavirus clinical trial (70,000 children. Health outcomes included home care cases, General Practioner (GP/Paediatrician, emergency department visits, hospitalisations and nosocomial infections. Results The model estimates that the introduction of a universal rotavirus vaccination programme with RotaTeq (90% coverage rate would reduce the rotavirus gastroenteritis (RVGE burden by 75% in Spain; 53,692 home care cases, 35,187 GP/Paediatrician visits, 34,287 emergency department visits, 10,987 hospitalisations and 2,053 nosocomial infections would be avoided. The introduction of RotaTeq would avoid about 76% of RVGE-related costs from both perspectives: \u20ac22 million from the national health system perspective and \u20ac38 million from the societal perspective. Conclusions A rotavirus vaccination programme with RotaTeq would reduce significantly the important medical and economic burden of RVGE in Spain.\n[Options for improving effectiveness of rotavirus vaccines in developing countries.](https://www.ncbi.nlm.nih.gov/pubmed/27835052)\nTissera, Marion S; Cowley, Daniel; Bogdanovic-Sakran, Nada; Hutton, Melanie L; Lyras, Dena; Kirkwood, Carl D; Buttery, Jim P\n2017-04-03\nRotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over 85% of deaths occur in developing countries. In industrialised countries, 2 live oral rotavirus vaccines licensed in 2006 quickly demonstrated high effectiveness, dramatically reducing severe rotavirus gastroenteritis admissions in many settings by more than 90%. In contrast, the same vaccines reduced severe rotavirus gastroenteritis by only 30-60% in developing countries, but have been proven life-saving. Bridging this \"efficacy gap\" offers the possibility to save many more lives of children under the age of 5. The reduced efficacy of rotavirus vaccines in developing settings may be related to differences in transmission dynamics, as well as host luminal, mucosal and immune factors. This review will examine strategies currently under study to target the issue of reduced efficacy and effectiveness of oral rotavirus vaccines in developing settings.\n[A gastrointestinal rotavirus infection mouse model for immune modulation studies](http://www.virologyj.com/content/8/1/109) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nvan Amerongen Geert\n2011-03-01\nFull Text Available Abstract Background Rotaviruses are the single most important cause of severe diarrhea in young children worldwide. The current study was conducted to assess whether colostrum containing rotavirus-specific antibodies (Gastrogard-R\u00ae could protect against rotavirus infection. In addition, this illness model was used to study modulatory effects of intervention on several immune parameters after re-infection. Methods BALB/c mice were treated by gavage once daily with Gastrogard-R\u00ae from the age of 4 to 10 days, and were inoculated with rhesus rotavirus (RRV at 7 days of age. A secondary inoculation with epizootic-diarrhea infant-mouse (EDIM virus was administered at 17 days of age. Disease symptoms were scored daily and viral shedding was measured in fecal samples during the post-inoculation periods. Rotavirus-specific IgM, IgG and IgG subclasses in serum, T cell proliferation and rotavirus-specific delayed-type hypersensitivity (DTH responses were also measured. Results Primary inoculation with RRV induced a mild but consistent level of diarrhea during 3-4 days post-inoculation. All mice receiving Gastrogard-R\u00ae were 100% protected against rotavirus-induced diarrhea. Mice receiving both RRV and EDIM inoculation had a lower faecal-viral load following EDIM inoculation then mice receiving EDIM alone or Gastrogard-R\u00ae. Mice receiving Gastrogard-R\u00ae however displayed an enhanced rotavirus-specific T-cell proliferation whereas rotavirus-specific antibody subtypes were not affected. Conclusions Preventing RRV-induced diarrhea by Gastrogard-R\u00ae early in life showed a diminished protection against EDIM re-infection, but a rotavirus-specific immune response was developed including both B cell and T cell responses. In general, this intervention model can be used for studying clinical symptoms as well as the immune responses required for protection against viral re-infection.\n[Diarrheal Diseases Hospitalization in Yemen before and after Rotavirus Vaccination](http://dx.doi.org/10.1155/2016/8485417) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMohammed Amood AL-Kamarany\n2016-01-01\nFull Text Available The study aims to assess the impact of rotavirus vaccine introduction on diarrheal diseases hospitalization and to identify the rotavirus genotypes most prevalent before and after vaccine introduction among children \u2264 5 years of age. Rotarix\u2122 \u00ae rotavirus vaccine is currently licensed for infants in Yemen and was introduced in 2012. The vaccination course consists of two doses. The first dose is administrated at 6 weeks of age and the second dose is completed by 10 weeks. Based on a longitudinal observational study, we assessed the impact of vaccination on rotavirus hospitalization before and after vaccination among children \u2264 5 years of age at the Yemeni-Swedish Hospital (YSH in Taiz, Yemen. Prevaccination covered January 2009\u2013July 2012 during which 2335 fecal samples were collected from children \u2264 5 years old. Postvaccination covered January 2013\u2013December 2014 during which 1114 fecal samples were collected. Rotavirus was detected by Enzyme Linkage Immunosorbent Assay (ELISA. The incidence of rotavirus hospitalization decreased from 43.79% in 2009 to 10.54% in 2014. Hospitalization due to rotavirus diarrhea was reduced by 75.93%. Vaccine coverage increased from 23% in 2012 to 72% in 2014. Also, the results showed that the most predominant genotypes in prevaccination period were G2P[4] (55.0%, followed by G1P[8] (15.0%, while in postvaccination period G1P[8] (31% was the predominant genotype, followed by G9P[8] (27.5%. In conclusion, rotavirus vaccination in Yemen resulted in sharp reduction in diarrheal hospitalization. A successful rotavirus vaccination program in Yemen will rely upon efficient vaccine delivery systems and sustained vaccine efficacy against diverse and evolving rotavirus strains.\n[Dengue, zika, chikungunya y el desarrollo de vacunas](https://www.openaire.eu/search/publication?articleId=od_______617::72f63e3faddc26d37afb5bec15e160d2)\nKantor, Isabel N\n2018-01-01\nDengue (DENV), zika (ZIKV) y chikungunya (CHIKV), tres arbovirosis transmitidas por mosquitos Aedes, se han propagado en las \u00faltimas d\u00e9cadas en zonas tropicales y subtropicales h\u00famedas. El dengue es epid\u00e9mico en \u00e1reas subtropicales de la Argentina. Despu\u00e9s de la infecci\u00f3n por DENV hay inmunidad duradera contra el serotipo infectante, pero aumenta el riesgo de enfermedad grave por los otros tres. La vacuna recombinante tetravalente, Dengvaxia\u00ae previene el dengue grave y la hospitalizaci\u00f3n en s...\n[Bovine rotavirus pentavalent vaccine development in India.](https://www.ncbi.nlm.nih.gov/pubmed/25091665)\nZade, Jagdish K; Kulkarni, Prasad S; Desai, Sajjad A; Sabale, Rajendra N; Naik, Sameer P; Dhere, Rajeev M\n2014-08-11\nA bovine rotavirus pentavalent vaccine (BRV-PV) containing rotavirus human-bovine (UK) reassortant strains of serotype G1, G2, G3, G4 and G9 has been developed by the Serum Institute of India Ltd, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), USA. The vaccine underwent animal toxicity studies and Phase I and II studies in adults, toddlers and infants. It has been found safe and immunogenic and will undergo a large Phase III study to assess efficacy against severe rotavirus gastroenteritis. Copyright \u00a9 2014. Published by Elsevier Ltd.\n[Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size](http://www.biomedcentral.com/1471-2458/11/S3/S16) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nBlack Robert E\n2011-04-01\nFull Text Available Abstract Background Diarrhea mortality remains a leading cause of child death and rotavirus vaccine an effective tool for preventing severe rotavirus diarrhea. New data suggest vaccine efficacy may vary by region. Methods We reviewed published vaccine efficacy trials to estimate a regional-specific effect of vaccine efficacy on severe rotavirus diarrhea and hospitalizations. We assessed the quality of evidence using a standard protocol and conducted meta-analyses where more than 1 data point was available. Results Rotavirus vaccine prevented severe rotavirus episodes in all regions; 81% of episodes in Latin America, 42.7% of episodes in high-mortality Asia, 50% of episodes in sub-Saharan Africa, 88% of episodes low-mortality Asia and North Africa, and 91% of episodes in developed countries. The effect sizes observed for preventing severe rotavirus diarrhea will be used in LiST as the effect size for rotavirus vaccine on rotavirus-specific diarrhea mortality. Conclusions Vaccine trials have not measured the effect of vaccine on diarrhea mortality. The overall quality of the evidence and consistency observed across studies suggests that estimating mortality based on a severe morbidity reduction is highly plausible.\n[Human rotavirus genotypes causing acute watery diarrhea among ...](https://www.ajol.info/index.php/njcp/article/download/111648/101421) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\n2014-06-17\nJun 17, 2014 ... vaccine with strains peculiar to this environment should be introduced. ..... Safety and efficacy of an attenuated vaccine against severe rotavirus ... prevalence of adenovirus serotypes 40 and 41, astrovirus, and rotavirus.\n[Eficacia y seguridad de una vacuna contra la leptospirosis humana en Cuba Efficacy and safety of a vaccine against human leptospirosis in Cuba](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892004000400005) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nRaydel Mart\u00ednez\n2004-04-01\nFull Text Available OBJETIVOS: Evaluar la eficacia de la vacuna cubana contra la leptospirosis vax-SPIRAL y aportar informaci\u00f3n adicional acerca de la seguridad de esta vacuna. M\u00c9TODOS: Ensayo de eficacia (fase III controlado, aleatorizado y con doble enmascaramiento de la vacuna cubana contra la leptospirosis vax-SPIRAL (Instituto Finlay, Cuba. Como control se utiliz\u00f3 la vacuna recombinante contra la hepatitis B Heberbiovac-HB (Heber Biotec, Cuba. Como unidad de aleatorizaci\u00f3n para la asignaci\u00f3n al grupo de estudio o al grupo testigo se emplearon los 523 consultorios de los m\u00e9dicos de familia existentes en los municipios seleccionados. El estudio abarc\u00f3 a toda persona de 20 a 64 a\u00f1os de edad de uno u otro sexo que resid\u00eda en los municipios de Ranchuelo, Quemado, Santo Domingo, Encrucijada, Corralillo, Cifuentes y Camajuan\u00ed, en la provincia de Villa Clara, ubicada en la regi\u00f3n central de Cuba, que acept\u00f3 participar voluntariamente en el ensayo. La vacunaci\u00f3n se efectu\u00f3 en los consultorios de los m\u00e9dicos de familia entre febrero y julio de 1998, con un intervalo de 6 semanas entre las dos dosis. El per\u00edodo de seguimiento fue de 12 meses. Se consider\u00f3 positivo un caso si hab\u00eda recibido las dos dosis de la vacuna asignada y hab\u00eda enfermado de leptospirosis, con diagn\u00f3stico confirmado mediante m\u00e9todos serol\u00f3gicos y microbiol\u00f3gicos, despu\u00e9s de 21 d\u00edas de aplicada la segunda dosis. Se calcularon la eficacia de la vacuna y el riesgo relativo (RR de enfermar de leptospirosis despu\u00e9s de la vacunaci\u00f3n. Para el estudio de seguridad se escogi\u00f3 a dos personas al azar entre las personas vacunadas en cada uno de los consultorios que participaron en el estudio de eficacia. El seguimiento de las reacciones adversas locales y sist\u00e9micas lo realizaron los m\u00e9dicos de familia durante los siete d\u00edas posteriores a la aplicaci\u00f3n de cada dosis. El nivel de significaci\u00f3n se fij\u00f3 en 0,05. RESULTADOS: En total se vacun\u00f3 a 101 832 personas, de las cuales 50\n[Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality From Diarrhea.](https://www.ncbi.nlm.nih.gov/pubmed/28430997)\nBurnett, Eleanor; Jonesteller, Christine L; Tate, Jacqueline E; Yen, Catherine; Parashar, Umesh D\n2017-06-01\nIn 2006, 2 rotavirus vaccines were licensed. We summarize the impact of rotavirus vaccination on hospitalizations and deaths from rotavirus and all-cause acute gastroenteritis (AGE) during the first 10 years since vaccine licensure, including recent evidence from countries with high child mortality. We used standardized guidelines (PRISMA) to identify observational evaluations of rotavirus vaccine impact among children rotavirus AGE were reduced by a median of 67% overall and 71%, 59%, and 60% in countries with low, medium, and high child mortality, respectively. Implementation of rotavirus vaccines has substantially decreased hospitalizations from rotavirus and all-cause AGE. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.\n[Impact and cost-effectiveness of rotavirus vaccination in Bangladesh.](https://www.ncbi.nlm.nih.gov/pubmed/28623028)\nPecenka, Clint; Parashar, Umesh; Tate, Jacqueline E; Khan, Jahangir A M; Groman, Devin; Chacko, Stephen; Shamsuzzaman, Md; Clark, Andrew; Atherly, Deborah\n2017-07-13\nDiarrheal disease is a leading cause of child mortality globally, and rotavirus is responsible for more than a third of those deaths. Despite substantial decreases, the number of rotavirus deaths in children under five was 215,000 per year in 2013. Of these deaths, approximately 41% occurred in Asia and 3% of those in Bangladesh. While Bangladesh has yet to introduce rotavirus vaccination, the country applied for Gavi support and plans to introduce it in 2018. This analysis evaluates the impact and cost-effectiveness of rotavirus vaccination in Bangladesh and provides estimates of the costs of the vaccination program to help inform decision-makers and international partners. This analysis used Pan American Health Organization's TRIVAC model (version 2.0) to examine nationwide introduction of two-dose rotavirus vaccination in 2017, compared to no vaccination. Three mortality scenarios (low, high, and midpoint) were assessed. Benefits and costs were examined from the societal perspective over ten successive birth cohorts with a 3% discount rate. Model inputs were locally acquired and complemented by internationally validated estimates. Over ten years, rotavirus vaccination would prevent 4000 deaths, nearly 500,000 hospitalizations and 3 million outpatient visits in the base scenario. With a Gavi subsidy, cost/disability adjusted life year (DALY) ratios ranged from $58/DALY to $142/DALY averted. Without a Gavi subsidy and a vaccine price of $2.19 per dose, cost/DALY ratios ranged from $615/DALY to $1514/DALY averted. The discounted cost per DALY averted was less than the GDP per capita for nearly all scenarios considered, indicating that a routine rotavirus vaccination program is highly likely to be cost-effective. Even in a low mortality setting with no Gavi subsidy, rotavirus vaccination would be cost-effective. These estimates exclude the herd immunity benefits of vaccination, so represent a conservative estimate of the cost-effectiveness of rotavirus vaccination\n[Administraci\u00f3n de vacunas y casos de muerte s\u00fabita del lactante en el Per\u00fa, 2001. \u00bfAsociaci\u00f3n o coincidencia temporal?](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::e53e6396d7036924ac4edb136005a9b2)\nVargas H, Javier; Centro Nacional de Salud P\u00fablica, Instituto Nacional de Salud. Lima, Per\u00fa.; Su\u00e1rez J, Magna; Centro Nacional de Salud P\u00fablica, Instituto Nacional de Salud. Lima, Per\u00fa.; Llamoga S, Alejandro; Centro Nacional de Salud P\u00fablica, Instituto Nacional de Salud. Lima, Per\u00fa.; Quispe T, Neyda; Centro Nacional de Salud P\u00fablica, Instituto Nacional de Salud. Lima, Per\u00fa.; Alva R, Fernando; Chu C, Julia; Centro Nacional de Producci\u00f3n de Biol\u00f3gicos, Instituto Nacional de Salud. Lima Per\u00fa.; Pereyra S, H\u00e9ctor; Oficina General de Epidemiolog\u00eda, Ministerio de Salud. Lima, Per\u00fa.; Ticona Z, Mar\u00eda; Oficina General de Epidemiolog\u00eda, Ministerio de Salud. Lima, Per\u00fa.; Medrano G, Jorge; Direcci\u00f3n General de Salud de las Personas, Ministerio de Salud. Lima, Per\u00fa.; Cerna D, Carolina; Direcci\u00f3n General de Salud de las Personas, Ministerio de Salud. Lima, Per\u00fa.\n2006-01-01\nObjetivos: Describir las caracter\u00edsticas cl\u00ednicas, socioecon\u00f3micas, y patol\u00f3gicas de nueve casos de lactantes que fallecieron horas despu\u00e9s de administr\u00e1rseles vacunas antipolio y DPT junto con anti Haemophilus influenzae b o asociada con antihepatitis B o BCG. Materiales y m\u00e9todos: Revisi\u00f3n de la historia cl\u00ednica, entrevista con el equipo de salud a cargo de la vacunaci\u00f3n y con los padres del lactante fallecido. Revisi\u00f3n de los informes del protocolo de autopsia e informes de anatom\u00eda patol\u00f3...\n[Epidemiology of rotavirus diarrhea in children under 5 years in ...](https://www.ajol.info/index.php/pamj/article/view/82072) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nBackground: Rotavirus still remains the major cause of diarrhea in children below 5 years. No data on rotavirus epidemiology is available in the Northern regions of Cameroon. We aimed to determine the prevalence of group A rotavirus (RVA) in children below 5 years with diarrhea in two regions of Northern Cameroon ...\n[Clinical characteristics of rotavirus diarrhea in hospitalized Romanian infants.](https://www.ncbi.nlm.nih.gov/pubmed/22929174)\nLesanu, Gabriela; Becheanu, Cristina Adriana; Vlad, Raluca Maria; Pacurar, Daniela; Tincu, Iulia Florentina; Smadeanu, Roxana Elena\n2013-01-01\nClinical characteristics of rotavirus enteritis were evaluated by comparison with acute diarrhea of other etiologies. We reviewed the medical records of children (aged 0-12 months) admitted with acute diarrhea in our hospital between January and December 2011. Of the 839 patients, 49.3% had rotavirus diarrhea. The incidence of severe disease was significantly higher for rotavirus diarrhea (65.2%, P < 0.01) than for other types of diarrheal disease.\n[Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Guatemala.](https://www.ncbi.nlm.nih.gov/pubmed/27059345)\nGasta\u00f1aduy, Paul A; Contreras-Rold\u00e1n, Ingrid; Bernart, Chris; L\u00f3pez, Beatriz; Benoit, Stephen R; Xuya, Marvin; Mu\u00f1oz, Fredy; Desai, Rishi; Quaye, Osbourne; Tam, Ka Ian; Evans-Bowen, Diana K; Parashar, Umesh D; Patel, Manish; McCracken, John P\n2016-05-01\nConcerns remain about lower effectiveness and waning immunity of rotavirus vaccines in resource-poor populations. We assessed vaccine effectiveness against rotavirus in Guatemala, where both the monovalent (RV1; 2-dose series) and pentavalent (RV5; 3-dose series) vaccines were introduced in 2010. A case-control evaluation was conducted in 4 hospitals from January 2012 to August 2013. Vaccine status was compared between case patients (children with laboratory-confirmed rotavirus diarrhea) and 2 sets of controls: nondiarrhea \"hospital\" controls (matched by birth date and site) and nonrotavirus \"test-negative\" diarrhea controls (adjusted for age, birth month/year, and site). Vaccine effectiveness ([1 - odds ratio of vaccination] \u00d7 100%) was computed using logistic regression models. We evaluated 213 case patients, 657 hospital controls, and 334 test-negative controls. Effectiveness of 2-3 doses of a rotavirus vaccine against rotavirus requiring emergency department visit or hospitalization was 74% (95% confidence interval [CI], 58%-84%) with hospital controls, and 52% (95% CI, 26%-69%) with test-negative controls. Using hospital controls, no significant difference in effectiveness was observed between infants 6-11 months (74% [95% CI, 18%-92%]) and children \u226512 months of age (71% [95% CI, 44%-85%]) (P= .85), nor between complete courses of RV1 (63% [95% CI, 23%-82%]) and RV5 (69% [95% CI, 29%-87%]) (P= .96). An uncommon G12P[8] strain, partially heterotypic to strains in both vaccines, was identified in 89% of cases. RV1 and RV5 were similarly effective against severe rotavirus diarrhea caused by a heterotypic strain in Guatemala. This supports broader implementation of rotavirus vaccination in low-income countries where >90% global deaths from rotavirus occur. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.\n[Streptococcus pneumoniae aislados durante 2002-2006: serotipos y resistencia antibi\u00f3tica. Correlaci\u00f3n con las vacunas existentes](http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1025-55832008000100006&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJos\u00e9 Mar\u00eda Guevara-Duncan\n2008-03-01\nFull Text Available Objetivos: Identificar los serotipos de S. pneumoniae aislados, correlacion\u00e1ndolos con los incluidos en las vacunas existentes y su resistencia antimicrobiana. Dise\u00f1o: Estudio descriptivo, observacional y longitudinal. Lugar: Instituto de Medicina Tropical Daniel A. Carri\u00f3n, Facultad de Medicina, UNMSM. Material biol\u00f3gico: Cepas de Streptococcus pneumoniae. Intervenciones: Cuarenta Streptococcus pneumoniae de nuestro cepario, aislados entre el 2002 y 2006, fueron serotipificados en el Instituto de Salud Carlos III en Madrid -Espa\u00f1a; 15 fueron invasivos, 11 aislados de infecciones localizadas, 6 de portadores y 8 eran multiresistentes. Principales medidas de resultados: Protecci\u00f3n de las vacunas existentes en nuestro medio a las infecciones causadas por Streptococcus pneumoniae. Resultados: Hubo 14 serotipos diferentes y los serogrupos m\u00e1s identificados fueron 23, 19 y 6. El 28,6% estaba contenido en la vacuna 7-valente, 42,9% en la 9-valente, 50% en la 11-valente y el 71,4% en la 23-valente; 57,5% fue resistente a la penicilina y 30% a eritromicina. El grupo de Streptococcus invasivo result\u00f3 m\u00e1s sensible a los antibi\u00f3ticos que los otros grupos. Los serotipos asociados a multirresistencia fueron 19F y 23F. Conclusiones: Ninguna de las vacunas protege a todas las infecciones causadas por Streptococcus pneumoniae, en nuestro medio.\n[Study on the relationship between infant rotavirus enteritis and breast feeding](https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=39093882) [International Nuclear Information System (INIS) ](http://inis.iaea.org/search/)\nChen Yanping; Liu Hui; Sun Xuerong; Wei Tao; Wang Bin\n2005-01-01\nObjective: To study the relationship between infant rotavirus enteritis and breast feeding, with emphasis on early immuno-protection provided by breast feeding as well as later possible hazards with rotavirus carrier mothers. Methods: Stool specimens from 520 infants with diarrhea were screened for rotavirus with colloid gold method. Positive specimens were confirmed with RT-PCR. Results: In local (Qingdao) infants with enteritis, the over-all incidence of rotavirus infection was 31.2%. Positive rate in breast-feeding infants was only 26.8%, being significantly lower than that in bottle-feeding ones (45.2%). The virus infectivity rate in both groups of breast- feeding infants (below 6 months and 7-12 months) was lower than the corresponding rate in the bottle feeding group. However, infant fed from rotavirus carriers had significantly higher fecal positive rate of rotavirus than that in infants fed from non-carriers. Conclusion: (1) At beginning, especially below 6 months, breast-feeding provided important protection again rotavirus enteritis in the infants. (2) certain infections could be transmitted through breast feedings, which deserved closer observation. (authors)\n[Epidemiological investigation of rotavirus infection in buffalo calves in Bangladesh](https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=21078892) [International Nuclear Information System (INIS) ](http://inis.iaea.org/search/)\nSamad, M.A.; Ahmed, M.W.\n1990-01-01\nA study on rotavirus infection in buffalo calves in Bangladesh was carried out to detect its association with diarrhoea. An overall 28% incidence of diarrhoeal diseases was recorded in rural buffalo calves. Rotavirus was detected in faecal samples from both diarrhoeic (12%) and non-diarrhoeic (3%) calves by enzyme linked immunosorbent assay. An association between diarrhoea and rotavirus infection was recorded in buffalo calves below 1 month of age in both diarrhoeic (27%) and non-diarrhoeic (7%) calves. Rotavirus infection in diarrhoeic buffalo calves was found to be highest in winter (16.7%), followed by summer (9.1%) and lowest in the rainy season (7.7%). Further studies on the epidemiological and prophylactic aspects of rotavirus infection should be conducted to control this infection in Bangladesh. (author). 21 refs, 2 tabs\n[Estudio histopatol\u00f3gico entre ratones infectados con Salmonella typhi sin vacunar y vacunados por diferentes v\u00edas con las vacunas polisacar\u00eddica y de c\u00e9lulas enteras](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2000000400004&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJuan F. Infante\n2000-12-01\nFull Text Available La fiebre tifoidea constituye una enfermedad propia del hombre. La misma es causada por Salmonella typhi y produce una respuesta inflamatoria en el tracto intestinal. Con el fin de establecer su control por vacunaci\u00f3n el Instituto Finlay ha desarrollado una vacuna a partir del polisac\u00e1rido capsular Vi. Para su estudio experimental no existe un modelo animal que reproduzca los s\u00edntomas y la patogenia de la enfermedad. El desarrollo de modelos experimentales y los estudios histopatol\u00f3gicos aportan informaciones al conocimiento de la enfermedad y a la interpretaci\u00f3n de los procesos inmunol\u00f3gicos. Nos propusimos caracterizar el cuadro histopatol\u00f3gico en los ratones utilizados en las pruebas de potencia de la vacuna antitifo\u00eddica basada en polisac\u00e1rido Vi purificado y su comparaci\u00f3n con la vacuna de c\u00e9lulas enteras. Se utilizaron 240 ratones de ambos sexos pertenecientes a la l\u00ednea C57BL/6 procedentes del Centro Nacional para la Producci\u00f3n de Animales de Laboratorio (CENPALAB, con un peso comprendido entre 18 y 22 g. Se evalu\u00f3 la protecci\u00f3n comparativa entre las v\u00edas intraperitoneal y subcut\u00e1nea utilizando dos inmun\u00f3genos, a partir del polisac\u00e1rido Vi y con la variante de c\u00e9lulas enteras. Se logr\u00f3 una considerable eficacia en rat\u00f3n C57BL/6 para reproducir las lesiones compatibles con Salmonella typhi en h\u00edgado y bazo. La sobrevivencia del grupo no vacunado fue de un 15%. La sobrevivencia de los ratones correspondientes al grupo vacunado con polisac\u00e1rido Vi oscil\u00f3 entre 90% y 100% para ambas v\u00edas, mientras que los vacunados con c\u00e9lulas enteras variaron entre 50% y 100% para la v\u00eda subcut\u00e1nea y entre 60% y 100% para la v\u00eda intraperitoneal todo lo cual evidencia la superioridad de la vacuna a partir del polisac\u00e1rido capsular Vi sobre la variante de c\u00e9lulas enteras en la especie rat\u00f3n C57BL/6\n[Desarrollo de una vacuna probi\u00f3tica para el tratamiento del c\u00e1ncer c\u00e9rvico-uterino](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::1ea3de1bdf059dfdef615fb2bb624b84)\nCort\u00e9s P\u00e9rez, Naima Gisela; Berm\u00fadez Humar\u00e1n, Luis Gilberto; Alcocer Gonz\u00e1lez, Juan Manuel; Gruss, Alexandra; Le Loir, Yves; Langella, Phillipe; Luna Leal, Roberto Montes de Oca\n2003-01-01\nDado que el virus del papiloma humano tipo 16 (HPV- 16) es la principal causa del c\u00e1ncer c\u00e9rvicouterino, hay una gran necesidad de desarrollar una vacuna profil\u00e1ctica y/o terap\u00e9utica. La oncoprote\u00edna E7 es constitutivamente producida por neoplasias cervicales y, por tanto, considerada como un blanco potencial para dirigir el desarrollo de una vacuna terap\u00e9utica contra el c\u00e1ncer c\u00e9rvico-uterino. En este trabajo desarrollamos un sistema inducible para expresar la prote\u00edn...\n[Inactivation of human and simian rotaviruses by ozone](http://www.etde.org/etdeweb/details.jsp?query_id=1&page=0&osti_id=5714984) [Energy Technology Data Exchange (ETDEWEB)](https://www.etde.org/etdeweb/fieldedsearch.jsp)\nVaughn, J.M.; Chen, Y.S.; Lindburg, K.; Morales, D.\n1987-09-01\nThe inactivation of simian rotavirus Sa-11 and human rotavirus type 2 (Wa) by ozone was compared at 4/sup 0/C by using single-particle virus stocks. Although the human strain was clearly more sensitive, both virus types were rapidly inactivated by ozone concentrations of 0.25 mg/liter or greater at all pH levels tested. Comparison of the virucidal activity of ozone with that of chlorine in identical experiments indicated little significant difference in rotavirus-inactivating efficiencies when the disinfectants were used at concentrations of 0.25 mg/liter or greater.\n[Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets.](https://www.ncbi.nlm.nih.gov/pubmed/20558244)\nWang, Yuhuan; Azevedo, Marli; Saif, Linda J; Gentsch, Jon R; Glass, Roger I; Jiang, Baoming\n2010-07-26\nLive oral rotavirus vaccines that are effective in middle and high income countries have been much less immunogenic and effective among infants in resource-limited settings. Several hypotheses might explain this difference, including neutralization of the vaccine by high levels of maternal antibody in serum and breast milk, severe malnutrition, and interference by other flora and viruses in the gut. We have pursued development of an alternative parenteral rotavirus vaccine with the goal of inducing comparable levels of immunogenicity and efficacy in populations throughout the world regardless of their income levels. In the present study, we assessed the immunogenicity and protection of a candidate inactivated rotavirus vaccine (IRV), the human strain CDC-9 (G1P[8]) formulated with aluminum phosphate, against rotavirus infection in gnotobiotic piglets. Three doses of IRV induced high titers of rotavirus-specific IgG and neutralizing activity in the sera of gnotobiotic piglets and protection against shedding of rotavirus antigen following oral challenge with a homologous virulent human strain Wa (G1P[8]). Our findings demonstrate the proof of concept for an IRV in a large animal model and provide evidence and justification for further clinical development as an alternative candidate vaccine. Published by Elsevier Ltd.\n[Rotavirus epidemiology and vaccine demand: considering Bangladesh chapter through the book of global disease burden.](https://www.ncbi.nlm.nih.gov/pubmed/29047020)\nMahmud-Al-Rafat, Abdullah; Muktadir, Abdul; Muktadir, Hasneen; Karim, Mahbubul; Maheshwari, Arpan; Ahasan, Mohammad Mainul\n2018-02-01\nRotavirus is the major cause of gastroenteritis in children throughout the world. Every year, a large number of children aged rotavirus-related diarrhoeal diseases. Though these infections are vaccine-preventable, the vast majority of children in low-income countries suffer from the infection. The situation leads to severe economic loss and constitutes a major public health problem. We searched electronic databases including PubMed and Google scholar using the following words: \"features of rotavirus,\" \"epidemiology of rotavirus,\" \"rotavirus serotypes,\" \"rotavirus in Bangladesh,\" \"disease burden of rotavirus,\" \"rotavirus vaccine,\" \"low efficacy of rotavirus vaccine,\" \"inactivated rotavirus vaccine\". Publications until July 2017 have been considered for this work. Currently, two live attenuated vaccines are available throughout the world. Many countries have included rotavirus vaccines in national immunization program to reduce the disease burden. However, due to low efficacy of the available vaccines, satisfactory outcome has not yet been achieved in developing countries such as Bangladesh. Poor economic, public health, treatment, and sanitation status of the low-income countries necessitate the need for the most effective rotavirus vaccines. Therefore, the present scenario demands the development of a highly effective rotavirus vaccine. In this regard, inactivated rotavirus vaccine concept holds much promise for reducing the current disease burden. Recent advancements in developing an inactivated rotavirus vaccine indicate a significant progress towards disease prophylaxis and control.\n[Characteristics of Rotavirus Diarrhea in Hospitalized Children in Kosovo](https://www.openaire.eu/search/publication?articleId=od_______908::6662ebe6e671dc11bcd99390828ac949)\nIsmaili-Jaha, Vlora; Shala, Muje; Azemi, Mehmedali; Hoxha-Kamberi, Teuta; Avdiu, Muharrem; Spahiu, Shqipe; Jaha, Luan\n2014-01-01\nBackground: Diarrhea is a leading cause of child mortality worldwide. Rotavirus is one of the most common causes of severe diarrhea and dehydration in children. Authors reviewed epidemiological and clinical data of the rotavirus diarrhea in Kosovo. Methods: This is a prospective study carried between January 1st and December 31st 2011. All data, comprising demographics, nutrition, clinical presentation, laboratory findings, management and outcome of the rotavirus diarrhea are collected on the...\n[Rotavirus vaccination and herd immunity: an evidence-based review](http://www.dovepress.com/rotavirus-vaccination-and-herd-immunity-an-evidence-based-review-a10247) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nSeybolt LM\n2012-06-01\nFull Text Available Lorna M Seybolt, Rodolfo E B\u00e9gu\u00e9Department of Pediatrics, Division of Infectious Diseases, Louisiana State University Health Sciences Center, New Orleans, LA, USAAbstract: Until recently, rotavirus was the most common cause of diarrhea in infants and young children with over 100 million cases and 400,000 deaths every year worldwide. Yet, its epidemiology is changing rapidly with the introduction of two rotavirus vaccines in the mid 2000s. Both vaccines were shown to be highly efficacious in prelicensure studies to reduce severe rotavirus disease; the efficacy being more pronounced in high- and middle-income countries than in low-income countries. Herd immunity \u2013 the indirect protection of unimmunized individuals as a result of others being immunized \u2013 was not expected to be a benefit of rotavirus vaccination programs since the vaccines were thought to reduce severe disease but not to decrease virus transmission significantly. Postlicensure studies, however, have suggested that this assumption may need reassessment. Studies in a variety of settings have shown evidence of greater than expected declines in rotavirus disease. While these studies were not designed specifically to detect herd immunity \u2013 and few failed to detect this phenomenon \u2013 the consistency of the evidence is compelling. These studies are reviewed and described here. While further work is needed, clarifying the presence of herd immunity is not just an academic exercise but an important issue for rotavirus control, especially in lower income countries where the incidence of the disease is highest and the direct protection of the vaccines is lower.Keywords: rotavirus, vaccine, herd immunity, efficacy\n[Effect of human rotavirus vaccine on severe diarrhea in African infants](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::d847e20ffc973c5d3418099c9da9c4d0)\nMadhi, Shabir A; Cunliffe, Nigel A; Steele, Duncan; Witte, Desir\u00e9e; Kirsten, Mari; Louw, Cheryl; Ngwira, Bagrey; Victor, John C; Gillard, Paul H; Cheuvart, Brigitte B; Han, Htay H; Neuzil, Kathleen M\n2016-01-01\n: Rotavirus is the most common cause of severe gastroenteritis among young children worldwide. Data are needed to assess the efficacy of the rotavirus vaccine in African children. : We conducted a randomized, placebo-controlled, multicenter trial in South Africa (3166 infants; 64.1% of the total) and Malawi (1773 infants; 35.9% of the total) to evaluate the efficacy of a live, oral rotavirus vaccine in preventing severe rotavirus gastroenteritis. Healthy infants were randomly assigned in a 1:...\n[Cost-Effectiveness of Rotavirus Vaccination in France-Accounting for Indirect Protection.](https://www.ncbi.nlm.nih.gov/pubmed/27712709)\nYamin, Dan; Atkins, Katherine E; Remy, Vanessa; Galvani, Alison P\nVaccination against rotavirus has shown great potential for reducing the primary cause of severe childhood gastroenteritis. Previous economic evaluations of rotavirus vaccination in France have not modeled the potential impact of vaccines on disease burden via reduced transmission. To determine the cost-effectiveness of the introduction of pentavalent rotavirus vaccination into the French infant vaccination schedule. We developed an age-structured model of rotavirus transmission calibrated to 6 years of French gastroenteritis incidence and vaccine clinical trial data. We evaluated the cost-effectiveness of pentavalent rotavirus vaccination considering that 75% of infants would receive the three-dose vaccine course. Our model predicts that rotavirus vaccination will decrease rotavirus gastroenteritis incidence and associated clinical outcomes in vaccinated and unvaccinated individuals, delay the seasonal peak of infection, and increase the age of infection. From the societal perspective, our base-case scenario predicts that vaccination coverage would be cost-effective at \u20ac115 or \u20ac135 per vaccine course at \u20ac28,500 and \u20ac39,500/quality-adjusted life-year (QALY) gained, respectively, and suggests that almost 95% of the financial benefits will be recouped within the first 5 years following vaccination implementation. From the third-party payer perspective, incremental cost-effectiveness ratios ranged from \u20ac12,500 to \u20ac20,000/QALY, respectively. Our uncertainty analysis suggests that findings were sensitive to various assumptions including the number of hospitalizations, outpatient visits, and the extent of QALY losses per rotavirus episode. Introducing pentavalent rotavirus vaccination into the French infant vaccination schedule would significantly reduce the burden of rotavirus disease in children, and could be cost-effective under plausible conditions. Copyright \u00a9 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by\n[Suspected zoonotic transmission of rotavirus group A in Danish adults](http://orbit.dtu.dk/ws/files/8054705/DEB93d01.pdf) [DEFF Research Database (Denmark)](http://forskningsbasen.deff.dk/?lang=eng)\nMidgley, S. E.; Hjulsager, Charlotte Kristiane; Larsen, Lars Erik\n2012-01-01\nGroup A rotaviruses infect humans and a variety of animals. In July 2006 a rare rotavirus strain with G8P[14] specificity was identified in the stool samples of two adult patients with diarrheoa, who lived in the same geographical area in Denmark. Nucleotide sequences of the VP7, VP4, VP6, and NSP4...... genes of the identified strains were identical. Phylogenetic analyses showed that both Danish G8P[14] strains clustered with rotaviruses of animal, mainly, bovine and caprine, origin. The high genetic relatedness to animal rotaviruses and the atypical epidemiological features suggest that these human G8...\n[Biennial pattern of rotavirus gastroenteritis in the Netherlands and a shifting age distribution following a low rotavirus season, 2010-2016.](https://www.narcis.nl/publication/RecordID/publicat%3A6823/uquery/rotavirus/id/8/Language/EN)\nVerberk, J.D.M.; Pijnacker, R.; Bruijning-Verhagen, P.; Franz, E.; Vennema, H.; Hooiveld, M.; Hahn\u00e9, S.J.M.; Melker, H.E. de\n2017-01-01\nA hyper-endemic rotavirus season was expected after a low-endemic 2014 season in the Netherlands. Rotavirus detections were however similar in 2015 and lower in 2016 compared with 2010-2013. Gastroenteritis consultations rates were also similar in 2015, but the age-distribution shifted to older\n[Determinants of rotavirus transmission : a lag non-linear time series analysis](https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F357089/uquery/rotavirus/id/12/Language/EN)\nvan Gaalen, Rolina D; van de Kassteele, Jan; Hahn\u00e9, Susan J M; Bruijning-Verhagen, Patricia; Wallinga, Jacco\nRotavirus is a common viral infection among young children. As in many countries, the infection dynamics of rotavirus in the Netherlands are characterized by an annual winter peak, which was notably low in 2014. Previous work suggested an association between weather factors and both rotavirus\n[Rotavirus in Ireland: national estimates of disease burden, 1997 to 1998.](http://www.lenus.ie/hse/handle/10147/209072) [LENUS (Irish Health Repository)](http://www.lenus.ie/hse/)\nLynch, M\n2012-02-03\nBACKGROUND: We estimated the disease burden caused by rotavirus hospitalizations in the Republic of Ireland by using national data on the number of hospitalizations for diarrhea in children and laboratory surveillance of confirmed rotavirus detections. METHODS: We examined trends in diarrheal hospitalizations among children <5 years old as coded by ICD-9-CM for the period January, 1997, to December, 1998. We collated data on laboratory-confirmed rotavirus detections nationally for the same period among children <2 years old. We calculated the overall contribution of rotavirus to laboratory-confirmed intestinal disease in children <5 years old from INFOSCAN, a disease bulletin for one-third of the population. We compared data from all sources and estimated the proportion of diarrheal hospitalizations that are likely the result of rotavirus in children <5 years old. RESULTS: In children <5 years old, 9% of all hospitalizations are for diarrheal illness. In this age group 1 in 8 are hospitalized for a diarrheal illness, and 1 in 17 are hospitalized for rotavirus by 5 years of age. In hospitalized children <2 years old, 1 in 38 have a laboratory confirmed rotavirus infection. CONCLUSIONS: The disease burden of rotavirus hospitalizations is higher than in other industrialized countries. Access to comprehensive national databases may have contributed to the high hospitalization rates, as well as a greater tendency to hospitalize children with diarrhea in Ireland.\n[In Vitro Antiviral Activity of Rubia Cordifolia Aerial Part Extract Against Rotavirus](http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00308/full) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nYuanyuan Sun\n2016-09-01\nFull Text Available The root of Rubia cordifolia (R. cordifolia has been used traditionally as a hemostatic agent, while the aerial part of the plant consisting of leaf and stem is known to exhibit anti-diarrheal properties and has been widely used as a remedy in many parts of China. As rotavirus is one of the most commonly associated diarrhea-causing pathogen, this study aims to investigate the anti-rotaviral effect of R. cordifolia aerial part (RCAP. The cytotoxicity of RCAP towards MA-104 cells was evaluated using the WST-8 assay. Colloidal gold method and real time polymerase chain reaction (qPCR assay were used to confirm the findings of the antiviral assay. Then, 4',6-diamidino-2-phenylindole (DAPI staining method was subsequently used to investigate the mode of death among the cells. And the representative components of aqueous extract were isolated and identified. It was shown that both the viability of MA-104 cells and the viral load were reduced with increasing concentration of the extract. DAPI staining showed that virus-induced apoptosis was the cause of the low cell viability and viral load, an effect which was accelerated with incubation in the aqueous herbal extract. The major compounds postulated to exhibit this activity were isolated from the aqueous herbal extract and identified to be compounds Xanthopurpurin and Vanillic Acid. This study showed that RCAP extract effectively inhibited rotavirus multiplication by promoting virus-induced apoptosis in MA-104 cells.\n[Avances en el desarrollo de vacunas contra la neosporosis bovina Advances in the development of vaccines for bovine neosporosis](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-75412012000300014) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nYanina P. Hecker\n2012-09-01\nFull Text Available La neosporosis es una enfermedad que ocasiona abortos en bovinos y est\u00e1 causada por un protozoo intracelular obligado denominado Neospora caninum. Las graves p\u00e9rdidas econ\u00f3micas que provoca en los sistemas de producci\u00f3n de bovinos justifica la necesidad de avanzar en el desarrollo de vacunas. La resistencia a par\u00e1sitos Apicomplexa est\u00e1 asociada a una respuesta inmune T helper 1 mediada por linfocitos T CD4 citot\u00f3xicos y a la producci\u00f3n de interfer\u00f3n-gamma, interleuquina-12, factor de necrosis tumoral e inmunoglobulina G2. La disminuci\u00f3n de la transmisi\u00f3n vertical en las sucesivas pre\u00f1eces y el bajo nivel de repetici\u00f3n de abortos en animales infectados sugieren la existencia de mecanismos inmunitarios de protecci\u00f3n. Hasta el momento se conoce que la inoculaci\u00f3n pre-servicio con taquizo\u00edtos vivos protege contra la infecci\u00f3n y el aborto. Los antecedentes de desarrollo de vacunas vivas contra otros protozoos estimulan a los investigadores a continuar en la b\u00fasqueda de una vacuna de este tipo contra N. caninum de buena eficacia. Por otra parte, una vacuna inactivada, aun con una baja eficacia, es \u00fatil en la prevenci\u00f3n del aborto en aquellos establecimientos donde la enfermedad es epizo\u00f3tica. Una vacuna contra la neosporosis deber\u00eda evitar el aborto, la transmisi\u00f3n transplacental y la persistencia de la infecci\u00f3n. Este trabajo menciona los diversos tipos de vacunas que han sido evaluados hasta el momento, incluyendo inmun\u00f3genos inactivos, taquizo\u00edtos vivos, ant\u00edgenos recombinantes y vacunas en vectores.Neosporosis, a disease caused by the obligate intracellular protozoan Neospora caninum, produces abortions in cattle. The severe economic losses in cattle industry justify the need to develop control measures for preventing bovine abortion. Apicomplexan parasitic resistance is associated with T helper 1 immune response mediated by CD4 cytotoxic T lymphocytes, the production of interferon-gamma, interleukin-12, tumor necrosis\n[VARIABILIDAD EN LA NOTIFICACI\u00d3N DE REACCIONES ADVERSAS A LAS VACUNAS DE LA GRIPE PAND\u00c9MICA Y ESTACIONAL. TEMPORADAS 2009-2010 Y 2010-2011, COMUNITAT VALENCIANA](https://www.openaire.eu/search/publication?articleId=doajarticles::6f322a77ce0bd5fd88c95f861a1a0782)\nAna Mar\u00eda Alguacil Ramos; Jos\u00e9 Antonio Lluch Rodrigo; Antonio Portero Alonso; Rosa Mart\u00edn Ivorra; Eliseo Pastor Villalba\n2012-01-01\nFundamentos: La p\u00e9rdida de confianza en la seguridad de las vacunas derivada de situaciones de alarma, como en el caso de la gripe pand\u00e9mica, puede afectar tanto a las coberturas vacunales como a la sensibilidad frente a la notificaci\u00f3n de las sospechas de reacciones adversas asociadas a vacunas (SRAAV). El objetivo del trabajo es describir los efectos adversos a la vacuna frente a la gripe pand\u00e9mica notificados en la temporada 2009-2010 y comparar si existen diferencias con los descritos con...\n[Simian rhesus rotavirus is a unique heterologous (non-lapine) rotavirus strain capable of productive replication and horizontal transmission in rabbits.](https://www.ncbi.nlm.nih.gov/pubmed/10769066)\nCiarlet, M; Estes, M K; Conner, M E\n2000-05-01\nSimian rhesus rotavirus (RRV) is the only identified heterologous (non-lapine) rotavirus strain capable of productive replication at a high inoculum dose of virus (>10(8) p.f.u.) in rabbits. To evaluate whether lower doses of RRV would productively infect rabbits and to obtain an estimate of the 50% infectious dose, rotavirus antibody-free rabbits were inoculated orally with RRV at inoculum doses of 10(3), 10(5) or 10(7) p.f.u. Based on faecal virus antigen or infectious virus shedding, RRV replication was observed with inoculum doses of 10(7) and 10(5) p.f.u., but not 10(3) p.f.u. Horizontal transmission of RRV to one of three mock-inoculated rabbits occurred 4-5 days after onset of virus antigen shedding in RRV-infected rabbits. Rabbits infected at 10(7) and 10(5), but not 10(3), p.f.u. of RRV developed rotavirus-specific immune responses and were completely (100%) protected from lapine ALA rotavirus challenge. These data confirm that RRV can replicate productively and spread horizontally in rabbits. In attempts to elucidate the genetic basis of the unusual replication efficacy of RRV in rabbits, the sequence of the gene encoding the lapine non-structural protein NSP1 was determined. Sequence analysis of the NSP1 of three lapine rotaviruses revealed a high degree of amino acid identity (85-88%) with RRV. Since RRV and lapine strains also share similar VP7s (96-97%) and VP4s (69-70%), RRV might replicate efficiently in rabbits because of the high relatedness of these three gene products, each implicated in host range restriction.\n[A systematic review of genetic diversity of human rotavirus circulating in South Korea.](https://www.ncbi.nlm.nih.gov/pubmed/25218045)\nThan, Van Thai; Jeong, Sunyoung; Kim, Wonyong\n2014-12-01\nRotavirus infections continue to be the leading cause of severe diarrhea in young Korean children. Rotavirus data acquired from uninterrupted surveillance studies between 1989 and 2009 in South Korea were analyzed to better understand the genetic diversity and evolution. The relationship between rotaviruses and the currently licensed rotavirus vaccine viruses was also examined. The most prevalent rotavirus strains, with genotype G1P[8], followed by G3P[8], G4P[6], and G2P[4], accounted for approximately 76.7% of the total identified strains, and more recently, rotavirus G9P[8] has significance increased to be the fifth most common genotype. Phylogenetic analyses underscored the heterogeneity between viral populations within each genotype, with different lineages and sub-lineages. Although the currently licensed rotavirus vaccines are effective, safe, and economical, additional data from rotavirus monitoring is necessary to evaluate the efficacy of these vaccines for their sustained use in South Korea. The present study provides comprehensive and up-to-date information regarding the epidemiology, genetic diversity, and evolution of the circulating rotaviruses in South Korea. Crown Copyright \u00a9 2014. Published by Elsevier B.V. All rights reserved.\n[Unexpectedly high burden of rotavirus gastroenteritis in very young infants](http://www.biomedcentral.com/1471-2431/10/40) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nReilly Megan\n2010-06-01\nFull Text Available Abstract Background The highest incidence of rotavirus gastroenteritis has generally been reported in children 6-24 months of age. Young infants are thought to be partially protected by maternal antibodies acquired transplacentally or via breast milk. The purpose of our study was to assess the age distribution of children with confirmed community-acquired rotavirus gastroenteritis presenting to an urban referral hospital. Methods Children presenting to The Children's Hospital of Philadelphia with acute gastroenteritis have been monitored for the presence of rotavirus antigen in the stool by ELISA (followed by genotyping if ELISA-positive since the 1994-95 epidemic season. Results Over the last 12 rotavirus seasons prior to the introduction of the pentavalent rotavirus vaccine in 2006, stool specimens from 1646 patients tested positive for community-acquired rotavirus infection. Gender or age was not recorded in 6 and 5 cases, respectively. Overall, 58% of the cases occurred in boys. G1 was the predominant VP7 serotype, accounting for 72% of cases. The median (IQR age was 11 (5-21 months. A total of 790 (48% cases occurred in children outside the commonly quoted peak age range, with 27% in infants 24 months of age. A total of 220 (13% cases occurred during the first 3 months of life, and the highest number of episodes per month of age [97 (6%] was observed during the second month of life. Conclusions The incidence of community-acquired rotavirus gastroenteritis monitored over 12 seasons in the prevaccine era at a major university hospital was nearly constant for each month of age during the first year of life, revealing an unexpectedly high incidence of symptomatic rotavirus disease in infants\n[Perspectivas para el desarrollo de vacunas e inmunoterapia contra c\u00e1ncer cervicouterino](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0036-36341998000100006) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nGUZM\u00c1N-ROJAS LILIANA\n1998-01-01\nFull Text Available El c\u00e1ncer cervicouterino representa un grave problema de salud p\u00fablica, debido a la asociaci\u00f3n de la neoplasia con el virus del papiloma humano; actualmente se realizan estudios usando estrategias dirigidas a combatir este pat\u00f3geno, mediante vacunas, que podr\u00edan ser de gran utilidad para el control de la progresi\u00f3n de la enfermedad. El estudio tanto de la inmunolog\u00eda humoral como celular ha servido para el desarrollo de vacunas. As\u00ed, la utilizaci\u00f3n de part\u00edculas virales sint\u00e9ticas para el estudio de anticuerpos neutralizantes y el uso de prote\u00ednas tempranas virales, entre otras, para la inducci\u00f3n de inmunidad mediada por c\u00e9lulas, han sido la pauta para realizar estudios que dirijan la respuesta inmune para prevenir la infecci\u00f3n celular tanto hacia c\u00e9lulas infectadas no transformadas como hacia c\u00e9lulas transformadas viralmente con resultados favorables.\n[Comparison of two recombinant hepatitis B vaccines and their interchangeability in Argentine infants Comparaci\u00f3n de dos vacunas recombinantes contra la hepatitis B y su intercambiabilidad en lactantes argentinos](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892004000100006) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMiguel Tregnaghi\n2004-01-01\n-B.OBJETIVO: Comparar dos vacunas pedi\u00e1tricas recombinantes contra la hepatitis B -Euvax-B y la vacuna de referencia Engerix-B- en cuanto a su inmunogenicidad y reactogenicidad, e investigar su intercambiabilidad, es decir, si el esquema de vacunaci\u00f3n contra la hepatitis B de tres dosis comenzado con una primera dosis de Engerix-B puede completarse con dos dosis de Euvax-B. M\u00c9TODOS: Este estudio se llev\u00f3 a cabo en la ciudad de C\u00f3rdoba, Argentina, entre marzo de 1999 y febrero de 2000. Se vacun\u00f3 contra la hepatitis B a tres grupos de 100 lactantes argentinos a los 0, 1 y 6 meses de edad. El grupo A recibi\u00f3 tres dosis de Euvax-B; el grupo B, tres dosis de Engerix-B; y el grupo C, una dosis de Engerix-B seguida de dos dosis de Euvax-B. Para evaluar la reactogenicidad se utiliz\u00f3 la informaci\u00f3n brindada por los padres acerca de determinados fen\u00f3menos locales o sist\u00e9micos solicitados por los investigadores que hubieran ocurrido durante los siete d\u00edas posteriores a la vacunaci\u00f3n. Para establecer si eran id\u00e9nticas cl\u00ednicamente las vacunas Euvax-B y Engerix-B se utilizaron las tasas de seroprotecci\u00f3n -es decir, t\u00edtulos de anticuerpos contra el ant\u00edgeno de superficie de hepatitis B (anti-HBsAg > 10 miliunidades internacionales por mililitro (mUI/mL- alcanzados dos meses despu\u00e9s de la tercera dosis. RESULTADOS: La reactogenicidad fue baja en los tres grupos de estudio. A los 5 meses de la segunda dosis (es decir, inmediatamente antes de la tercera dosis, las tasas de seroprotecci\u00f3n fueron 95,9%, 94,7% y 90,2% en los grupos A, B y C, respectivamente. Dos meses despu\u00e9s de la tercera dosis, todos los lactantes se encontraban protegidos, con concentraciones medias geom\u00e9tricas de anti-HBsAg de 2 468,1 mUI/mL en el grupo A, de 1 714,8 mUI/mL en el grupo B y de 2 075,3 mUI/mL en el grupo C. CONCLUSIONES: Las dos vacunas recombinantes contra la hepatitis B estudiadas fueron bien toleradas y altamente inmunog\u00e9nicas. La vacuna Euvax-B fue cl\u00ednicamente id\u00e9ntica (no inferior a la\n[Rotavirus I in feces of a cat with diarrhea.](https://www.ncbi.nlm.nih.gov/pubmed/28255929)\nPhan, Tung G; Leutenegger, Christian M; Chan, Roxanne; Delwart, Eric\n2017-06-01\nA divergent rotavirus I was detected using viral metagenomics in the feces of a cat with diarrhea. The eleven segments of rotavirus I strain Felis catus encoded non-structural and structural proteins with amino acid identities ranging from 25 to 79% to the only two currently sequenced members of that viral species both derived from canine feces. No other eukaryotic viral sequences nor bacterial and protozoan pathogens were detected in this fecal sample suggesting the involvement of rotavirus I in feline diarrhea.\n[molecular identification of rotavirus strains associated with diarrhea](https://www.ajol.info/index.php/bajopas/article/download/100013/89275) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nDR. AMINU\nABSTRACT. The study was carried out to determine the molecular characteristics of the rotavirus strains associated with diarrhea among children in Kwara state, Nigeria. A total of 150 stool samples were collected from diarrheic children. The stool samples were screened for rotavirus,using Enzyme linked Immunosorbent ...\n[Molecular identification of rotavirus strains associated with diarrhea ...](https://www.ajol.info/index.php/bajopas/article/view/100013) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nThe study was carried out to determine the molecular characteristics of the rotavirus strains associated with diarrhea among children in Kwara state, Nigeria. A total of 150 stool samples were collected from diarrheic children. The stool samples were screened for rotavirus,using Enzyme linked Immunosorbent assay (ELISA).\n[The clinical appearance of neonatal rotavirus infection: Association ...](https://www.ajol.info/index.php/samj/article/view/79034) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nBackgroundRotavirus is the most important aetiological agent causing severe gastroenteritis in children <2 years of age in South Africa and worldwide. Most endemic neonatal nursery strains are thought to be asymptomatic. However, serious conditions have been reported to be associated with rotavirus infection, such as ...\n[Caracter\u00edsticas de los v\u00eddeos en espa\u00f1ol publicados en YouTube sobre la vacuna contra el virus del papiloma humano](http://www.redalyc.org/articulo.oa?id=17033372012) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJos\u00e9 Tuells\n2015-01-01\nFull Text Available Fundamentos: Internet constituye un recurso de b\u00fasqueda de informaci\u00f3n relacionada con la salud. El objetivo de este trabajo fue conocer las caracter\u00edsticas de los v\u00eddeos en idioma espa\u00f1ol de YouTube relacionados con la vacuna contra el virus del papiloma humano (VPH. M\u00e9todos: Se realiz\u00f3 un estudio observacional a partir de una b\u00fasqueda en YouTube el 26 de julio de 2013, con las palabras claves: \u201cvacuna virus papiloma humano\u201d, \u201cvacuna VPH\u201d, \u201cvacuna Gardasil\u201d, \u201cvacuna Cervarix\u201d. Se establecieron categor\u00edas por tipo, fuente de publicaci\u00f3n y predisposici\u00f3n favorable o no hacia la vacuna. Se registr\u00f3 el n\u00famero de visitas, tiempo de duraci\u00f3n de los videos y origen de los 20 v\u00eddeos m\u00e1s visitados. Resultados. Se encontraron 1.080 videos registrados, 170 fueron seleccionados y clasificados como: noticias locales (n=39; 37 favorables, 2 desfavorables; 2:06:29; 42972 visitas, noticias nacionales (n=32; 30/2; 1:49:27; 50138 visitas, creados por subscritores de YouTube (n=21; 13/8; 2:50:35; 144655 visitas, entrevistas (n=21; 20/1; 1:44:39; 10991 visitas, anuncios (n=21; 19/2; 0:27:05; 28435 visitas, conferencias (n=17; 15/2; 3:25:39; 27206 visitas, documentales (n=16; 12/4; 2:11:31; 30629 visitas, y noticias internacionales (n=3; 3/0; 0:11:33; 1667 visitas. De los 20 videos m\u00e1s reproducidos predominan los favorables a la vacunaci\u00f3n (n=12; 0:43:43; 161.789 visitas frente a los desfavorables (n=8; 2:44:14; 86.583 visitas. Conclusiones. Predominan los videos que tiene una opini\u00f3n favorable hacia la vacuna contra el VPH, aunque los videos de contenido negativo son los m\u00e1s extensos y reproducidos-\n[Implementation of Rotavirus Surveillance and Vaccine Introduction - World Health Organization African Region, 2007-2016.](https://www.ncbi.nlm.nih.gov/pubmed/29095805)\nMwenda, Jason M; Burke, Rachel M; Shaba, Keith; Mihigo, Richard; Tevi-Benissan, Mable Carole; Mumba, Mutale; Biey, Joseph Nsiari-Muzeyi; Cheikh, Dah; Poy MSc, Alain; Zawaira, Felicitas R; Aliabadi, Negar; Tate, Jacqueline E; Hyde, Terri; Cohen, Adam L; Parashar, Umesh D\n2017-11-03\nRotavirus is a leading cause of severe pediatric diarrhea globally, estimated to have caused 120,000 deaths among children aged rotavirus vaccination for all infants worldwide (2). Two rotavirus vaccines are currently licensed globally: the monovalent Rotarix vaccine (RV1, GlaxoSmithKline; 2-dose series) and the pentavalent RotaTeq vaccine (RV5, Merck; 3-dose series). This report describes progress of rotavirus vaccine introduction (3), coverage (using estimates from WHO and the United Nations Children's Fund [UNICEF]) (4), and impact on pediatric diarrhea hospitalizations in the WHO African Region. By December 2016, 31 (66%) of 47 countries in the WHO African Region had introduced rotavirus vaccine, including 26 that introduced RV1 and five that introduced RV5. Among these countries, rotavirus vaccination coverage (completed series) was 77%, according to WHO/UNICEF population-weighted estimates. In 12 countries with surveillance data available before and after vaccine introduction, the proportion of pediatric diarrhea hospitalizations that were rotavirus-positive declined 33%, from 39% preintroduction to 26% following rotavirus vaccine introduction. These results support introduction of rotavirus vaccine in the remaining countries in the region and continuation of rotavirus surveillance to monitor impact.\n[Survival and detection of rotaviruses on environmental surfaces in day care centers.](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=239472)\nKeswick, B H; Pickering, L K; DuPont, H L; Woodward, W E\n1983-01-01\nPreviously, we demonstrated that children in day care centers commonly experience diarrhea due to rotavirus, giardia, and bacterial pathogens. Multiple agents frequently coexist, and the environment is heavily contaminated with enteric bacteria during outbreaks. A study of environmental surface contamination with rotavirus was performed during three non-outbreak periods. Of 25 samples collected from environmental surfaces and teachers hands at a day care center, 4 (16%) were positive for rotavirus antigen when a fluorescence assay was used. We also examined the survival of two animal viruses, rotavirus SA-11 and poliovirus type 1, and bacteriophage 12 on similar environmental surfaces in a laboratory. Poliovirus type 1 and bacteriophage f2 were more resistant to drying than rotavirus SA-11 and could be recovered after a 90-min exposure on a dry surface. Rotavirus SA-11 could be detected for 30 min. All three viruses survived longer when they were suspended in fecal material than when they were suspended in distilled water. These data suggest that several agents, including rotavirus, can remain viable on contaminated surfaces long enough to be transmitted to susceptible children. This finding helps explain why rotavirus shows a mode of spread like that of parasitic and bacterial agents within day care center settings. PMID:6314896\n[Report of the 5th European expert meeting on rotavirus vaccination (EEROVAC).](https://www.ncbi.nlm.nih.gov/pubmed/29211629)\nde Hoog, Marieke L A; Vesikari, Timo; Giaquinto, Carlo; Huppertz, Hans-Iko; Martinon-Torres, Federico; Bruijning-Verhagen, Patricia\n2018-04-03\nThe Fifth European Expert Meeting on Rotavirus Vaccination was convened in Utrecht, The Netherlands, in March 2017. The 2-day meeting included invited lectures as well as original oral and poster presentations and brought together experts from 21 countries. Summary findings of the meeting include: Rotavirus vaccination programmes in Europe have resulted in reductions of 60-90% in rotavirus outpatient visits and hospitalizations. Long term trends indicate this impact is sustained over the years. Herd effects, protecting unvaccinated children and neonates too young to be vaccinated have been observed in many European countries. Early evidence now also suggests that rotavirus vaccination may be instrumental in the prevention of celiac disease. Special attention should be given to preterm infants, who may age out of the vaccination window before hospital discharge and to HIV infected children who are at increased risk of severe rotavirus AGE. There is a small but increased risk of IS following rotavirus vaccination and parents should therefore be informed about possible signs and symptoms of IS. New insights in rotavirus genetic susceptibility and interactions with microbiome may open opportunities for interventions to improve protection by vaccination, in particular in LMIC. The development of several novel rotavirus vaccines discussed at the meeting is also promising in this respect.\n[Human rotavirus genotypes causing acute watery diarrhea among ...](https://www.ajol.info/index.php/njcp/article/view/111648) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nBackground: Diarrhea is a major cause of childhood morbidity and mortality in the developing countries. Rotavirus is a major cause of acute watery diarrhea. Aim: This study aims at characterizing the prevalent rotavirus G-genotypes among under.five children presenting with acute watery diarrhea in Benin City, Nigeria.\n[epidemiology of rotavirus and astrovirus infections in children](https://www.ajol.info/index.php/aam/article/viewFile/43204/26747) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nEmmanuel Ameh\nAbstract. Background: Recent estimates attribute 527 000 deaths in children less than five years of age to rotavirus diarrhea annually, with 145 000 occurring in sub-Saharan Africa. Human astroviruses have been identified as one of the most frequent causes of infantile diarrhea, second in incidence only to rotavirus.\n[The incidence and clinical presentation of infantile rotavirus ...](https://www.ajol.info/index.php/samj/article/view/50751) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nObjectives. An effective vaccine is needed to protect against severe rotavirus disease, an important cause of gastroenteritis. Since there are no data on the incidence and antigenic diversity of rotavirus infection in Sierra Leone, we studied its epidemiology to enable an effective vaccine strategy to be designed. Methods.\n[Human rotavirus group a serotypes causing gastroenteritis in ...](https://www.ajol.info/index.php/ejhs/article/view/112799) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nBackground: Rotavirus remains a leading cause of acute gastroenteritis in children worldwide with an estimated 2000 deaths each day in developing countries. Due to HIV/AIDS scourge in Kenya, it is possible that rotavirus-related gastroenteritis has been aggravated in adults. The Global Alliance for Immunizations has ...\n[Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix\u2122) in developed countries.](https://www.ncbi.nlm.nih.gov/pubmed/23017130)\nPlosker, Greg L\n2012-12-01\nThe most common cause of severe diarrhea in infants and young children is rotavirus gastroenteritis (RVGE), which is associated with significant morbidity, healthcare resource use, and direct and indirect costs in industrialized nations. The monovalent rotavirus vaccine RIX4414 (Rotarix\u2122) is administered as a two-dose oral series in infants and has demonstrated protective efficacy against RVGE in clinical trials conducted in developed countries. In addition, various naturalistic studies have demonstrated 'real-world' effectiveness after the introduction of widespread rotavirus vaccination programs in the community setting. Numerous cost-effectiveness analyses have been conducted in developed countries in which a universal rotavirus vaccination program using RIX4414 was compared with no universal rotavirus vaccination program. There was a high degree of variability in base-case results across studies even when the studies were conducted in the same country, often reflecting differences in the selection of data sources or assumptions used to populate the models. In addition, results were sensitive to plausible changes in a number of key input parameters. As such, it is not possible to definitively state whether a universal rotavirus vaccination program with RIX4414 is cost effective in developed countries, although results of some analyses in some countries suggest this is the case. In addition, international guidelines advocate universal vaccination of infants and children against rotavirus. It is also difficult to draw conclusions regarding the cost effectiveness of rotavirus vaccine RIX4414 relative to that of the pentavalent rotavirus vaccine, which is administered as a three-dose oral series. Although indirect comparisons in cost-effectiveness analyses indicate that RIX4414 provided more favorable incremental cost-effectiveness ratios when each vaccine was compared with no universal rotavirus vaccination program, results were generally sensitive to vaccine\n[Epidemiology of rotavirus-associated hospital admissions in the province of Ferrara, Italy.](https://www.ncbi.nlm.nih.gov/pubmed/19255784)\nMarsella, Maria; Raimondi, Licia; Bergamini, Mauro; Sprocati, Monica; Bigi, Ettore; De Sanctis, Vincenzo; Borgna-Pignatti, Caterina; Gabutti, Giovanni\n2009-12-01\nHospital discharge forms with specific codes for rotavirus gastroenteritis in children 0 to 14 years of age were reviewed in the period 2003-2005 in the province of Ferrara. A total of 4,238 children were admitted to the pediatric departments; 151 patients were diagnosed with rotavirus gastroenteritis. The average annual rate of hospitalization for rotavirus gastroenteritis was 1.54/1,000 children Italy and underline the potential impact of rotavirus vaccination in our province.\n[Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/20692030)\nArmah, George E; Sow, Samba O; Breiman, Robert F; Dallas, Michael J; Tapia, Milagritos D; Feikin, Daniel R; Binka, Fred N; Steele, A Duncan; Laserson, Kayla F; Ansah, Nana A; Levine, Myron M; Lewis, Kristen; Coia, Michele L; Attah-Poku, Margaret; Ojwando, Joel; Rivers, Stephen B; Victor, John C; Nyambane, Geoffrey; Hodgson, Abraham; Sch\u00f6del, Florian; Ciarlet, Max; Neuzil, Kathleen M\n2010-08-21\nRotavirus gastroenteritis causes many deaths in infants in sub-Saharan Africa. Because rotavirus vaccines have proven effective in developed countries but had not been tested in developing countries, we assessed efficacy of a pentavalent rotavirus vaccine against severe disease in Ghana, Kenya, and Mali between April, 2007, and March, 2009. In our multicentre, double-blind, placebo-controlled trial, undertaken in rural areas of Ghana and Kenya and an urban area of Mali, we randomly assigned infants aged 4-12 weeks without symptoms of gastrointestinal disorders in a 1:1 ratio to receive three oral doses of pentavalent rotavirus vaccine 2 mL or placebo at around 6 weeks, 10 weeks, and 14 weeks of age. Infants with HIV infection were not excluded. Randomisation was done by computer-generated randomisation sequence in blocks of six. We obtained data for gastrointestinal symptoms from parents on presentation to health-care facilities and clinical data were obtained prospectively by clinicians. The primary endpoint was severe rotavirus gastroenteritis (Vesikari score >or=11), detected by enzyme immunoassay, arising 14 days or more after the third dose of placebo or vaccine to end of study (March 31, 2009; around 21 months of age). Analysis was per protocol; infants who received scheduled doses of vaccine or placebo without intervening laboratory-confirmed naturally occurring rotavirus disease earlier than 14 days after the third dose and had complete clinical and laboratory results were included in the analysis. This study is registered with ClinicalTrials.gov, number NCT00362648. 5468 infants were randomly assigned to receive pentavalent rotavirus vaccine (n=2733) or placebo (n=2735). 2357 infants assigned to vaccine and 2348 assigned to placebo were included in the per-protocol analysis. 79 cases of severe rotavirus gastroenteritis were reported in 2610.6 person-years in the vaccine group, compared with 129 cases in 2585.9 person-years in the placebo group, resulting\n[Reduction in Diarrhea- and Rotavirus-related Healthcare Visits Among Children Introduction in Zimbabwe.](https://www.ncbi.nlm.nih.gov/pubmed/28640001)\nMujuru, Hilda A; Yen, Catherine; Nathoo, Kusum J; Gonah, Nhamo A; Ticklay, Ismail; Mukaratirwa, Arnold; Berejena, Chipo; Tapfumanei, Ottias; Chindedza, Kenneth; Rupfutse, Maxwell; Weldegebriel, Goitom; Mwenda, Jason M; Burnett, Eleanor; Tate, Jacqueline E; Parashar, Umesh D; Manangazira, Portia\n2017-10-01\nIn Zimbabwe, rotavirus accounted for 41%-56% of acute diarrhea hospitalizations before rotavirus vaccine introduction in 2014. We evaluated rotavirus vaccination impact on acute diarrhea- and rotavirus-related healthcare visits in children. We examined monthly and annual acute diarrhea and rotavirus test-positive hospitalizations and Accident and Emergency Department visits among children introduction (2012-2013) with postvaccine introduction (2015 and 2016) data for 2 of the hospitals. We examined monthly acute diarrhea hospitalizations by year and age group for 2013-2016 from surveillance hospital registers and monthly acute diarrhea outpatient visits reported to the Ministry of Health and Child Care during 2012-2016. Active surveillance data showed winter seasonal peaks in diarrhea- and rotavirus-related visits among children introduction; the percentage of rotavirus test-positive visits followed a similar seasonal pattern and decrease. Hospital register data showed similar pre-introduction seasonal variation and post-introduction declines in diarrhea hospitalizations among children 0-11 and 12-23 months of age. Monthly variation in outpatient diarrhea-related visits mirrored active surveillance data patterns. At 2 surveillance hospitals, the percentage of rotavirus-positive visits declined by 40% and 43% among children 0-11 months of age and by 21% and 33% among children 12-23 months of age in 2015 and 2016, respectively. Initial reductions in diarrheal illness among children introduction are encouraging. These early results provide evidence to support continued rotavirus vaccination and rotavirus surveillance in Zimbabwe.\n[Experimental reproduction of rotavirus and Salmonella pullorum ...](https://www.ajol.info/index.php/sokjvs/article/view/162311) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nGroup A chicks were inoculated with 1 X 106 pfu/ml of rotavirus, group B chicks were inoculated with 1 X 106 cfu/ml of Salmonella pullorum, group C chicks were inoculated with 1 X 106 pfu/ml of rotavirus and 1 X 106 cfu/ml of Salmonella pullorum, while group D birds were given 1ml of PBS alone. Birds in all groups were ...\n[Estimates of economic burden of providing inpatient care in childhood rotavirus gastroenteritis from Malaysia.](https://www.ncbi.nlm.nih.gov/pubmed/17608648)\nLee, Way Seah; Poo, Muhammad Izzuddin; Nagaraj, Shyamala\n2007-12-01\nTo estimate the cost of an episode of inpatient care and the economic burden of hospitalisation for childhood rotavirus gastroenteritis (GE) in Malaysia. A 12-month prospective, hospital-based study on children less than 14 years of age with rotavirus GE, admitted to University of Malaya Medical Centre, Kuala Lumpur, was conducted in 2002. Data on human resource expenditure, costs of investigations, treatment and consumables were collected. Published estimates on rotavirus disease incidence in Malaysia were searched. Economic burden of hospital care for rotavirus GE in Malaysia was estimated by multiplying the cost of each episode of hospital admission for rotavirus GE with national rotavirus incidence in Malaysia. In 2002, the per capita health expenditure by Malaysian Government was US$71.47. Rotavirus was positive in 85 (22%) of the 393 patients with acute GE admitted during the study period. The median cost of providing inpatient care for an episode of rotavirus GE was US$211.91 (range US$68.50-880.60). The estimated average cases of children hospitalised for rotavirus GE in Malaysia (1999-2000) was 8571 annually. The financial burden of providing inpatient care for rotavirus GE in Malaysian children was estimated to be US$1.8 million (range US$0.6 million-7.5 million) annually. The cost of providing inpatient care for childhood rotavirus GE in Malaysia was estimated to be US$1.8 million annually. The financial burden of rotavirus disease would be higher if cost of outpatient visits, non-medical and societal costs are included.\n[Expression and characterization of a novel truncated rotavirus VP4 for the development of a recombinant rotavirus vaccine.](https://www.ncbi.nlm.nih.gov/pubmed/29555220)\nLi, Yijian; Xue, Miaoge; Yu, Linqi; Luo, Guoxing; Yang, Han; Jia, Lianzhi; Zeng, Yuanjun; Li, Tingdong; Ge, Shengxiang; Xia, Ningshao\n2018-04-12\nThe outer capsid protein VP4 is an important target for the development of a recombinant rotavirus vaccine because it mediates the attachment and penetration of rotavirus. Due to the poor solubility of full-length VP4, VP8 was explored as candidate rotavirus vaccines in the past years. In previous studies, it has been found that the N-terminal truncated VP8 protein, VP8-1 (aa26-231), could be expressed in soluble form with improved immunogenicity compared to the core of VP8 (aa65-223). However, this protein stimulated only a weak immune response when aluminum hydroxide was used as an adjuvant. In addition, it should be noted that the protective efficacy of VP4 was higher than that of VP8 and VP5. In this study, it was found that when the N-terminal 25 amino acids were deleted, the truncated VP4 \u2217 (aa26-476) containing VP8 and the stalk domain of VP5 could be expressed in soluble form in E. coli and purified to homogeneous trimers. Furthermore, the truncated VP4 could induce high titers of neutralizing antibodies when aluminum adjuvant was used and conferred high protective efficacy in reducing the severity of diarrhea and rotavirus shedding in stools in animal models. The immunogenicity of the truncated VP4 was significantly higher than that of VP8 \u2217 and VP5 \u2217 alone. Taken together, the truncated VP4 \u2217 (aa26-476), with enhanced immunogenicity and immunoprotectivity, could be considered as a viable candidate for further development and has the potential to become a parenterally administered rotavirus vaccine. Copyright \u00a9 2018 Elsevier Ltd. All rights reserved.\n[Characteristics of Rotavirus Diarrhea in Hospitalized Children in Kosovo](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4272830)\nIsmaili-Jaha, Vlora; Shala, Muje; Azemi, Mehmedali; Hoxha-Kamberi, Teuta; Avdiu, Muharrem; Spahiu, Shqipe; Jaha, Luan\n2014-01-01\nBackground: Diarrhea is a leading cause of child mortality worldwide. Rotavirus is one of the most common causes of severe diarrhea and dehydration in children. Authors reviewed epidemiological and clinical data of the rotavirus diarrhea in Kosovo. Methods: This is a prospective study carried between January 1st and December 31st 2011. All data, comprising demographics, nutrition, clinical presentation, laboratory findings, management and outcome of the rotavirus diarrhea are collected on the specially designed form. Results: 116 children with rotavirus diarrhea are included in the study. The majority boys (74.4%) and children aged 0 \u2013 12 months (82.75%). Mean age of children in the study was 16.38 months. Almost every third child in the study was hypotrophic (29.2%). More than half of the infants (55.2%) were on mixed food, somewhat more than every third was breast feeding (36.45%), and every twelfth (8.33%) was on artificial milk (animal or formula). Apart from diarrhea, present in all patients, vomiting (97.41%) and fever (43.96%) were characteristics of the clinical presentation of the diarrhea. Two thirds of the children had mild grade dehydration (70.7%). All patients recovered with no sequels. Conclusion: Rotavirus continues to be responsible for a significant portion of acute diarrhea in Kosovo. Clinical features, epidemiological data and the agglutination test are safe enough to establish the diagnosis. Treated correctly rotavirus diarrhea has a favorable outcome. PMID:25568634\n[Cost-effectiveness of rotavirus vaccination in Albania.](https://www.ncbi.nlm.nih.gov/pubmed/25919162)\nAhmeti, Albana; Preza, Iria; Simaku, Artan; Nelaj, Erida; Clark, Andrew David; Felix Garcia, Ana Gabriela; Lara, Carlos; Hoestlandt, C\u00e9line; Blau, Julia; Bino, Silvia\n2015-05-07\nRotavirus vaccines have been introduced in several European countries but can represent a considerable cost, particularly for countries that do not qualify for any external financial support. This study aimed to evaluate the cost-effectiveness of introducing rotavirus vaccination into Albania's national immunization program and to inform national decision-making by improving national capacity to conduct economic evaluations of new vaccines. The TRIVAC model was used to assess vaccine impact and cost-effectiveness. The model estimated health and economic outcomes attributed to 10 successive vaccinated birth cohorts (2013-2022) from a government and societal perspective. Epidemiological and economic data used in the model were based on national cost studies, and surveillance data, as well as estimates from the scientific literature. Cost-effectiveness was estimated for both the monovalent (RV1) and pentavalent vaccines (RV5). A multivariate scenario analysis (SA) was performed to evaluate the uncertainty around the incremental cost-effectiveness ratios (ICERs). With 3% discounting of costs and health benefits over the period 2013-2022, rotavirus vaccination in Albania could avert 51,172 outpatient visits, 14,200 hospitalizations, 27 deaths, 950 disability-adjusted life-years (DALYs), and gain 801 life-years. When both vaccines were compared to no vaccination, the discounted cost per DALY averted was US$ 2008 for RV1 and US$ 5047 for RV5 from a government perspective. From the societal perspective the values were US$ 517 and US$ 3556, respectively. From both the perspectives, the introduction of rotavirus vaccine to the Albanian immunization schedule is either cost-effective or highly cost-effective for a range of plausible scenarios. In most scenarios, including the base-case scenario, the discounted cost per DALY averted was less than three times the gross domestic product (GDP) per capita. However, rotavirus vaccination was not cost-effective when rotavirus cases\n[Human rotavirus strain Wa downregulates NHE1 and NHE6 expressions in rotavirus-infected Caco-2 cells.](https://www.ncbi.nlm.nih.gov/pubmed/28289928)\nChen, Honglang; Song, Lijun; Li, Guixian; Chen, Wenfeng; Zhao, Shumin; Zhou, Ruoxia; Shi, Xiaoying; Peng, Zhenying; Zhao, Wenchang\n2017-06-01\nRotavirus (RV) is the most common cause of severe gastroenteritis and fatal dehydration in human infants and neonates of different species. However, the pathogenesis of rotavirus-induced diarrhea is poorly understood. Secretory diarrhea caused by rotavirus may lead to a combination of excessive secretion of fluid and electrolytes into the intestinal lumen. Fluid absorption in the small intestine is driven by Na + -coupled transport mechanisms at the luminal membrane, including Na + /H + exchanger (NHE). Here, we performed qRT-PCR to detect the transcription of NHEs. Western blotting was employed for protein detection. Furthermore, immunocytochemistry was used to validate the NHE's protein expression. Finally, intracellular Ca 2+ concentration was detected by confocal laser scanning microscopy. The results demonstrated that the NHE6 mRNA and protein expressed in the human colon adenocarcinoma cell line (Caco-2). Furthermore, RV-Wa induced decreased expression of the NHE1 and NHE6 in Caco-2 cell in a time-dependent manner. In addition, intracellular Ca 2+ concentration in RV-Wa-infected Caco-2 cells was higher than that in the mock-infected cells. Furthermore, RV-Wa also can downregulate the expression of calmodulin (CaM) and calmodulin kinase II (CaMKII) in Caco-2 cells. These findings provides important insights into the mechanisms of rotavirus-induced diarrhea. Further studies on the underlying pathophysiological mechanisms that downregulate NHEs in RV-induced diarrhea are required.\n[Vacunas de ADN: inducci\u00f3n de la respuesta inmunitaria DNA Vaccines: Induction of the immune response](http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342009000900012) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJavier Mota-S\u00e1nchez\n2009-01-01\nFull Text Available La efectividad de las vacunas y la inmunizaci\u00f3n en la prevenci\u00f3n de las enfermedades infecciosas es uno de los grandes avances de la medicina. En la actualidad, el acceso a la tecnolog\u00eda de punta en el \u00e1rea de la gen\u00f3mica y la prote\u00f3mica ha hecho posible acelerar el desarrollo de nuevos modelos de vacunas con caracter\u00edsticas mejoradas en aspectos fundamentales, como la inmunogenicidad y la seguridad. A casi dos d\u00e9cadas del primer informe, en el cual se demostr\u00f3 que un gen puede expresarse mediante la inyecci\u00f3n directa de ADN desnudo, las vacunas de ADN han probado ser eficientes para inducir una respuesta inmunitaria protectora contra par\u00e1sitos, virus y bacterias en diversos modelos animales. Esta revisi\u00f3n tiene por objetivo presentar un panorama general de las vacunas de ADN y los mecanismos mediante los cuales la inmunizaci\u00f3n con ant\u00edgenos insertados en vectores de ADN (pl\u00e1smidos inducen una respuesta inmunitaria.The effectiveness of vaccines and immunization in the prevention of infectious diseases is one of the greatest successes in medicine. In recent years, with access to cutting edge genomic and proteomic technology, it is possible to accelerate the development of new and improved vaccines with better immunogenicity and safety characteristics. Since the first report almost two decades ago, where it was demonstrated that gene expression is possible by directed injection of naked DNA, DNA vaccines have been proven to induce protective immune responses against parasites, virus and bacterium in diverse animal disease models. This review aims to present an overview about DNA vaccines and the mechanisms by which immune responses are induced after immunization with plasmid DNA-encoded antigens.\n[Diversity and zoonotic potential of rotaviruses in swine and cattle across Europe](http://www.forskningsdatabasen.dk/en/catalog/225710519) [DEFF Research Database (Denmark)](http://forskningsbasen.deff.dk/?lang=eng)\nMidgley, Sofie E.; B\u00e1nyai, Kriszti\u00e1n; Buesa, Javier\n2012-01-01\nGroup A rotaviruses can infect both humans and animals. Individual rotavirus strains can occasionally cross species barriers and might hereby contribute to the emergence of new genotypes in heterologous hosts. The incidence and impact of zoonotic rotavirus are not well defined, and one reason...... for this is a lack of data about strains circulating in suspected reservoir animal hosts. In this study we report the incidence, genetic diversity, and molecular epidemiology of rotaviruses detected in domestic cattle and swine in 6 European countries. From 2003 to 2007, 1101 and more than 2000 faecal specimens were...... collected from swine and cattle, both healthy and diarrhoeic, and tested for rotaviruses. Viruses from positive stools were genotyped and a subset of strains was characterized by nucleotide sequencing and phylogenetic analysis of the VP7 (G) and VP4 (P) genes. Rotaviruses were detected in 43% of bovine...\n[Immunogenicity and protective efficacy of yeast extracts containing rotavirus-like particles: a potential veterinary vaccine.](https://www.ncbi.nlm.nih.gov/pubmed/24593996)\nRodr\u00edguez-Limas, William A; Pastor, Ana Ruth; Esquivel-Soto, Ernesto; Esquivel-Guadarrama, Fernando; Ram\u00edrez, Octavio T; Palomares, Laura A\n2014-05-19\nRotavirus is the most common cause of severe diarrhea in many animal species of economic interest. A simple, safe and cost-effective vaccine is required for the control and prevention of rotavirus in animals. In this study, we evaluated the use of Saccharomyces cerevisiae extracts containing rotavirus-like particles (RLP) as a vaccine candidate in an adult mice model. Two doses of 1mg of yeast extract containing rotavirus proteins (between 0.3 and 3 \u03bcg) resulted in an immunological response capable of reducing the replication of rotavirus after infection. Viral shedding in all mice groups diminished in comparison with the control group when challenged with 100 50% diarrhea doses (DD50) of murine rotavirus strain EDIM. Interestingly, when immunizing intranasally protection against rotavirus infection was observed even when no increase in rotavirus-specific antibody titers was evident, suggesting that cellular responses were responsible of protection. Our results indicate that raw yeast extracts containing rotavirus proteins and RLP are a simple, cost-effective alternative for veterinary vaccines against rotavirus. Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.\n[Molecular characterization of a human G20P[28] rotavirus a strain with multiple genes related to bat rotaviruses.](https://www.ncbi.nlm.nih.gov/pubmed/29187315)\nEsona, Mathew D; Roy, Sunando; Rungsrisuriyachai, Kunchala; Gautam, Rashi; Hermelijn, Sandra; Rey-Benito, Gloria; Bowen, Michael D\n2018-01-01\nGroup A rotaviruses are the major cause of severe gastroenteritis in the young of mammals and birds. This report describes characterization of an unusual G20P[28] rotavirus strain detected in a 24month old child from Suriname. Genomic sequence analyses revealed that the genotype constellation of the Suriname strain RVA/Human-wt/SUR/2014735512/2013/G20P[28] was G20-P[28]-I13-R13-C13-M12-A23-N13-T15-E20-H15. Genes VP1, VP2, VP3, NSP1, NSP2, NSP3, NSP4 and NSP5 were recently assigned novel genotypes by the Rotavirus Classification Working Group (RCWG). Three of the 11 gene segments (VP7, VP4, VP6) were similar to cognate gene sequences of bat-like human rotavirus strain Ecu534 from Ecuador and the VP7, NSP3 and NSP5 gene segments of strain RVA/Human-wt/SUR/2014735512/2013/G20P[28] were found to be closely related to gene sequences of bat rotavirus strain 3081/BRA detected in Brazil. Although distantly related, the VP1 gene of the study strain and bat strain BatLi09 detected in Cameroon in 2014 are monophyletic. The NSP1 gene was found to be most closely related to human strain QUI-35-F5 from Brazil. These findings suggest that strain RVA/Human-wt/SUR/2014735512/2013/G20P[28] represents a zoonotic infection from a bat host. Published by Elsevier B.V.\n[NEW PREVENTION OPPORTUNITIES OF INFECTIOUS DISEASES. VACCINATION AGAINST ROTAVIRUS](http://pf.spr-journal.ru/jour/article/view/151) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nT. A. Grechukha\n2013-01-01\nFull Text Available The article covers the problem of the burden of rotavirus disease. Rotavirus infection is the leading cause of mortality among children under 5 years of age and is a major problem for a public healthcare. The world is actively engaged in the prevention of rotavirus infection since 2005. There is a lot of data on the efficacy and safety of this vaccine. Different foreign investigations have shown the herd immunity of the vaccine. The authors present data about the effectiveness and safety of vaccines, established during clinical studies of the foreign scientists.\n[Effects of wastewater sludge and its detergents on the stability of rotavirus](http://www.etde.org/etdeweb/details.jsp?query_id=1&page=0&osti_id=5157012) [Energy Technology Data Exchange (ETDEWEB)](https://www.etde.org/etdeweb/fieldedsearch.jsp)\nWard, R.L. (Sandia Labs., Albuquerque, NM); Ashley, C.S.\n1980-06-01\nWastewater sludge reduced the heat required to inactivate rotavirus SA-11, and ionic detergents were identified as the sludge components responsible for this effect. A similar result was found previously with reovirus. The quantitative effects of individual ionic detergents on rotavirus and reovirus were very different, and rotavirus was found to be extremely sensitive to several of these detergents. However, neither virus was destabilized by nonionic detergents. On the contrary, rotavirus was stabilized by a nonionic detergent against the potent destabilizing effects of the ionic detergent sodium dodecyl sulfate. The destabilizing effects of both cationic and anionic detergents on rotavirus were greatly altered by changes in the pH of the medium.\n[Fatores associados \u00e0 cobertura vacinal em adolescentes Factores asociados a la cobertura por vacunas en adolescentes Factors associated to the vaccination covering in adolescents](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-21002010000600013) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAyla Maria Calixto de Carvalho\n2010-01-01\nFull Text Available OBJETIVO: Analisar os fatores associados \u00e0 condi\u00e7\u00e3o de estar vacinado entre adolescentes de uma \u00e1rea da Estrat\u00e9gia Sa\u00fade da Fam\u00edlia de Teresina - PI. M\u00c9TODOS: Estudo de natureza quantitativa e do tipo seccional. A amostra foi constitu\u00edda por 261 adolescentes e a an\u00e1lise foi realizada por meio da estat\u00edstica descritiva. RESULTADOS: A cobertura vacinal contra rub\u00e9ola, sarampo e caxumba foi de 5,4%; para a vacina contra difteria e t\u00e9tano, foi de 22,9%; para a vacina contra hepatite-B: foi 27,2% e 35,2% para a vacina contra febre amarela. CONCLUS\u00c3O: A baixa cobertura vacinal encontrada neste estudo est\u00e1 relacionada: \u00e0s oportunidades perdidas de vacina\u00e7\u00e3o (65,5%; \u00e0 defici\u00eancia de conhecimento sobre as vacinas, a faixa et\u00e1ria maior de 15 anos (Raz\u00e3o da Preval\u00eancia (RP = 2,85; \u00cdndice de Confian\u00e7a (IC 95% = 1,63-4,99; o sexo masculino (RP = 2,04; IC95% =1,15-3,62.OBJETIVO: Analizar los factores asociados a la condici\u00f3n de estar vacunado entre adolescentes, en un \u00e1rea de la Estrategia Salud de la Familia, en la ciudad de Teresina, en el estado de Piau\u00ed. M\u00c9TODOS: Estudio de naturaleza cuantitativa y de tipo seccional. La muestra fue constituida por 261 adolescentes y el an\u00e1lisis fue realizado por medio de la estad\u00edstica descriptiva. RESULTADOS: La cobertura por vacuna contra rub\u00e9ola, sarampi\u00f3n e caxumba fue de 5,4%; para la vacuna contra la difteria y t\u00e9tano, fue de 22,9%; para la vacuna contra hepatitis-B, fue 27,2% y de 35,2% para la vacuna contra la fiebre amarilla. CONCLUSI\u00d3N: La baja cobertura por vacunaci\u00f3n encontrada en este estudio est\u00e1 relacionada a: 1 las oportunidades perdidas de vacunaci\u00f3n (65,5%; a la deficiencia de conocimiento sobre las vacunas, al intervalo de edad mayor de 15 a\u00f1os [Raz\u00f3n de la Prevalencia (RP = 2,85; \u00cdndice de Confianza (IC 95% = 1,63-4,99]; al sexo masculino (RP = 2,04; IC95% =1,15-3,62.OBJECTIVE: To analyze the factors associated to the condition of to be vaccinated among\n[Vacuna fenol-insoluble contra la brucelosis humana: evaluacion del poder inmunogenico en cobayos Phenol insoluble extract vaccine for the prevention of brucellosis in humans: evaluation in guinea pigs](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46651991000100005) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nJ. Bolpe\n1991-02-01\nFull Text Available Se examin\u00f3 una vacuna dise\u00f1ada para inmunizar al hombre, preparada con extracto de fenol insoluble, para determinar si proteg\u00eda a cobayos contra el desaf\u00edo con la cepa virulenta B. abortus 2308. Se incluyeron en el experimento las vacunas vivas atenuadas B. abortus cepa 19 y B. melitensis Rev. 1, para comparar los resultados. Se vacunaron 93 animales en cada grupo, que fueron subdivididos en subgrupos de 31 y se los desafi\u00f3 con 10(4, 10\u00b3 y 10\u00b2 unidades formadoras de colonias de la cepa B. abortus 2308 virulenta. El an\u00e1lisis global de los resultados demostr\u00f3 una protecci\u00f3n del 11.9% en animales vacunados con el extracto de fenol insoluble, 65% en los vacunados con B. abortus cepa 19 y 95% en el grupo que recibi\u00f3 vacuna B. melitensis Rev. 1.A phenol insoluble extract vaccine proposed to immunize men against brucellosis was tested for its ability in protecting guinea pigs against challenge with virulent Brucella abortus strain 2308. Living attenuated Brucella abortus strain 19 and B. melitensis Rev. 1 were included in the experiment for comparison. Ninety three animals were vaccinated in each group and subdivided in subgroups of 31 for challenge with 10(4,10\u00b3 and 10\u00b2 colony forming units of virulent B. abortus 2308. A global analysis of the results showed protection of 11.9%, 65% and 95% in animals vaccinated with phenol insoluble extract, strain 19 and Rev. 1, respectively.\n[Rotavirus Vaccine Response Correlates with the Infant Gut Microbiota Composition in Pakistan](https://www.narcis.nl/publication/RecordID/oai%3Apure.amc.nl%3Apublications%2Fdef4ddc5-eadc-4fd2-b315-fbfdd7324806/uquery/Rotavirus%20AND%20vaccine%20AND%20efficacy/id/6/Language/EN)\nHarris, Vanessa; Ali, Asad; Fuentes, Susana; Korpela, Katri; Kazi, Momin; Tate, Jacqueline; Parashar, Umesh; Wiersinga, W. Joost; Giaquinto, Carlo; de Weerth, Carolina; de Vos, Willem M.\n2017-01-01\nBackground Rotavirus (RV) is the leading cause of diarrhea-related death in children worldwide, and ninety-five percent of rotavirus deaths occur in Africa and Asia. Rotavirus vaccines (RVV) can dramatically reduce RV deaths, but have low efficacy in low-income settings where they are most needed.\n[ROTAVIRUS INFECTION. HOW TO REALLY PROTECT CHILDREN FROM SEVERE GASTROENTERITIS?](http://pf.spr-journal.ru/jour/article/view/169) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nT. A. Grechukha\n2013-01-01\nFull Text Available According to the statistics of the recent 5 years, the share of rotavirus gastroenterites is 44-47% of all acute intestinal infections in children under 5 years of age in the Russian Federation. Up to 5% of mortality rate in children under 5 years of age is connected with rotavirus gastroenteritis. Rotavirus gastroenteritis takes an especially severe course in children of 6-24 months of age. The only reliable method of preventing this infection is vaccination. The authors present information on the rotavirus strains dominant in Russia and abroad, efficacy and safety of immunization with a pentavalent vaccine and the recommended schemes of its administration. This vaccine is registered in the Russian Federation; it is to be first used in the nearest future.\n[Hospitalizations due to rotavirus gastroenteritis in Catalonia, Spain, 2003-2008](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3212997)\n2011-01-01\nBackground Rotavirus is the most common cause of severe gastroenteritis among young children in Spain and worldwide. We evaluated hospitalizations due to community and hospital-acquired rotavirus gastroenteritis (RVGE) and estimated related costs in children under 5 years old in Catalonia, Spain. Results We analyzed hospital discharge data from the Catalan Health Services regarding hospital admissions coded as infectious gastroenteritis in children under 5 for the period 2003-2008. In order to estimate admission incidence, we used population estimates for each study year published by the Statistic Institut of Catalonia (Idescat). The costs associated with hospital admissions due to rotavirus diarrhea were estimated for the same years. A decision tree model was used to estimate the threshold cost of rotavirus vaccine to achieve cost savings from the healthcare system perspective in Catalonia. From 2003 through 2008, 10655 children under 5 years old were admitted with infectious gastroenteritis (IGE). Twenty-two percent of these admissions were coded as RVGE, yielding an estimated average annual incidence of 104 RVGE hospitalizations per 100000 children in Catalonia. Eighty seven percent of admissions for RVGE occurred during December through March. The mean hospital stay was 3.7 days, 0.6 days longer than for other IGE. An additional 892 cases of presumed nosocomial RVGE were detected, yielding an incidence of 2.5 cases per 1000 child admissions. Total rotavirus hospitalization costs due to community acquired RVGE for the years 2003 and 2008 were 431,593 and 809,224 \u20ac, respectively. According to the estimated incidence and hospitalization costs, immunization would result in health system cost savings if the cost of the vaccine was 1.93 \u20ac or less. At a vaccine cost of 187 \u20ac the incremental cost per hospitalization prevented is 195,388 \u20ac (CI 95% 159,300; 238,400). Conclusions The burden of hospitalizations attributable to rotavirus appeared to be lower in\n[Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines.](https://www.ncbi.nlm.nih.gov/pubmed/22520134)\nPatel, Manish; Steele, A Duncan; Parashar, Umesh D\n2012-04-27\nIn recent years, two live, oral rotavirus vaccines have been successfully tested in developing and industrialized countries, and both vaccines are now recommended by the World Health Organization for all children worldwide. Both immunogenicity and efficacy of these rotavirus vaccines has been lower in developing compared to industrialized settings. We reviewed the data on the effect of trivalent OPV on the immunogenicity and efficacy of two rotavirus vaccines currently recommended by the WHO. While rotavirus vaccines have not affected immune responses to OPV, in general, the immune responses (i.e., antibody levels) to rotavirus vaccination were lower when rotavirus vaccines were co-administered with OPV. Limited data suggests that the interference is greater after the first dose of OPV, presumably because the first dose is associated with greatest intestinal replication of vaccine polio virus strains, and this interference is largely overcome with subsequent rotavirus vaccine doses. Despite the lower immunogenicity, one large efficacy study in middle income Latin American countries showed no decrease in protective efficacy of rotavirus vaccine in infants receiving concurrent OPV. While these data are encouraging and support simultaneous administration of rotavirus vaccines and OPV, additional evidence should be gathered as rotavirus vaccines are used more widely in developing country settings, where OPV is routinely used, rather than inactivated polio vaccine. Published by Elsevier Ltd.\n[Prevalence of Rotavirus in shellfish from Southern Kerala](http://www.veterinaryworld.org/Vol.7/October-2014/13.pdf) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nVysakh Mohan\n2014-10-01\nFull Text Available Aim: To study the prevalence of Rotavirus in shellfish from Southern Kerala. Materials and Methods: The shellfish samples after processing was concentrated using proteinase K. RNA was isolated from the concentrated samples using phenol chloroform method. Rota viral RNA was detected using reverse transcriptionpolymerase chain reaction. Results: A low prevalence of 2.5% (5/200 was obtained during the study. Rotavirus was detected in 2 out of 60 brown mussels (3.33%, 2 out of 70 yellow clams (2.86% and 1 out of 70 black clams (1.43%. Conclusion: Low prevalence of Rotavirus was obtained in our study. A more extensive study need to be conducted to estimate the prevalence of enteric virus in shellfish.\n[La evidencia acerca de la controversia de las vacunas que contienen timerosal y su asociaci\u00f3n con el autismo](https://www.openaire.eu/search/publication?articleId=doajarticles::9f083d9cb2b9e06dbceeb1cf2c0fabe3)\nLisset Garc\u00eda-Fern\u00e1ndez; Adri\u00e1n V Hern\u00e1ndez; V\u00edctor Su\u00e1rez Moreno; Fabi\u00e1n Fiestas\n2013-01-01\nLa vacunaci\u00f3n es una de las medidas de mayor impacto en la salud p\u00fablica para la reducci\u00f3n de la morbimortalidad infantil. El timerosal es un compuesto org\u00e1nico del mercurio utilizado como preservante de los frascos multidosis. Eventualmente, en el Per\u00fa, surgen olas de controversia acerca de la seguridad de estas vacunas, asoci\u00e1ndolas especialmente con el autismo. Como resultado de estas controversias, se han propuesto, incluso, leyes que proh\u00edben este tipo de vacunas, lo que tendr\u00eda un impor...\n[Rotavirus vaccine response correlates with the infant gut microbiota composition in Pakistan](https://www.narcis.nl/publication/RecordID/oai%3Alibrary.wur.nl%3Awurpubs%2F528628/uquery/Rotavirus%20AND%20vaccine%20AND%20efficacy/id/7/Language/EN)\nHarris, Vanessa C.; Ali, Asad; Fuentes, Susana; Korpela, Katri; Kazi, Momin; Tate, Jacqueline; Parashar, Umesh; Wiersinga, W.J.; Giaquinto, Carlo; Weerth, de Carolina; Vos, de Willem M.\n2017-01-01\nRotavirus (RV) is the leading cause of diarrhea-related death in children worldwide and ninety-five percent of rotavirus deaths occur in Africa and Asia. Rotavirus vaccines (RVV) can dramatically reduce RV deaths, but have low efficacy in low-income settings where they are most needed. The\n[Health and economic impact of rotavirus vaccination in GAVI-eligible countries](http://www.biomedcentral.com/1471-2458/10/253) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nSlichter David\n2010-05-01\nFull Text Available Abstract Background Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. Methods We synthesized population-level data from various sources (primarily from global-level databases for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$] per disability-adjusted life year (DALY averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. Results Under the base-case assumptions (70% coverage, vaccinating one single birth cohort would prevent about 55% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose, the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%. A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same\n[Rotavirus mortality confirmed by etiologic identification in Venezuelan children with diarrhea.](https://www.ncbi.nlm.nih.gov/pubmed/17468648)\nP\u00e9rez-Schael, Irene; Salinas, Bel\u00e9n; Gonz\u00e1lez, Rosabel; Salas, Hans; Ludert, Juan Ernesto; Escalona, Marisol; Alcal\u00e1, Ana; Rosas, Mar\u00eda Alejandra; Mater\u00e1n, Mercedes\n2007-05-01\nHospital-based studies to determine the etiology of deaths from diarrhea are scarce. In this study, we specifically analyzed deaths due to rotavirus to assess the rotavirus impact on diarrhea mortality. To determine the rotavirus proportion contributing to mortality due to diarrhea, we analyzed data obtained from a hospital-based mortality surveillance, conducted over 7 years, in the Ciudad Hospitalaria Dr. Enrique Tejera, Valencia, Venezuela. Rotavirus was identified in stool samples collected from children who died of diarrhea, by a confirmatory ELISA and/or reverse transcription polymerase chain reaction. Our results show that rotavirus (21%; 21/100) is the leading cause of death due to diarrhea among children causes in this age group. Shigella spp. (19%; 13/69) was the second most important cause of death, followed by calicivirus (6%; 3/53). Furthermore, this study documents a seasonal pattern in the deaths due to rotavirus (odds ratio 3.28; 95% confidence interval 1.13-9.76). For Venezuela, it is estimated that approximately 300 children cause of death due to diarrhea, which supports previous estimations. This is the first study to present data of cause-specific mortality due to diarrhea based on hospital surveillance of diarrhea etiologies.\n[Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay Impacto econ\u00f3mico de la vacuna antineumoc\u00f3cica conjugada en Brasil, Chile y Uruguay](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000800004) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nDagna O. Constenla\n2008-08-01\nFull Text Available OBJECTIVES: To evaluate the economic impact of vaccination with the pneumococcal 7-valent conjugate vaccine (PCV7 in Brazil, Chile, and Uruguay. METHODS: A decision analytic model was constructed to compare pneumococcal vaccination of children 0-5 years old with no vaccination in Brazil, Chile, and Uruguay. Costs and health outcomes were analyzed from the societal perspective. Vaccine, demographic, epidemiologic, and cost data were incorporated into this economic analysis. RESULTS: At the rate of diphtheria-tetanus-pertussis (DTP vaccine coverage and a vaccine price of US$ 53 per dose, PCV7 was projected to prevent 23 474 deaths per year in children under 5 years old in the three countries studied, thus averting 884 841 disability-adjusted life years (DALYs yearly. To vaccinate the entire birth cohort of the three countries, total vaccine costs would be US$ 613.9 million. At US$ 53 per dose, the cost per DALY averted from a societal perspective would range from US$ 664 (Brazil to US$ 2 019 (Chile. At a cost of US$ 10 per dose, vaccine cost is lower than the overall cost of illness averted (US$ 125 050 497 versus US$ 153 965 333, making it cost effective and cost-saving. CONCLUSIONS: The results of this study demonstrate that the incorporation of PCV7 vaccine at US$ 53 per dose confers health benefits at extra costs. It is unclear whether vaccination at the current price is affordable to these countries.OBJETIVOS: Evaluar el impacto econ\u00f3mico de la aplicaci\u00f3n de la vacuna antineumoc\u00f3cica conjugada heptavalente (PCV7 en Brasil, Chile y Uruguay. M\u00c9TODOS: Se elabor\u00f3 un modelo anal\u00edtico de decisiones para comparar la vacunaci\u00f3n antineumoc\u00f3cica de los ni\u00f1os de 0-5 a\u00f1os de edad con la no vacunaci\u00f3n, en Brasil, Chile y Uruguay. Los costos y los desenlaces para la salud se analizaron desde el punto de vista de la sociedad. Al an\u00e1lisis econ\u00f3mico se incorporaron los costos y los datos demogr\u00e1ficos, epidemiol\u00f3gicos y de la vacuna. RESULTADOS\n[Frequency of Rotavirus Infection among Children with Diarrhea in ...](https://www.ajol.info/index.php/sjms/article/view/104449) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nBackground: Rotaviruses are the major cause of gastroenteritis and diarrhea in infants and young children worldwide. Basic epidemiological data concerning rotaviruses among infants and children are necessary for health planners and care providers in Sudan. Method: Cross-sectional study was conducted at Omdurman ...\n[Rotavirus disease course among immunocompromised patients : 5-year observations from a tertiary care medical centre](https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F357639/uquery/rotavirus/id/11/Language/EN)\nBruijning-Verhagen, P; Nipshagen, M D; Graaf, H.; Bonten, M J M\n2017-01-01\nRotavirus (RV) is highly endemic inside and outside hospital-settings. Immunocompromised children and adults are at risk of complicated rotavirus gastroenteritis (RVGE), but general rotavirus disease severity in this group remains poorly described and rotavirus testing is not routinely performed\n[Dynamic modeling of cost-effectiveness of rotavirus vaccination, Kazakhstan.](https://www.ncbi.nlm.nih.gov/pubmed/24378188)\nFreiesleben de Blasio, Birgitte; Flem, Elmira; Latipov, Renat; Kuatbaeva, Ajnagul; Kristiansen, Ivar S\u00f8nb\u00f8\n2014-01-01\nThe government of Kazakhstan, a middle-income country in Central Asia, is considering the introduction of rotavirus vaccination into its national immunization program. We performed a cost-effectiveness analysis of rotavirus vaccination spanning 20 years by using a synthesis of dynamic transmission models accounting for herd protection. We found that a vaccination program with 90% coverage would prevent \u2248880 rotavirus deaths and save an average of 54,784 life-years for children vaccine cost at vaccination program costs would be entirely offset. To further evaluate efficacy of a vaccine program, benefits of indirect protection conferred by vaccination warrant further study.\n[Validaci\u00f3n de un ELISA tipo inhibici\u00f3n para cuantificar polisac\u00e1rido Vi en la vacuna antitifo\u00eddica cubana vax-TyVi](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200002&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nEsther Mar\u00eda Fajardo\n2006-08-01\nFull Text Available Se describe la validaci\u00f3n de un ELISA tipo inhibici\u00f3n, reportado por primera vez en la literatura cient\u00edfica para cuantificar un ant\u00edgeno vacunal: el polisac\u00e1rido Vi de Salmonella Typhi, para ser empleado en el control de la calidad de la vacuna antitifo\u00eddica cubana vax- TyVi\u00e2. El ensayo consta de seis pasos: 1 Recubrimiento de placa de reacci\u00f3n con poli-L-lisina y posteriormente polisac\u00e1rido Vi; 2 Bloqueo con leche descremada; 3 Inhibici\u00f3n o neutralizaci\u00f3n en tubos de suero anti-Vi de conejo, respectivamente, con polisac\u00e1rido Vi de Curva de Calibraci\u00f3n (concentraciones desde 1\u201332 \u03bcg/mL, control positivo y muestras de vacuna (3 diluciones; 4 Neutralizaci\u00f3n de anticuerpos anti-Vi libres, presentes en las mezclas anteriores, por el Polisac\u00e1rido de Recubrimiento; 5 Reconocimiento de anticuerpos anti-Vi unidos a la placa (conjugado anti-IgG de conejo-fosfatasa alcalina y 6 Revelado por reacci\u00f3n enzima-sustrato. Los par\u00e1metros de validaci\u00f3n estudiados y sus resultados fueron: 1 Precisi\u00f3n, expresada como coeficiente de variaci\u00f3n a tres niveles de concentraci\u00f3n de polisac\u00e1rido, comprendidos en el rango de su especificaci\u00f3n (35, 50 y 70 \u03bcg/mL y evaluada en t\u00e9rminos de repetibilidad; precisi\u00f3n intraensayos (cuatro analistas y reproducibilidad (seis analistas: \u00a3 20%; 2 Linealidad (100*R2: 99,68 %; 3 L\u00edmite de detecci\u00f3n: 0,5 \u03bcg/mL; 4 Exactitud (recuperaci\u00f3n para las tres diluciones de la muestra: entre 100 y 118%, y 5 Robustez: no influye 1,5 h de bloqueo (p = 0,52 ni \u00b1 5 min para leer placa (p = 0,56; influye grandemente la calidad del agua (p = 0,026, a favor del agua para inyecci\u00f3n. El ensayo es adecuado para los fines propuestos y es una medida de la inmunogenicidad in vitro del polisac\u00e1rido Vi.\n[Sunlight-induced inactivation of human Wa and porcine OSU rotaviruses in the presence of exogenous photosensitizers](http://repository.kaust.edu.sa/kaust/handle/10754/563024)\nRomero-Maraccini, Ofelia C.\n2013-10-01\nHuman rotavirus Wa and porcine rotavirus OSU solutions were irradiated with simulated solar UV and visible light in the presence of different photosensitizers dissolved in buffered solutions. For human rotavirus, the exogenous effects were greater than the endogenous effects under irradiation with full spectrum and UVA and visible light at 25 C. For porcine rotavirus, the exogenous effects with UVA and visible light irradiation were only observed at high temperatures, >40 C. The results from dark experiments conducted at different temperatures suggest that porcine rotavirus has higher thermostability than human rotavirus. Concentrations of 3\u2032-MAP excited triplet states of 1.8 fM and above resulted in significant human rotavirus inactivation. The measured excited triplet state concentrations of \u22640.45 fM produced by UVA and visible light irradiation of natural dissolved organic matter solutions were likely not directly responsible for rotavirus inactivation. Instead, the linear correlation for human rotavirus inactivation rate constant (kobs) with the phenol degradation rate constant (kexp) found in both 1 mM NaHCO3 and 1 mM phosphate-buffered solutions suggested that OH radical was a major reactive species for the exogenous inactivation of rotaviruses. Linear correlations between rotavirus kobs and specific UV254 nm absorbance of two river-dissolved organic matter and two effluent organic matter isolates indicated that organic matter aromaticity may help predict formation of radicals responsible for rotavirus inactivation. The results from this study also suggested that the differences in rotavirus strains should be considered when predicting solar inactivation of rotavirus in sunlit surface waters. \u00a9 2013 American Chemical Society.\n[Gene-Specific-Candidate-Driven Study to decipher Genetic Predisposition to Rotavirus Infection](https://www.canadianjbiotech.com/CAN_J_BIOTECH/Archives/v1/Special+Issue/cjb.2017-a65.pdf) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nKshitija Rane-Yadav\n2017-10-01\nFull Text Available Recent report of WHO shows 113000 children in India succumb to death due to Rotavirus diarrhea. Lack of knowledge about pathogenesis of virus has led to lack of therapy for severely infected patients. Previous studies have found that, animal rotavirus requires sialyl glycan moieties on cell surface for pathogenesis. Present study states that human rotaviruses also follows same path and this specificity of virus leads to host genetic predisposition for the infection as well as the disease. Two hundred children less than 5 years of age clinically suspected of viral diarrhea were screened for rotavirus infection. EDTA blood was processed for analyzing DNA sequences of various fucosyltransferase genes. Lewis antigens which are secretory form of ABO Histo Blood Group Antigens were correlated with the genotype of patient. Genetics of HBGA secretion, particularly, basis of Leb expression manifested by fucosyltransferase-2 enzyme was studied in healthy individuals and was compared in cases of rotavirus positive and negative diarrhea. Positive clinical isolates with various genotypes were purified from stool samples and gene for VP4 - surface spike protein was sequenced. Using Bioinformatics interphase, three dimensional protein structures were modeled and their functional domains were analyzed. All these modeled proteins were docked with Leb HBGA (Lewis-b Histo Blood Group Antigens using molecular docking software. In present study, to investigate possible association of the rotavirus with host genome, we screened highly suspected genes involved in expression of glycoproteins on enterocytes. This study performed for prevalent Indian strains of rotaviruses provides possible evidence that, VP8 domain of VP4 spike protein utilizes Leb surface antigen for attachment and entry to enterocytes in the intestine. The FUT2 and FUT3 gene has been found to show significant association with the rotavirus infection hence can serve as a biomarker for genetic\n[Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design.](https://www.ncbi.nlm.nih.gov/pubmed/27876198)\nSchwartz, Lauren M; Halloran, M Elizabeth; Rowhani-Rahbar, Ali; Neuzil, Kathleen M; Victor, John C\n2017-01-03\nThe test-negative design (TND), an epidemiologic method currently used to measure rotavirus vaccine (RV) effectiveness, compares the vaccination status of rotavirus-positive cases and rotavirus-negative controls meeting a pre-defined case definition for acute gastroenteritis. Despite the use of this study design in low-income settings, the TND has not been evaluated to measure rotavirus vaccine effectiveness. This study builds upon prior methods to evaluate the use of the TND for influenza vaccine using a randomized controlled clinical trial database. Test-negative vaccine effectiveness (VE-TND) estimates were derived from three large randomized placebo-controlled trials (RCTs) of monovalent (RV1) and pentavalent (RV5) rotavirus vaccines in sub-Saharan Africa and Asia. Derived VE-TND estimates were compared to the original RCT vaccine efficacy estimates (VE-RCTs). The core assumption of the TND (i.e., rotavirus vaccine has no effect on rotavirus-negative diarrhea) was also assessed. TND vaccine effectiveness estimates were nearly equivalent to original RCT vaccine efficacy estimates. Neither RV had a substantial effect on rotavirus-negative diarrhea. This study supports the TND as an appropriate epidemiologic study design to measure rotavirus vaccine effectiveness in low-income settings. Copyright \u00c2\u00a9 2016 The Author(s). Published by Elsevier Ltd.. All rights reserved.\n[Hospitalization of childhood rotavirus infection from Kuala Lumpur, Malaysia.](https://www.ncbi.nlm.nih.gov/pubmed/12969206)\nLee, W S; Veerasingam, P D; Goh, A Y T; Chua, K B\n2003-01-01\nTo determine the epidemiology of rotavirus gastroenteritis in children admitted to an urban hospital in a developing country from South-East Asia. Retrospective review of cases of acute gastroenteritis admitted to the children's ward of the University of Malaya Medical Centre, Kuala Lumpur, Malaysia, between 1996 and 1999. During the study period, 333 cases (24%) of 1362 stool samples, obtained from children admitted with acute diarrhoea, were positive for rotavirus. Acute gastroenteritis constituted 8.2%, and rotavirus infection 1.6% of all the paediatric admissions each year. Of the 271 cases analysed, 72% of the affected population were less than 2 years of age. Peak incidence of admissions was between January to March, and September to October. Dehydration was common (92%) but electrolyte disturbances, lactose intolerance (5.2%), prolonged diarrhoea (2.6%) and cow's milk protein intolerance was uncommon. No deaths were recorded. Rotavirus infection was a common cause of childhood diarrhoea that required hospital admission in an urban setting in Malaysia.\n[Dynamic Modeling of Cost-effectiveness of Rotavirus Vaccination, Kazakhstan](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3884708)\nFlem, Elmira; Latipov, Renat; Kuatbaeva, Ajnagul; Kristiansen, Ivar S\u00f8nb\u00f8\n2014-01-01\nThe government of Kazakhstan, a middle-income country in Central Asia, is considering the introduction of rotavirus vaccination into its national immunization program. We performed a cost-effectiveness analysis of rotavirus vaccination spanning 20 years by using a synthesis of dynamic transmission models accounting for herd protection. We found that a vaccination program with 90% coverage would prevent \u2248880 rotavirus deaths and save an average of 54,784 life-years for children <5 years of age. Indirect protection accounted for 40% and 60% reduction in severe and mild rotavirus gastroenteritis, respectively. Cost per life year gained was US $18,044 from a societal perspective and US $23,892 from a health care perspective. Comparing the 2 key parameters of cost-effectiveness, mortality rates and vaccine cost at\n[Zoonotic transmission of rotavirus in Denmark; a case report](http://www.forskningsdatabasen.dk/en/catalog/2389445944) [DEFF Research Database (Denmark)](http://forskningsbasen.deff.dk/?lang=eng)\nMidgley, Sofie; Gram, N.; Hjulsager, Charlotte Kristiane\nRotavirus type A infection is a common cause of hospitalisation of children. In addition, almost 30% of diagnosed persons in Denmark are adults. Rotavirus type A infection can also occur in a range of animals, including domestic dogs, cats, cattle, horses, and birds. There is some data suggesting...... direct transmission between animals and humans. Rotavirus genotyping is carried out in Denmark as part of the EUROTAnet vaccine study. In 2006 a total of 180 samples were successfully typed, and to date 85 samples from 2007 have been typed. 19 samples from pigs and 31 samples from cattle (from 2006...... and 2007) have also been typed. For the human samples all common human G types (1-4 and 9), as well the emerging G12 were identified, and were found in combination with the common P types ([4], [6], and [8]). Two samples contained a G8 P[goat] rotavirus (G8 98% identical to bovine G8, 96% identical to goat...\n[The Control of Rotavirus Gastroenteritis in The United States](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3540628)\nGlass, Roger I.; Parashar, Umesh; Patel, Manish; Tate, Jacqueline; Jiang, Baoming; Gentsch, Jon\n2012-01-01\nSince 2006, two new vaccines have been licensed to prevent rotavirus, the cause of 20% to 50% of severe acute gastroenteritis in young children worldwide. These vaccines have been implemented in national immunization programs in about 30 high- and middle-income countries, including the United States, and vaccine use has led to substantial decreases in diarrhea-related health care visits. In addition to reductions in diarrhea burden in vaccinated children, decreases have been observed in older, unvaccinated age groups in many settings, suggesting indirect benefits (i.e., herd immunity) from vaccination. Although the efficacy of these oral rotavirus vaccines is expectedly lower in developing countries in Asia and Africa, the public health benefits of vaccination in these settings, where more than 90% of the estimated 453,000 annual deaths from rotavirus occur, are likely to be substantial. Efforts continue to develop alternative rotavirus vaccines that could have a better efficacy and safety profile and may be less expensive. PMID:23303967\n[Delayed Dosing of Oral Rotavirus Vaccine Demonstrates Decreased Risk of Rotavirus Gastroenteritis Associated With Serum Zinc: A Randomized Controlled Trial.](https://www.ncbi.nlm.nih.gov/pubmed/27217217)\nColgate, E Ross; Haque, Rashidul; Dickson, Dorothy M; Carmolli, Marya P; Mychaleckyj, Josyf C; Nayak, Uma; Qadri, Firdausi; Alam, Masud; Walsh, Mary Claire; Diehl, Sean A; Zaman, K; Petri, William A; Kirkpatrick, Beth D\n2016-09-01\nRotavirus is the world's leading cause of childhood diarrheal death. Despite successes, oral rotavirus vaccines are less effective in developing countries. In an urban slum of Dhaka, we performed active diarrhea surveillance to evaluate monovalent G1P[8] rotavirus vaccine (RV1) efficacy and understand variables contributing to risk of rotavirus diarrhea (RVD). We performed a randomized controlled trial of monovalent oral rotavirus vaccine (RV1). Seven hundred healthy infants received RV1 or no RV1 (1:1) using delayed dosing (10 and 17 weeks) and were followed for 1 year. Intensive diarrhea surveillance was performed. The primary outcome was \u22651 episode of RVD. Nutritional, socioeconomic, and immunologic factors were assessed by logistic regression best-subsets analysis for association with risk of RVD and interactions with vaccine arm. Incidence of all RVD was 38.3 cases per 100 person-years. Per-protocol RV1 efficacy was 73.5% (95% confidence interval [CI], 45.8%-87.0%) against severe RVD and 51% (95% CI, 33.8%-63.7%) against all RVD. Serum zinc level (odds ratio [OR], 0.77; P = .002) and lack of rotavirus immunoglobulin A (IgA) seroconversion (OR, 1.95; P = .018) were associated with risk of RVD, independent of vaccination status. Water treatment and exclusive breastfeeding were of borderline significance. Factors not associated with RVD included height for age at 10 weeks, vitamin D, retinol binding protein, maternal education, household income, and sex. In an urban slum with high incidence of RVD, the efficacy of RV1 against severe RVD was higher than anticipated in the setting of delayed dosing. Lower serum zinc level and lack of IgA seroconversion were associated with increased risk of RVD independent of vaccination. NCT01375647. \u00a9 The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.\n[Vacuna contra la fiebre hemorr\u00e1gica argentina Candid#1 producida en la Argentina: Inmunogenicidad y seguridad Candid#1 vaccine against Argentine Hemorrhagic Fever produced in Argentina: Immunogenicity and safety](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802010000300002) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nDelia A. Enria\n2010-06-01\nFull Text Available Se realiz\u00f3 un estudio cl\u00ednico en 946 voluntarios humanos sanos, donde se compar\u00f3 la vacuna Candid#1 producida en Argentina con la elaborada en EE.UU., que hab\u00eda sido utilizada en estudios previos. Como objetivo primario se evalu\u00f3 la equivalencia en la eficacia utilizando como marcador subrogante a la inmunogenicidad medida por detecci\u00f3n de anticuerpos neutralizantes. Como objetivo secundario se evalu\u00f3 la equivalencia en inocuidad comparando las tasas de reacciones adversas. Ambas vacunas mostraron una tasa equivalente de inmunogenicidad ligeramente superior al 95.5%, que es la eficacia estimada para Candid #1 en estudios previos. No se observaron eventos adversos graves relacionados con la vacuna. Los eventos adversos generales considerados relacionados fueron de escasa significaci\u00f3n cl\u00ednica y de resoluci\u00f3n espont\u00e1nea o con tratamiento sintom\u00e1tico; se presentaron en los receptores de ambas vacunas en tasas equivalentes (29.9% para la vacuna fabricada en la Argentina y 35.0% para la fabricada en EE.UU., e incluyeron: cefalea, decaimiento, mialgias, plaquetopenia leve (A clinical study in 946 human volunteers was done to compare Candid #1 vaccine manufactured in Argentina with the vaccine produced in USA that had been previously used. The efficacy was evaluated using immunogenicity measured by the detection of neutralizing antibodies as a subrogate marker. Safety was evaluated comparing the rate of adverse events. Both vaccines showed a comparable rate of seroconversion, slighty higher than the efficacy estimated from previous studies (95.5%. There were no severe adverse events related to the vaccines. The general events considered related to the vaccines were not clinically relevant and disappeared either spontaneously or with symptomatic treatment. Similar rates of adverse events (29.9% for the Argentine vaccine and 35.0% for the USA vaccine were found for both vaccines. These included: headache, weakness, myalgias, mild low blood\n[Estudio de tolerancia local de la vacuna vax-TyVi\u00ae en ratas Sprague Dawley](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2005000100003&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nEligio Sosa Roble\n2005-05-01\nFull Text Available La vacuna antitifo\u00eddica vax-TyVi\u00ae consiste en una preparaci\u00f3n de polisac\u00e1rido capsular Vi de Salmonella typhi, el cual es diluido en una soluci\u00f3n buffer isot\u00f3nica soluci\u00f3n amortiguador, a la que se le a\u00f1ade fenol como preservo. Cada dosis de 0,5 mL contiene 25 \u03bcg de polisac\u00e1rido como sustancia activa. En nuestro pa\u00eds el esquema de vacunaci\u00f3n contra la fiebre tifoidea con vax- TyVi\u00ae se aplica a los alumnos de 9-10 a\u00f1os (5to grado, una 2da dosis a la edad de 12-13 a\u00f1os (8vo grado y una 3ra dosis a la edad de 16-17 a\u00f1os (11no grado. Adem\u00e1s, es vacunado el personal de riesgo de Salud P\u00fablica y el personal que manipula alimentos. En el presente trabajo se describe el ensayo de tolerancia local llevado a cabo con la vacuna vax-TyVi\u00ae durante su fase de estudios precl\u00ednicos, actualmente utilizada en la vacunaci\u00f3n contra la fiebre tifoidea en Cuba. Se emple\u00f3 un total de 170 ratas que fueron tratadas con la vacuna, su placebo (todos los componentes, excepto la materia prima activa, o que no recibieron tratamiento alguno (controles. Se realizaron observaciones cl\u00ednicas diarias durante todo el ensayo, se determin\u00f3 el consumo de agua y alimentos y se realizaron investigaciones anatomopatol\u00f3gicas a animales sacrificados 3, 7, 14, 21, 28, 35 y 42 d\u00edas despu\u00e9s de la inoculaci\u00f3n. No se observaron muertes ni s\u00edntomas de toxicidad; no se encontraron diferencias estad\u00edsticamente significativas entre los pesos vivos, el consumo de agua ni el de alimentos entre los grupos del ensayo. Tampoco se observaron lesiones anatomopatol\u00f3gicas que indicaran toxicidad por parte del producto inoculado. Los resultados permitieron concluir que la potencialidad de la vacuna vax-TyVi\u00ae para producir efectos adversos locales es baja.\n[La articulaci\u00f3n p\u00fablico-privada en la producci\u00f3n de vacunas en M\u00e9xico](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-11042016000400009&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nSilvia Tamez\nFull Text Available RESUMEN El art\u00edculo analiza el proceso de privatizaci\u00f3n de la atenci\u00f3n a la salud: la Articulaci\u00f3n P\u00fablico-Privada (APP. Espec\u00edficamente estudia la producci\u00f3n de vacunas em M\u00e9xico, tomando como caso los Laboratorios de Biol\u00f3gicos y Reactivos de M\u00e9xico, S.A. de C.V. (Birmex, empresa paraestatal, responsable de producir, distribuir e investigar biol\u00f3gicos y reactivos en M\u00e9xico. Interesa destacar el comportamiento de Birmex durante el periodo de la pandemia de influenza de 2009, producida por el virus de la influenza A subtipo H1N1. Los resultados muestran que gracias al impulso de las pol\u00edticas de liberalizaci\u00f3n y desregulaci\u00f3n, existe una apertura de los servicios p\u00fablicos a las corporaciones supranacionales.\n[Modern Views on Rotavirus Infection in Children: Epidemiological and Clinicopathogenetic Features](http://ai.zaslavsky.com.ua/article/view/82323) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nG.O. Lezhenko\n2014-04-01\nFull Text Available Based on the analysis of epidemiological, clinical and laboratory data characterizing the course of rotavirus infection in children of Zaporizhya region, there are provided the modern features of the disease. The authors marked dynamic changes in clinical and laboratory parameters of lactase deficiency, which occur during rotavirus infection in infants. The efficiency of Saccharomyces boulardii in complex treatment of rotavirus infection in children is shown.\n[Los precios de la carne vacuna en Buenos Aires colonial. Una interpelaci\u00f3n historiogr\u00e1fica e hist\u00f3rica](https://revistas.utadeo.edu.co/index.php/TyE/article/view/945/984) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAndrea Dupuy\n2014-12-01\nFull Text Available En el \u00e1mbito de los estudios de mercado, los precios constituyen los principales indicadores del comportamiento de la econom\u00eda, aun los de Antiguo R\u00e9gimen. El objetivo del presente trabajo es abordar el an\u00e1lisis de los precios de la carne vacuna de la ciudad de Buenos Aires colonial partiendo de la idea de que este mercado, al igual que los de las distintas ciudades hispanoamericanas, present\u00f3 a lo largo de la etapa colonial una regularidad predominante. Y aun cuando estuvo atravesado por situaciones cr\u00edticas de escasez, estos factores no lograron modificar sustancialmente, desde una mirada de largo plazo, las caracter\u00edsticas del mismo.\n[Characterization of rotavirus strains detected among children and adults with acute gastroenteritis in Ganozan, Saudi Arabia](https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=39120090) [International Nuclear Information System (INIS) ](http://inis.iaea.org/search/)\nKheyami, Ali M.; Dove, W.; Cunliffe, Nigel A.; Hart, C.A.; Areeshi, Mohammed Y.; Nakagomi, O.\n2008-01-01\nObjective was to assess the circulating rotavirus strains among hospitalized children and adults in Gizan City. This cross-sectional study was based in 5 hospitals in the Gizan area. Stool samples were collected between November 2004 and March 2005 from sequential patients with acute dehydrating diarrhea. Rotavirus antigen was detected in stool by enzyme-linked immunosorbent assay. The diversity of rotavirus strains was investigated using electropherotyping and reverse transcription-polymerase chain reaction amplification of the VP7 and VP4 genes (G and P genotyping). Rotavirus was detected in 54 of 454 (12%) subjects. The ages of those infected with rotavirus ranged from 15 days to 20 years, with a median age of 36 months. The highest rotavirus detection rate (24%) occurred in children in aged 48-59 months. Overall, 50 (93%) of strains could be assigned both a G- and P- type; G1P (8) was the most frequently detected strain type (n=48, 89%) with one rotavirus each of G2P (4) and G9P (8). Rotavirus strains circulating in Gizan would be well covered by current rotavirus vaccines. Rotavirus serotype G9 has been detected in Saudi Arabia for the first time. Continued surveillance of rotavirus strains is required. (author)\n[Milk Oligosaccharides Inhibit Human Rotavirus Infectivity in MA104 Cells.](https://www.ncbi.nlm.nih.gov/pubmed/28637685)\nLaucirica, Daniel R; Triantis, Vassilis; Schoemaker, Ruud; Estes, Mary K; Ramani, Sasirekha\n2017-09-01\nBackground: Oligosaccharides in milk act as soluble decoy receptors and prevent pathogen adhesion to the infant gut. Milk oligosaccharides reduce infectivity of a porcine rotavirus strain; however, the effects on human rotaviruses are less well understood. Objective: In this study, we determined the effect of specific and abundant milk oligosaccharides on the infectivity of 2 globally dominant human rotavirus strains. Methods: Four milk oligosaccharides-2'-fucosyllactose (2'FL), 3'-sialyllactose (3'SL), 6'-sialyllactose (6'SL), and galacto-oligosaccharides-were tested for their effects on the infectivity of human rotaviruses G1P[8] and G2P[4] through fluorescent focus assays on African green monkey kidney epithelial cells (MA104 cells). Oligosaccharides were added at different time points in the infectivity assays. Infections in the absence of oligosaccharides served as controls. Results: When compared with infections in the absence of glycans, all oligosaccharides substantially reduced the infectivity of both human rotavirus strains in vitro; however, virus strain-specific differences in effects were observed. Compared with control infections, the maximum reduction in G1P[8] infectivity was seen with 2'FL when added after the onset of infection (62% reduction, P rotaviruses in MA104 cells, primarily through an effect on the virus. Although breastfed infants are directly protected, the addition of specific oligosaccharides to infant formula may confer these benefits to formula-fed infants. \u00a9 2017 American Society for Nutrition.\n[Evaluaci\u00f3n de dos equipos inmunocromatogr\u00e1ficos comerciales para el diagn\u00f3stico r\u00e1pido de la infecci\u00f3n por rotavirus Evaluation of two immunochromatography kits for rapid diagnosis of rotavirus infections](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-75412008000300007) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nC. J. T\u00e9llez\n2008-09-01\nFull Text Available Se realiz\u00f3 un estudio prospectivo para evaluar dos equipos comerciales inmunocromatogr\u00e1ficos para el diagn\u00f3stico r\u00e1pido de infecci\u00f3n por rotavirus a partir de muestras fecales: VIKIA\u00ae Rota-Adeno, de bioM\u00e9rieux, y Simple Rota- Adeno, de Operon. Como m\u00e9todo de referencia se utiliz\u00f3 la transcripci\u00f3n reversa y reacci\u00f3n en cadena de la polimerasa (RT-PCR con cebadores espec\u00edficos del gen de la prote\u00edna VP7 de rotavirus del grupo A. La sensibilidad y la especificidad respecto de la RT-PCR fueron del 98,4% y 84,8% para el Simple Rota-Adeno, y del 100% y 24,2% para el VIKIA\u00ae Rota-Adeno. Es de destacar la baja especificidad de este \u00faltimo equipo diagn\u00f3stico, que present\u00f3 un elevado n\u00famero de falsos positivos, por lo que el valor predictivo de un resultado positivo es s\u00f3lo del 71,6%. Asimismo, se identificaron los genotipos de las cepas de rotavirus detectadas; la mayor\u00eda de ellas correspondieron al genotipo G9P(8 (65%, seguido de los genotipos G1P(8 (25,4% y G2P(8 (3,2%.A prospective study was conducted to evaluate two immunochromatography (ICG commercial kits for diagnosis of rotavirus infection, VIKIA\u00ae Rota-Adeno (bioM\u00e9rieux and Simple Rota-Adeno (Operon. Reverse transcriptase and polymerase chain reaction (RT-PCR with specific primers for the VP7 gene of group A rotavirus was used as the reference method. The sensitivity and specificity of the ICG tests compared with those of the reference method were 98.4% and 84.8%, respectively, for Simple Rota-Adeno (Operon, and 100% and 24.2% for VIKIA\u00ae Rota-Adeno (bioM\u00e9rieux. It is remarkable the low specificity of the latter method, which yields a high number of false positive results. The predictive value of a positive result by this method was only 71.6%. Most of the detected rotavirus strains corresponded to genotype G9P(8 (65%, followed by G1P(8 (25.4% and G2P(8 (3.2%.\n[Heterogeneity of Rotavirus Vaccine Efficacy Among Infants in Developing Countries.](https://www.ncbi.nlm.nih.gov/pubmed/27755463)\nGruber, Joann F; Hille, Darcy A; Liu, G Frank; Kaplan, Susan S; Nelson, Micki; Goveia, Michelle G; Mast, T Christopher\n2017-01-01\nRotavirus is the leading cause of severe diarrhea worldwide in young children. Although rotavirus vaccine efficacy is high in developed countries, efficacy is lower in developing countries. Here, we investigated heterogeneity of rotavirus vaccine efficacy by infant characteristics in developing countries. An exploratory, post hoc analysis was conducted using randomized controlled trial data of the pentavalent rotavirus vaccine (RV5) conducted in Africa and Asia (NCT00362648). Infants received either 3 doses of vaccine/placebo and were followed for up to 2 years. Within subgroups, vaccine efficacies and 95% confidence intervals (CIs) against rotavirus gastroenteritis (RVGE) were estimated using Poisson regression. We assessed heterogeneity of efficacy by age at first dose, gender, breastfeeding status and nutrition status. African children receiving the first dose at efficacy (23.7%; 95% CI: -8.2%-46.3%) than those vaccinated at \u22658 weeks (59.1%; 95% CI: 34.0%-74.6%). Marginally statistically significant differences were observed by age at first dose, gender and underweight status in Ghana and gender in Asian countries. Heterogeneity of efficacy was observed for age at first dose in African countries. This was an exploratory analysis; additional studies are needed to validate these results.\n[Vacuna atenuada de Salmonella como vector de ant\u00edgenos heter\u00f3logos](http://www.revistabiomedica.org/index.php/biomedica/article/view/1056) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nOscar G. G\u00f3mez\n2000-06-01\nFull Text Available Salmonella enterica, serotipo Typhi, es el agente etiol\u00f3gico de la fiebre tifoidea de los habitantes de las regiones m\u00e1s pobres del mundo y es, adem\u00e1s. el centro de atenci\u00f3n de muchos investigadores dados sus fascinantes mecanismos de invasi\u00f3n, multiplicaci\u00f3n intracelular y diseminaci\u00f3n intercelular que expresa in vivo e in vitro. Aunque estos mecanismos se asocian directamente con la patogenicidad y la severidad de la enfermedad, las mutaciones definidas en el cromosoma de Salmonella han permitido que estos mecanismos de virulencia se puedan utilizar en beneficio del hospedero. Las mutantes atenuadas de Salmonella son capaces de invadir las c\u00e9lulas M de la mucosa intestinal y de migrar a las c\u00e9lulas linfoides del sistema reticuloendotelial donde, en lugar de causar enfermedad, activan eficazmente las respuestas inmunes humoral y celular no s\u00f3lo contra el microorganismo mismo sino tambi\u00e9n contra aquellos antigenos heter\u00f3logos recombinantes que la bacteria pueda expresar y transportar. En la presente revisi\u00f3n, se discutir\u00e1n los avances m\u00e1s recientes en el campo de las vacunas vivas atenuadas de Salmonella, su evaluaci\u00f3n preclinica y clinica y, tambi\u00e9n, su aplicaci\u00f3n como vector de antigenos. Se dar\u00e1n a conocer las t\u00e9cnicas biomoleculares de clonaci\u00f3n y expresi\u00f3n procari\u00f3tica de las toxinas dift\u00e9rica, tet\u00e1nica y de pertusis. as\u00ed como de los ant\u00edgenos de Helicobacterpylori y de Plasmodium falciparum. Finalmente, se propone el uso de Salmonella atenuada como vector de vacunas de ADN para expresi\u00f3n eucari\u00f3tica de los ant\u00edgenos recombinantes. Los continuos esfuerzos cientificos y tecnol\u00f3gicos en el campo de la vacunaci\u00f3n con vectores vivos atenuados sugieren que Salmonella es una herramienta potencialmente \u00fatil para enfrentar el constante reto de la fiebre tifoidea. Igualmente, los estudios precl\u00ednicos y cl\u00ednicos de fase I demuestran la eficacia de la vacuna de Salmonella viva atenuada como vector de ant\u00edgenos heter\n[Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::861b6ca3ec07edefe4f370098a9ece41)\nFischer Walker, Christa L; Black, Robert E\n2011-01-01\nAbstract Background Diarrhea mortality remains a leading cause of child death and rotavirus vaccine an effective tool for preventing severe rotavirus diarrhea. New data suggest vaccine efficacy may vary by region. Methods We reviewed published vaccine efficacy trials to estimate a regional-specific effect of vaccine efficacy on severe rotavirus diarrhea and hospitalizations. We assessed the quality of evidence using a standard protocol and conducted meta-analyses where more than 1 data point ...\n[Rotavirus vaccines in Israel: Uptake and impact.](https://www.ncbi.nlm.nih.gov/pubmed/28281866)\nMuhsen, Khitam; Cohen, Daniel\n2017-07-03\nWe present an overview of the impact of universal rotavirus immunization with the pentavalent vaccine, RotaTeq, which was introduced in Israel in 2010. The vaccine is given free of charge at age 2, 4 and 6 months, with an 80% coverage that was shortly achieved during the universal immunization period. Compared to pre-universal immunization years (2008-2010), a reduction of 66-68% in the incidence of rotavirus gastroenteritis (RVGE) hospitalizations was observed in 2011-2015 among children aged 0-23 months in central and northern Israel. In southern Israel a reduction of 80-88% in RVGE hospital visit rate was found among Jewish children aged 0-23 months in 2011-2013. Among Bedouins, the respective decline was 62-75%. A significant reduction of 59% was also observed in RVGE clinic visits, presumably representing less severe illness. Indirect benefit was evident in children aged 24-59 months who were ineligible for universal immunization. Vaccine effectiveness against RVGE hospitalization was estimated at 86% in children aged 6-23 months. Changes in the circulating rotavirus genotypes occurred but the contribution of vaccine induced immune pressure is unclear. Universal rotavirus immunization was followed by an impressive decrease in the burden of RVGE in young children in Israel, likely attributed to good vaccine coverage and effectiveness.\n[MAVS protein is attenuated by rotavirus nonstructural protein 1.](http://europepmc.org/articles/PMC3958477?pdf=render) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nSatabdi Nandi\nFull Text Available Rotavirus is the single, most important agent of infantile gastroenteritis in many animal species, including humans. In developing countries, rotavirus infection attributes approximately 500,000 deaths annually. Like other viruses it establishes an intimate and complex interaction with the host cell to counteract the antiviral responses elicited by the cell. Among various pattern recognition receptors (PAMPs of the host, the cytosolic RNA helicases interact with viral RNA to activate the Mitochondrial Antiviral Signaling protein (MAVS, which regulates cellular interferon response. With an aim to identify the role of different PAMPs in rotavirus infected cell, MAVS was found to degrade in a time dependent and strain independent manner. Rotavirus non-structural protein 1 (NSP1 which is a known IFN antagonist, interacted with MAVS and degraded it in a strain independent manner, resulting in a complete loss of RNA sensing machinery in the infected cell. To best of our knowledge, this is the first report on NSP1 functionality where a signaling protein is targeted unanimously in all strains. In addition NSP1 inhibited the formation of detergent resistant MAVS aggregates, thereby averting the antiviral signaling cascade. The present study highlights the multifunctional role of rotavirus NSP1 and reinforces the fact that the virus orchestrates the cellular antiviral response to its own benefit by various back up strategies.\n[History of rotavirus research in children in Malawi: the pursuit of a killer](https://www.ajol.info/index.php/mmj/article/view/45631) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nRotavirus gastroenteritis is a major health problem among Malawian children. Studies spanning 20 years have described the importance, epidemiology and viral characteristics of rotavirus infections in the country. Despite a wide diversity of circulating rotavirus strains causing severe disease in young infants, a clinical trial ...\n[Immunogenicity and tolerability of inactivated flu vaccine In high risk and healthy children Inmunogenicidad y tolerancia de la vacuna inactivada anti-influenza en ni\u00f1os en alto riesgo y en controles sanos](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802007000400005) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMaria Luisa Avila Aguero\n2007-08-01\nFull Text Available We conducted this open study to evaluate the immunogenicity and safety of the inactivated influenza vaccine, Imovax Gripe\u00ae in 154 children between 6 and 36 months of age at high risk of influenza- related complications, and in a reference group of 64 healthy children. The study was conducted over two flu seasons, in which the vaccine contained the same A strains but different B strains. The results for the A/H3N2 and A/H1N1 strains from the two flu seasons were pooled, but those for the B strains were not. Anti-hemagglutinin (HA antibody titers were determined before, and one month after each vaccination, and safety was evaluated based on diary card reporting any adverse event observed, either included or not in the list of \"solicited events\". Within each group of vaccines, the seroconversion rates, seroprotection rates, and ratio of post- to prevaccination geometric mean titers (GMTR for the A/H3N2 and the A/H1N1 strains fulfilled all requirements of the criteria of the European Union Committee for Proprietary Medicinal Products (CPMP. The immune responses in high-risk and in healthy children were similar, and consistent with those observed in previous studies conducted in healthy children. The vaccine was equally well tolerated by all study groups. Reactogenicity was low and similar in both high-risk and healthy children. Overall from 9.5% to 15.4% of at-risk children and 12% of healthy children reported a solicited local reaction; 23.0 to 28.8% of high-risk and 25.3% of healthy children reported a solicited systemic reaction. The study results provide support for vaccination of children at high-risk of influenza related complications.Se realiz\u00f3 un estudio cl\u00ednico abierto para evaluar la inmunogen\u00edcidad y la seguridad de la vacuna inactivada anti-influenza, Imovax Gripe\u00ae, en 154 ni\u00f1os entre 6 y 36 meses de edad con alto riesgo de complicaciones ligadas a la influenza, y en un grupo de referencia de 64 ni\u00f1os sanos. El estudio fue\n[Rotavirus - Global research density equalizing mapping and gender analysis.](https://www.ncbi.nlm.nih.gov/pubmed/26611203)\nK\u00f6ster, Corinna; Klingelh\u00f6fer, Doris; Groneberg, David A; Schwarzer, Mario\n2016-01-02\nRotaviruses are the leading reason for dehydration and severe diarrheal disease and in infants and young children worldwide. An increasing number of related publications cause a crucial challenge to determine the relevant scientific output. Therefore, scientometric analyses are helpful to evaluate quantity as well as quality of the worldwide research activities on Rotavirus. Up to now, no in-depth global scientometric analysis relating to Rotavirus publications has been carried out. This study used scientometric tools and the method of density equalizing mapping to visualize the differences of the worldwide research effort referring to Rotavirus. The aim of the study was to compare scientific output geographically and over time by using an in-depth data analysis and New quality and quantity indices in science (NewQIS) tools. Furthermore, a gender analysis was part of the data interpretation. We retrieved all Rotavirus-related articles, which were published on \"Rotavirus\" during the time period from 1900 to 2013, from the Web of Science by a defined search term. These items were analyzed regarding quantitative and qualitative aspects, and visualized with the help of bibliometric methods and the technique of density equalizing mapping to show the differences of the worldwide research efforts. This work aimed to extend the current NewQIS platform. The 5906 Rotavirus associated articles were published in 138 countries from 1900 to 2013. The USA authored 2037 articles that equaled 34.5% of all published items followed by Japan with 576 articles and the United Kingdom - as the most productive representative of the European countries - with 495 articles. Furthermore, the USA established the most cooperations with other countries and was found to be in the center of an international collaborative network. We performed a gender analysis of authors per country (threshold was set at a publishing output of more than 100 articles by more than 50 authors whose names could be\n[Cost-effectiveness of rotavirus immunization in Vietnam: Results and challenges](https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F8c77f3fc-a978-4e42-9dda-1f2a84d6ef7a/uquery/rotavirus/id/1/Language/EN)\nTu, H.A.T.; Rozenbaum, M.; Coyte, P.C.; Li, S.C.; Postma, M.J.\n2011-01-01\nOBJECTIVES: To assess the cost-effectiveness of universal rotavirus immunization, explicitly the use of Rotateq\u00ae and affordability of implementing rotavirus immunization based on the Global Alliance for Vaccines and Immunization (GAVI)-subsidized vaccine price in the context of Vietnamese health\n[Identification of co-infection by rotavirus and parvovirus in dogs with gastroenteritis in Mexico](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1517-83822017000400769&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAriadna Flores Ortega\nFull Text Available ABSTRACT This is the first report on circulating canine rotavirus in Mexico. Fifty samples from dogs with gastroenteritis were analyzed used polymerase chain reaction and reverse transcription polymerase chain reaction in order to identify parvovirus and rotavirus, respectively; 7% of dogs were infected with rotavirus exclusively, while 14% were co-infected with both rotavirus and parvovirus; clinical signs in co-infected dogs were more severe.\n[Effect of human rotavirus vaccine on severe diarrhea in African infants.](https://www.ncbi.nlm.nih.gov/pubmed/20107214)\nMadhi, Shabir A; Cunliffe, Nigel A; Steele, Duncan; Witte, Desir\u00e9e; Kirsten, Mari; Louw, Cheryl; Ngwira, Bagrey; Victor, John C; Gillard, Paul H; Cheuvart, Brigitte B; Han, Htay H; Neuzil, Kathleen M\n2010-01-28\nRotavirus is the most common cause of severe gastroenteritis among young children worldwide. Data are needed to assess the efficacy of the rotavirus vaccine in African children. We conducted a randomized, placebo-controlled, multicenter trial in South Africa (3166 infants; 64.1% of the total) and Malawi (1773 infants; 35.9% of the total) to evaluate the efficacy of a live, oral rotavirus vaccine in preventing severe rotavirus gastroenteritis. Healthy infants were randomly assigned in a 1:1:1 ratio to receive two doses of vaccine (in addition to one dose of placebo) or three doses of vaccine--the pooled vaccine group--or three doses of placebo at 6, 10, and 14 weeks of age. Episodes of gastroenteritis caused by wild-type rotavirus during the first year of life were assessed through active follow-up surveillance and were graded with the use of the Vesikari scale. A total of 4939 infants were enrolled and randomly assigned to one of the three groups; 1647 infants received two doses of the vaccine, 1651 infants received three doses of the vaccine, and 1641 received placebo. Of the 4417 infants included in the per-protocol efficacy analysis, severe rotavirus gastroenteritis occurred in 4.9% of the infants in the placebo group and in 1.9% of those in the pooled vaccine group (vaccine efficacy, 61.2%; 95% confidence interval, 44.0 to 73.2). Vaccine efficacy was lower in Malawi than in South Africa (49.4% vs. 76.9%); however, the number of episodes of severe rotavirus gastroenteritis that were prevented was greater in Malawi than in South Africa (6.7 vs. 4.2 cases prevented per 100 infants vaccinated per year). Efficacy against all-cause severe gastroenteritis was 30.2%. At least one serious adverse event was reported in 9.7% of the infants in the pooled vaccine group and in 11.5% of the infants in the placebo group. Human rotavirus vaccine significantly reduced the incidence of severe rotavirus gastroenteritis among African infants during the first year of life. (Clinical\n[Group A rotavirus gastroenteritis: post-vaccine era, genotypes and zoonotic transmission](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4943361)\nLuchs, Adriana; Timenetsky, Maria do Carmo Sampaio Tavares\n2016-01-01\nABSTRACT This article provides a review of immunity, diagnosis, and clinical aspects of rotavirus disease. It also informs about the changes in epidemiology of diarrheal disease and genetic diversity of circulating group A rotavirus strains following the introduction of vaccines. Group A rotavirus is the major pathogen causing gastroenteritis in animals. Its segmented RNA genome can lead to the emergence of new or unusual strains in human populations via interspecies transmission and/or reassortment events. PMID:27462899\n[Pagos por desempe\u00f1o para mejorar el estado nutricional infantil: impacto de los convenios de apoyo presupuestario en tres regiones peruanas con alta prevalencia de desnutrici\u00f3n cr\u00f3nica infantil, 2010-2014](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1726-46342017000300365&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nViviana Cruzado de la Vega\nFull Text Available RESUMEN Objetivos. Estimar el impacto de un esquema de pago por desempe\u00f1o, denominado convenios de apoyo presupuestario, aplicado por el Gobierno a las tres regiones con mayores tasas de desnutrici\u00f3n cr\u00f3nica infantil (DCI en 2008, Apurimac, Ayacucho y Huancavelica, sobre indicadores de cobertura de servicios de cuidado infantil (vacunaci\u00f3n, controles de crecimiento y desarrollo infantil, suplemento de hierro y del estado nutricional del ni\u00f1o (desnutrici\u00f3n, anemia, diarrea. Mediante estos convenios se transfer\u00edan recursos a los presupuestos de dichas regiones condicionados al cumplimiento de compromisos de gesti\u00f3n y metas de cobertura con el objetivo de mejorar el estado nutricional infantil. Materiales y m\u00e9todos. A partir de los datos de la Encuesta Demogr\u00e1fica y de Salud Familiar de 2008 a 2014, se compara la evoluci\u00f3n en los indicadores evaluados de una muestra de ni\u00f1os que residen en los \u00e1mbitos donde se suscribieron los convenios y una muestra de control, mientras los convenios estuvieron vigentes y en los a\u00f1os posteriores para reportar el estimador de diferencias en diferencias del impacto promedio de los convenios Resultados. se encuentran impactos positivos sobre el incremento de coberturas de vacunas del esquema b\u00e1sico y de la vacuna rotavirus y, a trav\u00e9s de ellos, en la reducci\u00f3n de la ocurrencia de diarrea y desnutrici\u00f3n. Conclusiones. el esquema habr\u00eda sido efectivo en activar la cadena mayor cobertura de vacunas y menor DCI, pero no parece mejorar la cobertura de otras prestaciones como las atenciones de crecimiento y desarrollo del ni\u00f1o y entrega de suplementos de hierro al ni\u00f1o y gestante.\n[Rotavirus Virus-Like Particles as Surrogates in Environmental Persistence and Inactivation Studies](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=444800)\nCaballero, Santiago; Abad, F. Xavier; Loisy, Fabienne; Le Guyader, Fran\u00e7oise S.; Cohen, Jean; Pint\u00f3, Rosa M.; Bosch, Albert\n2004-01-01\nVirus-like particles (VLPs) with the full-length VP2 and VP6 rotavirus capsid proteins, produced in the baculovirus expression system, have been evaluated as surrogates of human rotavirus in different environmental scenarios. Green fluorescent protein-labeled VLPs (GFP-VLPs) and particles enclosing a heterologous RNA (pseudoviruses), whose stability may be monitored by flow cytometry and antigen capture reverse transcription-PCR, respectively, were used. After 1 month in seawater at 20\u00b0C, no significant differences were observed between the behaviors of GFP-VLPs and of infectious rotavirus, whereas pseudovirus particles showed a higher decay rate. In the presence of 1 mg of free chlorine (FC)/liter both tracers persisted longer in freshwater at 20\u00b0C than infectious viruses, whereas in the presence of 0.2 mg of FC/liter no differences were observed between tracers and infectious rotavirus at short contact times. However, from 30 min of contact with FC onward, the decay of infectious rotavirus was higher than that of recombinant particles. The predicted Ct value for a 90% reduction of GFP-VLPs or pseudoviruses induces a 99.99% inactivation of infectious rotavirus. Both tracers were more resistant to UV light irradiation than infectious rotavirus in fresh and marine water. The effect of UV exposure was more pronounced on pseudovirus than in GFP-VLPs. In all types of water, the UV dose to induce a 90% reduction of pseudovirus ensures a 99.99% inactivation of infectious rotavirus. Recombinant virus surrogates open new possibilities for the systematic validation of virus removal practices in actual field situations where pathogenic agents cannot be introduced. PMID:15240262\n[Rotavirus gastroenteritis in children in 4 regions in Brazil: a hospital-based surveillance study.](https://www.ncbi.nlm.nih.gov/pubmed/19817590)\nMunford, Veridiana; Gilio, Alfredo Elias; de Souza, Eloisa Correa; Cardoso, Debora Morais; Cardoso, Divina das Dores de Paula; Borges, Ana Maria Tavares; Costa, Paulo Sergio Sucasas da; Melga\u00e7o, Irene Angela Melo; Rosa, Humberto; Carvalho, Paulo Roberto Antonacci; Goldani, Marcelo Zubaran; Moreira, Edson Duarte; Santana, Ciria; El Khoury, Antoine; Ikedo, Fabio; R\u00e1cz, Maria Lucia\n2009-11-01\nRotavirus is a major cause of gastroenteritis in children. Knowledge of rotavirus genotypes is important for vaccination strategies. During 2005-2006, rotavirus surveillance studies were conducted in S\u00e3o Paulo, Salvador, Goi\u00e2nia, and Porto Alegre, Brazil. Stool samples were collected from children <5 years of age who had diarrhea and were screened by the Rotaclone Enzyme Immunoassay for the presence of rotavirus. Confirmed rotavirus-positive samples were characterized for P and G genotypes by reverse-transcriptase polymerase chain reaction. A total of 510 stool samples were collected. Of these, 221 (43.3%) were positive for rotavirus. Overall, G9 was the predominant G type, followed by G2, and G1; P[4] and P[8] were the predominant P types. The most frequent G/P genotype combination detected was G2P[4], followed by G9P[8], G9P[4], and G1P[8]. G2P[4] was the predominant type in Goi\u00e2nia and Salvador; G9P[8] and G1P[8] were predominant in S\u00e3o Paulo and Porto Alegre, respectively. The prevalence, seasonality, and genotype distribution of rotavirus infection varied in different regions in Brazil. With immunization programs, continuous monitoring of rotavirus types is important to detect novel and emerging strains.\n[Evidence for presumable feline origin of sporadic G6P[9] rotaviruses in humans.](https://www.ncbi.nlm.nih.gov/pubmed/29860097)\nPietsch, Corinna; Liebert, Uwe G\n2018-05-31\nSpecies A rotaviruses are highly diverse and impose a substantial burden to human and animal health. Interspecies transmission between livestock, domestic animals and humans is commonly observed, but spread of animal-like rotaviruses within the human population is limited. During the continued monitoring of rotavirus strains in Germany, an unusual G6P[9] rotavirus strain was detected in feces of a child. The complete rotavirus coding sequences revealed a unique G6-P[9]-I2-R2-C2-M2-A3-N2-T3-E2-H3 genotype constellation. The virus was phylogenetically related to feline G3P[9] strains and other human G6P[9] rotaviruses of presumable zoonotic origin. Analysis of primer binding sites of G6 specific genotyping revealed further evidence of a G6P[9] feline reservoir. Moreover, substantial deficits of conventional semi-nested PCR genotyping approaches in detecting contemporary G6P[9] were revealed. Rotavirus strain GER29-14 most likely resulted from a direct or recent interspecies transmission from a cat to human. Further studies could assess nucleic acid sequences and genotype constellations of feline rotavirus to confirm the likely feline origin of sporadic human G6P[9] strains. Copyright \u00a9 2018 Elsevier B.V. All rights reserved.\n[Impacto de la vacuna conjugada en la incidencia de meningitis por Haemophilus influenzae en el Distrito Federal de Brasil: resultados de tres a\u00f1os de seguimiento Impact of anti-Hib conjugate vaccine on the incidence of Haemophilus influenzae meningitis in Brazil's Federal District: results of a three-year follow-up](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892006000100005) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nHelen Selma de Abreu Freitas\n2006-01-01\nFull Text Available INTRODUCCI\u00d3N: Haemophilus influenzae del serotipo b (Hib es todav\u00eda un importante agente causal de procesos infecciosos. Su variante encapsulada es la causa de formas invasoras de enfermedad. En algunas poblaciones abor\u00edgenes, la incidencia de enfermedades causadas por Hib es mayor de 400 por 100 000 ni\u00f1os menores de 5 a\u00f1os. En los decenios de 1970 y 1980, tras la identificaci\u00f3n de anticuerpos protectores contra la c\u00e1psula de Hib, se desarrollaron vacunas contra este microorganismo. OBJETIVO: Estimar el impacto que ha tenido desde su introducci\u00f3n, en marzo de 1998, la vacunaci\u00f3n contra Hib en el Distrito Federal de Brasil. M\u00c9TODO: Con los datos de base poblacional del Sistema de Vigilancia de la Secretar\u00eda de Salud del Distrito Federal de Brasil, se compararon las tasas de incidencia de meningitis correspondientes a los tres a\u00f1os anteriores y posteriores a la introducci\u00f3n de la vacuna. Se compararon tambi\u00e9n los cambios en su tendencia. RESULTADOS: Al comparar los dos per\u00edodos se advierte una reducci\u00f3n de aproximadamente 90% en la incidencia de meningitis por Hib, cambio que no ocurre en el caso de las meningitis ocasionadas por otros agentes bacterianos. Se registr\u00f3 un aumento proporcional de los casos entre los ni\u00f1os de 6 meses de edad y menores, debido a la reducci\u00f3n de la incidencia entre los mayores de esa edad. CONCLUSI\u00d3N: La introducci\u00f3n de la vacuna conjugada en el Distrito Federal de Brasil redujo de 168 por 100 000 (1995-1997 a 15 por 100 000 (1999-2001 la incidencia de meningitis por Hib entre ni\u00f1os de 7 a 35 meses. Esto representa una reducci\u00f3n de 91,1%.INTRODUCTION: Type b Haemophilus influenzae (Hib continues to be an important causative agent of various infectious processes, and its encapsulated strains cause invasive disease. In some aboriginal populations, the incidence of Hib infections in children under five is greater than 400 per 100 000. In the seventies and eighties, vaccines against Hib were\n[Geo(spatial) Health Investigation of Rotavirus in an Endemic Region: Hydroclimatic Influences and Epidemiology of Rotavirus in Bangladesh](http://adsabs.harvard.edu/abs/2016AGUFMPA21B2210H)\nHasan, M. A.; Akanda, A. S.; Jutla, A.; Colwell, R. R.\n2016-12-01\nRotavirus is the leading cause of severe dehydrating diarrhea among children under 5. Over 80% of the approximate half a million child deaths every year occur in South Asia and sub-Saharan Africa alone. Although less explored than cholera as a climate driven and influenced global health problem, recent studies have showed that the disease shown strong seasonality and spatio-temporal variability depending on regional hydroclimatic and local environmental conditions. Understanding the epidemiology of this disease, especially the spatio-temporal incidence patterns with respect to environmental factors is vitally important to allow for identification of \"hotspots\", preventative preparations, and vaccination strategies to improve wellbeing of the vulnerable populations. With climate change, spatio-temporal signatures and footprints of the disease are changing along with increasing burden. However, a robust understanding of the relationships between rotavirus epidemiology and hydroclimatic drivers is yet to be developed. In this study, we evaluate the seasonality and epidemiologic characteristics of rotavirous infection and its spatio-temporal incidence patterns with respect to regional hydroclimatic variables and their extremes in an endemic region in South Asia. Hospital-based surveillance data from different geographic locations allowed us to explore the detailed spatial and temporal characteristics of rotavirus propagation under the influence of climate variables in both coastal and inland areas. The rotavirus transmission patterns show two peaks in a year in the capital city of Dhaka, where winter season (highest in January) shows a high peak and the July-August monsoon season shows a smaller peak. Correlation with climate variables revealed that minimum temperature has strong influence on the winter season outbreak, while rainfall extremes show a strong positive association with the secondary monsoon peak. Spatial analysis also revealed that humidity and soil\n[Prevalence and factors associated with rotavirus infection among children admitted with acute diarrhea in Uganda](http://www.biomedcentral.com/1471-2431/10/69) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMworozi Edison A\n2010-09-01\nFull Text Available Abstract Background Rotavirus remains the commonest cause of severe dehydrating diarrhea among children worldwide. Children in developing countries die more because of several factors including poorer access to hydration therapy and greater prevalence of malnutrition. Hitherto, the magnitude of rotavirus disease in Uganda has remained unknown. This study was therefore done to determine the prevalence and factors associated with rotavirus infection among children aged 3-59 months admitted with acute diarrhea to paediatric emergency ward of Mulago Hospital, Uganda Methods Three hundred and ninety children, aged between 3-59 months with acute diarrhoea were recruited. The clinical history, socio-demographic characteristics, physical examination findings and laboratory investigations were recorded. Stool samples were tested for rotavirus antigens using the DAKO IDEIA rotavirus EIA detection kit. Results The prevalence of rotavirus infection was 45.4%. On multivariate analysis rotavirus was significantly associated with a higher education (above secondary level of the mother [OR 1.8; 95% CI 1.1-2.7]; dehydration [OR 1.8; 95% CI 1.1-3.0] and breastfeeding [OR 2.6; 95% CI 1.4-4.0]. Although age was significantly associated with rotavirus on bivariate analysis; this association disappeared on multivariate analysis. No significant association was found between rotavirus infection and nutritional status, HIV status and attendance of day care or school. Conclusions Rotavirus infection is highly prevalent among children with acute diarrhoea admitted to Mulago Hospital in Uganda.\n[Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::c23dfc7fe0e27ffdb16f685de4ddbe7f)\nSchwartz, Lauren M.; Halloran, M. Elizabeth; Rowhani-Rahbar, Ali; Neuzil, Kathleen M.; Victor, John C.\n2017-01-01\nBackground The test-negative design (TND), an epidemiologic method currently used to measure rotavirus vaccine (RV) effectiveness, compares the vaccination status of rotavirus-positive cases and rotavirus-negative controls meeting a pre-defined case definition for acute gastroenteritis. Despite the use of this study design in low-income settings, the TND has not been evaluated to measure rotavirus vaccine effectiveness. Methods This study builds upon prior methods to evaluate the use of the T...\n[Estimated reductions in hospitalizations and deaths from childhood diarrhea following implementation of rotavirus vaccination in Africa.](https://www.ncbi.nlm.nih.gov/pubmed/28832219)\nShah, Minesh P; Tate, Jacqueline E; Mwenda, Jason M; Steele, A Duncan; Parashar, Umesh D\n2017-10-01\nRotavirus is the leading cause of hospitalizations and deaths from diarrhea. 33 African countries had introduced rotavirus vaccines by 2016. We estimate reductions in rotavirus hospitalizations and deaths for countries using rotavirus vaccination in national immunization programs and the potential of vaccine introduction across the continent. Areas covered: Regional rotavirus burden data were reviewed to calculate hospitalization rates, and applied to under-5 population to estimate baseline hospitalizations. Rotavirus mortality was based on 2013 WHO estimates. Regional pre-licensure vaccine efficacy and post-introduction vaccine effectiveness studies were used to estimate summary effectiveness, and vaccine coverage was applied to calculate prevented hospitalizations and deaths. Uncertainties around input parameters were propagated using boot-strapping simulations. In 29 African countries that introduced rotavirus vaccination prior to end 2014, 134,714 (IQR 112,321-154,654) hospitalizations and 20,986 (IQR 18,924-22,822) deaths were prevented in 2016. If all African countries had introduced rotavirus vaccines at benchmark immunization coverage, 273,619 (47%) (IQR 227,260-318,102) hospitalizations and 47,741 (39%) (IQR 42,822-52,462) deaths would have been prevented. Expert commentary: Rotavirus vaccination has substantially reduced hospitalizations and deaths in Africa; further reductions are anticipated as additional countries implement vaccination. These estimates bolster wider introduction and continued support of rotavirus vaccination programs.\n[Epidemiology of rotavirus infection among young children with acute diarrhoea in Burkina Faso](http://www.biomedcentral.com/1471-2431/10/94) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nHaukka Kaisa\n2010-12-01\nFull Text Available Abstract Background In anticipation of vaccine introduction, we assessed epidemiology of rotavirus disease among children visiting medical centre due to acute diarrhoea in Ouagadougou, Burkina Faso. Methods Between November 2008 and February 2010, stool specimens from 447 children less than 5 years of age suffering from diarrhoea were tested for the presence of rotavirus by antigen detection using an immunochromatographic test. Sociodemographic, environmental and clinical factors were assessed during the study. Results Rotavirus antigen was detected in 151 (33.8% of the patients. Most of the cases (94.2% were in children Conclusions The results of this study underscore the need to control rotavirus infections among young children in Burkina Faso and may argue a decision on the introduction of rotavirus vaccine in Burkina Faso.\n[Identification of co-infection by rotavirus and parvovirus in dogs with gastroenteritis in Mexico.](https://www.ncbi.nlm.nih.gov/pubmed/28716388)\nOrtega, Ariadna Flores; Mart\u00ednez-Casta\u00f1eda, Jos\u00e9 Sim\u00f3n; Bautista-G\u00f3mez, Linda G; Mu\u00f1oz, Ra\u00fal Fajardo; Hern\u00e1ndez, Israel Quijano\nThis is the first report on circulating canine rotavirus in Mexico. Fifty samples from dogs with gastroenteritis were analyzed used polymerase chain reaction and reverse transcription polymerase chain reaction in order to identify parvovirus and rotavirus, respectively; 7% of dogs were infected with rotavirus exclusively, while 14% were co-infected with both rotavirus and parvovirus; clinical signs in co-infected dogs were more severe. Copyright \u00a9 2017 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. All rights reserved.\n[Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/22520136)\nMadhi, S A; Kirsten, M; Louw, C; Bos, P; Aspinall, S; Bouckenooghe, A; Neuzil, K M; Steele, A D\n2012-04-27\nHuman rotavirus vaccine (HRV; i.e., Rotarix) reduced the incidence of severe rotavirus gastroenteritis (RVGE) by 77% (95% Confidence interval: 56-88%) during the first year of life in South Africa. Persistence of HRV-derived protection against RVGE during subsequent rotavirus seasons, although evident in industrialized settings, remains to be established in African settings. This study reports on the efficacy of HRV against severe RVGE over two consecutive rotavirus seasons in South African children. A prospective, double-blind, placebo controlled multi-centered trial in South Africa and Malawi randomly assigned infants in a 1:1:1 ratio to receive either two (10 and 14 weeks; HRV_2D) or three (6, 10 and 14 weeks; HRV_3D) doses of HRV or placebo. The primary analysis involved pooling of HRV_2D and HRV_3D arms. Episodes of gastroenteritis caused by wild-type rotavirus were identified through active follow-up surveillance and graded by the Vesikari scale. 1339 infants (447 in the HRV_2D group, 447 in the HRV_3D group and 445 in the placebo group) were enrolled in Year 2 of the study, including 1035 (77.3%) who were followed up over two consecutive rotavirus seasons (i.e., Cohort 2 subjects). Rotarix was associated with ongoing protection against severe RVGE, preventing 2.5 episodes per 100 vaccinated children over two consecutive rotavirus seasons; vaccine efficacy: 59% (95% Confidence interval: 1-83%). An exploratory analysis indicated better immunogenicity (among Cohort 1 subjects) and a higher point-efficacy estimate over two seasons in the HRV_3D compared to HRV_2D arms of the study in Cohort 2 subjects. Rotarix is associated with significant reductions in severe gastroenteritis episodes through 2 years of life among South African children. Further research is needed to determine the optimal dosing schedule of Rotarix in providing long-term protection against rotavirus illness in African children. Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.\n[Differences of Rotavirus Vaccine Effectiveness by Country: Likely Causes and Contributing Factors](http://www.mdpi.com/2076-0817/6/4/65) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nUlrich Desselberger\n2017-12-01\nFull Text Available Rotaviruses are a major cause of acute gastroenteritis in infants and young children worldwide and in many other mammalian and avian host species. Since 2006, two live-attenuated rotavirus vaccines, Rotarix\u00ae and RotaTeq\u00ae, have been licensed in >100 countries and are applied as part of extended program of vaccination (EPI schemes of childhood vaccinations. Whereas the vaccines have been highly effective in high-income countries, they were shown to be considerably less potent in low- and middle-income countries. Rotavirus-associated disease was still the cause of death in >200,000 children of <5 years of age worldwide in 2013, and the mortality is concentrated in countries of sub-Saharan Africa and S.E. Asia. Various factors that have been identified or suggested as being involved in the differences of rotavirus vaccine effectiveness are reviewed here. Recognition of these factors will help to achieve gradual worldwide improvement of rotavirus vaccine effectiveness.\n[B\u00fasqueda e identificaci\u00f3n de nuevos candidatos a vacuna contra la malaria producida por Plasmodium vivax](https://revistas.unal.edu.co/index.php/actabiol/article/view/27394) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAndr\u00e9s Mauricio Pinz\u00f3n Velasco\n2004-07-01\nbioinform\u00e1ticas, estableciendo diversos patrones de alineamiento, as\u00ed como niveles de similitud no menores al 40%. A pesar de un riguroso enmascaramiento tanto de las secuencias prot\u00e9icas de P. falciparum, como del genoma de P. vivax, en este \u00faltimo fue evidente una alta presencia de regiones repetitivas que no fueron enmascaradas por ninguna de las fuentes de ADN repetitivo presente en la base de datos de REPBASE, lo cual lleva a pensar que dichas regiones pueden ser espec\u00edficas de este tipo de organismos. Finalmente se encontraron coincidencias entre 76 secuencias proteicas con actividad antig\u00e9nica de P. falciparum y el genoma hasta ahora secuenciado de P. vivax, que cumpl\u00edan con los requisitos m\u00ednimos para establecer los niveles de coincidencia, entre las cuales se determin\u00f3 que cuatro constituyen importantes candidatos a una vacuna contra la malaria producida por P. vivax.\n[Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors.](https://www.ncbi.nlm.nih.gov/pubmed/29252042)\nVelasquez, Daniel E; Parashar, Umesh; Jiang, Baoming\n2018-02-01\nNumerous studies have shown that the oral rotavirus vaccines are less effective in infants born in low income countries compared to those born in developed countries. Identifying the specific factors in developing countries that decrease and/or compromise the protection that rotavirus vaccines offer, could lead to a path for designing new strategies for the vaccines' improvement. Areas covered: We accessed PubMed to identify rotavirus vaccine performance studies (i.e., efficacy, effectiveness and immunogenicity) and correlated performance with several risk factors. Here, we review the factors that might contribute to the low vaccine efficacy, including passive transfer of maternal rotavirus antibodies, rotavirus seasonality, oral polio vaccine (OPV) administered concurrently, microbiome composition and concomitant enteric pathogens, malnutrition, environmental enteropathy, HIV, and histo blood group antigens. Expert commentary: We highlight two major factors that compromise rotavirus vaccines' efficacy: the passive transfer of rotavirus IgG antibodies to infants and the co-administration of rotavirus vaccines with OPV. We also identify other potential risk factors that require further research because the data about their interference with the efficacy of rotavirus vaccines are inconclusive and at times conflicting.\n[Rotavirus in the Netherlands : Background information for the Health Council](https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F349679/uquery/rotavirus/id/5/Language/EN)\nVerberk, J D M; Bruijning, P.C.; de Melker, Hester\n2017-01-01\nRotavirus can cause a gastrointestinal infection and is common in young children. There are two vaccines available; both have to be administered via the mouth. The Dutch Health Council will advise the Ministry of Health, Welfare and Sport on how childhood vaccination against rotavirus will be made\n[Desarrollo y pruebas de campo de la vacuna sint\u00e9tica contra la malaria SPf66](https://revistas.unal.edu.co/index.php/revfacmed/article/view/27236) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMauricio Rojas\n1993-04-01\nFull Text Available De acuerdo a estad\u00edsticas recientes de la Organizaci\u00f3n Mundial de la Salud, se estima que 2100 millones de personas habitan en cerca de 100 pa\u00edses donde la malaria es una enfermedad end\u00e9mica, afectando cerca de 270 millones de individuos anualmente y siendo la causa directa de por 10 menos dos millones de muertos al a\u00f1o, especialmente de ni\u00f1os menores de cinco a\u00f1os de edad. Las medidas de control del vector y del par\u00e1sito con insecticidas y quimioterapia parec\u00edan ser suficientes para la erradicaci\u00f3n, pero a lo largo del tiempo se ha demostrado la poca eficacia de estas medidas, hacienda que el desarrollo de una vacuna sea esencial como un componente efectivo para el control y erradicaci\u00f3n de la malaria especialmente en los pa\u00edses del tercer mundo.\n[Distribution of rotavirus genotypes associated with acute diarrhoea in Zimbabwean children less than five years old before and after rotavirus vaccine introduction.](https://www.ncbi.nlm.nih.gov/pubmed/29628149)\nMukaratirwa, Arnold; Berejena, Chipo; Nziramasanga, Pasipanodya; Ticklay, Ismail; Gonah, Archebald; Nathoo, Kusum; Manangazira, Portia; Mangwanya, Douglas; Marembo, Joan; Mwenda, Jason M; Weldegebriel, Goitom; Seheri, Mapaseka; Tate, Jacqueline E; Yen, Catherine; Parashar, Umesh; Mujuru, Hilda\n2018-04-05\nSentinel surveillance for diarrhoea is important to monitor changes in rotavirus epidemiological trends and circulating genotypes among children under 5 years before and after vaccine introduction. The Zimbabwe Ministry of Health and Child Care introduced rotavirus vaccine in national immunization program in May 2014. Active hospital-based surveillance for diarrhoea was conducted at 3 sentinel sites from 2008 to 2016. Children aged less than 5 years, who presented with acute gastroenteritis as a primary illness and who were admitted to a hospital ward or treated at the emergency unit, were enrolled and had a stool specimen collected and tested for rotavirus by enzyme immunoassay (EIA). Genotyping of positive stools was performed using reverse-transcription polymerase chain reaction and genotyping assays. Pre-vaccine introduction, 10% of all positive stool specimens were genotyped and all adequate positive stools were genotyped post-vaccine introduction. During the pre-vaccine period, a total of 6491 acute gastroenteritis stools were collected, of which 3016 (46%) tested positive for rotavirus and 312 (10%) of the rotavirus positive stools were genotyped. During the post-vaccine period, a total of 3750 acute gastroenteritis stools were collected, of which 937 (25%) tested positive for rotavirus and 784 (84%) were genotyped. During the pre-vaccine introduction the most frequent genotype was G9P[8] (21%) followed by G2P[4] (12%), G1P[8] (6%), G2P[6] (5%), G12P[6] (4%), G9P[6] (3%) and G8P[4] (3%). G1P[8] (30%) was most dominant two years after vaccine introduction followed by G9P[6] (20%), G2P[4] (15%), G9P[8] (11%) and G1P[6] (4%). The decline in positivity rate is an indication of early vaccine impact. Diversity of circulating strains underscores the importance of continued monitoring and strain surveillance after vaccine introduction. Copyright \u00a9 2018. Published by Elsevier Ltd.\n[Influence of birth rates and transmission rates on the global seasonality of rotavirus incidence.](https://www.ncbi.nlm.nih.gov/pubmed/21508015)\nPitzer, Virginia E; Viboud, C\u00e9cile; Lopman, Ben A; Patel, Manish M; Parashar, Umesh D; Grenfell, Bryan T\n2011-11-07\nRotavirus is a major cause of mortality in developing countries, and yet the dynamics of rotavirus in such settings are poorly understood. Rotavirus is typically less seasonal in the tropics, although recent observational studies have challenged the universality of this pattern. While numerous studies have examined the association between environmental factors and rotavirus incidence, here we explore the role of intrinsic factors. By fitting a mathematical model of rotavirus transmission dynamics to published age distributions of cases from 15 countries, we obtain estimates of local transmission rates. Model-predicted patterns of seasonal incidence based solely on differences in birth rates and transmission rates are significantly correlated with those observed (Spearman's \u03c1 = 0.65, p birth rates and transmission rates and explore how vaccination may impact these patterns. Our results suggest that the relative lack of rotavirus seasonality observed in many tropical countries may be due to the high birth rates and transmission rates typical of developing countries rather than being driven primarily by environmental conditions. While vaccination is expected to decrease the overall burden of disease, it may increase the degree of seasonal variation in the incidence of rotavirus in some settings.\n[Short term clinical outcome of children with rotavirus infection at ...](https://www.ajol.info/index.php/eamj/article/view/63082) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nBackground: Rotavirus infection is the single most common cause of acute gastroenteritis in children under five years of age. Rotavirus gastroenteritis has a high morbidity and mortality in children in Kenya. Objectives: To determine the short term clinical outcome for children admitted to Kenyatta National Hospital with ...\n[The incidence of infants with rotavirus enteritis combined with lactose intolerance.](https://www.ncbi.nlm.nih.gov/pubmed/27005498)\nHu, Yulian; Gui, Linyan; Chang, Jing; Liu, Jingyan; Xu, Shuling; Deng, Caiyan; Yu, Fengqin; Ma, Zhanmin; Wang, Guangzhou; Zhang, Changjun\n2016-01-01\nThis study was to research the incidence of infants with rotavirus enteritis combined with lactose intolerance and the clinical effect of low lactose milk powder for infantile rotavirus enteritis with lactose intolerance. The control groups were 126 cases of infants with diarrhea randomly collected from our hospital at the same period, which their rotavirus detection was negative. The observation group was 185 cases of infants with rotavirus, which was tested to be positive. Through the urine galactose determination, 62 cases of the control group were positive and 124 cases of the observation group were positive. Then 124 cases of infants with rotavirus combined with lactose intolerance were randomly divided into two groups. 60 cases in the control group were given rehydration, correction of acidosis, oral smecta, Intestinal probiotics and other conventional treatment, then continued to the original feeding method. While, 64 cases in the treatment group, on the basis of routine treatment, applied the low lactose milk feeding. To observe the total effective rate for the two groups. The incidence of lactose intolerance in children with rotavirus enteritis (67.03%) was significantly higher than that of children with diarrhea (49.2%), which was tested to be negative. And the difference was statistically significant (plactose intolerance. The low lactose milk powder could improve the therapeutic effectively and could reduce the duration of disease, and restored to normal diet for 2 weeks feeding time.\n[The VP7 Outer Capsid Protein of Rotavirus Induces Polyclonal B-Cell Activation](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=421650)\nBlutt, Sarah E.; Crawford, Sue E.; Warfield, Kelly L.; Lewis, Dorothy E.; Estes, Mary K.; Conner, Margaret E.\n2004-01-01\nThe early response to a homologous rotavirus infection in mice includes a T-cell-independent increase in the number of activated B lymphocytes in the Peyer's patches. The mechanism of this activation has not been previously determined. Since rotavirus has a repetitively arranged triple-layered capsid and repetitively arranged antigens can induce activation of B cells, one or more of the capsid proteins could be responsible for the initial activation of B cells during infection. To address this question, we assessed the ability of rotavirus and virus-like particles to induce B-cell activation in vivo and in vitro. Using infectious rotavirus, inactivated rotavirus, noninfectious but replication-competent virus, and virus-like particles, we determined that neither infectivity nor RNA was necessary for B-cell activation but the presence of the rotavirus outer capsid protein, VP7, was sufficient for murine B-cell activation. Preincubation of the virus with neutralizing VP7 antibodies inhibited B-cell activation. Polymyxin B treatment and boiling of the virus preparation were performed, which ruled out possible lipopolysaccharide contamination as the source of activation and confirmed that the structural conformation of VP7 is important for B-cell activation. These findings indicate that the structure and conformation of the outer capsid protein, VP7, initiate intestinal B-cell activation during rotavirus infection. PMID:15194774\n[Overland Transport of Rotavirus and the Effect of Soil Type and Vegetation](http://www.mdpi.com/2073-4441/8/3/78) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nPaul C. Davidson\n2016-03-01\nFull Text Available Soil and vegetation are two critical factors for controlling the overland transport kinetics of pathogens in a natural environment. With livestock operations moving more towards concentrated animal operations, the need to dispose of a very large amount of manure in a localized area is becoming increasingly important. Animal manure contains a substantial amount of microbial pathogens, including rotavirus, which may pose a threat of contamination of water resources. This study examined the kinetics of rotavirus in overland transport, with an overall objective of optimizing the design of best management practices, especially vegetative filter strips. The overland transport of rotavirus was studied using three soil types (Catlin silt-loam, Darwin silty-clay, Alvin fine sandy-loam, spanning the entire spectrum of typical Illinois soil textures. A 20-min rainfall event was produced using a small-scale (1.07 m \u00d7 0.66 m laboratory rainfall simulator over a soil box measuring 0.610 m \u00d7 0.305 m. Each soil type was tested for rotavirus transport kinetics with bare surface conditions, as well as with Smooth Brome and Fescue vegetative covers. Surface runoff, near-surface runoff, soil cores, and vegetation were each analyzed for infective rotavirus particles using cell-culture infectivity assays. Results show that vegetation reduces the recovery of infective rotavirus particles in surface runoff by an average of 73%, in addition to delaying the time to peak recovery. The vegetation, in general, appeared to decrease the recovery of infective rotavirus particles in surface runoff by impeding surface flow and increasing the potential for infiltration into the soil profile.\n[Cost-effectiveness analysis of rotavirus vaccination in Argentina.](https://www.ncbi.nlm.nih.gov/pubmed/25919152)\nUrue\u00f1a, Anal\u00eda; Pippo, Tom\u00e1s; Betelu, Mar\u00eda Sol; Virgilio, Federico; Hern\u00e1ndez, Laura; Giglio, Norberto; Gentile, \u00c1ngela; Diosque, M\u00e1ximo; Vizzotti, Carla\n2015-05-07\nRotavirus is a leading cause of severe diarrhea in children under 5. In Argentina, the most affected regions are the Northeast and Northwest, where hospitalizations and deaths are more frequent. This study estimated the cost-effectiveness of adding either of the two licensed rotavirus vaccines to the routine immunization schedule. The integrated TRIVAC vaccine cost-effectiveness model from the Pan American Health Organization's ProVac Initiative (Version 2.0) was used to assess health benefits, costs savings, life-years gained (LYGs), DALYs averted, and cost/DALY averted of vaccinating 10 successive cohorts, from the health care system and societal perspectives. Two doses of monovalent (RV1) rotavirus vaccine and three doses of pentavalent (RV5) rotavirus vaccine were each compared to a scenario assuming no vaccination. The price/dose was US$ 7.50 and US$ 5.15 for RV1 and RV5, respectively. We ran both a national and sub-national analysis, discounting all costs and benefits 3% annually. Our base case results were compared to a range of alternative univariate and multivariate scenarios. The number of LYGs was 5962 and 6440 for RV1 and RV5, respectively. The cost/DALY averted when compared to no vaccination from the health care system and societal perspective was: US$ 3870 and US$ 1802 for RV1, and US$ 2414 and US$ 358 for RV5, respectively. Equivalent figures for the Northeast were US$ 1470 and US$ 636 for RV1, and US$ 913 and US$ 80 for RV5. Therefore, rotavirus vaccination was more cost-effective in the Northeast compared to the whole country; and, in the Northwest, health service's costs saved outweighed the cost of introducing the vaccine. Vaccination with either vaccine compared to no vaccination was highly cost-effective based on WHO guidelines and Argentina's 2011 per capita GDP of US$ 9090. Key variables influencing results were vaccine efficacy, annual loss of efficacy, relative coverage of deaths, vaccine price, and discount rate. Compared to no\n[Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants.](https://www.ncbi.nlm.nih.gov/pubmed/17380232)\nAraujo, Eliete C; Clemens, Sue Ann C; Oliveira, Consuelo S; Justino, Maria Cleonice A; Rubio, Pilar; Gabbay, Yvone B; da Silva, Veronilce B; Mascarenhas, Joana D P; Noronha, V\u00e2nia L; Clemens, Ralf; Gusm\u00e3o, Rosa Helena P; Sanchez, Nervo; Monteiro, Talita Ant\u00f4nia F; Linhares, Alexandre C\n2007-01-01\nTo determine the safety, immunogenicity and efficacy of two doses of rotavirus vaccine in healthy Brazilian infants. A randomized, multicenter, double-blind, placebo-controlled trial was conducted in Brazil, Mexico and Venezuela. Infants received two oral doses of vaccine or placebo at 2 and 4 months of age, concurrently with routine immunizations, except for oral poliomyelitis vaccine (OPV). This paper reports results from Bel\u00e9m, Brazil, where the number of subjects per group and the viral vaccine titers were: 194 (10(4.7) focus forming units - FFU), 196 (10(5.2) FFU), 194 (10(5.8) FFU) and 194 (placebo). Anti-rotavirus (anti-RV) antibody response was assessed in 307 subjects. Clinical severity of gastroenteritis episodes was measured using a 20-point scoring system with a score of >or= 11 defined as severe GE. The rates of solicited general symptoms were similar in vaccine and placebo recipients. At 2 months after the second dose, a serum IgA response to RV occurred in 54.7 to 74.4% of vaccinees. No interference was seen in the immunogenicity of routine vaccines. Vaccine efficacy against any rotavirus gastroenteritis (RVGE) was 63.5% (95%CI 20.8-84.4) for the highest concentration (10(5.8) FFU). Efficacy was 81.5% (95%CI 44.5-95.4) against severe RVGE. At its highest concentration (10(5.8) FFU), RIX4414 provided 79.8% (95%CI 26.4-96.3) protection against severe RVGE by G9 strain. RIX4414 was highly immunogenic with a low reactogenicity profile and did not interfere with seroresponse to diphtheria, tetanus, pertussis, hepatitis B and Hib antigens. Two doses of RIX4414 provided significant protection against severe GE caused by RV.\n[Frequently Asked Questions about Rotavirus](http://www.nfid.org/idinfo/rotavirus/faqs.html)\n... Scientific Achievement John P. Utz Leadership Award Dr. Charles M\u00e9rieux Award for Achievement in Vaccinology and Immunology ... There's no reliable way to predict how rotavirus will affect your child. New and expecting parents should ...\n[Desarrollo de una vacuna profil\u00e1ctica de segunda generaci\u00f3n contra el papilomavirus humano Development of a second generation prophylactic vaccine against human papillomavirus](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802011000500015) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAlonso Leonardo\n2011-06-01\nFull Text Available Los papilomavirus humanos (HPV son el agente etiol\u00f3gico del c\u00e1ncer cervical (CC, la segunda causa de muerte por c\u00e1ncer en mujeres. Se estima que medio mill\u00f3n de nuevos c\u00e1nceres se diagnostica cada a\u00f1o, ocurriendo la mayor\u00eda de ellos en pa\u00edses en v\u00edas de desarrollo debido a la ausencia o ineficiencia de los programas masivos de detecci\u00f3n temprana. Recientemente se han introducido en el mercado dos vacunas profil\u00e1cticas contra las principales cepas oncog\u00e9nicas de HPV, la cepa 16 y 18, responsables por el 80% de todos los CC. Estas vacunas se obtienen en forma recombinante y han demostrado ser extremadamente seguras y eficaces. Sin embargo, su impacto inmediato en la incidencia de la infecci\u00f3n por HPV en pa\u00edses en v\u00edas de desarrollo ser\u00e1 m\u00ednimo, debido principalmente al alto costo de las mismas. Existe la necesidad de contar con vacunas de segunda generaci\u00f3n, de bajo costo y de aplicaci\u00f3n masiva que permitan disminuir sensiblemente el n\u00famero de CC en la poblaci\u00f3n. Con este objetivo hemos desarrollado una plataforma de expresi\u00f3n recombinante que permite obtener part\u00edculas tipo virus (VLPs con las cuales es posible formular vacunas efectivas y accesibles contra la infecci\u00f3n por HPV.Human papillomaviruses (HPV are the etiologic agent for cervical cancer (CC, the second cause of cancer death in women worldwide. It is estimated that half a million new cases are diagnosed each year, mostly in developing countries due to the lack of massive programs for early detection of the virus. Recently, two prophylactic vaccines against the main oncogenic HPV types 16 and 18 (responsible for 80% of CC have been introduced into market. Both of these vaccines, obtained as recombinants, have been shown to be safe and effective; however, their high cost works against its immediate impact in the incidence of HPV infection in developing and low-income countries. There is a need to have in hand second generation, low cost vaccines of massive use\n[Rotavirus Infection in Four States in North-western Nigeria | Aminu ...](https://www.ajol.info/index.php/njm/article/view/37397) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nBackground: Rotaviruses are associated with ~ 611,000 deaths worldwide and with 33,000 deaths in Nigeria in children < 5 years of age annually. However, limited data exit on rotavirus (RV) infection in North-western Nigeria. This study surveyed RV infection in four states in Northwestern Nigeria. Methods: During July ...\n[Rotavirus-Like Particles: A Novel Nanocarrier for the Gut](http://dx.doi.org/10.1155/2010/317545) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nNaima G. Cortes-Perez\n2010-01-01\nFull Text Available The delivery of bioactive molecules directly to damaged tissues represents a technological challenge. We propose here a new system based on virus-like particles (VLP from rotavirus, with a marked tropism for the gut to deliver bio-active molecules to intestinal cells. For this, nonreplicative VLP nanoparticles were constructed using a baculovirus expression system and used to deliver an exogenous biomolecule, the green fluorescent protein (GFP, into either MA104 cells or intestinal cells from healthy and 2,4,6-trinitrobenzene sulfonic acid (TNBS-treated mice. Our results show that expression of rotavirus capsid proteins in baculovirus led to the auto assembly of VLP that display similar properties to rotavirus. In vitro experiments showed that VLP were able to enter into MA104 cells and deliver the reporter protein. Intragastric administration of fluorescent VLP in healthy and TNBS-treated mice resulted in the detection of GFP and viral proteins in intestinal samples. Our results demonstrate an efficient entry of non-replicative rotavirus VLP into the epithelial cell line MA104 and provide the first in vivo evidence of the potential of these nanoparticles as a promising safe candidate for drug delivery to intestinal cells.\n[Prospective study of the burden of rotavirus gastroenteritis in Danish children and their families](http://www.forskningsdatabasen.dk/en/catalog/188922403) [DEFF Research Database (Denmark)](http://forskningsbasen.deff.dk/?lang=eng)\nHoffmann, Thomas; Iturriza, Miren; Faaborg-Andersen, Jens\n2011-01-01\nThis was the first study to characterize the total burden of rotavirus gastroenteritis (RVGE) at both hospital and general physician (GP) clinics in Denmark, and also the first to confirm rotavirus (RV) as the leading cause of acute gastroenteritis (GE) among children......This was the first study to characterize the total burden of rotavirus gastroenteritis (RVGE) at both hospital and general physician (GP) clinics in Denmark, and also the first to confirm rotavirus (RV) as the leading cause of acute gastroenteritis (GE) among children...\n[Rotavirus Vaccines: a story of success with challenges ahead [version 1; referees: 3 approved](https://f1000research.com/articles/6-1517/v1) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMiguel O\u2019Ryan\n2017-08-01\nFull Text Available Approximately 40 years have passed since the discovery of the rotavirus and 10 years since the introduction and progressive dissemination of rotavirus vaccines worldwide. Currently, 92 countries have introduced rotavirus vaccines into national or subnational programs with evident impact in disease reduction. Two vaccines have been widely used, and four additional vaccines have been licensed and are being used in defined regions. In this context, one main issue that remains unsolved is the lower vaccine efficacy/effectiveness in low-income countries. An additional partially answered issue relates to rotavirus strain circulation in vaccinated populations. These issues are discussed in this review. The most imperative challenge ahead is to fulfill the WHO\u2019s recommendation to introduce rotavirus vaccines in all countries.\n[An atypical rotavirus detected in a child with gastroenteritis in Rio de Janeiro, Brazil](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761983000300002) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nH. G. Pereira\n1983-09-01\nFull Text Available Particles morphologically identical to rotaviruses were found in the faeces of a nine week-old child with gastroenteritis. Analysis of the viral RNA genome by polyacrylamine gel electrophoresis revealed 10 bands (probably 11 segments some of wich differed in migration rate from those of the great majority of rotaviruses infecting man and other animal hosts. The virus was not detected by a highly sensitive enzyme immunoassay (ELISA and therefore probably lacked the crossreactive antigen(s shared by the majority rotaviruses. This was the only strain with such behaviour among 230 rotaviruses of human origin examined in this laboratory since 1979. The implications of the existence of non-crossreactive rotaviruses are discussed.Part\u00edculas morfologicamente id\u00eanticas a rotavirus foram encontradas nas fezes de uma crian\u00e7a de dois meses com gastroenterite. An\u00e1lise do genoma viral por eletroforese em gel de poliacrilamida revelou 10 faixas (provavelmente 11 segmentos de RNA, algumas das quais diferem em velocidade de migra\u00e7\u00e3o das observadas na grande maioria de rotavirus de hospedeiros humanos e de diversas esp\u00e9cies de animais. O v\u00edrus n\u00e3o foi revelado por um ensaio imuno-enzim\u00e1tico de alta sensibilidade, o que sugere a aus\u00eancia do ant\u00edgeno de grupo que da rea\u00e7\u00f5es cruzadas entre a maioria dos rotavirus. O v\u00edrus descrito no presente trabalho foi o \u00fanico com tal comportamento entre 230 amostras analisadas por n\u00f3s desde 1979. A relev\u00e2ncia de exist\u00eancia de rotavirus n\u00e3o relacionados antigenicamente a outros membros do grupo \u00e9 discutida.\n[Prevalence of rotavirus antibodies in breast milk and inhibitory effects to rotavirus vaccines.](https://www.ncbi.nlm.nih.gov/pubmed/25668672)\nTrang, Nguyen V; Braeckman, Tessa; Lernout, Tinne; Hau, Vu T B; Anh, Le T K; Luan, Le T; Van Damme, Pierre; Anh, Dang D\n2014-01-01\nRotavirus (RV) is the most common cause of childhood diarrhea worldwide, and several vaccines have been successfully developed to reduce the burden of disease. However, lower vaccine immunogenicity and efficacy in developing countries might be related to the virus-neutralizing activity of breast milk. We examined possible differences in breast milk antibody levels (total IgA antibody, RV-specific antibodies, and RV-neutralizing antibodies) between healthy mothers living in a rural area (n=145) and mothers living in an urban area (n=147) of Vietnam. Total IgA concentration was significantly higher in samples from mothers in the rural region than in samples from mothers in the urban region, whereas urban mothers had significantly higher RV-specific IgA antibody titers than did rural mothers. Neutralizing antibodies against RV strain G1P[8] were undetected in nearly one-half of the breast milk samples (45-48%), whereas the majority of the remaining samples had low antibody titers (2-16). Despite these low titers, the breast milk still reduced vaccine strain titers (2\u00d710(6) plaque forming units/mL) up to 80% or more, even at a milk-to-virus ratio of 1:8. An increase in neutralizing anti-G1P[8] antibody titers (Pvaccine efficacy and immunogenicity in Vietnamese infants.\n[Rotavirus and other enteropathogens in childhood acute diarrhoea: a study of two centres in Malaysia.](https://www.ncbi.nlm.nih.gov/pubmed/16925536)\nLee, Way S; Rajasekaran, Ganeswrie; Pee, Susan; Karunakaran, Rina; Hassan, Hamimah H; Puthucheary, Savithri D\n2006-09-01\nTo study the role of rotavirus in children hospitalised for acute gastroenteritis (AGE) in two urban hospitals in Malaysia. A 12-month prospective study (January to December 2002), in children younger than 14 years with AGE hospitalised to the paediatric units of University of Malaya Medical Centre (UMMC), Kuala Lumpur; and Hospital Sultanah Aminah (HSA), Johor Bahru, Malaysia was conducted. In 2002, 399 and 1307 children with AGE were admitted to UMMC and HSA, respectively. Two hundred and eighty-eight (72%) stool samples from UMMC and 901 (69%) samples from HSA were analysed. Rotavirus was the most common aetiological agent identified in both centres (average 32%; UMMC 35%, HSA 30%, P = 0.94). The peak age group for rotavirus-related hospitalisation was 24-35 months for UMMC and 12-23 months for HSA. Nine percent of patients hospitalised for rotavirus infection in UMMC and 22% of patients in HSA were older than 5 years of age. An outbreak of rotavirus infection within the communities served by both centres resulting in an increase in hospital admissions of rotavirus gastroenteritis was observed in both units from January to March 2002. The peak age group for rotavirus-related hospital admission in this study was much older, between 12 to 35 months. It is uncertain whether this was related to the outbreak of rotavirus gastroenteritis observed within two urban areas from January to March 2002 causing re-infection with rotavirus in older children.\n[Understanding reduced rotavirus vaccine efficacy in low socio-economic settings.](http://europepmc.org/articles/PMC3412858?pdf=render) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nBenjamin A Lopman\nFull Text Available Rotavirus vaccine efficacy ranges from >90% in high socio-economic settings (SES to 50% in low SES. With the imminent introduction of rotavirus vaccine in low SES countries, understanding reasons for reduced efficacy in these settings could identify strategies to improve vaccine performance.We developed a mathematical model to predict rotavirus vaccine efficacy in high, middle and low SES based on data specific for each setting on incidence, protection conferred by natural infection and immune response to vaccination. We then examined factors affecting efficacy.Vaccination was predicted to prevent 93%, 86% and 51% of severe rotavirus gastroenteritis in high, middle and low SES, respectively. Also predicted was that vaccines are most effective against severe disease and efficacy declines with age in low but not high SES. Reduced immunogenicity of vaccination and reduced protection conferred by natural infection are the main factors that compromise efficacy in low SES.The continued risk of severe disease in non-primary natural infections in low SES is a key factor underpinning reduced efficacy of rotavirus vaccines. Predicted efficacy was remarkably consistent with observed clinical trial results from different SES, validating the model. The phenomenon of reduced vaccine efficacy can be predicted by intrinsic immunological and epidemiological factors of low SES populations. Modifying aspects of the vaccine (e.g. improving immunogenicity in low SES and vaccination program (e.g. additional doses may bring improvements.\n[Understanding reduced rotavirus vaccine efficacy in low socio-economic settings.](https://www.ncbi.nlm.nih.gov/pubmed/22879893)\nLopman, Benjamin A; Pitzer, Virginia E; Sarkar, Rajiv; Gladstone, Beryl; Patel, Manish; Glasser, John; Gambhir, Manoj; Atchison, Christina; Grenfell, Bryan T; Edmunds, W John; Kang, Gagandeep; Parashar, Umesh D\n2012-01-01\nRotavirus vaccine efficacy ranges from >90% in high socio-economic settings (SES) to 50% in low SES. With the imminent introduction of rotavirus vaccine in low SES countries, understanding reasons for reduced efficacy in these settings could identify strategies to improve vaccine performance. We developed a mathematical model to predict rotavirus vaccine efficacy in high, middle and low SES based on data specific for each setting on incidence, protection conferred by natural infection and immune response to vaccination. We then examined factors affecting efficacy. Vaccination was predicted to prevent 93%, 86% and 51% of severe rotavirus gastroenteritis in high, middle and low SES, respectively. Also predicted was that vaccines are most effective against severe disease and efficacy declines with age in low but not high SES. Reduced immunogenicity of vaccination and reduced protection conferred by natural infection are the main factors that compromise efficacy in low SES. The continued risk of severe disease in non-primary natural infections in low SES is a key factor underpinning reduced efficacy of rotavirus vaccines. Predicted efficacy was remarkably consistent with observed clinical trial results from different SES, validating the model. The phenomenon of reduced vaccine efficacy can be predicted by intrinsic immunological and epidemiological factors of low SES populations. Modifying aspects of the vaccine (e.g. improving immunogenicity in low SES) and vaccination program (e.g. additional doses) may bring improvements.\n[Inhibition of cyclooxygenase activity reduces rotavirus infection at a postbinding step.](https://www.narcis.nl/publication/RecordID/oai%3Arepub.eur.nl%3A13485/uquery/Rotavirus/id/20/Language/EN)\nJ.W. Rossen (John); J. Bouma (Janneke); R.H. Raatgeep (Rolien); H.A. B\u00fcller (Hans); A.W.C. Einerhand (Sandra)\n2004-01-01\ntextabstractElevated levels of prostaglandins (PGs), products of cyclooxygenases (COXs), are found in the plasma and stool of rotavirus-infected children. We sought to determine the role of COXs, PGs, and the signal transduction pathways involved in rotavirus infection to elucidate\n[Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Co-Administered with Measles, Yellow Fever and Meningitis A Vaccines in 9-month-old Malian Infants.](https://www.ncbi.nlm.nih.gov/pubmed/29659924)\nHaidara, Fadima C; Tapia, Milagritos D; Sow, Samba O; Doumbia, Moussa; Coulibaly, Flanon; Diallo, Fatoumata; Traor\u00e9, Awa; Kodio, Mamoudou; Kelly, Corey L; Fitzpatrick, Meagan; Kotloff, Karen; Victor, John C; Neuzil, Kathleen\n2018-04-12\nRotavirus vaccines given to infants are safe and efficacious. A booster dose of rotavirus vaccine could extend protection into the second year of life in low resource countries. We conducted an open-label, individual-randomized trial in Bamako, Mali. We assigned 600 9- to 11-month old infants to measles (MV), yellow fever (YFV), and meningococcal A conjugate vaccines with or without pentavalent rotavirus vaccine (PRV). We assessed non-inferiority of seroconversion and seroresponse rates (<10% difference) to MV, YFV and MenAV. We compared the seroresponse to PRV. Seroconversion to measles occurred in 255/261 (97.7%) and 246/252 (97.6%) of the PRV and control group; difference, 0.1% (95% CI, - 4.0 to 4.2). Seroresponse to YFV occurred in 48.1% (141/293) of the PRV group compared to 52.2% (153/293) of the control group; difference - 4.1% (95% CI, -12.2 to 4.0). A 4-fold rise in meningococcal A bactericidal titer was observed in 273/292 (93.5%) PRV recipients and 276/293 (94.2%) controls; difference, -0.7% (95% CI, - 5.2 to 3.8). Rises in anti-rotavirus IgA and IgG geometric mean concentrations were higher among PRV recipients (118 [95% CI, 91 to 154] and 364 [95% CI, 294 to 450]) compared to controls (68 [95% CI, 50 to 92] and 153 [95% CI, 114 to 207]. PRV did not interfere with MV and MenAV; this study could not rule out interference with YFV. PRV increased serum rotavirus antibody levels. NCT02286895.\n[Genetic Diversity of Circulating Rotavirus Strains in Tanzania Prior to the Introduction of Vaccination](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4028215)\nMoyo, Sabrina J.; Blomberg, Bj\u00f8rn; Hanevik, Kurt; Kommedal, Oyvind; Vainio, Kirsti; Maselle, Samuel Y.; Langeland, Nina\n2014-01-01\nBackground Tanzania currently rolls out vaccination against rotavirus-diarrhea, a major cause of child illness and death. As the vaccine covers a limited number of rotavirus variants, this study describes the molecular epidemiology of rotavirus among children under two years in Dar es Salaam, Tanzania, prior to implementation of vaccination. Methods Stool specimens, demographic and clinical information, were collected from 690 children admitted to hospital due to diarrhea (cases) and 545 children without diarrhea (controls) during one year. Controls were inpatient or children attending child health clinics. Rotavirus antigen was detected using ELISA and positive samples were typed by multiplex semi-nested PCR and sequencing. Results The prevalence of rotavirus was higher in cases (32.5%) than in controls (7.7%, Protavirus prevalence was higher in cool (23.9%) than hot months (17.1%) of the year (P = 0.012). We also observed significant seasonal variation of G genotypes. Rotavirus was most frequently found in the age group of four to six months. The prevalence of rotavirus in cases was lower in stunted children (28.9%) than in non-stunted children (40.1%, P = 0.003) and lower in HIV-infected (15.4%, 4/26) than in HIV-uninfected children (55.3%, 42/76, PRotavirus infection and circulating genotypes showed seasonal variation. This study also suggests that rotavirus may not be an opportunistic pathogen in children infected with HIV. PMID:24844631\n[Pron\u00f3stico de la diarrea por rotavirus](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0036-36342001000600002) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMota-Hern\u00e1ndez Felipe\n2001-01-01\nFull Text Available Objetivo. Comparar la gravedad de la diarrea por rotavirus (RV y por no rotavirus. Material y m\u00e9todos. Estudio transversal en 520 lactantes con diarrea aguda, efectuado entre octubre de 1994 y marzo de 1995 en siete centros del primer nivel de atenci\u00f3n en cinco estados de M\u00e9xico. El diagn\u00f3stico de RV se realiz\u00f3 con ensayo inmunoenzim\u00e1tico o por electroforesis. El an\u00e1lisis se hizo a trav\u00e9s de medidas de tendencia central. Los resultados se presentan como promedio y desviaci\u00f3n est\u00e1ndar o mediana o variaci\u00f3n. Resultados. Se aisl\u00f3 RV en 264 lactantes (50.7% con predominio en varones de 6 meses a un a\u00f1o. Las manifestaciones cl\u00ednicas fueron significativamente diferentes entre el grupo rotavirus positivo y el grupo rotavirus negativo en mediana de evacuaciones por 24 horas, frecuencia de v\u00f3mitos, temperatura > 38\u00b0 C, deshidrataci\u00f3n y calificaci\u00f3n de gravedad, respectivamente. Conclusiones. Estos resultados mostraron peor pron\u00f3stico por mayor gravedad de la diarrea por RV en lactantes, con relaci\u00f3n a otra etiolog\u00eda. El texto completo en ingl\u00e9s de este art\u00edculo est\u00e1 disponible en: http://www.insp.mx/salud/index.html\n[Cost effectiveness of a pentavalent rotavirus vaccine in Oman.](https://www.ncbi.nlm.nih.gov/pubmed/24941946)\nAl Awaidy, Salah Thabit; Gebremeskel, Berhanu G; Al Obeidani, Idris; Al Baqlani, Said; Haddadin, Wisam; O'Brien, Megan A\n2014-06-17\nRotavirus gastroenteritis (RGE) is the leading cause of diarrhea in young children in Oman, incurring substantial healthcare and economic burden. We propose to formally assess the potential cost effectiveness of implementing universal vaccination with a pentavalent rotavirus vaccine (RV5) on reducing the health care burden and costs associated with rotavirus gastroenteritis (RGE) in Oman A Markov model was used to compare two birth cohorts, including children who were administered the RV5 vaccination versus those who were not, in a hypothetical group of 65,500 children followed for their first 5 years of life in Oman. The efficacy of the vaccine in reducing RGE-related hospitalizations, emergency department (ED) and office visits, and days of parental work loss for children receiving the vaccine was based on the results of the Rotavirus Efficacy and Safety Trial (REST). The outcome of interest was cost per quality-adjusted life year (QALY) gained from health care system and societal perspectives. A universal RV5 vaccination program is projected to reduce, hospitalizations, ED visits, outpatient visits and parental work days lost due to rotavirus infections by 89%, 80%, 67% and 74%, respectively. In the absence of RV5 vaccination, RGE-related societal costs are projected to be 2,023,038 Omani Rial (OMR) (5,259,899 United States dollars [USD]), including 1,338,977 OMR (3,481,340 USD) in direct medical costs. However, with the introduction of RV5, direct medical costs are projected to be 216,646 OMR (563,280 USD). Costs per QALY saved would be 1,140 OMR (2,964 USD) from the health care payer perspective. An RV5 vaccination program would be considered cost saving, from the societal perspective. Universal RV5 vaccination in Oman is likely to significantly reduce the health care burden and costs associated with rotavirus gastroenteritis and may be cost-effective from the payer perspective and cost saving from the societal perspective.\n[One Family's Struggles with Rotavirus](https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_g8nXbL&server=pvlbsrch10&v%3astate=root%7croot&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc5&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&)\nFull Text Available ... hiv/aids overview current news labs links & resources hpv overview why vaccinate posters buttons and banners videos ... q & a videos chickenpox (varicella) hepatitis b hib hpv pertussis (whooping cough) pneumococcal rotavirus shingles media room ...\n[One Family's Struggles with Rotavirus](https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_IEqMB7&server=pvlbsrch14&v%3astate=root%7croot&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc8&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&)\nFull Text Available ... immunizations current news Flu's Gonna Lose hepatitis a & b vaccines im/sq how to do kids infect ... vaccine safety q & a videos chickenpox (varicella) hepatitis b hib hpv pertussis (whooping cough) pneumococcal rotavirus shingles ...\n[One Family's Struggles with Rotavirus](https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_RXXm9N&server=pvlbsrch10&v%3astate=root%7croot-60-10%7c0&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc64&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&)\nFull Text Available ... freed meet keri russell posters grand article rich media video/audio pneumonia tb overview links & resources families ... hib hpv pertussis (whooping cough) pneumococcal rotavirus shingles media room Flu's Gonna Lose M.O.V.E. ...\n[One Family's Struggles with Rotavirus](https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_KVEpez&server=pvlbsrch10&v%3astate=root%7croot&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc9&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&)\nFull Text Available ... to do kids infect kids links & resources M.O.V.E. parents for prevention publications schedules & records ... rotavirus shingles media room Flu's Gonna Lose M.O.V.E. newsfeeds PSAs publications infectious disease workshop ...\n[SHIFT IN HUMAN ROTAVIRUS DISTRIBUTION IN BELO HORIZONTE, BRAZIL DETECTED BY RIBONUCLEIC ACID ELECTROPHORESIS](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652013000200137&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMillan Scarabeli Alves Coelho da Silva\n2013-04-01\nFull Text Available Rotavirus has been considered the main agent of infectious diarrhea especially among younger children. We addressed the prevalence of rotavirus-associated diarrhea and the diversity of circulating electropherotypes by immunochromatography and RNA electrophoresis. Stool samples were taken from 391 children (267 with diarrhea from the lower socioeconomic stratum who sought treatment in the Hospital Infantil Jo\u00e3o Paulo II/Belo Horizonte, during 2005 and 2006. Rotavirus was detected in 79/20.2% of subjects, 64/24.0% with diarrhea and 15/12.1% with no diarrhea. The virus was strongly associated with diarrhea (p = 0.003. A total of 76/19.4% and 69/17.6% rotavirus-positive children were identified by immunochromatography and electrophoresis, respectively. Rotavirus-associated diarrhea was more frequently detected in dry months (p < 0.001 and almost exclusively in children aged up to three years. Long profile strains prevailed (54/78.3% but a shift toward short electropherotype was identified. Despite the decrease seen in 2006, rotavirus infection is still very common in our area. Although viral RNA electrophoresis is useful as a typing method, it should not be used exclusively in the diagnosis of rotavirus infection. We confirmed a shift from long to short profile strains, as already described for other South American countries.\n[Importance of rotavirus as a cause of gastroenteritis in Jordan: a hospital based study.](https://www.ncbi.nlm.nih.gov/pubmed/16857608)\nKhuri-Bulos, Najwa; Al Khatib, Mohammad\n2006-01-01\nRotavirus is recognized to be a very important cause of GE in younger children in both developed as well as developing countries, but causes most of the mortality and morbidity in the latter. The recent introduction of a rotavirus vaccine in some parts of the world makes it necessary for us to determine the impact of this organism in our population with the aim of determining the need for the vaccine. In order to determine this, a study was conducted at the JUH and 3 other private hospitals. At the JUH, 64/256 (25%) of children with GE had rotavirus in 1995. The proportions of cases attributed to rotavirus in the other 3 y were 70/199 (35.2%), 69/279 (24.7%) and 76/294 (25.8%) for 2002, 2003 and 2004, respectively. The cumulative proportion of cases attributable to rotavirus gastroenteritis in all the y was 27.14%. With regard to the 3 private hospitals, rotavirus accounted for 38/225 (16.9%), 140/664 (21%) and 668/1496 (44.6%) at the Khalidy, Jordan and Islamic hospitals, respectively. It is concluded that rotavirus is a significant cause of GE in Jordanian children regardless of their social background, and attempt at controlling this infection may be warranted.\n[Nationwide survey of rotavirus-associated encephalopathy and sudden unexpected death in Japan.](https://www.ncbi.nlm.nih.gov/pubmed/23972382)\nKawamura, Yoshiki; Ohashi, Masahiro; Ihira, Masaru; Hashimoto, Shuji; Taniguchi, Koki; Yoshikawa, Tetsushi\n2014-08-01\nRotavirus can cause severe complications such as encephalopathy/encephalitis and sudden unexpected death. The incidence of rotavirus-associated encephalopathy/encephalitis or sudden unexpected death remains unknown. To clarify the clinical features of rotavirus-associated encephalitis/encephalopathy and sudden unexpected death, we conducted a nationwide survey in Japan. A two-part questionnaire was designed to determine the number of the cases and the clinical features of severe cases of rotavirus infection, including encephalitis/encephalopathy and sudden unexpected death, between 2009 and 2011. Of the 1365 questionnaires sent to hospitals, 963 (70.5%) were returned and eligible for analysis. We determined 58 cases of rotavirus-associated encephalitis/encephalopathy and 7 cases of sudden unexpected death. These patients were diagnosed with rotavirus infection by immunochromatography. Although 36/58 (62.1%) encephalitis/encephalopathy patients had no sequelae, 15/58 (25.9%) patients had neurological sequelae, and 7/58 (12.1%) patients had fatal outcomes. Pleocytosis was observed in 9/40 (22.5%) patients and cerebrospinal fluid protein levels were elevated in only 4/40 (10%) patients. Elevated lactate dehydrogenase (LDH) (>500 IU/L) or acidemia (pHdeath were 44.0 and 4.9 cases in Japan, respectively. Elevated LDH (>500 IU/L) or acidemia (pH<7.15) were related to a poor prognosis of the encephalitis/encephalopathy. Copyright \u00a9 2013 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.\n[African Journals Online (AJOL)](http://www.ajol.info/index.php)\nUser\nestimated 453, 000 resulting in the death of a child younger than five years. In Sub-Saharan Africa and. Asia, according to Kotloff et al., (2013), rotavirus is one of the four most common causes of moderate to severe diarrhea among children <5 years of age. Diarrhea is one of the documented '10 killer conditions' among ...\n[Factores asociados a una respuesta inadecuada a la vacunaci\u00f3n contra la hepatitis B en personal sanitario](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1135-57271998000600004) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nTolosa Mart\u00ednez Natividad\n1998-01-01\nFull Text Available FUNDAMENTO: La vacuna recombinante contra la hepatitis B confiere inmunidad aproximadamente en el 95 % de los casos, pero existe un porcentaje que responde insuficientemente. El objetivo de este trabajo es evaluar los factores que se asocian con una inadecuada respuesta inmunitaria. M\u00c9TODOS: Se trata de un estudio observacional y anal\u00edtico en el que se sigue retrospectivamente una cohorte de sujetos vacunados frente al virus de la hepatitis B (VHB. Se recogieron las variables de inter\u00e9s del personal sanitario que cumpl\u00eda los criterios de inclusi\u00f3n, del \u00c1rea de Salud 9 de la Comunidad Valenciana (n=827. Tras la vacunaci\u00f3n se determin\u00f3 la titulaci\u00f3n de anticuerpos de superficie (antiHBs para comprobar la respuesta, consider\u00e1ndose niveles protectores los superiores a 10 mUI/ml. RESULTADOS: Se produjo una adecuada seroconversi\u00f3n en el 94,4% de los vacunados. La baja o nula respuesta a la vacuna se asoci\u00f3 significativamente y de forma independiente con variables como el sexo masculino, la edad, el \u00edndice de masa corporal (IMC y el tabaquismo. El consumo de alcohol y los niveles de GPT, aunque no se relacionaron de forma significativa con la respuesta a la vacuna, actuaron como posibles factores de confusi\u00f3n. CONCLUSIONES: La inmunogenicidad de la vacuna es satisfactoria. Es importante cuantificar los niveles de antiHBs, sobretodo cuando hay factores predictivos de mala respuesta. De esta manera, es posible identificar a aquellos que precisan dosis de recuerdo y a los no respondedores, evit\u00e1ndose as\u00ed situaciones de falsa sensaci\u00f3n de protecci\u00f3n frente al VHB.\n[Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants.](https://www.ncbi.nlm.nih.gov/pubmed/17606534)\nRuiz-Palacios, Guillermo M; Guerrero, M Lourdes; Bautista-M\u00e1rquez, Aurora; Ortega-Gallegos, Hilda; Tuz-Dzib, Fernando; Reyes-Gonz\u00e1lez, Leticia; Rosales-Pedraza, Gustavo; Mart\u00ednez-L\u00f3pez, Julia; Casta\u00f1\u00f3n-Acosta, Erika; Cervantes, Yolanda; Costa-Clemens, SueAnn; DeVos, Beatrice\n2007-08-01\nImmunization against rotavirus has been proposed as the most cost-effective intervention to reduce the disease burden associated with this infection worldwide. The objective of this study was to determine the dose response, immunogenicity, and efficacy of 2 doses of an oral, attenuated monovalent G1[P8] human rotavirus vaccine in children from the same setting in Mexico, where the natural protection against rotavirus infection was studied. From June 2001 through May 2003, 405 healthy infants were randomly assigned to 1 of 3 vaccine groups (virus concentrations 10(4.7), 10(5.2), and 10(5.8) infectious units) and to a placebo group and were monitored to the age of 2 years. The vaccine/placebo was administered concurrently with diphtheria-tetanus toxoid-pertussis/hepatitis B/Haemophilus influenzae type b vaccine at 2 and 4 months of age. After the administration of the first vaccine/placebo dose, weekly home visits to collect information regarding infant health were conducted. Stool samples were collected during each gastroenteritis episode and tested for rotavirus antigen and serotype. The vaccine was well tolerated and induced a greater rate of seroconversion than observed in infants who received placebo. For the pooled vaccine groups, efficacy after 2 oral doses was 80% and 95% against any and severe rotavirus gastroenteritis, respectively. Efficacy was 100% against severe rotavirus gastroenteritis and 70% against severe gastroenteritis of any cause with the vaccine at the highest virus concentration (10(5.8) infectious units). The predominant infecting rotavirus serotype in this cohort was wild-type G1 (85%). Adverse events, including fever, irritability, loss of appetite, cough, diarrhea, and vomiting, were similar among vaccinees and placebo recipients. This new oral, live, attenuated human rotavirus vaccine was safe, immunogenic, and highly efficacious in preventing any and, more importantly, severe rotavirus gastroenteritis in healthy infants. This vaccine\n[Inhibition of cyclooxygenase activity reduces rotavirus infection at a postbinding step](https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F22d7a844-9de3-4204-99de-bc8404317792/uquery/rotavirus/id/7/Language/EN)\nRossen, John W A; Bouma, Janneke; Raatgeep, Rolien H C; B\u00fcller, Hans A; Einerhand, Alexandra W C\nElevated levels of prostaglandins (PGs), products of cyclooxygenases (COXs), are found in the plasma and stool of rotavirus-infected children. We sought to determine the role of COXs, PGs, and the signal transduction pathways involved in rotavirus infection to elucidate possible new targets for\n[Health economics of rotavirus immunization in Vietnam : Potentials for favorable cost-effectiveness in developing countries](https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F6184a5d4-f127-4c0f-b534-c0c19a06e710/uquery/rotavirus/id/13/Language/EN)\nTu, Hong-Anh T.; Rozenbaum, Mark H.; Coyte, Peter C.; Li, Shu Chuen; Woerdenbag, Herman J.; Postma, Maarten J.\n2012-01-01\nIntroduction: Rotavirus is the most common cause of severe diarrhoea worldwide. Vietnam is situated in the region of high rotavirus infection incidence and eligible for financial support to introduce rotavirus vaccines into the Expanded Program of Immunization (EPI) from the GAVI. This study was\n[[Prospective study of rotavirus infection in a maternity unit. Demonstration of a nosocomial infection].](https://www.ncbi.nlm.nih.gov/pubmed/4074098)\nBrussieux, J; Boisivon, A; Michelon, B\n1985-10-01\nEighty-eight children born at the maternity hospital in Saint-Germain-en-Laye between May 24 and June 7, 1983 were followed clinically, with a special supervision concerning stools, weight curves and the way of feeding. Stool samplings looking for Rotavirus were performed in all the children and their mothers, at the 3rd and 6th days of life. No mother was found with Rotavirus infection. In neonates, Rotavirus excretion was significantly related to a slow down in weight curves and the occurrence of diarrhea. All rotaviruses had the same electrophoretype. Breast-feeding had an undeniable protective effect.\n[Rotavirus RRV associates with lipid membrane microdomains during cell entry](http://dx.doi.org/10.1016/j.virol.2004.02.018) [International Nuclear Information System (INIS) ](http://inis.iaea.org/search/)\nIsa, Pavel; Realpe, Mauricio; Romero, Pedro; Lopez, Susana; Arias, Carlos F.\n2004-01-01\nRotavirus cell entry is a multistep process, not completely understood, which requires at least four interactions between the virus and cell surface molecules. In this work, we investigated the role of the sphingolipid- and cholesterol-enriched lipid microdomains (rafts) in the entry of rotavirus strain RRV to MA104 cells. We found that ganglioside GM1, integrin subunits \u03b12 and \u03b23, and the heat shock cognate protein 70 (hsc70), all of which have been implicated as rotavirus receptors, are associated with TX-100 and Lubrol WX detergent-resistant membranes (DRMs). Integrin subunits \u03b12 and \u03b23 were found to be particularly enriched in DRMs resistant to lysis by Lubrol WX. When purified RRV particles were incubated with cells at 4 deg. C, about 10% of the total infectious virus was found associated with DRMs, and the DRM-associated virus increased to 37% in Lubrol-resistant membrane domains after 60-min incubation at 37 deg. C. The virus was excluded from DRMs if the cells were treated with methyl-\u03b2-cyclodextrin (M\u03b2CD). Immunoblot analysis of the viral proteins showed that the virus surface proteins became enriched in DRMs upon incubation at 37 deg. C, being almost exclusively localized in Lubrol-resistant DRMs after 60 min. These data suggest that detergent-resistant membrane domains play an important role in the cell entry of rotaviruses, which could provide a platform to facilitate the efficient interaction of the rotavirus receptors with the virus particle\n[Rotavirus genotypes associated with acute diarrhea in Egyptian infants.](https://www.ncbi.nlm.nih.gov/pubmed/24343617)\nAhmed, Salwa F; Mansour, Adel M; Klena, John D; Husain, Tupur S; Hassan, Khaled A; Mohamed, Farag; Steele, Duncan\n2014-01-01\nBefore the introduction of rotavirus vaccine in Egypt, information on the burden of disease and the circulating rotavirus genotypes is critical to monitor vaccine effectiveness. A cohort of 348 Egyptian children was followed from birth to 2 years of age with twice-weekly home visits to detect diarrheal illness. VP7 and VP4 genes were genotyped by reverse-transcription polymerase chain reaction and DNA sequencing. Forty percentage of children had rotavirus-associated diarrhea at least once by their second birthday. One hundred and twelve children experienced a single rotavirus diarrheal episodes (RDE) at a median age of 9 months; while 27 infants had their second RDE at a median age of 15 months and 1 infant had 3 RDE at the age of 2, 16 and 22 months. Of the 169 RDE, 82% could be assigned a G-type, while 58% had been identified a P-type. The most prevalent genotype was G2 (32%), followed by G1 (24%) and G9 (19%). G2P[4] rotavirus episodes were significantly associated with fever (P = 0.03) and vomiting (P = 0.06) when compared with other genotypes. G2 strains were the predominant genotype causing 50% of the second RDE while G9 represented 25% of the second RDE. Genotypes identified are similar to those detected globally except for absence of G4. Our finding that 75% of the second RDE were due to G2 and G9 indicates a possible reduction in natural protection afforded by these types compared with G1, where 90% of G1 cases did not experience a second xposure, indicating greater protection against recurrent symptomatic infection.\n[New tetrameric forms of the rotavirus NSP4 with antiparallel helices.](https://www.ncbi.nlm.nih.gov/pubmed/29455326)\nKumar, Sushant; Ramappa, Raghavendra; Pamidimukkala, Kiranmayee; Rao, C D; Suguna, K\n2018-06-01\nRotavirus nonstructural protein 4, the first viral enterotoxin to be identified, is a multidomain, multifunctional glycoprotein. Earlier, we reported a Ca 2+ -bound coiled-coil tetrameric structure of the diarrhea-inducing region of NSP4 from the rotavirus strains SA11 and I321 and a Ca 2+ -free pentameric structure from the rotavirus strain ST3, all with a parallel arrangement of \u03b1-helices. pH was found to determine the oligomeric state: a basic pH favoured a tetramer, whereas an acidic pH favoured a pentamer. Here, we report two novel forms of the coiled-coil region of NSP4 from the bovine rotavirus strains MF66 and NCDV. These crystallized at acidic pH, forming antiparallel coiled-coil tetrameric structures without any bound Ca 2+ ion. Structural and mutational studies of the coiled-coil regions of NSP4 revealed that the nature of the residue at position 131 (Tyr/His) plays an important role in the observed structural diversity.\n[Projecting the effectiveness of RotaTeq\u00ae against rotavirus-related hospitalisations in Brazil](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762011000500004&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAntoine Chaouki El Khoury\n2011-08-01\nFull Text Available RotaTeq\u00ae (Merck & Company, Inc, Whitehouse Station, NJ, USA is an oral pentavalent rotavirus vaccine (RV5 that has shown high and consistent efficacy in preventing rotavirus gastroenteritis (RGE in randomised clinical trials previously conducted in industrialised countries with high medical care resources. To date, the efficacy and effectiveness data for RV5 are available in some Latin American countries, but not Brazil. In this analysis, we projected the effectiveness of RV5 in terms of the percentage reduction in RGE-related hospitalisations among children less than five years of age in four regions of Brazil, using a previously validated mathematical model. The model inputs included hospital-based rotavirus surveillance data from Goi\u00e2nia, Porto Alegre, Salvador and S\u00e3o Paulo from 2005-2006, which provided the proportions of rotavirus attributable to serotypes G1, G2, G3, G4 and G9, and published rotavirus serotype-specific efficacy from the Rotavirus Efficacy and Safety Trial. The model projected an overall percentage reduction of 93% in RGE-related hospitalisations, with an estimated annual reduction in RGE-related hospitalisations between 42,991-77,383 in the four combined regions of Brazil. These results suggest that RV5 could substantially prevent RGE-related hospitalisations in Brazil.\n[Cyclosporin A Inhibits Rotavirus Replication and Restores Interferon-Beta Signaling Pathway In Vitro and In Vivo](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3749198)\nHe, Haiyang; Wu, Yuzhang\n2013-01-01\nRotavirus (RV) is the most common cause of severe diarrhea among infants and young children. Currently, there is no specific drug available against rotavirus, largely due to the lack of an ideal target molecule which has hampered drug development. Our previous studies have revealed that cyclosporin A (CsA) might be potentially useful as an anti-RV drug. We therefore used both cellular and mouse models to study the immunological safety and effectiveness of CsA as an anti-RV drug. We found that CsA treatment of HT-29 cells before, during, and after viral infection efficiently inhibited Wa strain RV replication and restored IFN-\u03b2 expression in a HT-29 cell line model. Exploring the underlying mechanisms showed that CsA promoted Interferon Regulatory Factor-5 (IRF-5) expression (a key positive regulator of the type I IFN signaling pathway), but not IRF-1, IRF-3, or IRF-7. Additionally, CsA inhibited SOCS-1 expression (the key negative regulator of IFN-\u03b1/\u03b2), but not SOCS-2 or SOCS-3. The antiviral effect of CsA was confirmed in an RV-infected neonatal mouse model by evaluation of antigen clearance and assessment of changes in intestinal tissue pathology. Also, no differences in T cell frequency or proliferation between the CsA- and vehicle-treated groups were observed. Thus, both our in vitro and in vivo findings suggest that CsA, through modulating the expression of key regulators in IFN signaling pathway, promote type I IFN-based intracellular innate immunity in RV host cells. These findings suggest that CsA may be a useful candidate to develop a new anti-RV strategy, although further evaluation and characterization of CsA on RV-induced diarrhea are warranted. PMID:23990993\n[Sunlight-induced inactivation of human Wa and porcine OSU rotaviruses in the presence of exogenous photosensitizers](https://repository.kaust.edu.sa/handle/10754/563024)\nRomero-Maraccini, Ofelia C.; Sadik, Nora J.; Rosado-Lausell, Sahid L.; Pugh, Charles R.; Niu, Xi-Zhi; Croue, Jean-Philippe; Nguyen, Thanh Ha\n2013-01-01\ndark experiments conducted at different temperatures suggest that porcine rotavirus has higher thermostability than human rotavirus. Concentrations of 3\u2032-MAP excited triplet states of 1.8 fM and above resulted in significant human rotavirus inactivation\n[One Family's Struggles with Rotavirus](https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_8qfcbE&server=pvlbsrch10&v%3astate=root%7croot&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc1&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&)\nFull Text Available ... immunizations about immunizations current news Flu's Gonna Lose hepatitis a & b vaccines im/sq how to do kids ... abcs of mmr & dtp thimerosal vaccine safety q & a videos chickenpox (varicella) hepatitis b hib hpv pertussis (whooping cough) pneumococcal rotavirus ...\n[One Family's Struggles with Rotavirus](https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_m9gXyw&server=pvlbsrch14&v%3astate=root%7croot&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc3&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&)\nFull Text Available ... and meningitis Stiletto and Extremus posters videos mono pertussis Silence the Sounds of Pertussis Acalla los Sonidos de la Tos Ferina AAP ... a videos chickenpox (varicella) hepatitis b hib hpv pertussis (whooping cough) pneumococcal rotavirus shingles media room Flu's ...\n[Whole genome detection of rotavirus mixed infections in human, porcine and bovine samples co-infected with various rotavirus strains collected from sub-Saharan Africa.](https://www.ncbi.nlm.nih.gov/pubmed/25701122)\nNyaga, Martin M; Jere, Khuzwayo C; Esona, Mathew D; Seheri, Mapaseka L; Stucker, Karla M; Halpin, Rebecca A; Akopov, Asmik; Stockwell, Timothy B; Peenze, Ina; Diop, Amadou; Ndiaye, Kader; Boula, Angeline; Maphalala, Gugu; Berejena, Chipo; Mwenda, Jason M; Steele, A Duncan; Wentworth, David E; Mphahlele, M Jeffrey\n2015-04-01\nGroup A rotaviruses (RVA) are among the main global causes of severe diarrhea in children under the age of 5years. Strain diversity, mixed infections and untypeable RVA strains are frequently reported in Africa. We analysed rotavirus-positive human stool samples (n=13) obtained from hospitalised children under the age of 5years who presented with acute gastroenteritis at sentinel hospital sites in six African countries, as well as bovine and porcine stool samples (n=1 each), to gain insights into rotavirus diversity and evolution. Polyacrylamide gel electrophoresis (PAGE) analysis and genotyping with G-(VP7) and P-specific (VP4) typing primers suggested that 13 of the 15 samples contained more than 11 segments and/or mixed G/P genotypes. Full-length amplicons for each segment were generated using RVA-specific primers and sequenced using the Ion Torrent and/or Illumina MiSeq next-generation sequencing platforms. Sequencing detected at least one segment in each sample for which duplicate sequences, often having distinct genotypes, existed. This supported and extended the PAGE and RT-PCR genotyping findings that suggested these samples were collected from individuals that had mixed rotavirus infections. The study reports the first porcine (MRC-DPRU1567) and bovine (MRC-DPRU3010) mixed infections. We also report a unique genome segment 9 (VP7), whose G9 genotype belongs to lineage VI and clusters with porcine reference strains. Previously, African G9 strains have all been in lineage III. Furthermore, additional RVA segments isolated from humans have a clear evolutionary relationship with porcine, bovine and ovine rotavirus sequences, indicating relatively recent interspecies transmission and reassortment. Thus, multiple RVA strains from sub-Saharan Africa are infecting mammalian hosts with unpredictable variations in their gene segment combinations. Whole-genome sequence analyses of mixed RVA strains underscore the considerable diversity of rotavirus sequences and\n[Obtenci\u00f3n y evaluaci\u00f3n preliminar de un virus canarypox recombinante como candidato a vacuna antirr\u00e1bica Development and preliminary assessment of a recombinant canarypox virus as an antirabic vaccine candidate](https://www.openaire.eu/search/publication?articleId=doajarticles::0f1a7e9d964b5b4dd7e2026d0f5f7623)\nFlavia Zanetti; Liliana Rudak; Mat\u00edas Micucci; Daniela Conte Grand; Andrea Luque; Susana Russo; Oscar Taboga; Oscar P\u00e9rez; Gabriela Calamante\n2012-01-01\nEn la Argentina, la rabia est\u00e1 circunscripta a algunas provincias del norte. La disponibilidad de nuevas vacunas que eliminen la manipulaci\u00f3n del virus r\u00e1bico y que permitan el control de la enfermedad es de importancia estrat\u00e9gica nacional y regional. Las vacunas basadas en poxvirus recombinantes se han utilizado con \u00e9xito como vacunas antirr\u00e1bicas a nivel mundial. SI bien estos sistemas no est\u00e1n disponibles comercialmente, la plataforma de obtenci\u00f3n de virus canarypox (CNPV) recombinantes y...\n[Analysis of complete genome sequences of G9P[19] rotavirus strains from human and piglet with diarrhea provides evidence for whole-genome interspecies transmission of nonreassorted porcine rotavirus.](https://www.ncbi.nlm.nih.gov/pubmed/27894992)\nYodmeeklin, Arpaporn; Khamrin, Pattara; Chuchaona, Watchaporn; Kumthip, Kattareeya; Kongkaew, Aphisek; Vachirachewin, Ratchaya; Okitsu, Shoko; Ushijima, Hiroshi; Maneekarn, Niwat\n2017-01-01\nWhole genomes of G9P[19] human (RVA/Human-wt/THA/CMH-S070-13/2013/G9P[19]) and porcine (RVA/Pig-wt/THA/CMP-015-12/2012/G9P[19]) rotaviruses concurrently detected in the same geographical area in northern Thailand were sequenced and analyzed for their genetic relationships using bioinformatic tools. The complete genome sequence of human rotavirus RVA/Human-wt/THA/CMH-S070-13/2013/G9P[19] was most closely related to those of porcine rotavirus RVA/Pig-wt/THA/CMP-015-12/2012/G9P[19] and to those of porcine-like human and porcine rotaviruses reference strains than to those of human rotavirus reference strains. The genotype constellation of G9P[19] detected in human and piglet were identical and displayed as the G9-P[19]-I5-R1-C1-M1-A8-N1-T1-E1-H1 genotypes with the nucleotide sequence identities of VP7, VP4, VP6, VP1, VP2, VP3, NSP1, NSP2, NSP3, NSP4, and NSP5 at 99.0%, 99.5%, 93.2%, 97.7%, 97.7%, 85.6%, 89.5%, 93.2%, 92.9%, 94.0%, and 98.1%, respectively. The findings indicate that human rotavirus strain RVA/Human-wt/THA/CMH-S070-13/2013/G9P[19] containing the genome segments of porcine genetic backbone is most likely a human rotavirus of porcine origin. Our data provide an evidence of interspecies transmission and whole-genome transmission of nonreassorted G9P[19] porcine RVA to human occurring in nature in northern Thailand. Copyright \u00a9 2016. Published by Elsevier B.V.\n[THE PREVENTION OF ROTAVIRUS INFECTION: THE MODERN VIEW OF THE POSSIBILITY](http://detinf.elpub.ru/jour/article/view/40) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nT. A. Grechukha\n2014-01-01\nFull Text Available Rotavirus is a major public health problem in all countries. The incidence of rotavirus infection is growing steadily in the Russian Federation and over the past 10 years increased by 7 times, amounting to 72 cases per 100,000 in 2010. The rotavirus vaccine was registered in the Russian Federation in 2012 and successfully applied from 2013. The vaccine used for more than 8 years and have enough experience on the efficacy and safety. Different foreign investigations have shown the herd immunity of the vaccine. The authors present data about the effectiveness and safety of vaccines, established during clinical studies of the foreign scientists.\n[Cost-effectiveness of rotavirus immunization in vietnam: Exploring impacts of herd immunity and patterns of breastfeedingof](https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F1ba3edf5-275c-4d4f-86f5-3cec4c41aff2/uquery/Management%20AND%20developing%20AND%20country%20AND%20perspective/id/18/Language/EN)\nTu, H.A.T.; Coyte, P.; Li, S.C.; Postma, M.J.\n2012-01-01\nOBJECTIVES: : Rotavirus is the most common cause of severe diarrhoea worldwide. This study was designed to evaluate the cost-effectiveness of rotavirus immunization in Vietnam taking into account herd immunity and patterns of breastfeeding. The affordability of implementing universal rotavirus\n[The role of the intestinal microbiome in rotavirus vaccine immunogenicity : An exploration from correlation to causation](https://www.narcis.nl/publication/RecordID/oai%3Adare.uva.nl%3Apublications%2F213ab654-4e76-4031-aeda-d48134ac7b6c/uquery/rotavirus/id/6/Language/EN)\nHarris, V.C.\n2018-01-01\nRotavirus (RV) is one of the leading causes of serious gastroenteritis and diarrheal deaths in children under the age of five across the globe. Rotavirus vaccines (RVV) protect infants, reducing rotavirus disease, diarrheal outpatient visits, hospitalizations, and deaths following introduction into\n[Detection of rotavirus VP7 gene in helmeted guinea fowls and ...](https://www.ajol.info/index.php/sokjvs/article/view/152781) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nRotaviruses classified into groups A through H are important etiological agents of gastroenteritis in man and animal. In Nigeria vaccination of infants has continuously been carried out, however the disease is still a burden to the nation which remains one of the countries with the highest cases of rotavirus gastroenteritis.\n[Rotavirus disease in Guinea-Bissau, West Africa: a review of longitudinal community and hospital studies](http://www.forskningsdatabasen.dk/en/catalog/112109447) [DEFF Research Database (Denmark)](http://forskningsbasen.deff.dk/?lang=eng)\nFischer, Thea K\u00f8lsen; Aaby, Peter; M\u00f8lbak, K\u00e5re\n2010-01-01\nRotavirus is one of the most common causes of childhood diarrheal disease and deaths in sub-Saharan Africa. This article reviews community- and hospital-based surveillance of rotavirus disease in Bissau, Guinea-Bissau, West Africa. Here, rotavirus infections exhibit a seasonal pattern, with annual...... epidemics occurring during the relatively dry and cooler months, from January to April, and few cases registered from May to December. Most children (74%) experience their first infection before the age of 2 years, and rotavirus has been identified as the most pathogenic of all diarrheal agents during 2...\n[Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/23499605)\nLau, Yu-Lung; Nelson, E Anthony S; Poon, Kin-Hung; Chan, Paul K S; Chiu, Susan; Sung, Rita; Leung, Chi Wai; Ng, Daniel; Ma, Yee Man; Chan, Desmond; Lee, Tsz Leung; Tang, Joyce; Kwan, Yat Wah; Ip, Patricia; Ho, Marco; Fung, Lai-Wah Eva; Tang, Haiwen; Suryakiran, P V; Han, Htay Htay; Bock, Hans\n2013-04-26\nA phase III, double-blind, randomized, controlled trial was conducted in Hong Kong to evaluate the efficacy, safety and immunogenicity of a human rotavirus vaccine, RIX4414 (Rotarix) against severe rotavirus gastroenteritis in children up to three years of age. Healthy infants aged 6-12 weeks were enrolled between 08-December-2003 and 31-August-2005 and received two oral doses of either RIX4414 vaccine (N=1513) or placebo (N=1512) given 2 months apart. Vaccine efficacy was assessed from two weeks post-Dose 2 until the children were two and three years of age. Anti-rotavirus IgA seroconversion rate was calculated pre-vaccination and 1-2 months post-Dose 2 using ELISA (cut-off=20 U/mL) for 100 infants. Safety was assessed until the children were two years of age; serious adverse events (SAEs) were recorded throughout the study period. In children aged two and three years of life, vaccine efficacy against severe rotavirus gastroenteritis was 95.6% (95% CI: 73.1%-99.9%) and 96.1% (95% CI: 76.5%-99.9%), respectively. The seroconversion rate 1-2 months after the second dose of RIX4414 was 97.5% (95% CI: 86.8%-99.9%). At least one SAE was recorded in 439 and 477 infants who were administered RIX4414 and placebo, respectively (p-value=0.130). Six intussusception cases were reported (RIX4414=4; placebo=2) and none was assessed to be vaccine-related. RIX4414 was efficacious, immunogenic and safe in the prevention of rotavirus gastroenteritis for at least two years post-vaccination in Hong Kong children. Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.\n[Prospective evaluation of indirect costs due to acute rotavirus gastroenteritis in Spain: the ROTACOST study](http://www.biomedcentral.com/1471-2431/11/81) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nS\u00e1nchez-Lastres Juan\n2011-09-01\nFull Text Available Abstract Background The effect of rotavirus in developed countries is mainly economic. This study aimed to assess the indirect costs induced by rotavirus acute gastroenteritis (RVAGE in Spain. Methods A prospective observational study was conducted from October 2008 to June 2009. It included 682 children up to 5 years of age with acute gastroenteritis (AGE who attended primary care (n = 18 and emergency room/hospital settings (n = 10, covering the regions of Galicia and Asturias (North-west Spain. All non-medical expenses incurred throughout the episode were recorded in detail using personal interviews and telephone contact. Results Among the 682 enrolled children, 207 (30.4% were rotavirus positive and 170 (25% had received at least one dose of rotavirus vaccine. The mean (standard deviation indirect cost caused by an episode of AGE was estimated at 135.17 (182.70 Euros. Costs were 1.74-fold higher when AGE was caused by rotavirus compared with other etiologies: 192.7 (219.8 Euros vs. 111.6 (163.5 Euros (p Conclusions Rotavirus generates a significant indirect economic burden. Our data should be considered in the decision-making process of the eventual inclusion of rotavirus vaccine in the national immunization schedule of well developed countries.\n[Uptake of yeast (Saccharomyces boulardii) in normal and rotavirus treated intestine.](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1383299)\nCartwright-Shamoon, J; Dickson, G R; Dodge, J; Carr, K E\n1996-01-01\nBACKGROUND: There has recently been a growing interest in the use of the non-pathogenic yeast Saccharomyces boulardii, in the treatment of gastrointestinal disorders, including diarrhoea. The full effects of administration of the yeast are not fully understood. AIMS: To investigate the morphological effects of inoculated S boulardii on mouse intestinal villi, both in control animals and those treated with rotavirus. METHODS: Seven day old BALB/c seronegative mice were intubated with either rotavirus (30 microliters orally) or S boulardii (1.5 g/kg) or both rotavirus and S boulardii administered together. Control animals were given saline only. Animals were killed by decapitation 48 hours post-treatment. The middle region of the small intestine was studied using light microscopy and transmission and scanning electron microscopy, including backscattered electron imaging. RESULTS: Animals treated with rotavirus with or without S boulardii developed severe diarrhoea and showed morphological villous changes such as stromal separation and increased epithelial vacuolation. Specimens treated with S boulardii contained yeast particles within the mucosal tissues. CONCLUSION: The administration of S boulardii did not influence the changes produced by rotavirus, but yeast particles appeared to be taken up by the villous mucosa, with the predominant route apparently being uptake between adjacent epithelial cells. Images Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 PMID:8991857\n[Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States.](https://www.ncbi.nlm.nih.gov/pubmed/20083525)\nBoom, Julie A; Tate, Jacqueline E; Sahni, Leila C; Rench, Marcia A; Hull, Jennifer J; Gentsch, Jon R; Patel, Manish M; Baker, Carol J; Parashar, Umesh D\n2010-02-01\nThe goal was to assess the effectiveness of complete (3-dose) or partial (1- or 2-dose) immunization with pentavalent rotavirus vaccine (RV5) against rotavirus acute gastroenteritis (AGE) in US clinical practice. A case-control evaluation was conducted in February through June 2008 at an emergency department in Houston, Texas. Case patients with rotavirus AGE (N = 90) were identified through testing for rotavirus in fecal specimens obtained from 205 children 15 days through 23 months of age presenting with AGE. Control groups included rotavirus-negative AGE patients (N = 115), concurrently enrolled patients with acute respiratory infection (ARI) (N = 228), and up to 10 age- and zip code-matched children sampled from the Houston-Harris County Immunization Registry (HHCIR) for each case patient >8 months of age. Immunization data were obtained from parent records, health care providers, and/or the HHCIR. Vaccine effectiveness was calculated as 1 minus odds of RV5 vaccination for case patients versus control patients, after adjustment for age at presentation and birth date. The vaccine effectiveness of a complete RV5 series was 89% (95% confidence interval [CI]: 70%-96%) and 85% (95% CI: 55%-95%) with rotavirus-negative AGE and ARI control patients, respectively. Immunization data were available for 44% of case patients (n = 40) from the HHCIR; the estimated 3-dose vaccine effectiveness with these HHCIR control patients was 82% (95% CI: 19%-96%). A complete RV5 series conferred 100% protection (95% CI: 71%-100%) against severe rotavirus disease requiring hospitalization and 96% protection (95% CI: 72%-99%) against disease requiring intravenous hydration. Vaccine effectiveness of 1 and 2 doses against hospitalization and emergency department visits was 69% (95% CI: 13%-89%) and 81% (95% CI: 13%-96%), respectively, using rotavirus-negative AGE and ARI control groups combined. In this setting, a complete series of RV5 was highly effective against severe rotavirus AGE\n[Vitamin A deficiency impairs adaptive B and T cell responses to a prototype monovalent attenuated human rotavirus vaccine and virulent human rotavirus challenge in a gnotobiotic piglet model.](http://europepmc.org/articles/PMC3846786?pdf=render) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nKuldeep S Chattha\nFull Text Available Rotaviruses (RV are a major cause of gastroenteritis in children. Widespread vitamin A deficiency is associated with reduced efficacy of vaccines and higher incidence of diarrheal infections in children in developing countries. We established a vitamin A deficient (VAD gnotobiotic piglet model that mimics subclinical vitamin A deficiency in children to study its effects on an oral human rotavirus (HRV vaccine and virulent HRV challenge. Piglets derived from VAD and vitamin A sufficient (VAS sows were orally vaccinated with attenuated HRV or mock, with/without supplemental vitamin A and challenged with virulent HRV. Unvaccinated VAD control piglets had significantly lower hepatic vitamin A, higher severity and duration of diarrhea and HRV fecal shedding post-challenge as compared to VAS control pigs. Reduced protection coincided with significantly higher innate (IFN\u03b1 cytokine and CD8 T cell frequencies in the blood and intestinal tissues, higher pro-inflammatory (IL12 and 2-3 fold lower anti-inflammatory (IL10 cytokines, in VAD compared to VAS control pigs. Vaccinated VAD pigs had higher diarrhea severity scores compared to vaccinated VAS pigs, which coincided with lower serum IgA HRV antibody titers and significantly lower intestinal IgA antibody secreting cells post-challenge in the former groups suggesting lower anamnestic responses. A trend for higher serum HRV IgG antibodies was observed in VAD vs VAS vaccinated groups post-challenge. The vaccinated VAD (non-vitamin A supplemented pigs had significantly higher serum IL12 (PID2 and IFN\u03b3 (PID6 compared to vaccinated VAS groups suggesting higher Th1 responses in VAD conditions. Furthermore, regulatory T-cell responses were compromised in VAD pigs. Supplemental vitamin A in VAD pigs did not fully restore the dysregulated immune responses to AttHRV vaccine or moderate virulent HRV diarrhea. Our findings suggest that that VAD in children in developing countries may partially contribute to more\n[Relevance of Helicobacter pylori virulence factors for vaccine development Relevancia de los factores de virulencia de helicobacter pylori para el desarrollo de vacunas](http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342009000900010) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nLuz del Carmen Hern\u00e1ndez-Hern\u00e1ndez\n2009-01-01\nFull Text Available Helicobacter pylori infection increases the risk for a wide spectrum of clinical outcomes, ranging from peptic ulcer disease to gastric cancer. However, the infection induces gastric and duodenal ulceration or gastric cancer in only a minority of infected subjects because H. pylori strains are genetically diverse and express different virulence factors. Individuals infected with strains that express these virulence factors probably develop severe diseases such as gastric cancer. Nevertheless, the ancient relationship between H. pylori and humans suggests that some strains could be beneficial to human health, which means that generalized administration of antibiotic therapy could eventually cause problems. The development of vaccines based on virulence factors that provide long-term protection is the best strategy for control and/or elimination of pathogenic strains. The different immunization schemes and formulations designed to evaluate the vaccines based on virulence factors in animal models have offered promising results. However, it is necessary to determine whether or not these results can be reproduced in humans. This article reviews recent vaccination studies that explore this possibility: oral vaccines using urease or inactivated whole cells plus LT as adjuvant and urease expressed in Salmonella spp. vectors, as well as a parenteral multicomponent vaccine plus aluminum hydroxide as adjuvant. Although these studies have achieved limited success, they have established support for the development of an effective vaccine against this infection.La infecci\u00f3n por Helicobacter pylori incrementa el riesgo de un amplio espectro de cuadros cl\u00ednicos, que van de la \u00falcera p\u00e9ptica al c\u00e1ncer g\u00e1strico. Sin embargo, la infecci\u00f3n s\u00f3lo induce ulceraci\u00f3n g\u00e1strica y duodenal o c\u00e1ncer g\u00e1strico en la minor\u00eda de los sujetos infectados debido que las cepas de H. pylori son gen\u00e9ticamente diversas y expresan diferentes factores de virulencia. As\n[Acute Rotavirus-Induced Diarrhea in Children: Clinical Picture, Diagnosis, Treatment](http://ai.zaslavsky.com.ua/article/view/78704) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nS.L. Niankovskyi\n2015-09-01\nFull Text Available The paper considers the current aspects of epidemiology, diagnosis, clinical picture and treatment of acute rotavirus-induced diarrhea in children. There are presented the basic thesis of ESPGHAN consensus (2014 about acute diarrheas. There was analyzed the effectiveness of probiotic Subalin producing interferon for the treatment of acute rotavirus-induced diarrhea. It was demonstrated its effectiveness according to the literature review and own data.\n[[Reverse genetics system of rotaviruses: development and application for analysis of VP4 spike protein].](https://www.ncbi.nlm.nih.gov/pubmed/24769586)\nKomoto, Satoshi\n2013-01-01\nThe rotavirus genome is composed of 11 gene segments of double-stranded (ds)RNA. Reverse genetics is the powerful and ideal methodology for the molecular analysis of virus biology, which enables the virus genome to be artificially manipulated. Although reverse genetics systems exist for nearly all major groups of RNA viruses, development of such a system for rotaviruses is more challenging owing in part to the technical complexity of manipulation of their multi-segmented genome. A breakthrough in the field of rotavirus reverse genetics came in 2006, when we established the first reverse genetics system for rotaviruses, which is a partially plasmid-based system that permits replacement of a viral gene segment with the aid of a helper virus. Although this helper virus-driven system is technically limited and gives low levels of recombinant viruses, it allows alteration of the rotavirus genome, thus contributing to our understanding of these medically important viruses. In this review, I describe the development and application of our rotavirus reverse genetics system, and its future perspectives.\n[Analysis of Host Range Restriction Determinants in the Rabbit Model: Comparison of Homologous and Heterologous Rotavirus Infections](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=109534)\nCiarlet, Max; Estes, Mary K.; Barone, Christopher; Ramig, Robert F.; Conner, Margaret E.\n1998-01-01\nThe main limitation of both the rabbit and mouse models of rotavirus infection is that human rotavirus (HRV) strains do not replicate efficiently in either animal. The identification of individual genes necessary for conferring replication competence in a heterologous host is important to an understanding of the host range restriction of rotavirus infections. We recently reported the identification of the P type of the spike protein VP4 of four lapine rotavirus strains as being P[14]. To determine whether VP4 is involved in host range restriction in rabbits, we evaluated infection in rotavirus antibody-free rabbits inoculated orally with two P[14] HRVs, PA169 (G6) and HAL1166 (G8), and with several other HRV strains and animal rotavirus strains of different P and G types. We also evaluated whether the parental rhesus rotavirus (RRV) (P5B[3], G3) and the derived RRV-HRV reassortant candidate vaccine strains RRV \u00d7 D (G1), RRV \u00d7 DS-1 (G2), and RRV \u00d7 ST3 (G4) would productively infect rabbits. Based on virus shedding, limited replication was observed with the P[14] HRV strains and with the SA11 Cl3 (P[2], G3) and SA11 4F (P6[1], G3) animal rotavirus strains, compared to the homologous ALA strain (P[14], G3). However, even limited infection provided complete protection from rotavirus infection when rabbits were challenged orally 28 days postinoculation (DPI) with 103 50% infective doses of ALA rabbit rotavirus. Other HRVs did not productively infect rabbits and provided no significant protection from challenge, in spite of occasional seroconversion. Simian RRV replicated as efficiently as lapine ALA rotavirus in rabbits and provided complete protection from ALA challenge. Live attenuated RRV reassortant vaccine strains resulted in no, limited, or productive infection of rabbits, but all rabbits were completely protected from heterotypic ALA challenge. The altered replication efficiency of the reassortants in rabbits suggests a role for VP7 in host range restriction\n[Meeting the challenge: prevention of pneumococcal disease with conjugate vaccines Al encuentro del reto: prevenci\u00f3n de la enfermedad neumoc\u00f3cica con vacunas conjugadas](http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342001000400012) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nIrma Gabriela Ech\u00e1niz-Avil\u00e9s\n2001-08-01\nFull Text Available Streptococcus pneumoniae is one of the leading causes of both invasive and noninvasive diseases in the pediatric population and continues to represent a significant public health burden worldwide. The increasing incidence of antibioticresistant strains of the pathogen has complicated treatment and management of the various pneumococcal disease manifestations. Thus, the best management strategy may be the prevention of pneumococcal diseases through vaccination. Although several pneumococcal conjugate vaccines have been clinically studied in infants and children, only a 7-valent conjugate vaccine (PNCRM7; Prevnar\u00ae/Prevenar\u00ae is currently approved for the prevention of invasive disease. Vaccination with PNCRM7 is safe and effective in infants and young children. Routine vaccination with the conjugate vaccine could improve outcomes by safeguarding against the development of antibiotic-resistant strains of S. pneumoniae, thus simplifying the management of pneumococcal disease. Additionally, the overall costs associated with the treatment of pneumococcal diseases could be substantially reduced, particularly in developing countries. The time has come for fully applying this new advancement against S. pneumoniae, to benefit the children of the world. The Spanish version of this paper is available at: http://www.insp.mx/salud/index.htmlStreptococcus pneumoniae es uno de los principales agentes causantes de enfermedades invasoras y no invasoras en la poblaci\u00f3n pedi\u00e1trica y sigue representando uno de los principales problemas de salud p\u00fablica a nivel mundial. La incidencia creciente de cepas resistentes a diversos antimicrobianos ha complicado el tratamiento y manejo de varias de las manifestaciones de la enfermedad neumoc\u00f3cica. Con \u00e9stas consideraciones, la mejor estrategia de manejo es la prevenci\u00f3n de \u00e9stas enfermedades a trav\u00e9s de la vacunaci\u00f3n. A pesar de que se han estudiado diversas vacunas neumoc\u00f3cicas conjugadas en ni\u00f1os, solo una\n[Molecular characterization of different equine-like G3 rotavirus strains from Germany.](https://www.ncbi.nlm.nih.gov/pubmed/29128517)\nPietsch, Corinna; Liebert, Uwe G\n2018-01-01\nThe genetic heterogeneity of rotaviruses constitutes a substantial burden to human and animal health. Occasional interspecies transmissions can generate novel virus strains in the human population. We detected equine-like G3P[8] strains in feces sampled from three children in Germany in 2015 and 2016, respectively. Thereof two showed a DS-1-like backbone. In one strain the NSP2 gene segment was of distinct genotype (G3-P[8]-I2-R2-C2-M2-A2-N1-T2-E2-H2). Phylogenetic analyses of the German strains showed a relation to other equine-like G3 rotaviruses circulating in different countries. The reconstruction of reassortment events in the evolution of novel equine-like G3 rotaviruses suggests an independent introduction of the three strains into the local human rotavirus population. Copyright \u00a9 2017 Elsevier B.V. All rights reserved.\n[Inhibition of rotavirus ECwt infection in ICR suckling mice by N-acetylcysteine, peroxisome proliferator-activated receptor gamma agonists and cyclooxygenase-2 inhibitors](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762013000600741&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nCarlos Arturo Guerrero\n2013-09-01\nFull Text Available Live attenuated vaccines have recently been introduced for preventing rotavirus disease in children. However, alternative strategies for prevention and treatment of rotavirus infection are needed mainly in developing countries where low vaccine coverage occurs. In the present work, N-acetylcysteine (NAC, ascorbic acid (AA, some nonsteroidal anti-inflammatory drugs (NSAIDs and peroxisome proliferator-activated receptor gamma (PPAR\u03b3 agonists were tested for their ability to interfere with rotavirus ECwt infectivity as detected by the percentage of viral antigen-positive cells of small intestinal villi isolated from ECwt-infected ICR mice. Administration of 6 mg NAC/kg every 8 h for three days following the first diarrhoeal episode reduced viral infectivity by about 90%. Administration of AA, ibuprofen, diclofenac, pioglitazone or rosiglitazone decreased viral infectivity by about 55%, 90%, 35%, 32% and 25%, respectively. ECwt infection of mice increased expression of cyclooxygenase-2, ERp57, Hsc70, NF-\u03baB, Hsp70, protein disulphide isomerase (PDI and PPAR\u03b3 in intestinal villus cells. NAC treatment of ECwt-infected mice reduced Hsc70 and PDI expression to levels similar to those observed in villi from uninfected control mice. The present results suggest that the drugs tested in the present work could be assayed in preventing or treating rotaviral diarrhoea in children and young animals.\n[Determinants of Parents' Decision to Vaccinate Their Children against Rotavirus: Results of a Longitudinal Study](https://eric.ed.gov/?q=rotavirus&id=EJ986531)\nDube, E.; Bettinger, J. A.; Halperin, B.; Bradet, R.; Lavoie, F.; Sauvageau, C.; Gilca, V.; Boulianne, N.\n2012-01-01\nRotavirus disease is a common cause of health care utilization and almost all children are affected by the age of 5 years. In Canada, at the time of this survey (2008-09), immunization rates for rotavirus were less than 20%. We assessed the determinants of a parent's acceptance to have their child immunized against rotavirus. The survey\u2026\n[One Family's Struggles with Rotavirus](https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_rA4nvL&server=pvlbsrch10&v%3astate=root%7croot&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc3&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&)\nFull Text Available ... thimerosal vaccine safety q & a videos chickenpox (varicella) hepatitis b hib hpv pertussis (whooping cough) pneumococcal rotavirus shingles media room Flu's Gonna Lose M.O.V.E. newsfeeds PSAs publications infectious disease workshop pediatric hepatitis report someone you know has hbv/hcv standard ...\n[IMPLICACIONES \u00c9TICAS Y SOCIALES DE LA INTRODUCCI\u00d3N DE LA VACUNA CONTRA EL VIRUS DEL PAPILOMA HUMANO EN M\u00c9XICO: REFLEXIONES SOBRE UNA PROPUESTA DE INTERVENCI\u00d3N IMPLICA\u00c7\u00d5ES \u00c9TICAS E SOCIAIS DA INTRODU\u00c7\u00c3O DA VACINA CONTRA O VIRUS DO PAPILOMA HUMANO NO M\u00c9XICO: REFLEX\u00d5ES SOBRE UMA PROPOSTA DE INTERVEN\u00c7\u00c3O ETHICAL AND SOCIAL IMPLICATIONS OF THE INTRODUCTION OF THE VACCINE AGAINST THE HUMAN PAPILLOMA VIRUS IN MEXICO: REFLECTIONS ON A PROPOSED INTERVENTION](https://www.openaire.eu/search/publication?articleId=doajarticles::f3f4ecc159ebb48d37bb75cddc626a36)\nAlejandra Prieto de la Rosa; Cristina Guti\u00e9rrez Delgado; Dafna Feinholz Klip; Gisela Morales Gonz\u00e1lez; Renee Witlen\n2008-01-01\nEl objetivo de este trabajo es identificar aspectos \u00e9ticos y sociales relacionados con la introducci\u00f3n de la vacuna contra el virus del papiloma humano (VPH) en M\u00e9xico para una decisi\u00f3n informada y justa que considere no s\u00f3lo los aspectos financieros. De acuerdo con la informaci\u00f3n sobre eficiencia y costo de la vacuna, su introducci\u00f3n al sistema p\u00fablico mexicano puede acarrear consecuencias no previstas para las participantes y para toda la sociedad, por lo que debe examinarse en el contexto ...\n[Presence of rotavirus and free-living amoebae in the water supplies of Karachi, Pakistan](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5459539)\nYousuf, Farzana Abubakar; Siddiqui, Ruqaiyyah; Khan, Naveed Ahmed\n2017-01-01\nABSTRACT Rotavirus and pathogenic free-living amoebae are causative agents of important health problems, especially for developing countries like Pakistan where the population has limited access to clean water supplies. Here, we evaluated the prevalence of rotavirus and free-living amoebae (Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri) in drinking water supplies of Karachi, Pakistan. Six water filtration plants that supply drinking water to the population of Karachi were investigated. Additionally, drinking water samples from households were analyzed for the presence of rotavirus and free-living amoebae. Rotavirus was present in 35% of the water samples collected from water filtration plants; however, domestic tap water samples had a prevalence of only 5%. Out of 20 water samples from filtration plants, 13 (65%) were positive for Acanthamoeba spp., and one (5%) was positive for B. mandrillaris. Out of 20 drinking water samples collected from different areas of Karachi, 35% were positive for Acanthamoeba spp. Rotavirus was detected in 5% of the drinking water samples tested. Overall, these findings showed for the first time the presence of rotavirus, in addition to pathogenic free-living amoebae in drinking water supplies of Karachi that could be an important public health risk for the affected population. PMID:28591260\n[Presence of rotavirus and free-living amoebae in the water supplies of Karachi, Pakistan](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652017005000502&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nFarzana Abubakar Yousuf\nFull Text Available ABSTRACT Rotavirus and pathogenic free-living amoebae are causative agents of important health problems, especially for developing countries like Pakistan where the population has limited access to clean water supplies. Here, we evaluated the prevalence of rotavirus and free-living amoebae (Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri in drinking water supplies of Karachi, Pakistan. Six water filtration plants that supply drinking water to the population of Karachi were investigated. Additionally, drinking water samples from households were analyzed for the presence of rotavirus and free-living amoebae. Rotavirus was present in 35% of the water samples collected from water filtration plants; however, domestic tap water samples had a prevalence of only 5%. Out of 20 water samples from filtration plants, 13 (65% were positive for Acanthamoeba spp., and one (5% was positive for B. mandrillaris. Out of 20 drinking water samples collected from different areas of Karachi, 35% were positive for Acanthamoeba spp. Rotavirus was detected in 5% of the drinking water samples tested. Overall, these findings showed for the first time the presence of rotavirus, in addition to pathogenic free-living amoebae in drinking water supplies of Karachi that could be an important public health risk for the affected population.\n[Rotavirus Infection and Disease in a Multisite Birth Cohort: Results From the MAL-ED Study.](https://www.ncbi.nlm.nih.gov/pubmed/28472348)\nMohan, Venkata Raghava; Karthikeyan, Ramanujam; Babji, Sudhir; McGrath, Monica; Shrestha, Sanjaya; Shrestha, Jasmin; Mdumah, Estomih; Amour, Caroline; Samie, Amidou; Nyathi, Emanuel; Haque, Rashidul; Qureshi, Shahida; Yori, Pablo Pe\u00f1ataro; Lima, Aldo A M; Bodhidatta, Ladaporn; Svensen, Erling; Bessong, Pascal; Ahmed, Tahmeed; Seidman, Jessica C; Zaidi, Anita K M; Kosek, Margaret N; Guerrant, Richard L; Gratz, Jean; Platts-Mills, James A; Lang, Dennis R; Gottlieb, Michael; Houpt, Eric R; Kang, Gagandeep\n2017-08-01\nIn a multicountry birth cohort study, we describe rotavirus infection in the first 2 years of life in sites with and without rotavirus vaccination programs. Children were recruited by 17 days of age and followed to 24 months with collection of monthly surveillance and diarrheal stools. Data on sociodemographics, feeding, and illness were collected at defined intervals. Stools were tested for rotavirus and sera for antirotavirus immunoglobulins by enzyme immunoassays. A total of 1737 children contributed 22646 surveillance and 7440 diarrheal specimens. Overall, rotavirus was detected in 5.5% (408/7440) of diarrheal stools, and 344 (19.8%) children ever had rotavirus gastroenteritis. Household overcrowding and a high pathogen load were consistent risk factors for infection and disease. Three prior infections conferred 74% (P < .001) protection against subsequent infection in sites not using vaccine. In Peru, incidence of rotavirus disease was relatively higher during the second year of life despite high vaccination coverage. Rotavirus infection and disease were common, but with significant heterogeneity by site. Protection by vaccination may not be sustained in the second year of life in settings with high burdens of transmission and poor response to oral vaccines. \u00a9 The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.\n[Desarrollo de vacunas contra el virus de la inmunodeficiencia humana tipo 1: Relevancia de la inmunidad celular contra subtipos Development of vaccines for HIV-1: Relevance of subtype-specific cellular immunity](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802010000600014) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAna Mar\u00eda Rodr\u00edguez\n2010-12-01\nFull Text Available Han pasado casi 30 a\u00f1os de la detecci\u00f3n de los primeros casos de infecci\u00f3n con HIV-1 y a\u00fan no se ha conseguido desarrollar una vacuna efectiva y segura. A pesar del impacto positivo sobre la pandemia que se ha conseguido gracias a los avances en la terapia antirretroviral (TARV, el HIV/sida sigue constituyendo un grave problema para la salud p\u00fablica, especialmente en los pa\u00edses en desarrollo, donde es dif\u00edcil el acceso al tratamiento. En el mundo, 33 millones de personas viven con el virus del sida, mientras que en la Argentina se calcula que habr\u00eda unos 120 000 infectados. Uno de los desaf\u00edos para lograr una vacuna contra el HIV es la variabilidad viral. El grupo M, responsable de la pandemia, se encuentra dividido en 10 subtipos y varios sub-subtipos, adem\u00e1s de las 48 formas recombinantes circulantes y m\u00e1s de cien formas recombinantes \u00fanicas. La epidemia de HIV en nuestro pa\u00eds es tan compleja como en el resto del mundo, con la co-circulaci\u00f3n principalmente de virus pertenecientes al subtipo B y recombinantes BF (CRF12_BF y derivadas. A pesar de la cantidad de trabajos dedicados a la caracterizaci\u00f3n de la respuesta inmune y al desarrollo de vacunas, no queda claro cu\u00e1l es el impacto de la variabilidad en la elecci\u00f3n del ant\u00edgeno. Trabajos realizados en nuestro laboratorio demuestran el papel que juega la inmunidad celular con respecto a las variantes recombinantes BF, tanto en humanos como en modelos animales. Estos resultados son de importancia en el desarrollo de futuras vacunas para nuestra regi\u00f3n.It has been almost 30 years since the detection of the first HIV-1 cases and yet an effective and safe vaccine has not been developed. Although, advances in antiretroviral therapy (HAART have produced a major impact on the pandemic, and even though HIV/aids remains a major concern for developing countries, where access to therapy is limited. The last report from UNAIDS notified 33 million people living with HIV/aids, worldwide\n[Rotavirus epidemiology and surveillance before vaccine introduction in Argentina, 2012-2014.](https://www.ncbi.nlm.nih.gov/pubmed/27487415)\nDegiuseppe, Juan Ignacio; Reale, Ezequiel Agust\u00edn; Stupka, Juan Andr\u00e9s\n2017-03-01\nGroup A Rotavirus has been widely described as one of the most important infantile diarrheal pathogens worldwide. In Argentina, it is responsible for over 200,000 acute diarrhea cases and from 30 to 50 deaths annually in children under 5 years. The aim of this study is to analyze frequency, seasonality, age group distribution, and circulating genotypes based on data notified in the 2012-2014 period and in turn to assess the pre-vaccine scenario, considering that rotavirus vaccine was introduced in 2015. Data were taken from the Viral Diarrhea Notification module of the Argentine SNVS-SIVILA surveillance tool. Analyses of circulating genotypes were performed on rotavirus-positive stool specimens by conventional binary characterization of the outermost capsid genes. Overall data showed rotavirus detection in about 25% of samples tested, and higher rates in children under 2 years old were observed. Rotavirus positive cases were distributed according to a typical winter seasonal pattern. A heterogeneous regional pattern of prevalence was also observed, with higher rates detected in the North region. Genotype co-circulation and annual fluctuation were observed. In general, G1P[8], G2P[4], G3P[8], and G12P[8] were the most frequently detected genotypes. This study represents the last survey taken of a population considered to be na\u00efve. J. Med. Virol. 89:423-428, 2017. \u00a9 2016 Wiley Periodicals, Inc. \u00a9 2016 Wiley Periodicals, Inc.\n[Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis.](https://www.ncbi.nlm.nih.gov/pubmed/23871824)\nVerguet, St\u00e9phane; Murphy, Shane; Anderson, Benjamin; Johansson, Kjell Arne; Glass, Roger; Rheingans, Richard\n2013-10-01\nAn estimated 4% of global child deaths (approximately 300,000 deaths) were attributed to rotavirus in 2010. About a third of these deaths occurred in India and Ethiopia. Public finance of rotavirus vaccination in these two countries could substantially decrease child mortality and also reduce rotavirus-related hospitalizations, prevent health-related impoverishment and bring significant cost savings to households. We use a methodology of 'extended cost-effectiveness analysis' (ECEA) to evaluate a hypothetical publicly financed program for rotavirus vaccination in India and Ethiopia. We measure program impact along four dimensions: 1) rotavirus deaths averted; 2) household expenditures averted; 3) financial risk protection afforded; 4) distributional consequences across the wealth strata of the country populations. In India and Ethiopia, the program would lead to a substantial decrease in rotavirus deaths, mainly among the poorer; it would reduce household expenditures across all income groups and it would effectively provide financial risk protection, mostly concentrated among the poorest. Potential indirect benefits of vaccination (herd immunity) would increase program benefits among all income groups, whereas potentially decreased vaccine efficacy among poorer households would reduce the equity benefits of the program. Our approach incorporates financial risk protection and distributional consequences into the systematic economic evaluation of vaccine policy, illustrated here with the case study of public finance for rotavirus vaccination. This enables selection of vaccine packages based on the quantitative inclusion of information on equity and on how much financial risk protection is being bought per dollar expenditure on vaccine policy, in addition to how much health is being bought. Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.\n[Engineered Lactobacillus rhamnosus GG expressing IgG-binding domains of protein G: Capture of hyperimmune bovine colostrum antibodies and protection against diarrhea in a mouse pup rotavirus infection model.](https://www.ncbi.nlm.nih.gov/pubmed/24291196)\nG\u00fcnayd\u0131n, G\u00f6k\u00e7e; Zhang, Ran; Hammarstr\u00f6m, Lennart; Marcotte, Harold\n2014-01-16\nRotavirus-induced diarrhea causes more than 500,000 deaths annually in the world, and although vaccines are being made available, new effective treatment strategies should still be considered. Purified antibodies derived from hyperimmune bovine colostrum (HBC), from cows immunized with rotavirus, were previously used for treatment of rotavirus diarrhea in children. A combination of HBC antibodies and a probiotic strain of Lactobacillus (L. rhamnosus GG) was also found to be more effective than HBC alone in reducing diarrhea in a mouse model of rotavirus infection. In order to further improve this form of treatment, L. rhamnosus GG was engineered to display surface expressed IgG-binding domains of protein G (GB1, GB2, and GB3) which capture HBC-derived IgG antibodies (HBC-IgG) and thus target rotavirus. The expression of IgG-binding domains on the surface of the bacteria as well as their binding to HBC-IgG and to rotavirus (simian strain RRV) was demonstrated by Western blot, flow cytometry, and electron microscopy. The prophylactic effect of engineered L. rhamnosus GG and anti-rotaviral activity of HBC antibodies was evaluated in a mouse pup model of RRV infection. The combination therapy with engineered L. rhamnosus GG (PG3) and HBC was significantly more effective in reducing the prevalence, severity, and duration of diarrhea in comparison to HBC alone or a combination of wild-type L. rhamnosus GG and HBC. The new therapy reduces the effective dose of HBC between 10 to 100-fold and may thus decrease treatment costs. This antibody capturing platform, tested here for the first time in vivo, could potentially be used to target additional gastrointestinal pathogens. Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.\n[Efficacy of the oral pentavalent rotavirus vaccine in Mali.](https://www.ncbi.nlm.nih.gov/pubmed/22520140)\nSow, Samba O; Tapia, Milagritos; Haidara, Fadima C; Ciarlet, Max; Diallo, Fatoumata; Kodio, Mamoudou; Doumbia, Moussa; Demb\u00e9l\u00e9, Rokiatou D; Traor\u00e9, Oumou; Onwuchekwa, Uma U; Lewis, Kristen D C; Victor, John C; Steele, A Duncan; Neuzil, Kathleen M; Kotloff, Karen L; Levine, Myron M\n2012-04-27\nThe oral, pentavalent rotavirus vaccine (PRV), RotaTeq was assessed for prevention of severe rotavirus gastroenteritis (RVGE) in young children in two multi-site, randomized, placebo-controlled field trials; one in Asia (Vietnam and Bangladesh) and the other in sub-Saharan Africa (Ghana, Kenya and Mali). The efficacy results for the Mali site of the multi-country trial are presented here. We randomly assigned infants in a 1:1 ratio to receive 3 doses of PRV/placebo at approximately 6, 10, and 14 weeks of age. Gastroenteritis episodes were captured passively at the local health centers and by home visits. The primary study outcome was severe RVGE, as defined by a score of \u2265 11 using the Vesikari Clinical Scoring System occurring \u2265 14 days after the third dose until the end of the study. Other efficacy analyses included efficacy against severe RVGE through the first year and during the second years of life, as well as efficacy after receiving at least one dose of vaccine. In total, 1960 infants were enrolled in the trial at the Mali site and sera were collected on a subset of infants (approximately 150) for immunogenicity testing. In the first year of follow-up, largely due to cultural practices to visit traditional healers as the first point of care, the point estimate of efficacy was unreliable: the per protocol vaccine efficacy against severe RVGE was 1% (95% confidence interval [CI]: -431.7, 81.6); the intention-to-treat vaccine efficacy was 42.9% (95% CI: -125.7, 87.7). During the second year of follow-up, after the surveillance system was modified to adapt to local customs and health care seeking practices, the point estimate of per-protocol vaccine efficacy was 19.2% (95% CI: -23.1,47.3%). 82.5% of Malian infants (95% CI: 70.1,91.3%) who received PRV mounted a seroresponse (\u2265 3-fold rise from baseline (prevaccination) to post-dose 3 vaccination) of anti-rotavirus immunoglobulin A antibody, with a post third-dose geometric mean titer (GMT) of 31.3 units\n[Rotavirus 2/6 Viruslike Particles Administered Intranasally with Cholera Toxin, Escherichia coli Heat-Labile Toxin (LT), and LT-R192G Induce Protection from Rotavirus Challenge](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=109829)\nO\u2019Neal, Christine M.; Clements, John D.; Estes, Mary K.; Conner, Margaret E.\n1998-01-01\nWe have shown that rotavirus 2/6 viruslike particles composed of proteins VP2 and VP6 (2/6-VLPs) administered to mice intranasally with cholera toxin (CT) induced protection from rotavirus challenge, as measured by virus shedding. Since it is unclear if CT will be approved for human use, we evaluated the adjuvanticity of Escherichia coli heat-labile toxin (LT) and LT-R192G. Mice were inoculated intranasally with 10 \u03bcg of 2/6-VLPs combined with CT, LT, or LT-R192G. All three adjuvants induced equivalent geometric mean titers of rotavirus-specific serum antibody and intestinal immunoglobulin G (IgG). Mice inoculated with 2/6-VLPs with LT produced significantly higher titers of intestinal IgA than mice given CT as the adjuvant. All mice inoculated with 2/6-VLPs mixed with LT and LT-R192G were totally protected (100%) from rotavirus challenge, while mice inoculated with 2/6-VLPs mixed with CT showed a mean 91% protection from challenge. The availability of a safe, effective mucosal adjuvant such as LT-R192G will increase the practicality of administering recombinant vaccines mucosally. PMID:9525668\n[Economic evaluation of routine infant rotavirus immunisation program in Japan.](https://www.ncbi.nlm.nih.gov/pubmed/27763810)\nHoshi, Shu-Ling; Kondo, Masahide; Okubo, Ichiro\n2017-05-04\nTwo rotavirus vaccines are currently available in Japan. We estimated the incremental cost-effectiveness ratio (ICER) of routine infant rotavirus immunisation program without defining which vaccine to be evaluated, which reflects the current deliberation at the Health Science Council in charge of Immunisation and Vaccine established by the Ministry of Health, Labor and Welfare of Japan. Three ICERs were estimated, one from payers' perspective and 2 from societal perspective depending on the scenarios to uptake vaccines. The health statuses following the birth cohort were as follows: not infected by rotavirus, asymptomatic infection, outpatients after infection, hospitalised after infection, developing encephalitis/encephalopathy followed by recovery, sequelae, and death. Costs of per course of vaccination was \u00a530,000 (US$283; US$1 = \u00a5106). The model runs for 60 months with one month cycle. From payers' perspective, estimated ICERs were \u00a56,877,000 (US$64,877) per QALY. From societal perspective, immunisation program turns out to be cost-saving for 75% simultaneous vaccination scenario, while it is at \u00a5337,000 (US$3,179) per QALY gained with vaccine alone scenario. The probability of rotavirus immunisation program to be under \u00a55,000,000 (US$47,170) per QALY was at 19.8%, 40.7%, and 75.6% when costs per course of vaccination were set at \u00a530,000 (US$283), \u00a525,000 (US$236), and \u00a520,000 (US$189), respectively. Rotavirus immunisation program has a potential to be cost-effective from payers' perspective and even cost-saving from societal perspective in Japan, however, caution should be taken with regard to the interpretation of the results as cost-effectiveness is critically dependent on vaccination costs.\n[Acute myositis associated with concurrent infection of rotavirus and norovirus in a 2-year-old girl](http://www.pagepress.org/journals/index.php/pr/article/view/5873) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nKei Yamamoto\n2015-09-01\nFull Text Available Rotavirus and norovirus are common pathogens associated with gastroenteritis in children. Although rotavirus occasionally induces central nervous system disease, only 3 cases with rotavirus-induced acute myositis have been reported in the English literature. We recently treated a female patient with acute myositis associated with gastroenteritis induced by concurrent infection with rotavirus and norovirus. Having suffered from gastroenteritis for 3 days, she suddenly developed myositis affecting her lower extremities with concomitant creatine kinase elevation. Herein, we present our patient and review the previous cases including those reported in the Japanese literature.\n[Obtenci\u00f3n y evaluaci\u00f3n preliminar de un virus canarypox recombinante como candidato a vacuna antirr\u00e1bica Development and preliminary assessment of a recombinant canarypox virus as an antirabic vaccine candidate](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-75412012000200004) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nFlavia Zanetti\n2012-06-01\nFull Text Available En la Argentina, la rabia est\u00e1 circunscripta a algunas provincias del norte. La disponibilidad de nuevas vacunas que eliminen la manipulaci\u00f3n del virus r\u00e1bico y que permitan el control de la enfermedad es de importancia estrat\u00e9gica nacional y regional. Las vacunas basadas en poxvirus recombinantes se han utilizado con \u00e9xito como vacunas antirr\u00e1bicas a nivel mundial. SI bien estos sistemas no est\u00e1n disponibles comercialmente, la plataforma de obtenci\u00f3n de virus canarypox (CNPV recombinantes ya ha sido implementada en nuestro laboratorio. El objetivo de este trabajo fue obtener y evaluar un candidato a vacuna antirr\u00e1bica basado en CNPV recombinantes que expresan la glicoprote\u00edna G (RG del virus r\u00e1bico (RV. Se construy\u00f3 un virus recombinante que expresa la secuencia codificante de RG (CNPV-RG. La inoculaci\u00f3n de ratones con este virus indujo altos t\u00edtulos de anticuerpos seroneutralizantes de RV (3,58 y 9,76 Ul/ml despu\u00e9s de una o dos inmunizaciones, respectivamente y protegi\u00f3 al 78 % de los animales desafiados intracerebralmente con RV. Adem\u00e1s, se determin\u00f3 que el CNPV-RG posee una potencia relativa de 3,5 Ul/ml. Los resultados obtenidos constituyen la primera etapa en la evaluaci\u00f3n del CNPV-RG como candidato a vacuna antirr\u00e1bica. Se requerir\u00e1n nuevos ensayos para confirmar su utilidad en especies de inter\u00e9s veterinario.In Argentina, rabies is limited to some northern provinces. Availability of new vaccines abolishing the handling of the rabies virus and allowing disease control has regional and national strategic importance. Vaccines based on recombinant poxviruses have been successfully used as antirabic vaccines worldwide. Although these systems are not commercially available, the platform to obtain recombinant canarypox viruses (CNPV has been previously set up in our laboratory. The aim of this work was the development and evaluation of an antirabic vaccine candidate based on recombinant CNPV expressing the rabies virus (RV\n[The Role of Rotavirus Infection Requiring Treatment in a Hospital in Children with Diarrheal Syndrome](http://gastro.zaslavsky.com.ua/article/view/86388) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nYu.Yu. Stepanova\n2013-11-01\nFull Text Available The aim of this research was to investigate the prognostic and diagnostic value of some clinical and biological factors in the development of acute intestinal rotavirus infection in children. We observed 161 children aged 1 month to 6 years. 81 children were diagnosed with rotavirus infection, and 80 \u2014 with secretory diarrhea of unknown origin. Treatment of children was carried out in a hospital. Analysis of clinical and anamnestic data enabled to choose the most prognostically and diagnostically important predictors out of 117 studied risk factors. The authors investigated the association of clinical and biological factors with the severity of rotavirus infection, which would highlight the groups of children with high risk of rotavirus infection, which requires treatment in a hospital. The practical application of the results of this work should be the optimization of early diagnostics of rotavirus infections and timeliness of preventive measures.\n[Vacunas para la prevenci\u00f3n de la gripe en personas de edad avanzada](http://www.sciencedirect.com/science/article/pii/S0716864010706088) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nTom Jefferson\n2010-09-01\nConclusiones de los autores: Las pruebas disponibles son de calidad deficiente y no proporcionan orientaci\u00f3n con respecto a la seguridad, la eficacia o la efectividad de las vacunas contra la gripe en las personas de 65 a\u00f1os de edad o m\u00e1s. Para resolver la incertidumbre se debe realizar un ensayo aleatorio controlado con placebo, con financiamiento p\u00fablico y con poder estad\u00edstico adecuado, durante varias estaciones.\n[Genetic Factors in the Pathogenesis of Rotavirus Infection in Children](http://childshealth.zaslavsky.com.ua/article/view/84825) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nI.I. Nezgoda\n2013-08-01\nFull Text Available The paper presents the results of examination of 40 children with a diagnosis of rotavirus infection. We examined and analyzed the clinical course of rotavirus infection depending on the genotype in polymorphism C > T at position 13910 of lactase gene (LCT. It is found that the most severe course of infection is associated with genotypes that are responsible for lactose intolerance \u2014 C/C-13910 and C/T-13910.\n[Prevalence and characterization of rotaviruses in children hospitalized for diarrheal disease in a tertiary care hospital, Pune](http://www.ijmm.org/article.asp?issn=0255-0857;year=2017;volume=35;issue=1;spage=33;epage=36;aulast=Pol) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nSae Satish Pol\n2017-01-01\nFull Text Available Background: Diarrhoea remains the second most common cause of death among children below 5 years globally. Among various enteric pathogens, rotavirus appears to be the most important aetiological agent of acute gastroenteritis in infants and young children. Increased understanding of epidemiology of rotavirus infections is needed to improve the vaccine efficacy. Aim: This study aims to determine prevalence rotavirus infection and prevalent circulating strains of rotavirus in and around Pune. Setting and Design: Prospective hospital-based study. The study was approved by Institutional Ethical Committee. Materials and Methods: Stool samples (n = 100 were collected from children aged <5 years, hospitalised for acute diarrhoea in paediatric ward at a tertiary care hospital. Samples were subjected for rotavirus antigen capture ELISA. The viral RNA was subjected to multiplex reverse transcription polymerase chain reaction to amplify VP7 genotypes G1\u2013G4, G8\u2013G10 and G12 and VP4 genotypes P[4], P[6], P[8], P[9], P[10] and P[11]. Nontypable rotavirus strains were sequenced. Results: About 35% stool samples were positive for rotavirus antigen by ELISA. G9P[4] (28.6% was found to be the most prevalent rotavirus strain. The detection of emerging strain G12P[6] (14.3% and rare reassortant strain G9P[4] was the significant finding. Conclusion: Genotypes found in circulation are not present in the currently used vaccine. Thus, an emergence of newer genotypes over a period calls for the continued surveillance and genomic characterisation of rotaviruses to improve the vaccine efficacy.\n[Estimating global, regional and national rotavirus deaths in children aged <5 years: Current approaches, new analyses and proposed improvements.](http://europepmc.org/articles/PMC5593200?pdf=render) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nAndrew Clark\nFull Text Available Rotavirus is a leading cause of diarrhoeal mortality in children but there is considerable disagreement about how many deaths occur each year.We compared CHERG, GBD and WHO/CDC estimates of age under 5 years (U5 rotavirus deaths at the global, regional and national level using a standard year (2013 and standard list of 186 countries. The global estimates were 157,398 (CHERG, 122,322 (GBD and 215,757 (WHO/CDC. The three groups used different methods: (i to select data points for rotavirus-positive proportions; (ii to extrapolate data points to individual countries; (iii to account for rotavirus vaccine coverage; (iv to convert rotavirus-positive proportions to rotavirus attributable fractions; and (v to calculate uncertainty ranges. We conducted new analyses to inform future estimates. We found that acute watery diarrhoea was associated with 87% (95% CI 83-90% of U5 diarrhoea hospitalisations based on data from 84 hospital sites in 9 countries, and 65% (95% CI 57-74% of U5 diarrhoea deaths based on verbal autopsy reports from 9 country sites. We reanalysed data from the Global Enteric Multicenter Study (GEMS and found 44% (55% in Asia, and 32% in Africa rotavirus-positivity among U5 acute watery diarrhoea hospitalisations, and 28% rotavirus-positivity among U5 acute watery diarrhoea deaths. 97% (95% CI 95-98% of the U5 diarrhoea hospitalisations that tested positive for rotavirus were entirely attributable to rotavirus. For all clinical syndromes combined the rotavirus attributable fraction was 34% (95% CI 31-36%. This increased by a factor of 1.08 (95% CI 1.02-1.14 when the GEMS results were reanalysed using a more sensitive molecular test.We developed consensus on seven proposals for improving the quality and transparency of future rotavirus mortality estimates.\n[Interactions between Rotavirus and Suwannee River Organic Matter: Aggregation, Deposition, and Adhesion Force Measurement](http://repository.kaust.edu.sa/kaust/handle/10754/598642)\nGutierrez, Leonardo\n2012-08-21\nInteractions between rotavirus and Suwannee River natural organic matter (NOM) were studied by time-resolved dynamic light scattering, quartz crystal microbalance, and atomic force microscopy. In NOM-containing NaCl solutions of up to 600 mM, rotavirus suspension remained stable for over 4 h. Atomic force microscopy (AFM) measurement for interaction force decay length at different ionic strengths showed that nonelectrostatic repulsive forces were mainly responsible for eliminating aggregation in NaCl solutions. Aggregation rates of rotavirus in solutions containing 20 mg C/L increased with divalent cation concentration until reaching a critical coagulation concentration of 30 mM CaCl2 or 70 mM MgCl2. Deposition kinetics of rotavirus on NOM-coated silica surface was studied using quartz crystal microbalance. Experimental attachment efficiencies for rotavirus adsorption to NOM-coated surface in MgCl2 solution were lower than in CaCl2 solution at a given divalent cation concentration. Stronger adhesion force was measured for virus-virus and virus-NOM interactions in CaCl2 solution compared to those in MgCl2 or NaCl solutions at the same ionic strength. This study suggested that divalent cation complexation with carboxylate groups in NOM and on virus surface was an important mechanism in the deposition and aggregation kinetics of rotavirus. \u00a9 2012 American Chemical Society.\n[Effect of breastfeeding promotion interventions on cost-effectiveness of rotavirus immunization in Indonesia](https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F39bd7b4b-d84d-49b3-bdeb-3091271cca90/uquery/rotavirus/id/16/Language/EN)\nSuwantika, Auliya A.; Postma, Maarten J.\n2013-01-01\nBACKGROUND: Rotavirus infection has been reported to be responsible for the majority of severe diarrhea in children under-5-years-old in Indonesia. Breast milk is considered to give protection against rotavirus infection. Increasing breastfeeding promotion programs could be an alternative target to\n[Progress in the introduction of the rotavirus vaccine in Latin America and the Caribbean: four years of accumulated experience.](https://www.ncbi.nlm.nih.gov/pubmed/21183843)\nde Oliveira, Lucia Helena; Danovaro-Holliday, M Carolina; Sanwogou, N Jennifer; Ruiz-Matus, Cuauhtemoc; Tambini, Gina; Andrus, Jon Kim\n2011-01-01\nTwo effective and safe rotavirus vaccines became available in 2006 and have been recommended for use in all countries by the World Health Organization. This article provides an update on the use of rotavirus vaccine in Latin American and Caribbean (LAC) countries. Data reported by LAC countries to the Pan American Health Organization (PAHO) were reviewed. As of May 2010, 14 LAC countries and 1 territory have introduced the rotavirus vaccine into their national expanded program on immunization (EPI). Reported coverage levels for rotavirus vaccine are lower than those for other EPI vaccines recommended at the same age. A total of 15 LAC countries are part of the PAHO's LAC rotavirus surveillance network; 12 of them are using the vaccine. LAC countries are conducting several studies on rotavirus vaccine effectiveness, cost-effectiveness, and monitoring safety. Also, LAC countries are generating lessons learned on the public health implications of introducing a new vaccine into the EPI. Nine countries and the Cayman Islands pay for the entire cost of the vaccine using government funds. All but 2 countries purchase their rotavirus vaccine through PAHO's Revolving Fund. Rotavirus vaccine introduction in LAC has been faster than for other new vaccines, but coverage levels need to increase to maximize the effect of the intervention. Rotavirus surveillance needs to expand and be strengthened to better assess the effect of vaccine use. LAC countries will continue to provide useful data to monitor rotavirus trends and vaccine effect.\n[Strain diversity plays no major role in the varying efficacy of rotavirus vaccines: an overview.](https://www.ncbi.nlm.nih.gov/pubmed/25460825)\nVelasquez, Daniel E; Parashar, Umesh D; Jiang, Baoming\n2014-12-01\nWhile a monovalent Rotarix\u00ae [RV1] and a pentavalent RotaTeq\u00ae [RV5] have been extensively tested and found generally safe and equally efficacious in clinical trials, the question still lingers about the evolving diversity of circulating rotavirus strains over time and their relationship with protective immunity induced by rotavirus vaccines. We reviewed data from clinical trials and observational studies that assessed the efficacy or field effectiveness of rotavirus vaccines against different rotavirus strains worldwide. RV1 provided broad clinical efficacy and field effectiveness against severe diarrhea due to all major circulating strains, including the homotypic G1P[8] and the fully heterotypic G2P[4] strains. Similarly, RV5 provided broad efficacy and effectiveness against RV5 and non-RV5 strains throughout different locations. Rotavirus vaccination provides broad heterotypic protection; however continuing surveillance is needed to track the change of circulating strains and monitor the effectiveness and safety of vaccines. Published by Elsevier B.V.\n[Rotavirus VP7, and VP4 Types circulating in Plateau State Nigeria ...](https://www.ajol.info/index.php/hmrj/article/view/33826) [African Journals Online (AJOL)](http://www.ajol.info/index.php)\nObjective: To determine the rotavirus genotypes circulating in Plateau State using RT \u2013 PCR. Materials and Methods: Thirty one rotavirus isolates recovered from diarrhoeic stools in 1998 and 1999 were analyzed using nested multiplex RT \u2013 PCR technique for the determination of VP7 and VP4 genotypes. Results: VP7 ...\n[Real-time RT-PCR, a necessary tool to support the diagnosis and surveillance of rotavirus in Mexico.](https://www.ncbi.nlm.nih.gov/pubmed/29329758)\nDe La Cruz Hern\u00e1ndez, Sergio Isaac; Anaya Molina, Yazmin; G\u00f3mez Santiago, Fabi\u00e1n; Ter\u00e1n Vega, Heidi Lizbeth; Monroy Leyva, Elda; M\u00e9ndez P\u00e9rez, H\u00e9ctor; Garc\u00eda Lozano, Herlinda\n2018-04-01\nRotavirus produces diarrhea in children under 5 years old. Most of those conventional methods such as polyacrylamide gel electrophoresis (PAGE) and reverse transcription-polymerase chain reaction (RT-PCR) have been used for rotavirus detection. However, these techniques need a multi-step process to get the results. In comparison with conventional methods, the real-time RT-PCR is a highly sensitive method, which allows getting the results in only one day. In this study a real-time RT-PCR assay was tested using a panel of 440 samples from patients with acute gastroenteritis, and characterized by PAGE and RT-PCR. The results show that the real-time RT-PCR detected rotavirus from 73% of rotavirus-negative samples analyzed by PAGE and RT-PCR; thus, the percentage of rotavirus-positive samples increased to 81%. The results indicate that this real-time RT-PCR should be part of a routine analysis, and as a support of the diagnosis of rotavirus in Mexico. Copyright \u00a9 2017 Elsevier Inc. All rights reserved.\n[Epidemiological features of rotavirus infection in Goi\u00e2nia, Goi\u00e1s, Brazil, from 1986 to 2000](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762003000100004) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nDivina das D\u00f4res de Paula Cardoso\n2003-01-01\nFull Text Available A total of 2,605 faecal specimens from children up to 10 years old with or without diarrhoea were collected. Samples were obtained from 1986 to 2000 in hospitals, outpatient clinics and day-care centers in Goi\u00e2nia, Goi\u00e1s. Two methodologies for viral detection were utilized: a combined enzyme immunoassay for rotavirus and adenovirus and polyacrylamide gel electrophoresis. Results showed 374 (14.4% faecal specimens positive for Rotavirus A, most of them collected from hospitalized children. A significant detection rate of rotavirus during the period from April to August, dry season in Goi\u00e2nia, and different frequencies of viral detection throughout the years of study were also observed. Rotavirus was significantly related to hospitalization and to diarrhoeal illness in children up to 24 months old. This study reinforces the importance of rotavirus as a cause of diarrhoea in children and may be important in regards to the implementation of rotavirus vaccination strategies in our country.\n[Reactogenicidad e inmunogenicidad de una nueva vacuna de toxoide tet\u00e1nico y dift\u00e9rico con concentraci\u00f3n reducida en adolescentes cubanos](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200003&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nRolando Felipe Ochoa.\n2006-08-01\nFull Text Available Se realiz\u00f3 un estudio aleatorizado, controlado y a doble ciegas en 225 adolescentes cubanos entre 13 y 16 a\u00f1os de edad, con el objetivo de evaluar la reactogenicidad y la inmunogenicidad de una nueva vacuna de toxoide tet\u00e1nico y toxoide dift\u00e9rico con concentraci\u00f3n reducida, producida en el Instituto Finlay, con respecto a su similar comercial IMOVAX dT adult de Aventis Pasteur. Se tomaron muestras de suero antes y 21 d\u00edas despu\u00e9s de la vacunaci\u00f3n. La reactogenicidad de ambas vacunas fue similar. Los s\u00edntomas y signos, tanto locales como generales fueron moderados y aparecieron principalmente durante las primeras 72 h despu\u00e9s de la vacunaci\u00f3n. Todos los voluntarios vacunados alcanzaron niveles protectores (\u00b30,1 UI/mL de antitoxina contra el t\u00e9tanos y la difteria. El 99,25% de los inmunizados con la vacuna experimental y el 98,36% de los voluntarios del grupo control presentaron niveles de antitoxina tet\u00e1nica correspondientes a una protecci\u00f3n de larga duraci\u00f3n (\u00b31,0 UI/mL; para la antitoxina dift\u00e9rica se alcanzaron estos niveles en el 81,20% y 80,33% de los voluntarios en cada grupo. Los t\u00edtulos medios geom\u00e9tricos de antitoxina tet\u00e1nica (21,73 UI/mL y antitoxina dift\u00e9rica (2,55 UI/mL inducidos por la nueva vacuna fueron superiores (p<0,05 a los del grupo control: 15,55 UI/mL y 1,84 UI/Ml respectivamente(p<0.05.\n[Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.](https://www.ncbi.nlm.nih.gov/pubmed/25919149)\nSigei, Charles; Odaga, John; Mvundura, Mercy; Madrid, Yvette; Clark, Andrew David\n2015-05-07\nRotavirus vaccines have the potential to prevent a substantial amount of life-threatening gastroenteritis in young African children. This paper presents the results of prospective cost-effectiveness analyses for rotavirus vaccine introduction for Kenya and Uganda. In each country, a national consultant worked with a national technical working group to identify appropriate data and validate study results. Secondary data on demographics, disease burden, health utilization, and costs were used to populate the TRIVAC cost-effectiveness model. The baseline analysis assumed an initial vaccine price of $0.20 per dose, corresponding to Gavi, the Vaccine Alliance stipulated copay for low-income countries. The incremental cost-effectiveness of a 2-dose rotavirus vaccination schedule was evaluated for 20 successive birth cohorts from the government perspective in both countries, and from the societal perspective in Uganda. Between 2014 and 2033, rotavirus vaccination can avert approximately 60,935 and 216,454 undiscounted deaths and hospital admissions respectively in children under 5 years in Kenya. In Uganda, the respective number of undiscounted deaths and hospital admission averted is 70,236 and 329,779 between 2016 and 2035. Over the 20-year period, the discounted vaccine program costs are around US$ 80 million in Kenya and US$ 60 million in Uganda. Discounted government health service costs avoided are US$ 30 million in Kenya and US$ 10 million in Uganda (or US$ 18 million including household costs). The cost per disability-adjusted life-year (DALY) averted from a government perspective is US$ 38 in Kenya and US$ 34 in Uganda (US$ 29 from a societal perspective). Rotavirus vaccine introduction is highly cost-effective in both countries in a range of plausible 'what-if' scenarios. The involvement of national experts improves the quality of data used, is likely to increase acceptability of the results in decision-making, and can contribute to strengthened national\n[Prospective evaluation of indirect costs due to acute rotavirus gastroenteritis in Spain: the ROTACOST study.](https://www.ncbi.nlm.nih.gov/pubmed/21917176)\nBouz\u00f3n-Alejandro, Marta; Redondo-Collazo, Lorenzo; S\u00e1nchez-Lastres, Juan Manuel; Martin\u00f3n-Torres, Nazareth; Martin\u00f3n-S\u00e1nchez, Jos\u00e9 Mar\u00eda; Martin\u00f3n-Torres, Federico\n2011-09-14\nThe effect of rotavirus in developed countries is mainly economic. This study aimed to assess the indirect costs induced by rotavirus acute gastroenteritis (RVAGE) in Spain. A prospective observational study was conducted from October 2008 to June 2009. It included 682 children up to 5 years of age with acute gastroenteritis (AGE) who attended primary care (n = 18) and emergency room/hospital settings (n = 10), covering the regions of Galicia and Asturias (North-west Spain). All non-medical expenses incurred throughout the episode were recorded in detail using personal interviews and telephone contact. Among the 682 enrolled children, 207 (30.4%) were rotavirus positive and 170 (25%) had received at least one dose of rotavirus vaccine. The mean (standard deviation) indirect cost caused by an episode of AGE was estimated at 135.17 (182.70) Euros. Costs were 1.74-fold higher when AGE was caused by rotavirus compared with other etiologies: 192.7 (219.8) Euros vs. 111.6 (163.5) Euros (p purchase of material. Patients with RVAGE were admitted to hospital more frequently than those with other etiologies (47.8% vs 14%, p decision-making process of the eventual inclusion of rotavirus vaccine in the national immunization schedule of well developed countries.\n[Pediatric Rotavirus Gastroenteritis: A 2 year Analysis to Understand Current Prevalence in Mumbai](http://www.ojhas.org/issue37/2011-1-15.htm) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nVidya Nerurkar\n2011-04-01\nFull Text Available Many studies have established the high prevalence of paediatric Rotavirus gastroenteritis in India. The importance of rapid diagnosis of rotavirus infection has also been stressed upon, to initiate prompt rehydration therapy and prevent unnecessary use of antibiotics .We undertook a retrospective analysis of 327 paediatric stool specimens to understand the current prevalence and seasonal distribution of cases in Mumbai and its surrounding areas. Overall Rotavirus positivity rate was 37.9 %, with peak positivity in winter seasons. Infections were more common upto 2 years of age. Incidence of bacterial and parasitic coinfections was low.\n[New approaches in oral rotavirus vaccines.](https://www.ncbi.nlm.nih.gov/pubmed/25268934)\nKuate Defo, Zenas; Lee, Byong\n2016-05-01\nRotavirus is the leading cause of severe dehydrating diarrhea worldwide, and affects primarily developing nations, in large part because of the inaccessibility of vaccines and high rates of mortality present therein. At present, there exist two oral rotaviral vaccines, Rotarix\u2122 and RotaTeq\u2122. These vaccines are generally effective in their actions: however, associated costs often stymie their effectiveness, and they continue to be associated with a slight risk of intussusception. While different programs are being implemented worldwide to enhance vaccine distribution and monitor vaccine administration for possible intussusception in light of recent WHO recommendation, another major problem persists: that of the reduced efficacy of the existing rotaviral vaccines in developing countries over time. The development of new oral rotavirus vaccine classes - live-attenuated vaccines, virus-like particles, lactic acid bacteria-containing vaccines, combination therapy with immunoglobulins, and biodegradable polymer-encapsulated vaccines - could potentially circumvent these problems.\n[SPREAD AND PRIMARY MANIFESTATIONS OF ROTAVIRUS INFECTION MORBIDITY IN DIFFERENT PARTS OF THE WORLD](http://pf.spr-journal.ru/jour/article/view/193) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nV. V. Kudryavtsev\n2013-01-01\nFull Text Available The article presents data on the peculiarities of the rotavirus infection spreading in the Russian Federation and other certain countries. It is shown that morbidity levels depend on both objective (population size and territory density, transmission paths activity and subjective (detectability levels factors. It has been established that children 0-3 years of age are the most susceptible to rotavirus infection. The epidemic process development intensity is higher in bigger cities. Considerable regional and seasonal changeability of circulating rotavirus strains is noted.\n[Socio-demographic, Clinical and Laboratory Features of Rotavirus Gastroenteritis in Children Treated in Pediatric Clinic](https://www.openaire.eu/search/publication?articleId=od_______908::bd3535f913b4fa6805664189d8556c48)\nAzemi, Mehmedali; Berisha, Majlinda; Ismaili-Jaha, Vlora; Kolgeci, Selim; Avdiu, Muharrem; Jakupi, Xhevat; Hoxha, Rina; Hoxha-Kamberi, Teuta\n2013-01-01\nAim: The aim of work was presentation of several socio-demographic, clinical and laboratory characteristics of gastroenteritis caused by rotavirus. The examinees and methods: The examinees were children under the age of five years treated at the Pediatric Clinic due to acute gastroenteritis caused by rotavirus. Rotavirus is isolated by method chromatographic immunoassay by Cer Test Biotec. Results: From the total number of patients (850) suffering from acute gastroenteritis, feces test on bac...\n[Epidemiologic Association Between FUT2 Secretor Status and Severe Rotavirus Gastroenteritis in Children in the United States](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4856001)\nPayne, Daniel C.; Currier, Rebecca L.; Staat, Mary A.; Sahni, Leila C.; Selvarangan, Rangaraj; Halasa, Natasha B.; Englund, Janet A.; Weinberg, Geoffrey A.; Boom, Julie A.; Szilagyi, Peter G.; Klein, Eileen J.; Chappell, James; Harrison, Christopher J.; Davidson, Barbara S.; Mijatovic-Rustempasic, Slavica; Moffatt, Mary D.; McNeal, Monica; Wikswo, Mary; Bowen, Michael D.; Morrow, Ardythe L.; Parashar, Umesh D.\n2016-01-01\nIMPORTANCE A genetic polymorphism affecting FUT2 secretor status in approximately one-quarter of humans of European descent affects the expression of histo-blood group antigens on the mucosal epithelia of human respiratory, genitourinary, and digestive tracts. These histo-blood group antigens serve as host receptor sites necessary for attachment and infection of some pathogens, including norovirus. OBJECTIVE We investigated whether an association exists between FUT2 secretor status and laboratory-confirmed rotavirus infections in US children. DESIGN, SETTING, AND PARTICIPANTS Multicenter case-control observational study involving active surveillance at 6 US pediatric medical institutions in the inpatient and emergency department clinical settings. We enrolled 1564 children younger than 5 years with acute gastroenteritis (diarrhea and/or vomiting) and 818 healthy controls frequency matched by age and month, from December 1, 2011, through March 31, 2013. MAIN OUTCOMES AND MEASURES Paired fecal-saliva specimens were tested for rotavirus and for secretor status. Comparisons were made between rotavirus test\u2013positive cases and healthy controls stratified by ethnicity and vaccination status. Adjusted multivariable analyses assessed the preventive association of secretor status against severe rotavirus gastroenteritis. RESULTS One (0.5%) of 189 rotavirus test\u2013positive cases was a nonsecretor, compared with 188 (23%) of 818 healthy control participants (P < .001). Healthy control participants of Hispanic ethnicity were significantly less likely to be nonsecretors (13%) compared with healthy children who were not of Hispanic ethnicity (25%) (P < .001). After controlling for vaccination and other factors, children with the nonsecretor FUT2 polymorphism appeared statistically protected (98% [95% CI, 84%\u2013100%]) against severe rotavirus gastroenteritis. CONCLUSIONS AND RELEVANCE Severe rotavirus gastroenteritis was virtually absent among US children who had a genetic\n[Diversity in Rotavirus\u00e2Host Glycan Interactions: A \u00e2Sweet\u00e2 SpectrumSummary](http://www.sciencedirect.com/science/article/pii/S2352345X16300066) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nSasirekha Ramani\n2016-05-01\nFull Text Available Interaction with cellular glycans is a critical initial step in the pathogenesis of many infectious agents. Technological advances in glycobiology have expanded the repertoire of studies delineating host glycan\u00e2pathogen interactions. For rotavirus, the VP8* domain of the outer capsid spike protein VP4 is known to interact with cellular glycans. Sialic acid was considered the key cellular attachment factor for rotaviruses for decades. Although this is true for many rotavirus strains causing infections in animals, glycan array screens show that many human rotavirus strains bind nonsialylated glycoconjugates, called histo-blood group antigens, in a strain-specific manner. The expression of histo-blood group antigens is determined genetically and is regulated developmentally. Variations in glycan binding between different rotavirus strains are biologically relevant and provide new insights into multiple aspects of virus pathogenesis such as interspecies transmission, host range restriction, and tissue tropism. The genetics of glycan expression may affect susceptibility to different rotavirus strains and vaccine viruses, and impact the efficacy of rotavirus vaccination in different populations. A multidisciplinary approach to understanding rotavirus\u00e2host glycan interactions provides molecular insights into the interaction between microbial pathogens and glycans, and opens up new avenues to translate findings from the bench to the human population. Keywords: Rotavirus, VP8*, Glycans, Sia, Histo-Blood Group Antigens\n[Growth of (20 anti 21)AlGaN, GaN and InGaN by metal organic vapor phase epitaxy](http://www.etde.org/etdeweb/details.jsp?query_id=1&page=0&osti_id=22185738) [Energy Technology Data Exchange (ETDEWEB)](https://www.etde.org/etdeweb/fieldedsearch.jsp)\nPloch, S.; Wernicke, T.; Rass, J.; Pristovsek, M. [TU Berlin, Institut fuer Festkoerperphysik, Hardenbergstr. 36, 10623 Berlin (Germany); Weyers, M. [Ferdinand-Braun-Institut, Leibniz Institut fuer Hoechstfrequenztechnik, Gustav-Kirchhoff-Str. 4, 12489 Berlin (Germany); Kneissl, M. [TU Berlin, Institut fuer Festkoerperphysik, Hardenbergstr. 36, 10623 Berlin (Germany); Ferdinand-Braun-Institut, Leibniz Institut fuer Hoechstfrequenztechnik, Gustav-Kirchhoff-Str. 4, 12489 Berlin (Germany)\n2012-07-01\nGreen InGaN-based laser diodes on (20 anti 21)GaN substrates have recently demonstrated performances exceeding those of conventional (0001) oriented devices. However little is known regarding the growth parameters. We have investigated growth of AlGaN, GaN and InGaN on (20 anti 21)GaN substrates by MOVPE. Smooth GaN layers with a rms roughness <0.5 nm were obtained by low growth temperatures and reactor pressures. The layers exhibit undulations along [10 anti 14] similar to the GaN substrate. AlGaN and InGaN layers exhibit an increased surface roughness. Undulation bunching was observed and attributed to reduced adatom surface mobility due to the binding energy of Al and the low growth temperature for InGaN respectively or strain relaxation. AlGaN and InGaN heterostructures on (20 anti 21)GaN relax by layer tilt accompanied by formation of misfit dislocations, due to shear strain of the unit cell. This relaxation mechanism leads to a reduced critical layer thickness of (20 anti 21)AlGaN layers and InGaN multi quantum wells (MQW) in comparison to (0001). PL spectral broadening of 230 meV of (20 anti 21)InGaN single QWs emitting at 415 nm can be reduced by increased growth temperature or increased number of QWs with reduced thickness.\n[La construcci\u00f3 de fets cient\u00edfics : La vacuna SPf66](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::69504224a67a1db5cf7f4eafc85160f1)\nNaspleda Pardo, Joan\n2015-01-01\nEn aquest treball, a partir de la teoria de l'actor-xarxa i la Sociologia del Coneixement Cient\u00edfic (SCC), analitzem la creaci\u00f3 i evoluci\u00f3 de la vacuna contra la mal\u00e0ria de l'equip del Dr. Manuel Elkin Patarroyo, durant els anys 80 i 90 del passat segle, per mostrar com les interaccions socials participen de manera decisiva en l'acceptaci\u00f3 o rebuig d'una proposta cient\u00edfica. En este trabajo, a partir de la teor\u00eda del actor-red y la Sociolog\u00eda del Conocimiento Cient\u00edfico (SCC), analizamos l...\n[La segunda expedici\u00f3n de Balmis, revoluci\u00f3n y vacuna](https://www.openaire.eu/search/publication?articleId=od_______935::d513a40dc09e50440853f4ad3258003a)\nTuells Hern\u00e1ndez, Jos\u00e9; Duro Torrijos, Jos\u00e9 Luis\n2013-01-01\nCuatro a\u00f1os despu\u00e9s de concluir la Real Expedici\u00f3n Filantr\u00f3pica de la Vacuna (REFV) (1803-1806) en calidad de director, Francisco Xavier Balmis emprendi\u00f3 una nueva comisi\u00f3n con destino a M\u00e9xico que le mantuvo all\u00ed desde 1810 a 1813. El objetivo inicial para el que fue comisionado pasaba por verificar si la estrategia de vacunaci\u00f3n implantada a trav\u00e9s de las Juntas era eficaz y, asimismo, encontrar una fuente de fluido vacuno aut\u00f3ctona que permitiera continuar la acci\u00f3n vacunadora. Balmis ejer...\n[Stability of live attenuated rotavirus vaccine with selected preservatives and primary containers.](https://www.ncbi.nlm.nih.gov/pubmed/27085171)\nLal, Manjari; Jarrahian, Courtney; Zhu, Changcheng; Hosken, Nancy A; McClurkan, Chris L; Koelle, David M; Saxon, Eugene; Roehrig, Andrew; Zehrung, Darin; Chen, Dexiang\n2016-05-11\nRotavirus infection, which can be prevented by vaccination, is responsible for a high burden of acute gastroenteritis disease in children, especially in low-income countries. An appropriate formulation, packaging, and delivery device for oral rotavirus vaccine has the potential to reduce the manufacturing cost of the vaccine and the logistical impact associated with introduction of a new vaccine, simplify the vaccination procedure, and ensure that the vaccine is safely and accurately delivered to children. Single-dose prefilled presentations can be easy to use; however, they are typically more expensive, can be a bottleneck during production, and occupy a greater volume per dose vis-\u00e0-vis supply chain storage and medical waste disposal, which is a challenge in low-resource settings. Multi-dose presentations used thus far have other issues, including increased wastage of vaccine and the need for separate delivery devices. In this study, the goals were to evaluate both the technical feasibility of using preservatives to develop a liquid multi-dose formulation and the primary packaging alternatives for orally delivered, liquid rotavirus vaccines. The feasibility evaluation included evaluation of commonly used preservatives for compatibility with rotavirus vaccines and stability testing of rotavirus vaccine in various primary containers, including Lameplast's plastic tubes, BD's oral dispenser version of Uniject\u2122 (Uniject DP), rommelag's blow-fill-seal containers, and MEDInstill's multi-dose vial and pouch. These presentations were compared to a standard glass vial. The results showed that none of the preservatives tested were compatible with a live attenuated rotavirus vaccine because they had a detrimental effect on the viability of the virus. In the presence of preservatives, vaccine virus titers declined to undetectable levels within 1 month. The vaccine formulation without preservatives maintained a stability profile over 12 months in all primary containers\n[Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger.](https://www.ncbi.nlm.nih.gov/pubmed/28328346)\nIsanaka, Sheila; Guindo, Ousmane; Langendorf, Celine; Matar Seck, Amadou; Plikaytis, Brian D; Sayinzoga-Makombe, Nathan; McNeal, Monica M; Meyer, Nicole; Adehossi, Eric; Djibo, Ali; Jochum, Bruno; Grais, Rebecca F\n2017-03-23\nEach year, rotavirus gastroenteritis is responsible for about 37% of deaths from diarrhea among children younger than 5 years of age worldwide, with a disproportionate effect in sub-Saharan Africa. We conducted a randomized, placebo-controlled trial in Niger to evaluate the efficacy of a live, oral bovine rotavirus pentavalent vaccine (BRV-PV, Serum Institute of India) to prevent severe rotavirus gastroenteritis. Healthy infants received three doses of the vaccine or placebo at 6, 10, and 14 weeks of age. Episodes of gastroenteritis were assessed through active and passive surveillance and were graded on the basis of the score on the Vesikari scale (which ranges from 0 to 20, with higher scores indicating more severe disease). The primary end point was the efficacy of three doses of vaccine as compared with placebo against a first episode of laboratory-confirmed severe rotavirus gastroenteritis (Vesikari score, \u226511) beginning 28 days after dose 3. Among the 3508 infants who were included in the per-protocol efficacy analysis, there were 31 cases of severe rotavirus gastroenteritis in the vaccine group and 87 cases in the placebo group (2.14 and 6.44 cases per 100 person-years, respectively), for a vaccine efficacy of 66.7% (95% confidence interval [CI], 49.9 to 77.9). Similar efficacy was seen in the intention-to-treat analyses, which showed a vaccine efficacy of 69.1% (95% CI, 55.0 to 78.7). There was no significant between-group difference in the risk of adverse events, which were reported in 68.7% of the infants in the vaccine group and in 67.2% of those in the placebo group, or in the risk of serious adverse events (in 8.3% in the vaccine group and in 9.1% in the placebo group); there were 27 deaths in the vaccine group and 22 in the placebo group. None of the infants had confirmed intussusception. Three doses of BRV-PV, an oral rotavirus vaccine, had an efficacy of 66.7% against severe rotavirus gastroenteritis among infants in Niger. (Funded by M\ufffd\n[Prevalence of rotavirus in children hospitalized with acute gastroenteritis in Imam Sajjad Hospital of Yasuj, 2011](http://armaghanj.yums.ac.ir/browse.php?a_code=A-10-1-254&slc_lang=en&sid=1) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nP Khodadadi\n2013-04-01\nFull Text Available Abstract Background & Aim: Rotavirus infection is the most common cause of dehydrating and gastroenteritis among children worldwide. . The aim of this study was to determine the prevalence of rotavirus in children hospitalized with acute gastroenteritis in Imam Sajjad Hospital of Yasuj. Methods: This cross sectional \u2013 descriptive study was done on 184 stool samples of children younger than 7 years of age hospitalized at Imam Sajjad hospital of Yasuj in 2011 due to acute gastroenteritis. All samples were routinely analyzed for detection of rotavirus by Enzyme Immunoassay (EIA test. Data was analyzed by SPSS version 16, Chi-square test and Fisher's exact test. Results: Of the 184 samples analyzed, 52(28.26% were positive.The Results showed significant relationship between the seasonal distribution and virus detection (p=0/001. The highest incidence of rotavirus was seen in autumn with frequency of (48.08% and the lowest in spring (5.77%. Conclusions: According to high prevalence of rotavirus infection, continual surveillance is necessary to provide useful data for formulating effective vaccines and perform diarrhea prevention programs. Key words: Rotavirus, Gastroenteritis, Prevalence, Elisa\n[Use of Internet Search Data to Monitor Rotavirus Vaccine Impact in the United States, United Kingdom, and Mexico.](https://www.ncbi.nlm.nih.gov/pubmed/28369477)\nShah, Minesh P; Lopman, Benjamin A; Tate, Jacqueline E; Harris, John; Esparza-Aguilar, Marcelino; Sanchez-Uribe, Edgar; Richardson, Vesta; Steiner, Claudia A; Parashar, Umesh D\n2018-02-19\nPrevious studies have found a strong correlation between internet search and public health surveillance data. Less is known about how search data respond to public health interventions, such as vaccination, and the consistency of responses in different countries. In this study, we aimed to study the correlation between internet searches for \"rotavirus\" and rotavirus disease activity in the United States, United Kingdom, and Mexico before and after introduction of rotavirus vaccine. We compared time series of internet searches for \"rotavirus\" from Google Trends with rotavirus laboratory reports from the United States and United Kingdom and with hospitalizations for acute gastroenteritis in the United States and Mexico. Using time and location parameters, Google quantifies an internet query share (IQS) to measure the relative search volume for specific terms. We analyzed the correlation between IQS and laboratory and hospitalization data before and after national vaccine introductions. There was a strong positive correlation between the rotavirus IQS and laboratory reports in the United States (R2 = 0.79) and United Kingdom (R2 = 0.60) and between the rotavirus IQS and acute gastroenteritis hospitalizations in the United States (R2 = 0.87) and Mexico (R2 = 0.69) (P United States and by 70% (95% CI, 55%-86%) in Mexico. In the United Kingdom, there was a loss of seasonal variation after vaccine introduction. Rotavirus internet search data trends mirrored national rotavirus laboratory trends in the United States and United Kingdom and gastroenteritis-hospitalization data in the United States and Mexico; lower correlations were found after rotavirus vaccine introduction. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.\n[Improving hepatitis B immunization among high-risk adolescents: a low-cost intervention on the Mexico-United States border Mejores pr\u00e1cticas de inmunizaci\u00f3n anti-hepatitis B para adolescentes en alto riesgo: intervenci\u00f3n de bajo costo en la frontera mexicano-estadounidense](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001000400004) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nKathleen M. O'Rourke\n2001-04-01\ntercera dosis de la vacuna anti-hepatitis B. Resultados. En total, 32% de los adolescentes recibieron la primera dosis de vacuna, 9% la segunda y 2% la tercera. El factor de mayor valor predictivo en relaci\u00f3n con haber recibido una o dos dosis de vacuna fue el haber proporcionado la vacuna en la cl\u00ednica para ETS, en vez de haber remitido al adolescente a una cl\u00ednica independiente para la vacunaci\u00f3n (riesgo relativo [RR] de haber recibido la primera vacuna = 7,3; RR de haber recibido la segunda = 3,8. Tambi\u00e9n se encontr\u00f3 una asociaci\u00f3n entre diversas creencias en materia de salud y el haber sido vacunado. Conclusiones. Los resultados de nuestro estudio indican que los programas de vacunaci\u00f3n contra la hepatitis B pueden mejorarse si la vacuna se aplica en un local de f\u00e1cil acceso, si se instruye a los adolescentes sobre los factores de riesgo de contraer la hepatitis B y si se subrayan las dificultades que entra\u00f1a el tratamiento de esta infecci\u00f3n.\n[Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data.](http://europepmc.org/articles/PMC3548809?pdf=render) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nBaudouin Standaert\nFull Text Available BACKGROUND: Published economic assessments of rotavirus vaccination typically use modelling, mainly static Markov cohort models with birth cohorts followed up to the age of 5 years. Rotavirus vaccination has now been available for several years in some countries, and data have been collected to evaluate the real-world impact of vaccination on rotavirus hospitalisations. This study compared the economic impact of vaccination between model estimates and observed data on disease-specific hospitalisation reductions in a country for which both modelled and observed datasets exist (Belgium. METHODS: A previously published Markov cohort model estimated the impact of rotavirus vaccination on the number of rotavirus hospitalisations in children aged <5 years in Belgium using vaccine efficacy data from clinical development trials. Data on the number of rotavirus-positive gastroenteritis hospitalisations in children aged <5 years between 1 June 2004 and 31 May 2006 (pre-vaccination study period or 1 June 2007 to 31 May 2010 (post-vaccination study period were analysed from nine hospitals in Belgium and compared with the modelled estimates. RESULTS: The model predicted a smaller decrease in hospitalisations over time, mainly explained by two factors. First, the observed data indicated indirect vaccine protection in children too old or too young for vaccination. This herd effect is difficult to capture in static Markov cohort models and therefore was not included in the model. Second, the model included a 'waning' effect, i.e. reduced vaccine effectiveness over time. The observed data suggested this waning effect did not occur during that period, and so the model systematically underestimated vaccine effectiveness during the first 4 years after vaccine implementation. CONCLUSIONS: Model predictions underestimated the direct medical economic value of rotavirus vaccination during the first 4 years of vaccination by approximately 10% when assessing\n[Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model](https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2Fc11a0ded-b830-4723-83ab-afbad5fe39df/uquery/rotavirus/id/20/Language/EN)\nRozenbaum, M.H.; Mangen, M.J.J.; Giaquinto, C.; Wilschut, J.C.; Hak, E.; Postma, M.J.\n2011-01-01\nBackground: Each year rotavirus gastroenteritis results in thousands of paediatric hospitalisations and primary care visits in the Netherlands. While two vaccines against rotavirus are registered, routine immunisation of infants has not yet been implemented. Existing cost-effectiveness studies\n[Oral live attenuated human rotavirus vaccine (RotarixTM offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000700002&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMaria Cleonice A Justino\n2012-11-01\nFull Text Available In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the live attenuated monovalent rotavirus vaccine RIX4414 was evaluated in 15,183 healthy infants followed up during the first two years of life. Bel\u00e9m was the only site in Brazil included in this multicentre trial. The study in Bel\u00e9m included a subset of 653 infants who were followed up until 24 months of age for protection against severe rotavirus gastroenteritis. These subjects were randomly assigned in a 1:1 ratio to receive two doses of vaccine (n = 328 or two doses of placebo (n = 325 at approximately two and four months of age. Of the 653 enrolled infants, 23 dropped out during the study period. For the combined two-year period, the efficacy of RIX4414 was 72.3% [95% confidence interval (CI 37.5-89.1%] against severe rotavirus-related gastroenteritis, reaching a protection rate of 81.8% (95% CI 36.4-96.6% against circulating wild-type G9 rotavirus strains. It is concluded that two doses of RIX4414 are highly efficacious against severe rotavirus gastroenteritis in Bel\u00e9m during the first two years of life and provide high protection against the worldwide emergence and spread of G9P[8] strains.\n[Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis.](http://europepmc.org/articles/PMC3479108?pdf=render) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nManish M Patel\nFull Text Available BACKGROUND: To minimize potential risk of intussusception, the World Health Organization (WHO recommended in 2009 that rotavirus immunization should be initiated by age 15 weeks and completed before 32 weeks. These restrictions could adversely impact vaccination coverage and thereby its health impact, particularly in developing countries where delays in vaccination often occur. METHODS AND FINDINGS: We conducted a modeling study to estimate the number of rotavirus deaths prevented and the number of intussusception deaths caused by vaccination when administered on the restricted schedule versus an unrestricted schedule whereby rotavirus vaccine would be administered with DTP vaccine up to age 3 years. Countries were grouped on the basis of child mortality rates, using WHO data. Inputs were estimates of WHO rotavirus mortality by week of age from a recent study, intussusception mortality based on a literature review, predicted vaccination rates by week of age from USAID Demographic and Health Surveys, the United Nations Children's Fund (UNICEF Multiple Indicator Cluster Surveys (MICS, and WHO-UNICEF 2010 country-specific coverage estimates, and published estimates of vaccine efficacy and vaccine-associated intussusception risk. On the basis of the error estimates and distributions for model inputs, we conducted 2,000 simulations to obtain median estimates of deaths averted and caused as well as the uncertainty ranges, defined as the 5th-95th percentile, to provide an indication of the uncertainty in the estimates. We estimated that in low and low-middle income countries a restricted schedule would prevent 155,800 rotavirus deaths (5th-95th centiles, 83,300-217,700 while causing potentially 253 intussusception deaths (76-689. In contrast, vaccination without age restrictions would prevent 203,000 rotavirus deaths (102,000-281,500 while potentially causing 547 intussusception deaths (237-1,160. Thus, removing the age restrictions would avert an\n[Epidemiology and genetic diversity of rotavirus strains in children with acute gastroenteritis in Lahore, Pakistan.](http://europepmc.org/articles/PMC3692488?pdf=render) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMuhammad Masroor Alam\nFull Text Available Pakistan harbors high disease burden of gastro-enteric infections with majority of these caused by rotavirus. Unfortunately, lack of proper surveillance programs and laboratory facilities have resulted in scarcity of available data on rotavirus associated disease burden and epidemiological information in the country. We investigated 1306 stool samples collected over two years (2008-2009 from hospitalized children under 5 years of age for the presence of rotavirus strains and its genotypic diversity in Lahore. The prevalence rate during 2008 and 2009 was found to be 34% (n = 447 out of 1306. No significant difference was found between different age groups positive for rotavirus (p>0.05. A subset of EIA positive samples was further screened for rotavirus RNA through RT-PCR and 44 (49.43% samples, out of total 89 EIA positive samples, were found positive. G and P type prevalence was found as follows: G1P [4] = 3(6.81%; G1P [6] = 9(20.45%; G1P [8] = 1(2.27%; G2P [4] = 21(47.72%; G2P [8] = 1(2.27%; G9P [4] = 1(2.27%; G9P [6] = 1(2.27% and G9P [8] = 7(15.90%. Phylogenetic analysis revealed that the VP7 and VP4 sequences clustered closely with the previously detected strains in the country as well as Belgian rotaviruses. Antigenic characterization was performed by analyzing major epitopes in the immunodominant VP7 and VP4 gene segments. Although the neutralization conferring motifs were found variable between the Pakistani strains and the two recommended vaccines strains (Rotarix\u2122 and RotaTeq\u2122, we validate the use of rotavirus vaccine in Pakistan based on the proven and recognized vaccine efficacy across the globe. Our findings constitute the first report on rotavirus' genotype diversity, their phylogenetic relatedness and epidemiology during the pre-vaccination era in Lahore, Pakistan and support the immediate introduction of rotavirus vaccine in the routine immunization program of the country.\n[A proposed framework for evaluating and comparing efficacy estimates in clinical trials of new rotavirus vaccines.](https://www.ncbi.nlm.nih.gov/pubmed/25091673)\nNeuzil, Kathleen M; Zaman, K; Victor, John C\n2014-08-11\nOral rotavirus vaccines have yielded different point estimates of efficacy when tested in different populations. While population and environmental factors may account for these differences, study design characteristics should also be considered. We review the study design elements of rotavirus vaccine trials that may affect point estimates of efficacy, and propose a framework for evaluating new rotavirus vaccines. Copyright \u00a9 2014. Published by Elsevier Ltd.\n[Economic evaluations of rotavirus immunization for developing countries : a review of the literature](https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F9f3a5331-c4b9-41a9-9692-7e3ef6a5f30a/uquery/rotavirus/id/4/Language/EN)\nTu, H.A.T.; Woerdenbag, H.J.; Kane, S.; Rozenbaum, M.H.; Li, S.C.; Postma, M.J.\nDiarrhea is a leading cause of mortality for children under 5 years of age, and rotavirus is identified as the main cause of severe diarrhea worldwide. Since 2006, two rotavirus vaccines, Rotarix and Rotateq, have been available in the market. These vaccines have proved to have high efficacy in\n[Anafilaxia associada \u00e0 vacina contra sarampo, caxumba e rub\u00e9ola Anafilaxia asociada a la vacuna contra sarampi\u00f3n, varicela y rub\u00e9ola Anaphylaxis associated with the vaccine against measles, mumps and rubella](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102010000200020) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nIolanda Maria Novadzki\n2010-04-01\nFull Text Available Estudo do tipo caso-controle cujo objetivo foi descrever os casos e as causas de anafilaxia associada \u00e0 vacina contra sarampo, caxumba e rub\u00e9ola. Foram estudados 22 casos notificados em crian\u00e7as de Curitiba, PR, durante Campanha Nacional de Vacina\u00e7\u00e3o de 2004, que apresentaram manifesta\u00e7\u00f5es mucocut\u00e2neas. Para o controle, foram selecionadas 66 crian\u00e7as vizinhas dos casos, que n\u00e3o apresentaram sintomatologia ap\u00f3s a aplica\u00e7\u00e3o vacinal. Foram realizadas dosagens s\u00e9ricas de anticorpos para os ant\u00edgenos vacinais, IgE total e espec\u00edficas para diversos al\u00e9rgenos, e testes cut\u00e2neos. A resposta vacinal foi adequada, a dosagem de IgE espec\u00edfica e os testes cut\u00e2neos mostraram que os al\u00e9rgenos potenciais constituintes da vacina e a atopia n\u00e3o foram relacionados \u00e0s rea\u00e7\u00f5es anafil\u00e1ticas. Os testes cut\u00e2neos com a vacina e o dextrano foram positivos somente nos casos, sugerindo sensibiliza\u00e7\u00e3o por algum componente residual da vacina e poss\u00edvel rea\u00e7\u00e3o cruzada com o dextrano.Estudio del tipo caso-control cuyo objetivo fue describir los casos y las causas de anafilaxia asociada a la vacuna contra sarampi\u00f3n, varicela y rub\u00e9ola. Fueron estudiados 22 casos notificados en ni\u00f1os de Curitiba, Sureste de Brasil, durante Campa\u00f1a Nacional de Vacunaci\u00f3n de 2004, que presentaron manifestaciones mococut\u00e1neas. Para el control, fueron seleccionados 66 ni\u00f1os vecinos de los casos, que no presentaron sintomatolog\u00eda posterior a la aplicaci\u00f3n vacunal. Fueron realizadas dosificaciones s\u00e9ricas de anticuerpos para los ant\u00edgenos vacunales, IgE total y espec\u00edficas para diversos al\u00e9rgenos, y pruebas cut\u00e1neas. La respuesta vacunal fue adecuada, la dosificaci\u00f3n de IgE espec\u00edfica y las pruebas cut\u00e1neas mostraron que los al\u00e9rgenos potenciales constituyentes de la vacuna y la atopia no fueron relacionados a las reacciones anafil\u00e1cticas. Las pruebas cut\u00e1neas con la vacuna y el dextrano fueron positivas solamente en los casos, sugiriendo\n[Reduction in Rotavirus-associated Acute Gastroenteritis Following Introduction of Rotavirus Vaccine Into Australia's National Childhood Vaccine Schedule](https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2Fae43d31d-8ba3-4679-88ba-ae168f0d1069/uquery/gastroenteritis/id/15/Language/EN)\nButtery, Jim P.; Lambert, Stephen B.; Grimwood, Keith; Nissen, Michael D.; Field, Emma J.; Macartney, Kristine K.; Akikusa, Jonathan D.; Kelly, Julian J.; Kirkwood, Carl D.\nIntroduction: Rotavirus vaccines were introduced into the funded Australian National Immunization Program (NIP) in July 2007. Due to purchasing arrangements, individual states and territories chose either a 2-dose RV1 (Rotarix, GSK) regimen or 3-dose RV5 (Rotateq, Merck/CSL) regimen. This allowed\n[Validaci\u00f3n del m\u00e9todo de Ellman para la determinaci\u00f3n de la concentraci\u00f3n de grupos sulfhidrilosa muestras de la producci\u00f3n de la vacuna sint\u00e9tica contra el Haemophilus influenzae tipo b](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2014000200006&lng=es&nrm=iso) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nMayra Wood-Duque\n2014-08-01\nFull Text Available e valid\u00f3 el m\u00e9todo de Ellman para la determinaci\u00f3n de grupos sulfhidrilos de la producci\u00f3n del Ingrediente Farmac\u00e9utico Activo de la vacuna contra el Haemophilusinfluenzaetipo b (Hib. Se evaluaron los par\u00e1metros: linealidad, rango de trabajo, especificidad, exactitud y precisi\u00f3n. El m\u00e9todo fue lineal en el rango de 0,25-4 mM/L. Se demostr\u00f3 que la t\u00e9cnica fue espec\u00edfica con una exactitud entre 95 y 105%. La repetibilidad y la precisi\u00f3n intermedia mostraron coeficientes de variaci\u00f3n inferiores al 5% y 10% respectivamente, por debajo de los criterios de aceptaci\u00f3n requeridos para estos par\u00e1metros. Se estableci\u00f3 el reactivo hidrocloruro de L-ciste\u00edna monohidratado como control positivo del m\u00e9todo. Este ensayo por su precisi\u00f3n, especificidad y exactitud se convierte en una eficaz herramienta para el control del proceso de obtenci\u00f3n de esta vacuna.\n[Que hay en el horizonte sobre el virus del papiloma humano, vacunas y el control del c\u00e1ncer](http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342007000300011&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nPatricia J. Garc\u00eda\n2007-07-01\nFull Text Available Esta revisi\u00f3n provee una visi\u00f3n general sobre las infecciones genitales producidas por el virus del papiloma humano (VPH y de las neoplasias relacionadas con \u00e9ste y la informaci\u00f3n sobre las expectativas crecientes de la vacunaci\u00f3n como medio de prevenci\u00f3n. Se explora como se han desarrollado las vacunas contra el VPH y que aspectos hay que tener en cuenta para una posible implementaci\u00f3n de un programa de vacunaci\u00f3n para prevenir el c\u00e1ncer cervical, como los costos, el p\u00fablico objetivo (varones, mujeres o ambos, grupos de riesgo, a que edad vacunarlos, consideraciones que debemos tener en cuenta en la promoci\u00f3n de la vacuna, que pasar\u00eda con los programas de detecci\u00f3n precoz de c\u00e1ncer cervical y cuales son los potenciales problemas que tendr\u00eda en pa\u00edses en desarrollo.\n[Molecular characterization of group A rotaviruses detected in children with gastroenteritis in Ireland in 2006-2009.](http://www.lenus.ie/hse/handle/10147/198762) [LENUS (Irish Health Repository)](http://www.lenus.ie/hse/)\nCashman, O\n2012-02-01\nSUMMARYCommunity and hospital-acquired cases of human rotavirus are responsible for millions of gastroenteritis cases in children worldwide, chiefly in developing countries, and vaccines are now available. During surveillance activity for human rotavirus infections in Ireland, between 2006 and 2009, a total of 420 rotavirus strains were collected and analysed. Upon either PCR genotyping and sequence analysis, a variety of VP7 (G1-G4 and G9) and VP4 (P[4], P[6], P[8] and P[9]) genotypes were detected. Strains G1P[8] were found to be predominant throughout the period 2006-2008, with slight fluctuations seen in the very limited samples available in 2008-2009. Upon either PCR genotyping and sequence analysis of selected strains, the G1, G3 and G9 viruses were found to contain E1 (Wa-like) NSP4 and I1 VP6 genotypes, while the analysed G2 strains possessed E2 NSP4 and I2 VP6 genotypes, a genetic make-up which is highly conserved in the major human rotavirus genogroups Wa- and Kun-like, respectively. Upon sequence analysis of the most common VP4 genotype, P[8], at least two distinct lineages were identified, both unrelated to P[8] Irish rotaviruses circulating in previous years, and more closely related to recent European humans rotaviruses. Moreover, sequence analysis of the VP7 of G1 rotaviruses revealed the onset of a G1 variant, previously unseen in the Irish population.\n[Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine.](https://www.ncbi.nlm.nih.gov/pubmed/23343932)\nGrant, Lindsay; Watt, James; Moulton, Lawrence; Weatherholtz, Robert; Reid, Raymond; Santosham, Mathuram; O'Brien, Katherine\n2013-06-01\nAcute gastroenteritis (AGE) is recognized as a global, common threat to child survival, especially in developing countries. Rotavirus, in particular, has been implicated as a leading cause of severe AGE; however, there are numerous other pathogens that also cause AGE. Several studies have demonstrated that oral vaccination against rotavirus has generated the unanticipated benefit of protecting against AGE caused by nonrotavirus pathogens. Safety and efficacy of the pentavalent bovine-human reassortant rotavirus vaccine were studied in multiple populations, including children of the Navajo and White Mountain Apache tribes in the southwestern United States. Stool specimens were collected from children with AGE and tested for rotavirus using an enzyme immunoassay. Analyses were conducted to detect the presence or absence of a vaccine effect on incidence, severity, and duration of AGE in which rotavirus was not detected. The majority of AGE (N = 558: 472 nonrotavirus vs 86 rotavirus) occurred between August 2002 and March 2004 among children ranging from ages 4 to 23 months. The incidence of nonrotavirus AGE was similar by vaccine groups with an incidence rate ratio of 1.07 (incidence rate ratio = vaccinated/unvaccinated, 95% confidence interval 0.89-1.29). The hazards of first, second, third, or any AGE in which rotavirus was not detected differed little by vaccination status (P > 0.05). Duration of symptoms and severity of nonrotavirus AGE were similar by vaccine group. There was no vaccine effect on frequency or severity of nonrotavirus AGE.\n[Comparison of 2 Assays for Diagnosing Rotavirus and Evaluating Vaccine Effectiveness in Children with Gastroenteritis](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3739503)\nMijatovic-Rustempasic, Slavica; Tam, Ka Ian; Lyde, Freda C.; Payne, Daniel C.; Szilagyi, Peter; Edwards, Kathryn; Staat, Mary Allen; Weinberg, Geoffrey A.; Hall, Caroline B.; Chappell, James; McNeal, Monica; Gentsch, Jon R.; Bowen, Michael D.; Parashar, Umesh D.\n2013-01-01\nWe compared rotavirus detection rates in children with acute gastroenteritis (AGE) and in healthy controls using enzyme immunoassays (EIAs) and semiquantitative real-time reverse transcription PCR (qRT-PCR). We calculated rotavirus vaccine effectiveness using different laboratory-based case definitions to determine which best identified the proportion of disease that was vaccine preventable. Of 648 AGE patients, 158 (24%) were EIA positive, and 157 were also qRT-PCR positive. An additional 65 (10%) were qRT-PCR positive but EIA negative. Of 500 healthy controls, 1 was EIA positive and 24 (5%) were qRT-PCR positive. Rotavirus vaccine was highly effective (84% [95% CI 71%\u201391%]) in EIA-positive children but offered no significant protection (14% [95% CI \u2212105% to 64%]) in EIA-negative children for whom virus was detected by qRT-PCR alone. Children with rotavirus detected by qRT-PCR but not by EIA were not protected by vaccination, suggesting that rotavirus detected by qRT-PCR alone might not be causally associated with AGE in all patients. PMID:23876518\n[Overcoming perceptions of financial barriers to rotavirus vaccine introduction in Asia.](https://www.ncbi.nlm.nih.gov/pubmed/23955246)\nNelson, E Anthony S; de Quadros, Ciro A; Santosham, Mathuram; Parashar, Umesh D; Steele, Duncan\n2013-11-01\nDespite a WHO recommendation in 2009, reaffirmed in 2013, that all countries should consider introducing rotavirus vaccines into their National Immunization Programs, as of June 2013 only 45 have done so. One major consideration appears to have been the costs of the vaccine to countries. Of concern, is that Asian countries have been slow to introduce rotavirus vaccines despite having robust data that could inform the decision-making process. Although decisions on new vaccine introduction are very complex and vary by country and region, economic evaluations are often pivotal once vaccine efficacy and safety has been established, and disease burden documented and communicated. Unfortunately, with private sector list prices of vaccines often used in economic evaluations, rather than a potential public health sector pricing structure, policy-makers may defer decisions on rotavirus vaccine introduction based on the belief that \"the vaccine price is too high,\" even though this might be based on erroneous data. The Pan American Health Organization's Revolving Fund provides one example of how vaccine price can be made more competitive and transparent through a regional tendering process. Other mechanisms, such as tiered pricing and UNICEF procurement, also exist that could help Asian and other countries move forward more quickly with rotavirus vaccine introduction.\n[Nlrp9b inflammasome restricts rotavirus infection in intestinal epithelial cells.](https://www.ncbi.nlm.nih.gov/pubmed/28636595)\nZhu, Shu; Ding, Siyuan; Wang, Penghua; Wei, Zheng; Pan, Wen; Palm, Noah W; Yang, Yi; Yu, Hua; Li, Hua-Bing; Wang, Geng; Lei, Xuqiu; de Zoete, Marcel R; Zhao, Jun; Zheng, Yunjiang; Chen, Haiwei; Zhao, Yujiao; Jurado, Kellie A; Feng, Ningguo; Shan, Liang; Kluger, Yuval; Lu, Jun; Abraham, Clara; Fikrig, Erol; Greenberg, Harry B; Flavell, Richard A\n2017-06-29\nRotavirus, a leading cause of severe gastroenteritis and diarrhoea in young children, accounts for around 215,000 deaths annually worldwide. Rotavirus specifically infects the intestinal epithelial cells in the host small intestine and has evolved strategies to antagonize interferon and NF-\u03baB signalling, raising the question as to whether other host factors participate in antiviral responses in intestinal mucosa. The mechanism by which enteric viruses are sensed and restricted in vivo, especially by NOD-like receptor (NLR) inflammasomes, is largely unknown. Here we uncover and mechanistically characterize the NLR Nlrp9b that is specifically expressed in intestinal epithelial cells and restricts rotavirus infection. Our data show that, via RNA helicase Dhx9, Nlrp9b recognizes short double-stranded RNA stretches and forms inflammasome complexes with the adaptor proteins Asc and caspase-1 to promote the maturation of interleukin (Il)-18 and gasdermin D (Gsdmd)-induced pyroptosis. Conditional depletion of Nlrp9b or other inflammasome components in the intestine in vivo resulted in enhanced susceptibility of mice to rotavirus replication. Our study highlights an important innate immune signalling pathway that functions in intestinal epithelial cells and may present useful targets in the modulation of host defences against viral pathogens.\n[Nlrp9b inflammasome restricts rotavirus infection in intestinal epithelial cells](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5787375)\nZhu, Shu; Ding, Siyuan; Wang, Penghua; Wei, Zheng; Pan, Wen; Palm, Noah W; Yang, Yi; Yu, Hua; Li, Hua-Bing; Wang, Geng; Lei, Xuqiu; de Zoete, Marcel R.; Zhao, Jun; Zheng, Yunjiang; Chen, Haiwei; Zhao, Yujiao; Jurado, Kellie A.; Feng, Ningguo; Shan, Liang; Kluger, Yuval; Lu, Jun; Abraham, Clara; Fikrig, Erol; Greenberg, Harry B.; Flavell, Richard A.\n2018-01-01\nRotavirus, a leading cause of severe gastroenteritis and diarrhoea in young children, accounts for around 215,000 deaths annually worldwide1. Rotavirus specifically infects the intestinal epithelial cells in the host small intestine and has evolved strategies to antagonize interferon and NF-\u03baB signalling2\u20135, raising the question as to whether other host factors participate in antiviral responses in intestinal mucosa. The mechanism by which enteric viruses are sensed and restricted in vivo, especially by NOD-like receptor (NLR) inflammasomes, is largely unknown. Here we uncover and mechanistically characterize the NLR Nlrp9b that is specifically expressed in intestinal epithelial cells and restricts rotavirus infection. Our data show that, via RNA helicase Dhx9, Nlrp9b recognizes short double-stranded RNA stretches and forms inflammasome complexes with the adaptor proteins Asc and caspase-1 to promote the maturation of interleukin (Il)-18 and gasdermin D (Gsdmd)-induced pyroptosis. Conditional depletion of Nlrp9b or other inflammasome components in the intestine in vivo resulted in enhanced susceptibility of mice to rotavirus replication. Our study highlights an important innate immune signalling pathway that functions in intestinal epithelial cells and may present useful targets in the modulation of host defences against viral pathogens. PMID:28636595\n[Overcoming perceptions of financial barriers to rotavirus vaccine introduction in Asia](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3981852)\nNelson, E Anthony S; de Quadros, Ciro A; Santosham, Mathuram; Parashar, Umesh D; Steele, A Duncan\n2013-01-01\nDespite a WHO recommendation in 2009, reaffirmed in 2013, that all countries should consider introducing rotavirus vaccines into their National Immunization Programs, as of June 2013 only 45 have done so. One major consideration appears to have been the costs of the vaccine to countries. Of concern, is that Asian countries have been slow to introduce rotavirus vaccines despite having robust data that could inform the decision-making process. Although decisions on new vaccine introduction are very complex and vary by country and region, economic evaluations are often pivotal once vaccine efficacy and safety has been established, and disease burden documented and communicated. Unfortunately, with private sector list prices of vaccines often used in economic evaluations, rather than a potential public health sector pricing structure, policy-makers may defer decisions on rotavirus vaccine introduction based on the belief that \u201cthe vaccine price is too high,\u201d even though this might be based on erroneous data. The Pan American Health Organization\u2019s Revolving Fund provides one example of how vaccine price can be made more competitive and transparent through a regional tendering process. Other mechanisms, such as tiered pricing and UNICEF procurement, also exist that could help Asian and other countries move forward more quickly with rotavirus vaccine introduction. PMID:23955246\n[Oral immunization with rotavirus VP7 expressed in transgenic potatoes induced high titers of mucosal neutralizing IgA](http://dx.doi.org/10.1016/S0042-6822(03)00280-0) [International Nuclear Information System (INIS) ](http://inis.iaea.org/search/)\nWu Yuzhang; Li Jintao; Mou Zhirong; Fei Lei; Ni Bing; Geng Miao; Jia Zhengcai; Zhou Wei; Zou Liyun; Tang Yan\n2003-01-01\nRotaviruses (RV) are a common cause of severe diarrhea in young children, resulting in nearly one million deaths worldwide annually. Rotavirus VP7 was the rotavirus neutralizing protein. Previous study reported that VP7 DNA vaccine can induce high levels of IgG in mice but cannot protect mice against challenge (Choi, A.H., Basu, M., Rae, M.N., McNeal, M.M., Ward, R.L., 1998. Virology 250, 230-240). We found that rotavirus VP7 could maintain its neutralizing immunity when it was transformed into the potato genome. Mice immunized with the transformed tubers successfully elicited serum IgG and mucosal IgA specific for VP7. The mucosal IgA titer was as high as 1000, while serum IgG titer was only 600. Neutralizing assays indicated that IgA could neutralize rotavirus. These results indicate the potential usefulness of plants for production and delivery of edible rotavirus vaccines\n[Rotavirus Vaccine will Improve Child Survival by More than Just Preventing Diarrhea: Evidence from Bangladesh.](https://www.ncbi.nlm.nih.gov/pubmed/29210350)\nSaha, Senjuti; Santosham, Mathuram; Hussain, Manzoor; Black, Robert E; Saha, Samir K\n2018-02-01\nDespite the high burden of rotavirus diarrhea, uptake of rotavirus vaccines in Asia remains low. This primarily stems from a perception of rotavirus as a non-life-threatening pathogen amidst a background of competing health priorities and limited resources. In the largest pediatric hospital of Bangladesh, where there is a fierce competition for beds, we found that between November 2015 and October 2016, 12% of 23,064 admissions were due to gastrointestinal infections, 54% of which were caused by rotavirus. One in four cases requiring hospitalization, or 5,879 cases, was refused because of unavailability of beds. Most refused cases were of pneumonia (22%), severe perinatal asphyxia (17%), preterm birth complications (7%), and meningitis (2%), all of which bear high risks of death or disability, if not treated timely. When determining vaccine policies and conducting vaccine impact studies, it would be shortsighted to not consider the impact on morbidity and mortality of cases that are refused admission because of the hospitalization of children with a preventable disease as rotavirus diarrhea. In our hospital, routine use of a rotavirus vaccine with 41% efficacy will release 629 beds per year to accommodate previously refused cases. Based on evidence, we make the case that introduction of this vaccine in Bangladesh and the surrounding region will prevent morbidity and mortality, both directly and indirectly, and help us ensure survival and well-being of all children.\n[Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.](https://www.ncbi.nlm.nih.gov/pubmed/19817600)\nFlem, Elmira T; Latipov, Renat; Nurmatov, Zuridin S; Xue, Yiting; Kasymbekova, Kaliya T; Rheingans, Richard D\n2009-11-01\nWe examined the cost-effectiveness of a rotavirus immunization program in Kyrgyzstan, a country eligible for vaccine funding from the GAVI Alliance. We estimated the burden of rotavirus disease and its economic consequences by using national and international data. A cost-effectiveness analysis was conducted from government and societal perspectives, along with a range of 1-way sensitivity analyses. Rotavirus-related hospitalizations and outpatient visits cost US$580,864 annually, of which $421,658 (73%) is direct medical costs and $159,206 (27%) is nonmedical and indirect costs. With 95% coverage, vaccination could prevent 75% of rotavirus-related hospitalizations and deaths and 56% of outpatient visits and could avert $386,193 (66%) in total costs annually. The medical break-even price at which averted direct medical costs equal vaccination costs is $0.65/dose; the societal break-even price is $1.14/dose for a 2-dose regimen. At the current GAVI Alliance-subsidized vaccine price of $0.60/course, rotavirus vaccination is cost-saving for the government. Vaccination is cost-effective at a vaccine price $9.41/dose, according to the cost-effectiveness standard set by the 2002 World Health Report. Addition of rotavirus vaccines to childhood immunization in Kyrgyzstan could substantially reduce disease burden and associated costs. Vaccination would be cost-effective from the national perspective at a vaccine price $9.41 per dose.\n[Electron microscopic analysis of rotavirus assembly-replication intermediates](http://dx.doi.org/10.1016/j.virol.2015.01.003) [International Nuclear Information System (INIS) ](http://inis.iaea.org/search/)\nBoudreaux, Crystal E.; Kelly, Deborah F.; McDonald, Sarah M.\n2015-01-01\nRotaviruses (RVs) replicate their segmented, double-stranded RNA genomes in tandem with early virion assembly. In this study, we sought to gain insight into the ultrastructure of RV assembly-replication intermediates (RIs) using transmission electron microscopy (EM). Specifically, we examined a replicase-competent, subcellular fraction that contains all known RV RIs. Three never-before-seen complexes were visualized in this fraction. Using in vitro reconstitution, we showed that ~15-nm doughnut-shaped proteins in strings were nonstructural protein 2 (NSP2) bound to viral RNA transcripts. Moreover, using immunoaffinity-capture EM, we revealed that ~20-nm pebble-shaped complexes contain the viral RNA polymerase (VP1) and RNA capping enzyme (VP3). Finally, using a gel purification method, we demonstrated that ~30\u201370-nm electron-dense, particle-shaped complexes represent replicase-competent core RIs, containing VP1, VP3, and NSP2 as well as capsid proteins VP2 and VP6. The results of this study raise new questions about the interactions among viral proteins and RNA during the concerted assembly\u2013replicase process. - Highlights: \u2022 Rotaviruses replicate their genomes in tandem with early virion assembly. \u2022 Little is known about rotavirus assembly-replication intermediates. \u2022 Assembly-replication intermediates were imaged using electron microscopy\n[Electron microscopic analysis of rotavirus assembly-replication intermediates](http://www.etde.org/etdeweb/details.jsp?query_id=1&page=0&osti_id=22470156) [Energy Technology Data Exchange (ETDEWEB)](https://www.etde.org/etdeweb/fieldedsearch.jsp)\nBoudreaux, Crystal E.; Kelly, Deborah F. [Virginia Tech Carilion School of Medicine and Research Institute, Roanoke, VA (United States); McDonald, Sarah M., E-mail: mcdonaldsa@vtc.vt.edu [Virginia Tech Carilion School of Medicine and Research Institute, Roanoke, VA (United States); Department of Biomedical Sciences and Pathobiology, Virginia\u2014Maryland Regional College of Veterinary Medicine, Blacksburg, VA (United States)\n2015-03-15\nRotaviruses (RVs) replicate their segmented, double-stranded RNA genomes in tandem with early virion assembly. In this study, we sought to gain insight into the ultrastructure of RV assembly-replication intermediates (RIs) using transmission electron microscopy (EM). Specifically, we examined a replicase-competent, subcellular fraction that contains all known RV RIs. Three never-before-seen complexes were visualized in this fraction. Using in vitro reconstitution, we showed that ~15-nm doughnut-shaped proteins in strings were nonstructural protein 2 (NSP2) bound to viral RNA transcripts. Moreover, using immunoaffinity-capture EM, we revealed that ~20-nm pebble-shaped complexes contain the viral RNA polymerase (VP1) and RNA capping enzyme (VP3). Finally, using a gel purification method, we demonstrated that ~30\u201370-nm electron-dense, particle-shaped complexes represent replicase-competent core RIs, containing VP1, VP3, and NSP2 as well as capsid proteins VP2 and VP6. The results of this study raise new questions about the interactions among viral proteins and RNA during the concerted assembly\u2013replicase process. - Highlights: \u2022 Rotaviruses replicate their genomes in tandem with early virion assembly. \u2022 Little is known about rotavirus assembly-replication intermediates. \u2022 Assembly-replication intermediates were imaged using electron microscopy.\n[Concomitant Rotavirus and Salmonella Infections in Children with Acute Diarrhea](http://www.sciencedirect.com/science/article/pii/S1875957209600231) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nWen-Tzong Lan\n2009-02-01\nConclusion: Concomitant rotavirus and Salmonella infections accounted for 3.7% of cases in this study. Patients in group C (30.0% had a significantly higher incidence of hypokalemia than group R (7.3% or S (8.8%. Group C consisted of 33 cases of the 895 reviewed cases (3.7%. In a child with rotavirus gastroenteritis, concomitant infection with Salmonella should be considered if the child has sustained a high fever (\u2265 39\u00b0C for over 4 days and a green stool with mucus and blood.\n[Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5839333)\nAliabadi, N.; Tate, J.E.; Parashar, U.D.\n2018-01-01\nRotavirus vaccines have demonstrated significant impact in reducing the burden of morbidity and mortality from childhood diarrhoea in countries that have implemented routine vaccination to date. Despite this success, in many countries, rotavirus vaccine coverage remains lower than that of other routine childhood vaccines. Several issues may potentially affect vaccine uptake, namely safety concerns related to intussusception with consequent age restrictions on rotavirus vaccination, contamination with porcine circovirus, vaccine-derived reassortant strains and hospitalization in newborn nurseries at time of administration of live oral rotavirus vaccine. In addition to these safety concerns, other factors may also affect uptake, including lower vaccine efficacy in the developing world, potential emergence of strains escaping from vaccine protection resulting in lower overall impact of a vaccination programme and sustainable vaccine financing. Although further work is needed to address some of these concerns, global policy bodies have reaffirmed that the benefits of rotavirus vaccination outweigh the risks, and vaccine use is recommended globally. PMID:27129416\n[Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines.](https://www.ncbi.nlm.nih.gov/pubmed/27129416)\nAliabadi, N; Tate, J E; Parashar, U D\n2016-12-01\nRotavirus vaccines have demonstrated significant impact in reducing the burden of morbidity and mortality from childhood diarrhoea in countries that have implemented routine vaccination to date. Despite this success, in many countries, rotavirus vaccine coverage remains lower than that of other routine childhood vaccines. Several issues may potentially affect vaccine uptake, namely safety concerns related to intussusception with consequent age restrictions on rotavirus vaccination, contamination with porcine circovirus, vaccine-derived reassortant strains and hospitalization in newborn nurseries at time of administration of live oral rotavirus vaccine. In addition to these safety concerns, other factors may also affect uptake, including lower vaccine efficacy in the developing world, potential emergence of strains escaping from vaccine protection resulting in lower overall impact of a vaccination programme and sustainable vaccine financing. Although further work is needed to address some of these concerns, global policy bodies have reaffirmed that the benefits of rotavirus vaccination outweigh the risks, and vaccine use is recommended globally. Published by Elsevier Ltd.\n[Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh.](https://www.ncbi.nlm.nih.gov/pubmed/22520143)\nZaman, K; Yunus, M; El Arifeen, Shams; Azim, Tasnim; Faruque, A S G; Huq, Ehsanul; Hossain, Ilias; Luby, Stephen P; Victor, John C; Dallas, Michael J; Lewis, Kristen D C; Rivers, Stephen B; Steele, A Duncan; Neuzil, Kathleen M; Ciarlet, Max; Sack, David A\n2012-04-27\nAn efficacy clinical trial with pentavalent rotavirus vaccine (PRV), RotaTeq(\u00ae), was conducted at Matlab field site of ICDDR,B, Bangladesh from March 2007 to March 2009. The methodology, including operation logistics, and lessons-learned are described in this report. Vaccination was organized at 41 fixed-site clinics twice/month. A total of 1136 infants were randomized 1:1 to receive 3 doses of PRV/placebo at approximately 6-, 10-, and 14-weeks of age with routine vaccines of the Expanded Programme on Immunization (EPI) schedule. Twelve field-workers routinely visited study participants for safety and efficacy follow-up. The study was conducted following good clinical practices and maintaining cold-chain requirements. There were no temperature deviations of clinical vaccine supplies. Data entry was done using the source documents to a central database developed by the sponsor which was linked to web. Among enrolled infants, 1128 (99.3%) received 3 doses of PRV/placebo and efficacy follow-up was conducted for a median of 554 days. For the evaluation of immunogenicity, blood samples were collected from 150 participants predose 1 and from 147 (98%) of the same participants post dose 3. Stool samples were collected from 778 (99.9%) acute gastroenteritis episodes among children who reported to diarrhoea treatment centres. Thirty-nine serious adverse events, including 6 deaths, occurred among study participants. The efficacy of PRV against severe rotavirus gastroenteritis was 42.7% through the entire follow-up period; serum anti-rotavirus IgA response was 78.1%. Inclement weather, difficult transportation, and movement of study participants were some of the challenges identified. This is the first vaccine trial in rural Bangladesh with online data entry. The study was well accepted in the community and was completed successfully. Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.\n[Rotavirus vaccine a\u00e2\u201a\u00ac\u201c What are the concerns of the developing countries?](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::65b6b604c194368acb33dec6a36fd039)\nSHAH, Nitin K\n2010-01-01\nIt is estimated that 0.6 million children die annually due to rotavirus diarrhea under the age of 5 years world over. 90% of these deaths occur in developing countries. Western data suggests that current rotavirus vaccines have 85-95% efficacy against severe rotavirus gastroenteritis (RVGE). There are concerns while using the same in developing countries. Data from African trial has shown 76% efficacy against severe RVGE. Efficacy in malnourished children has been found to be 73% as against 7...\n[Vacunaci\u00f3n de la poblaci\u00f3n de 65 a\u00f1os en Castilla-La Mancha con la vacuna antineumoc\u00f3cica conjugada 13valente (VNC13](http://www.revista-socampar.com/images/articulos/ArticulosSeparadosNum6/Articulo%20especial.pdf) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70)\nSOCAMPAR\n2018-03-01\nFull Text Available La estrategia de vacunaci\u00f3n antineumoc\u00f3cica en adultos a partir de los 65 a\u00f1os de edad ha ido modific\u00e1ndose, tras la aprobaci\u00f3n de la vacuna 13valente conjugada (VNC13 para adultos y la recomendaci\u00f3n de los Centros de Control y Prevenci\u00f3n de enfermedad de EEUU (CDC en el a\u00f1o 2014 de incluir la vacuna VNC13 a la poblaci\u00f3n a partir de 65 a\u00f1os de edad, a partir de los resultados del estudio CAPiTA. Diversos pa\u00edses, y en Espa\u00f1a varias Comunidades Auto- n\u00f3micas, ya han incluido la vacuna VNC13 en los calendarios vacunales de adultos a partir de los 65 a\u00f1os. En este documento, las sociedades: Sociedad de M\u00e9dicos Generales y de Familia de Castilla-La Mancha, Sociedad Castellano Manchega de Patolog\u00eda Respiratoria, Sociedad Castellano Manchega de M\u00e9dicos Preventivistas, Sociedad Castellano Manchega de Geriatr\u00eda, Sociedad Castellano Manchega de M\u00e9dicos Internistas (Secci\u00f3n Infecciosas, Socie- dad Castellano Manchega de Farmacia Familiar y Comunitaria presentamos a la Direcci\u00f3n General de Salud P\u00fablica de la Junta de Comunidades de Castilla-La Mancha nuestra propuesta y justificaci\u00f3n para la inclusi\u00f3n de la vacuna VNC13 en cohorte de 65 a\u00f1os de edad de Castilla-La Mancha", "language": null, "image": null, "pagetype": null, "links": ["#", "//worldwidescience.org/index.html", "//worldwidescience.org/about.html", "//worldwidescience.org/news.html", "//worldwidescience.org/wws", "//worldwidescience.org/contact.html", "//worldwidescience.org/sitemap.html", "//worldwidescience.org/help.html", "#", "#", "#", "#", "#", "#", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998000500007", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892004001200002", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001001000004", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892013001000002&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998000200001", "https://doaj.org/search#.V6PA8bgrK70", "http://www.revistabiomedica.org/index.php/biomedica/article/view/2011", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998000600003&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998000600003", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000400008", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892004000100014", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/23596320", "https://www.science.gov/", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000400001", "https://doaj.org/search#.V6PA8bgrK70", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5858916", "https://www.science.gov/", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892006000900001", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000200004", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=od______1472::a09ac4cf255ae73a6b4363b1bbc0a6ad", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/24240068", "https://www.science.gov/", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998001000001&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "http://revistamedicina.net/ojsanm/index.php/Revistamedicina/article/view/903", "https://doaj.org/search#.V6PA8bgrK70", "http://www.redalyc.org/articulo.oa?id=83743886006", "https://doaj.org/search#.V6PA8bgrK70", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892007000300011", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=dedup_wf_001::9c7220297c636745e06628ec37f2b47e", "https://www.openaire.eu/search/advanced/publications", "http://www.revistas.usach.cl/ojs/index.php/historiasocial/article/view/319", "https://doaj.org/search#.V6PA8bgrK70", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200001&lng=es&nrm=iso&tlng=es", "https://doaj.org/search#.V6PA8bgrK70", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2004000200001&lng=es&nrm=iso&tlng=es", "https://doaj.org/search#.V6PA8bgrK70", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=150959", "https://www.science.gov/", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892009000600003", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=doajarticles::d1c5d56abb3c55f6f0d140a1ec694442", "https://www.openaire.eu/search/advanced/publications", "http://www.redalyc.org/articulo.oa?id=17020115007", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998001000001", "https://doaj.org/search#.V6PA8bgrK70", "http://riiad.org/index.php/riiad/article/view/riiad.2017.2.05", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=od______1404::4f4db4f9056e1f4cbb5edb2cfbec944e", "https://www.openaire.eu/search/advanced/publications", "https://www.openaire.eu/search/publication?articleId=doajarticles::10bf287ae0007ca1c04dfbe102687a3b", "https://www.openaire.eu/search/advanced/publications", "http://revistabionatura.com/2017.02.01.7.html", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1135-57271997000200003", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/28634691", "https://www.science.gov/", "http://www.redalyc.org/articulo.oa?id=17023106004", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998001000006", "https://doaj.org/search#.V6PA8bgrK70", "https://www2c.cdc.gov/podcasts/player.asp?f=8630175", "http://www2c.cdc.gov/podcasts/search.asp", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2004000200002&lng=es&nrm=iso&tlng=es", "https://doaj.org/search#.V6PA8bgrK70", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.openaire.eu/search/publication?articleId=od______3040::cc271e44d67bb301b8673ae704eb1321", "https://www.openaire.eu/search/advanced/publications", "http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802010000300002&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=od______3272::e04c2a8ca070b76a97f8c299cefc6434", "https://www.openaire.eu/search/advanced/publications", "https://www.openaire.eu/search/publication?articleId=od______1326::8fd162326a4cf806bef07884700a3945", "https://www.openaire.eu/search/advanced/publications", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892007000300003", "https://doaj.org/search#.V6PA8bgrK70", "https://medlineplus.gov/druginfo/meds/a607024.html", "https://www.science.gov/", "https://revistas.unal.edu.co/index.php/revfacmed/article/view/22140", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1726-46342015000300021&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "http://www.revistabiomedica.org/index.php/biomedica/article/view/1320", "https://doaj.org/search#.V6PA8bgrK70", "https://kidshealth.org/en/parents/rotavirus.html", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/29649603", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4185955", "https://www.science.gov/", "http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802010000600014&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=doajarticles::4639710bd8874709386dd27339826e1d", "https://www.openaire.eu/search/advanced/publications", "https://www.cdc.gov/rotavirus/about/symptoms.html", "https://www.science.gov/", "https://www.cdc.gov/rotavirus/about/treatment.html", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/23597719", "https://www.science.gov/", "https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2Ffc35074c-bf0d-40e5-b7ec-0c349ee5cfb9/uquery/Rotavirus/id/19/Language/EN", "http://www.narcis.nl", "http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802011000500015&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5355572", "https://www.science.gov/", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/26626122", "https://www.science.gov/", "https://doi.org/10.4137/VRT.S563", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/28414969", "https://www.science.gov/", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892006000300006", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=od______1404::6574285bd1662fef225103ab5f2fa6f1", "https://www.openaire.eu/search/advanced/publications", "http://revistamedicina.net/ojsanm/index.php/Revistamedicina/article/view/92", "https://doaj.org/search#.V6PA8bgrK70", "http://www.sciencedirect.com/science/article/pii/S0929664612000952", "https://doaj.org/search#.V6PA8bgrK70", "http://www.sciencedirect.com/science/article/pii/S0716864017300160", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/28627429", "https://www.science.gov/", "https://www.openaire.eu/search/publication?articleId=od_______908::f1b3fdda30fee87b8342a3ebe47df54f", "https://www.openaire.eu/search/advanced/publications", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1726-46342013000200018&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4710432", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/26598569", "https://www.science.gov/", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1135-57271999000400003", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=od______1404::05502ca26081377cb9ac9b967d7e66d8", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/26454434", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5330216", "https://www.science.gov/", "https://medlineplus.gov/rotavirusinfections.html", "https://www.science.gov/", "http://www.redalyc.org/articulo.oa?id=17043728001", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=dedup_wf_001::61ee14b25b56c72855596bb426219d56", "https://www.openaire.eu/search/advanced/publications", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "http://www.redalyc.org/articulo.oa?id=17015304012", "https://doaj.org/search#.V6PA8bgrK70", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3106224", "https://www.science.gov/", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000900005", "https://doaj.org/search#.V6PA8bgrK70", "http://asclepio.revistas.csic.es/index.php/asclepio/article/view/71/74", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892002001000005", "https://doaj.org/search#.V6PA8bgrK70", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2010000300001&lng=es&nrm=iso&tlng=es", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=od______3056::d4191acb1173d7dbea934cb8c961809f", "https://www.openaire.eu/search/advanced/publications", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4103797", "https://www.science.gov/", "https://www.openaire.eu/search/publication?articleId=od______1326::8ba7ba7cedd44552d4d60ca52f50c9aa", "https://www.openaire.eu/search/advanced/publications", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5774175", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/28780116", "https://www.science.gov/", "http://www.biomedcentral.com/1471-2180/7/86", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=doajarticles::e763456eb267d72953262b77223c70f4", "https://www.openaire.eu/search/advanced/publications", "http://www.revistabiomedica.org/index.php/biomedica/article/view/2007", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/20006144", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/22885016", "https://www.science.gov/", "https://www.openaire.eu/search/publication?articleId=od______1325::4966a7cc814137a440382bdf643c90d0", "https://www.openaire.eu/search/advanced/publications", "https://revistas.unal.edu.co/index.php/actabiol/article/view/11338", "https://doaj.org/search#.V6PA8bgrK70", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2016000200003&lng=es&nrm=iso&tlng=es", "https://doaj.org/search#.V6PA8bgrK70", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2007000300004&lng=es&nrm=iso&tlng=es", "https://doaj.org/search#.V6PA8bgrK70", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200005&lng=es&nrm=iso&tlng=es", "https://doaj.org/search#.V6PA8bgrK70", "http://www.sciencedirect.com/science/article/pii/S0716864014700689", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/29444124", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/22252206", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/27059357", "https://www.science.gov/", "http://www.dovepress.com/prevention-of-rotavirus-gastroenteritis-in-infants-and-children-rotavi-a4944", "https://doaj.org/search#.V6PA8bgrK70", "https://www.termedia.pl/ABO-blood-grouping-in-Egyptian-children-with-rotavirus-gastroenteritis,41,30725,1,1.html", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/29466164", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/11715170", "https://www.science.gov/", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001001000004&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "https://www.cdc.gov/features/rotavirus/", "https://www.science.gov/", "https://www2c.cdc.gov/podcasts/player.asp?f=8630647", "http://www2c.cdc.gov/podcasts/search.asp", "https://www.ncbi.nlm.nih.gov/pubmed/28893479", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4896777", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/25424931", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/27642146", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3982048", "https://www.science.gov/", "https://medlineplus.gov/languages/rotavirusinfections.html", "https://www.science.gov/", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2010000200006&lng=es&nrm=iso", "https://doaj.org/search#.V6PA8bgrK70", "http://www.redalyc.org/articulo.oa?id=17074415", "https://doaj.org/search#.V6PA8bgrK70", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "http://www.biomedcentral.com/1471-2458/9/29", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/22520123", "https://www.science.gov/", "https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=38058367", "http://inis.iaea.org/search/", "http://www.ijmm.org/article.asp?issn=0255-0857;year=2006;volume=24;issue=4;spage=252;epage=257;aulast=Kang", "https://doaj.org/search#.V6PA8bgrK70", "http://ejournal.stitmuh-pacitan.ac.id/index.php/attajdid/article/view/22", "https://doaj.org/search#.V6PA8bgrK70", "http://europepmc.org/articles/PMC1852122?pdf=render", "https://doaj.org/search#.V6PA8bgrK70", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1852122", "https://www.science.gov/", "http://www.virologyj.com/content/9/1/137", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/29281659", "https://www.science.gov/", "https://www.openaire.eu/search/publication?articleId=od______3056::5d7a8a9d35638166a4e7ccabd8678667", "https://www.openaire.eu/search/advanced/publications", "https://www.openaire.eu/search/publication?articleId=od______1404::4dfcdb9afa501d98d59e07e37c0dec1f", "https://www.openaire.eu/search/advanced/publications", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891997001200001", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891997001200001&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "http://www.sciencedirect.com/science/article/pii/S2255553613000785", "https://doaj.org/search#.V6PA8bgrK70", "https://www.narcis.nl/publication/RecordID/oai%3Arepub.eur.nl%3A6760/uquery/Gene%2Bexpression%2BmRNA%2B/id/8/Language/EN", "http://www.narcis.nl", "http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802005000400008", "https://doaj.org/search#.V6PA8bgrK70", "http://www.etde.org/etdeweb/details.jsp?query_id=1&page=0&osti_id=21484941", "https://www.etde.org/etdeweb/fieldedsearch.jsp", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=110343", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/29754701", "https://www.science.gov/", "http://europepmc.org/articles/PMC4249891?pdf=render", "https://doaj.org/search#.V6PA8bgrK70", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4249891", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/22228235", "https://www.science.gov/", "https://www.openaire.eu/search/publication?articleId=od______1325::3699ed70c8821c924c79160abcf4fcaf", "https://www.openaire.eu/search/advanced/publications", "https://www.ajol.info/index.php/ajhs/article/viewFile/30763/23063", "http://www.ajol.info/index.php", "http://www.forskningsdatabasen.dk/en/catalog/2389446027", "http://forskningsbasen.deff.dk/?lang=eng", "https://www.ncbi.nlm.nih.gov/pubmed/22974466", "https://www.science.gov/", "https://www.openaire.eu/search/publication?articleId=od______3056::c178bdb2747b8762099be70feeaa7237", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/29142125", "https://www.science.gov/", "https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_ndovhy&server=pvlbsrch10&v%3astate=root%7croot-70-10%7c0&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc73&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&", "http://www.nlm.nih.gov/medlineplus/videosandcooltools.html", "https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_seiady&server=pvlbsrch13&v%3astate=root%7croot&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc3&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&", "http://www.nlm.nih.gov/medlineplus/videosandcooltools.html", "http://www.biomedcentral.com/1471-2431/9/11", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/24758998", "https://www.science.gov/", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75152009000200004", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892000001000002", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892000001000002&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=dedup_wf_001::079e97a5d510c0250481d9007f374dfc", "https://www.openaire.eu/search/advanced/publications", "http://www.cdc.gov/eid/content/13/6/pdfs/855.pdf", "http://forskningsbasen.deff.dk/?lang=eng", "https://www.ncbi.nlm.nih.gov/pubmed/28481726", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/24200975", "https://www.science.gov/", "http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342006000100007&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.cdc.gov/vaccines/parents/diseases/child/rotavirus.html", "https://www.science.gov/", "http://europepmc.org/articles/PMC5744930?pdf=render", "https://doaj.org/search#.V6PA8bgrK70", "https://tools.cdc.gov/medialibrary/index.aspx#/media/id/304033", "http://www2c.cdc.gov/podcasts/search.asp", "http://www.biomedcentral.com/1471-2334/12/213", "https://doaj.org/search#.V6PA8bgrK70", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5443368", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/28059609", "https://www.science.gov/", "https://www.openaire.eu/search/publication?articleId=doajarticles::136a986051855d4bcd529e7bf176cfb3", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/23246261", "https://www.science.gov/", "http://www.sst.dk/publ/Publ2012/06juni/MTV-RotavirusMedBilag.pdf%20", "http://forskningsbasen.deff.dk/?lang=eng", "http://journal.fk.unpad.ac.id/index.php/mkb/article/view/29", "https://doaj.org/search#.V6PA8bgrK70", "http://www.dovepress.com/human-rotavirus-genotypes-circulating-in-brazil-before-and-after-a-nat-a6925", "https://doaj.org/search#.V6PA8bgrK70", "http://www.virologyj.com/content/4/1/31", "https://doaj.org/search#.V6PA8bgrK70", "https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=49051232", "http://inis.iaea.org/search/", "http://mimmun.ru/mimmun/article/view/1065", "https://doaj.org/search#.V6PA8bgrK70", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2017000100001&lng=es&nrm=iso&tlng=es", "https://doaj.org/search#.V6PA8bgrK70", "http://www.dicle.edu.tr/fakulte/tip/dergi/yayin/381/21.pdf", "https://doaj.org/search#.V6PA8bgrK70", "http://www.danmedj.dk/portal/page/portal/danmedj.dk/dmj_forside/PAST_ISSUE/2011/DMB_2011_10/A4323/A4323.pdf", "http://forskningsbasen.deff.dk/?lang=eng", "http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0213-91112005000600006", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=od______1404::024354d31010002918ddb339dc0408a6", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/19062768", "https://www.science.gov/", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1726-46342012000200017", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=od_______908::82c738f1ea1c402e082680d4f3a8efe8", "https://www.openaire.eu/search/advanced/publications", "https://www.openaire.eu/search/publication?articleId=dedup_wf_001::9f9342f04c4ecfc6206eb357ddd593ea", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/22939015", "https://www.science.gov/", "https://www.openaire.eu/search/publication?articleId=doajarticles::665616b0e79abcde2883f393f494e02c", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/22520119", "https://www.science.gov/", "http://europepmc.org/articles/PMC3706538?pdf=render", "https://doaj.org/search#.V6PA8bgrK70", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1472071", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/27830685", "https://www.science.gov/", "https://www.openaire.eu/search/publication?articleId=doajarticles::cd2d869696f88a55899ab58f2ce979f2", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/26440913", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/26823214", "https://www.science.gov/", "http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102009000600013", "https://doaj.org/search#.V6PA8bgrK70", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2017000100003&lng=es&nrm=iso&tlng=es", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/28719399", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/21668823", "https://www.science.gov/", "https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=20063690", "http://inis.iaea.org/search/", "http://www.etde.org/etdeweb/details.jsp?query_id=1&page=0&osti_id=6207519", "https://www.etde.org/etdeweb/fieldedsearch.jsp", "https://www.openaire.eu/search/publication?articleId=od_______908::5fac479ef6fc442bc7d919a6997b1203", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/28333764", "https://www.science.gov/", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ajol.info/index.php/aam/article/viewFile/43201/26744", "http://www.ajol.info/index.php", "http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342010000300007", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=od_______296::4dfda7f2f3e4339756541268672e7022", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/25795258", "https://www.science.gov/", "http://europepmc.org/articles/PMC5100943?pdf=render", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/27824918", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/26092449", "https://www.science.gov/", "https://www.openaire.eu/search/publication?articleId=doajarticles::3941e408f16fd779b922d875bd01b15f", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/28693503", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/26116250", "https://www.science.gov/", "https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=39076497", "http://inis.iaea.org/search/", "http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342009000400004", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-75412005000200010", "https://doaj.org/search#.V6PA8bgrK70", "http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0465-546X2007000400010", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/28161962", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5580433", "https://www.science.gov/", "https://www2c.cdc.gov/podcasts/player.asp?f=10650", "http://www2c.cdc.gov/podcasts/search.asp", "http://mji.ui.ac.id/journal/index.php/mji/article/view/1957", "https://doaj.org/search#.V6PA8bgrK70", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200004&lng=es&nrm=iso&tlng=es", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/27059358", "https://www.science.gov/", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "http://www.sciencedirect.com/science/article/pii/S071686401470063X", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/28746261", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3982044", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/22520135", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/28820385", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/26710540", "https://www.science.gov/", "https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=22065961", "http://inis.iaea.org/search/", "http://dx.doi.org/10.1155/2010/708460", "https://doaj.org/search#.V6PA8bgrK70", "https://www.gpo.gov/fdsys/pkg/FR-2010-08-11/pdf/2010-19782.pdf", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/23658521", "https://www.science.gov/", "http://europepmc.org/articles/PMC3642062?pdf=render", "https://doaj.org/search#.V6PA8bgrK70", "http://www.biomedcentral.com/1471-2334/13/54", "https://doaj.org/search#.V6PA8bgrK70", "http://www.revistabiomedica.org/index.php/biomedica/article/view/44", "https://doaj.org/search#.V6PA8bgrK70", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4298538", "https://www.science.gov/", "http://www.biomedcentral.com/1471-2458/10/469", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/27835052", "https://www.science.gov/", "http://www.virologyj.com/content/8/1/109", "https://doaj.org/search#.V6PA8bgrK70", "http://dx.doi.org/10.1155/2016/8485417", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=od_______617::72f63e3faddc26d37afb5bec15e160d2", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/25091665", "https://www.science.gov/", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "http://www.biomedcentral.com/1471-2458/11/S3/S16", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ajol.info/index.php/njcp/article/download/111648/101421", "http://www.ajol.info/index.php", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892004000400005", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/28430997", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/28623028", "https://www.science.gov/", "https://www.openaire.eu/search/publication?articleId=dedup_wf_001::e53e6396d7036924ac4edb136005a9b2", "https://www.openaire.eu/search/advanced/publications", "https://www.ajol.info/index.php/pamj/article/view/82072", "http://www.ajol.info/index.php", "https://www.ncbi.nlm.nih.gov/pubmed/22929174", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/27059345", "https://www.science.gov/", "http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1025-55832008000100006&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=39093882", "http://inis.iaea.org/search/", "https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=21078892", "http://inis.iaea.org/search/", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2000000400004&lng=es&nrm=iso&tlng=es", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=dedup_wf_001::1ea3de1bdf059dfdef615fb2bb624b84", "https://www.openaire.eu/search/advanced/publications", "http://www.etde.org/etdeweb/details.jsp?query_id=1&page=0&osti_id=5714984", "https://www.etde.org/etdeweb/fieldedsearch.jsp", "https://www.ncbi.nlm.nih.gov/pubmed/20558244", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/29047020", "https://www.science.gov/", "https://www.openaire.eu/search/publication?articleId=od_______908::6662ebe6e671dc11bcd99390828ac949", "https://www.openaire.eu/search/advanced/publications", "http://www.dovepress.com/rotavirus-vaccination-and-herd-immunity-an-evidence-based-review-a10247", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=dedup_wf_001::d847e20ffc973c5d3418099c9da9c4d0", "https://www.openaire.eu/search/advanced/publications", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/27712709", "https://www.science.gov/", "http://orbit.dtu.dk/ws/files/8054705/DEB93d01.pdf", "http://forskningsbasen.deff.dk/?lang=eng", "https://www.narcis.nl/publication/RecordID/publicat%3A6823/uquery/rotavirus/id/8/Language/EN", "http://www.narcis.nl", "https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F357089/uquery/rotavirus/id/12/Language/EN", "http://www.narcis.nl", "http://www.lenus.ie/hse/handle/10147/209072", "http://www.lenus.ie/hse/", "http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00308/full", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-75412012000300014", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=doajarticles::6f322a77ce0bd5fd88c95f861a1a0782", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/10769066", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/25218045", "https://www.science.gov/", "http://www.biomedcentral.com/1471-2431/10/40", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0036-36341998000100006", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892004000100006", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/28255929", "https://www.science.gov/", "https://www.ajol.info/index.php/bajopas/article/download/100013/89275", "http://www.ajol.info/index.php", "https://www.ajol.info/index.php/bajopas/article/view/100013", "http://www.ajol.info/index.php", "https://www.ajol.info/index.php/samj/article/view/79034", "http://www.ajol.info/index.php", "http://www.redalyc.org/articulo.oa?id=17033372012", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/29095805", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=239472", "https://www.science.gov/", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/29211629", "https://www.science.gov/", "https://www.ajol.info/index.php/njcp/article/view/111648", "http://www.ajol.info/index.php", "https://www.ajol.info/index.php/aam/article/viewFile/43204/26747", "http://www.ajol.info/index.php", "https://www.ajol.info/index.php/samj/article/view/50751", "http://www.ajol.info/index.php", "https://www.ajol.info/index.php/ejhs/article/view/112799", "http://www.ajol.info/index.php", "https://www.ncbi.nlm.nih.gov/pubmed/23017130", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/19255784", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/20692030", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/28640001", "https://www.science.gov/", "https://www.ajol.info/index.php/sokjvs/article/view/162311", "http://www.ajol.info/index.php", "https://www.ncbi.nlm.nih.gov/pubmed/17608648", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/29555220", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4272830", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/25919162", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/28289928", "https://www.science.gov/", "http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342009000900012", "https://doaj.org/search#.V6PA8bgrK70", "http://www.forskningsdatabasen.dk/en/catalog/225710519", "http://forskningsbasen.deff.dk/?lang=eng", "https://www.ncbi.nlm.nih.gov/pubmed/24593996", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/29187315", "https://www.science.gov/", "http://pf.spr-journal.ru/jour/article/view/151", "https://doaj.org/search#.V6PA8bgrK70", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "http://www.etde.org/etdeweb/details.jsp?query_id=1&page=0&osti_id=5157012", "https://www.etde.org/etdeweb/fieldedsearch.jsp", "http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-21002010000600013", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46651991000100005", "https://doaj.org/search#.V6PA8bgrK70", "https://www.narcis.nl/publication/RecordID/oai%3Apure.amc.nl%3Apublications%2Fdef4ddc5-eadc-4fd2-b315-fbfdd7324806/uquery/Rotavirus%20AND%20vaccine%20AND%20efficacy/id/6/Language/EN", "http://www.narcis.nl", "http://pf.spr-journal.ru/jour/article/view/169", "https://doaj.org/search#.V6PA8bgrK70", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3212997", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/22520134", "https://www.science.gov/", "http://www.veterinaryworld.org/Vol.7/October-2014/13.pdf", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=doajarticles::9f083d9cb2b9e06dbceeb1cf2c0fabe3", "https://www.openaire.eu/search/advanced/publications", "https://www.narcis.nl/publication/RecordID/oai%3Alibrary.wur.nl%3Awurpubs%2F528628/uquery/Rotavirus%20AND%20vaccine%20AND%20efficacy/id/7/Language/EN", "http://www.narcis.nl", "http://www.biomedcentral.com/1471-2458/10/253", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/17468648", "https://www.science.gov/", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000800004", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ajol.info/index.php/sjms/article/view/104449", "http://www.ajol.info/index.php", "https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F357639/uquery/rotavirus/id/11/Language/EN", "http://www.narcis.nl", "https://www.ncbi.nlm.nih.gov/pubmed/24378188", "https://www.science.gov/", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200002&lng=es&nrm=iso&tlng=es", "https://doaj.org/search#.V6PA8bgrK70", "http://repository.kaust.edu.sa/kaust/handle/10754/563024", "http://repository.kaust.edu.sa", "https://www.canadianjbiotech.com/CAN_J_BIOTECH/Archives/v1/Special+Issue/cjb.2017-a65.pdf", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/27876198", "https://www.science.gov/", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/12969206", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3884708", "https://www.science.gov/", "http://www.forskningsdatabasen.dk/en/catalog/2389445944", "http://forskningsbasen.deff.dk/?lang=eng", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3540628", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/27217217", "https://www.science.gov/", "http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802010000300002", "https://doaj.org/search#.V6PA8bgrK70", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2005000100003&lng=es&nrm=iso&tlng=es", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-11042016000400009&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "http://ai.zaslavsky.com.ua/article/view/82323", "https://doaj.org/search#.V6PA8bgrK70", "https://revistas.utadeo.edu.co/index.php/TyE/article/view/945/984", "https://doaj.org/search#.V6PA8bgrK70", "https://inis.iaea.orgsearchsinglerecord.aspx?recordsFor=SingleRecord&RN=39120090", "http://inis.iaea.org/search/", "https://www.ncbi.nlm.nih.gov/pubmed/28637685", "https://www.science.gov/", "http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-75412008000300007", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/27755463", "https://www.science.gov/", "http://www.revistabiomedica.org/index.php/biomedica/article/view/1056", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=dedup_wf_001::861b6ca3ec07edefe4f370098a9ece41", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/28281866", "https://www.science.gov/", "http://europepmc.org/articles/PMC3958477?pdf=render", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ajol.info/index.php/mmj/article/view/45631", "http://www.ajol.info/index.php", "http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802007000400005", "https://doaj.org/search#.V6PA8bgrK70", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/26611203", "https://www.science.gov/", "https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F8c77f3fc-a978-4e42-9dda-1f2a84d6ef7a/uquery/rotavirus/id/1/Language/EN", "http://www.narcis.nl", "http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1517-83822017000400769&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/20107214", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4943361", "https://www.science.gov/", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1726-46342017000300365&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=444800", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/19817590", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/29860097", "https://www.science.gov/", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892006000100005", "https://doaj.org/search#.V6PA8bgrK70", "http://adsabs.harvard.edu/abs/2016AGUFMPA21B2210H", "https://www.science.gov/", "http://www.biomedcentral.com/1471-2431/10/69", "https://doaj.org/search#.V6PA8bgrK70", "https://www.openaire.eu/search/publication?articleId=dedup_wf_001::c23dfc7fe0e27ffdb16f685de4ddbe7f", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/28832219", "https://www.science.gov/", "http://www.biomedcentral.com/1471-2431/10/94", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/28716388", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/22520136", "https://www.science.gov/", "http://www.mdpi.com/2076-0817/6/4/65", "https://doaj.org/search#.V6PA8bgrK70", "https://revistas.unal.edu.co/index.php/actabiol/article/view/27394", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/29252042", "https://www.science.gov/", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F349679/uquery/rotavirus/id/5/Language/EN", "http://www.narcis.nl", "https://revistas.unal.edu.co/index.php/revfacmed/article/view/27236", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/29628149", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/21508015", "https://www.science.gov/", "https://www.ajol.info/index.php/eamj/article/view/63082", "http://www.ajol.info/index.php", "https://www.ncbi.nlm.nih.gov/pubmed/27005498", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=421650", "https://www.science.gov/", "http://www.mdpi.com/2073-4441/8/3/78", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/25919152", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/17380232", "https://www.science.gov/", "http://www.nfid.org/idinfo/rotavirus/faqs.html", "https://www.science.gov/", "http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802011000500015", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ajol.info/index.php/njm/article/view/37397", "http://www.ajol.info/index.php", "http://dx.doi.org/10.1155/2010/317545", "https://doaj.org/search#.V6PA8bgrK70", "http://www.forskningsdatabasen.dk/en/catalog/188922403", "http://forskningsbasen.deff.dk/?lang=eng", "https://f1000research.com/articles/6-1517/v1", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761983000300002", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/25668672", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/16925536", "https://www.science.gov/", "http://europepmc.org/articles/PMC3412858?pdf=render", "https://doaj.org/search#.V6PA8bgrK70", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/22879893", "https://www.science.gov/", "https://www.narcis.nl/publication/RecordID/oai%3Arepub.eur.nl%3A13485/uquery/Rotavirus/id/20/Language/EN", "http://www.narcis.nl", "https://www.ncbi.nlm.nih.gov/pubmed/29659924", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4028215", "https://www.science.gov/", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0036-36342001000600002", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/24941946", "https://www.science.gov/", "https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_g8nXbL&server=pvlbsrch10&v%3astate=root%7croot&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc5&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&", "http://www.nlm.nih.gov/medlineplus/videosandcooltools.html", "https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_IEqMB7&server=pvlbsrch14&v%3astate=root%7croot&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc8&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&", "http://www.nlm.nih.gov/medlineplus/videosandcooltools.html", "https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_RXXm9N&server=pvlbsrch10&v%3astate=root%7croot-60-10%7c0&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc64&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&", "http://www.nlm.nih.gov/medlineplus/videosandcooltools.html", "https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_KVEpez&server=pvlbsrch10&v%3astate=root%7croot&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc9&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&", "http://www.nlm.nih.gov/medlineplus/videosandcooltools.html", "http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652013000200137&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/16857608", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/23972382", "https://www.science.gov/", "https://www.ajol.info/index.php/bajopas/article/download/139683/129390", "http://www.ajol.info/index.php", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1135-57271998000600004", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/17606534", "https://www.science.gov/", "https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F22d7a844-9de3-4204-99de-bc8404317792/uquery/rotavirus/id/7/Language/EN", "http://www.narcis.nl", "https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F6184a5d4-f127-4c0f-b534-c0c19a06e710/uquery/rotavirus/id/13/Language/EN", "http://www.narcis.nl", "https://www.ncbi.nlm.nih.gov/pubmed/4074098", "https://www.science.gov/", "http://dx.doi.org/10.1016/j.virol.2004.02.018", "http://inis.iaea.org/search/", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/24343617", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/29455326", "https://www.science.gov/", "http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762011000500004&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3749198", "https://www.science.gov/", "https://repository.kaust.edu.sa/handle/10754/563024", "http://repository.kaust.edu.sa", "https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_8qfcbE&server=pvlbsrch10&v%3astate=root%7croot&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc1&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&", "http://www.nlm.nih.gov/medlineplus/videosandcooltools.html", "https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_m9gXyw&server=pvlbsrch14&v%3astate=root%7croot&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc3&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&", "http://www.nlm.nih.gov/medlineplus/videosandcooltools.html", "https://www.ncbi.nlm.nih.gov/pubmed/25701122", "https://www.science.gov/", "https://www.openaire.eu/search/publication?articleId=doajarticles::0f1a7e9d964b5b4dd7e2026d0f5f7623", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/27894992", "https://www.science.gov/", "http://detinf.elpub.ru/jour/article/view/40", "https://doaj.org/search#.V6PA8bgrK70", "https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F1ba3edf5-275c-4d4f-86f5-3cec4c41aff2/uquery/Management%20AND%20developing%20AND%20country%20AND%20perspective/id/18/Language/EN", "http://www.narcis.nl", "https://www.narcis.nl/publication/RecordID/oai%3Adare.uva.nl%3Apublications%2F213ab654-4e76-4031-aeda-d48134ac7b6c/uquery/rotavirus/id/6/Language/EN", "http://www.narcis.nl", "https://www.ajol.info/index.php/sokjvs/article/view/152781", "http://www.ajol.info/index.php", "http://www.forskningsdatabasen.dk/en/catalog/112109447", "http://forskningsbasen.deff.dk/?lang=eng", "https://www.ncbi.nlm.nih.gov/pubmed/23499605", "https://www.science.gov/", "http://www.biomedcentral.com/1471-2431/11/81", "https://doaj.org/search#.V6PA8bgrK70", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1383299", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/20083525", "https://www.science.gov/", "http://europepmc.org/articles/PMC3846786?pdf=render", "https://doaj.org/search#.V6PA8bgrK70", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342009000900010", "https://doaj.org/search#.V6PA8bgrK70", "http://ai.zaslavsky.com.ua/article/view/78704", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/24769586", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=109534", "https://www.science.gov/", "http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342001000400012", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/29128517", "https://www.science.gov/", "http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762013000600741&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "https://eric.ed.gov/?q=rotavirus&id=EJ986531", "https://www.science.gov/", "https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3afile=viv_rA4nvL&server=pvlbsrch10&v%3astate=root%7croot&url=http%3a%2f%2fwww.pkids.org%2fimmunizations%2fvideos%2frotavirus.html&rid=Ndoc3&v%3aframe=redirect&v%3aredirect-hash=25848be6460b91ca58e8f4da423331da&", "http://www.nlm.nih.gov/medlineplus/videosandcooltools.html", "https://www.openaire.eu/search/publication?articleId=doajarticles::f3f4ecc159ebb48d37bb75cddc626a36", "https://www.openaire.eu/search/advanced/publications", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5459539", "https://www.science.gov/", "http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652017005000502&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/28472348", "https://www.science.gov/", "http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802010000600014", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/27487415", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/23871824", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/24291196", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/22520140", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=109829", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/27763810", "https://www.science.gov/", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "http://www.pagepress.org/journals/index.php/pr/article/view/5873", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-75412012000200004", "https://doaj.org/search#.V6PA8bgrK70", "http://gastro.zaslavsky.com.ua/article/view/86388", "https://doaj.org/search#.V6PA8bgrK70", "http://www.sciencedirect.com/science/article/pii/S0716864010706088", "https://doaj.org/search#.V6PA8bgrK70", "http://childshealth.zaslavsky.com.ua/article/view/84825", "https://doaj.org/search#.V6PA8bgrK70", "http://www.ijmm.org/article.asp?issn=0255-0857;year=2017;volume=35;issue=1;spage=33;epage=36;aulast=Pol", "https://doaj.org/search#.V6PA8bgrK70", "http://europepmc.org/articles/PMC5593200?pdf=render", "https://doaj.org/search#.V6PA8bgrK70", "http://repository.kaust.edu.sa/kaust/handle/10754/598642", "http://repository.kaust.edu.sa", "https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F39bd7b4b-d84d-49b3-bdeb-3091271cca90/uquery/rotavirus/id/16/Language/EN", "http://www.narcis.nl", "https://www.ncbi.nlm.nih.gov/pubmed/21183843", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/25460825", "https://www.science.gov/", "https://www.ajol.info/index.php/hmrj/article/view/33826", "http://www.ajol.info/index.php", "https://www.ncbi.nlm.nih.gov/pubmed/29329758", "https://www.science.gov/", "http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762003000100004", "https://doaj.org/search#.V6PA8bgrK70", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200003&lng=es&nrm=iso&tlng=es", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/25919149", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/21917176", "https://www.science.gov/", "http://www.ojhas.org/issue37/2011-1-15.htm", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/25268934", "https://www.science.gov/", "http://pf.spr-journal.ru/jour/article/view/193", "https://doaj.org/search#.V6PA8bgrK70", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.openaire.eu/search/publication?articleId=od_______908::bd3535f913b4fa6805664189d8556c48", "https://www.openaire.eu/search/advanced/publications", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4856001", "https://www.science.gov/", "http://www.sciencedirect.com/science/article/pii/S2352345X16300066", "https://doaj.org/search#.V6PA8bgrK70", "http://www.etde.org/etdeweb/details.jsp?query_id=1&page=0&osti_id=22185738", "https://www.etde.org/etdeweb/fieldedsearch.jsp", "https://www.openaire.eu/search/publication?articleId=dedup_wf_001::69504224a67a1db5cf7f4eafc85160f1", "https://www.openaire.eu/search/advanced/publications", "https://www.openaire.eu/search/publication?articleId=od_______935::d513a40dc09e50440853f4ad3258003a", "https://www.openaire.eu/search/advanced/publications", "https://www.ncbi.nlm.nih.gov/pubmed/27085171", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/28328346", "https://www.science.gov/", "http://armaghanj.yums.ac.ir/browse.php?a_code=A-10-1-254&slc_lang=en&sid=1", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/28369477", "https://www.science.gov/", "http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001000400004", "https://doaj.org/search#.V6PA8bgrK70", "http://europepmc.org/articles/PMC3548809?pdf=render", "https://doaj.org/search#.V6PA8bgrK70", "https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2Fc11a0ded-b830-4723-83ab-afbad5fe39df/uquery/rotavirus/id/20/Language/EN", "http://www.narcis.nl", "http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000700002&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "http://europepmc.org/articles/PMC3479108?pdf=render", "https://doaj.org/search#.V6PA8bgrK70", "http://europepmc.org/articles/PMC3692488?pdf=render", "https://doaj.org/search#.V6PA8bgrK70", "https://www.ncbi.nlm.nih.gov/pubmed/25091673", "https://www.science.gov/", "https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F9f3a5331-c4b9-41a9-9692-7e3ef6a5f30a/uquery/rotavirus/id/4/Language/EN", "http://www.narcis.nl", "http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102010000200020", "https://doaj.org/search#.V6PA8bgrK70", "https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2Fae43d31d-8ba3-4679-88ba-ae168f0d1069/uquery/gastroenteritis/id/15/Language/EN", "http://www.narcis.nl", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2014000200006&lng=es&nrm=iso", "https://doaj.org/search#.V6PA8bgrK70", "http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342007000300011&lng=en&tlng=en", "https://doaj.org/search#.V6PA8bgrK70", "http://www.lenus.ie/hse/handle/10147/198762", "http://www.lenus.ie/hse/", "https://www.ncbi.nlm.nih.gov/pubmed/23343932", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3739503", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/23955246", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/28636595", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5787375", "https://www.science.gov/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3981852", "https://www.science.gov/", "http://dx.doi.org/10.1016/S0042-6822(03)00280-0", "http://inis.iaea.org/search/", "https://www.ncbi.nlm.nih.gov/pubmed/29210350", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/19817600", "https://www.science.gov/", "http://dx.doi.org/10.1016/j.virol.2015.01.003", "http://inis.iaea.org/search/", "http://www.etde.org/etdeweb/details.jsp?query_id=1&page=0&osti_id=22470156", "https://www.etde.org/etdeweb/fieldedsearch.jsp", "http://www.sciencedirect.com/science/article/pii/S1875957209600231", "https://doaj.org/search#.V6PA8bgrK70", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5839333", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/27129416", "https://www.science.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/22520143", "https://www.science.gov/", "https://www.openaire.eu/search/publication?articleId=dedup_wf_001::65b6b604c194368acb33dec6a36fd039", "https://www.openaire.eu/search/advanced/publications", "http://www.revista-socampar.com/images/articulos/ArticulosSeparadosNum6/Articulo%20especial.pdf", "https://doaj.org/search#.V6PA8bgrK70", "#", "#", "#", "#", "#", "#", "http://worldwidescience.org/disclaimer.html", null, "http://www.science.gov", "http://worldwidescience.org"]}